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Abstract 
Malignant hyperthermia (MH) presents in susceptible individuals following 
exposure to volatile anaesthetic agents, manifesting as Ca2+ dysregulation via 
aberrant activity of the ryanodine receptor 1 (RYR1) – the major Ca2+ release 
unit of skeletal muscle sarcoplasmic reticulum (SR).  Progress in the 
characterisation of RYR1 variants identified in MH susceptible individuals has 
been hindered by characterisation processes that rely on the cloning and 
heterologous expression of the large, ~15 kb RYR1 gene.  A novel CRISPR-
Cas9 based method for variant characterisation was developed to circumvent 
existing limitations of variant characterisation.  The p.D3986E and p.S1728F 
variants were introduced into C2C12 myoblasts.  In addition to the desired 
integration of the repair template, this resulted in a range of erroneous 
integrations and undesired editing events.  Nonetheless, this work provides a 
substantial foundation for future development of CRISPR-Cas9 genome editing 
in the MH field and highlights key areas for future optimisation. 
 
It has been speculated that variants in genes other than the RYR1 and 
CACNA1S could contribute to MH susceptibility in the proportion of MH cases 
for which no genetic cause has been ascertained.  Next generation sequencing 
of fifty genes associated with Ca2+ handling, performed by the Leeds MH Unit, 
identified two calsequestrin-1 (CASQ1) variants, p.I138T and p.F186Y, in an 
MH individual and an exertional heat illness (EHI) individual, respectively.  An 
additional variant, CASQ1 p.E364K was identified in an MHShc individual by 
colleagues in the Australian population.  EHI has significant clinical overlap with 
MH and MH-associated RYR1 variants have been detected in EHI patients.  
CASQ1 is thought to be the major Ca2+ binding protein of skeletal muscle SR 
and a regulator of RYR1 activity.  CASQ1 null mice have been shown to exhibit 
an MH and EHI-like phenotype in response to halothane and heat, respectively.    
In this project, CASQ1 variants p.F186Y and p.I138T were shown to have 
reduced Ca2+ binding and polymerisation capacities compared CASQ1 WT and 
CASQ1 p.E364K.  These data suggest that the highly conserved CASQ1 
p.F186Y and p.I138T variants could act to influence the MH/EHI phenotype. 
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Chapter 1 - Introduction 
1.1 Clinical manifestation of malignant hyperthermia 
First described in the 1960s (Denborough and Lovell, 1960), malignant 
hyperthermia (MH) is a disorder of calcium handling that manifests, in 
susceptible individuals, following exposure to volatile anaesthetics and/or the 
muscle relaxant, succinylcholine.  Uncontrolled calcium ion (Ca2+) release from 
the sarcoplasmic reticulum (SR) of skeletal muscle induces a hypermetabolic 
state leading to hyperthermia, muscle rigidity, acidosis, arrhythmia, increased 
creatine kinase (CK) levels and rhabdomyolysis (Rosenberg et al., 2015; Jiang 
et al., 2008).   Left untreated, rhabdomyolysis can cause life-threatening 
hyperkalaemia and with a rise in body temperature, disseminated intravascular 
coagulation is the usual cause of death (Kim, 2012; Rosenberg et al., 2015).  
MH reactions are treated with the muscle relaxant, dantrolene.  Whilst it has 
long been known that dantrolene suppresses the release of Ca2+ from the SR 
(Ellis and Bryant, 1972), its mechanism of action was only recently elucidated.  
Choi et al. (2017) identified that dantrolene increases the affinity of the major 
Ca2+ release unit in SR, the ryanodine receptor 1 (RYR1), to Mg2+ which exerts 
an inhibitory effect on the RYR1.  Treatment of MH reactions with dantrolene 
has reduced the mortality from MH reactions to <5% (Litman and Rosenberg, 
2005). 
1.2 Epidemiology of MH 
Estimates of the incidence of MH vary from 1 in 10,000 to 1 in 250,000 
(Halliday, 2003; Ording, 1985) but the prevalence of variants in genes 
associated with MH may be as high as 1 in 2000 (Monnier et al., 2002); 
however, these numbers are difficult to ascertain as MH does not usually 
present on an individual’s first exposure to anaesthetics, exposure may be 
limited to a short duration, reactions may be mild and only a small proportion of 
the general population are exposed per year (Rosenberg et al., 2015).  
Interestingly, MH is more prevalent in males than females.  Estimates of the 
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difference in incidence between males and females range from a 2.2:1 ratio to 
4:1 in a Japanese study (Strazis and Fox, 1993; Migita et al., 2007).  In the 
North American MH Registry (NAMHR), 78% of MH cases were observed in 
males (Brandom and Larach, 2002).  Between the years of 1990-2010, 68% of 
MH proband referrals to the Leeds MH unit were male (Gupta and Hopkins, 
2017).   
1.3 Skeletal muscle calcium homeostasis  
1.3.1 Fibre types 
Mammalian skeletal muscles are comprised of a mixture of fibre types, allowing 
them to perform diverse functions from endurance exercise to short, rapid 
contractions.  Whole muscles were initially characterised based on their 
contractile speed and colour – slow twitch muscles, associated with endurance, 
appeared red due to high levels of myoglobin and fast twitch muscles, 
associated with rapid contraction, appeared white (Needham, 1926).  Muscle 
fibre type characterisation transpired as more complex following biochemical 
advances including histochemical staining for succinate dehydrogenase (SDH), 
an enzyme involved in oxidative metabolism, and the identification of 
differential expression of myosin isoforms (Edstrom and Kugelberg, 1968).   
 
There are four major fibre types in adult mammals, type 1, type 2A, type 2B 
and type 2X.  Type 1 fibres are referred to as slow fibres, with high levels of 
SDH histochemical staining and a reliance upon oxidative metabolism for 
energy production, resulting in large numbers of mitochondria (Peter et al., 
1972).  Type 1 fibres express the MYH7 gene which encodes the beta(β)-
myosin heavy chain (MyHC-β) (Stuart et al., 2016).  The fast fibres are divided 
into three major forms, type 2A, 2B and 2X.  Type 2A fibres express the MYH2 
gene encoding the myosin heavy chain 2A protein (MyHC-2A) and rely upon 
both oxidative metabolism and glycolysis for energy production, with 
intermediate resistance to fatigue (Stuart et al., 2016; Schiaffino and Reggiani, 
2011).  Type 2B fibres utilise glycolysis only, with low levels of SDH staining, 
low mitochondrial numbers and low resistance to fatigue (Schiaffino and 
Reggiaini, 2011).  In small mammals, type 2B fibres express the MYH4 gene 
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which encodes the myosin heavy chain 2B protein (MyHC-2B) and type 2X 
fibres (which have fatigue resistance between type 2A and type 2B fibres) 
express the MYH1 gene which encodes the myosin heavy chain 2X protein 
(MyHC-2X) (Schiaffino et al., 1989; Smerdu et al., 1994). 
 
In humans, western blots failed to show MyHC-2B expression in type 2B fibres 
but did detect MyHC-2X.  It is therefore considered that human type 2B fibres 
are homologous to small mammal type 2X fibres (Hilber et al., 1999).  A 
number of additional ‘hybrid’ fibre types have been observed in humans 
including type 1C, 2C and 2AC which express varying levels of MyHC-β and 
MyHC-2A and type 2AB, which express varying levels of MyHC-2A and MyHC-
2X (Scott et al., 2001) 
 
1.3.2 Excitation contraction coupling 
Excitation contraction coupling (ECC) begins with the initiation of an action 
potential that is propagated down invaginations of the sarcolemma into the cell 
known as transverse tubules (t-tubules) (Figure 1.1) (Sandow, 1952).  In the 
triad regions, where t-tubules are flanked by membranes of the SR, voltage 
change is detected by the dihydropyridine receptor (DHPR) Ca2+ channel 
(Franzini-Armstrong, 1970; Rios and Brum, 1987).  Upon the detection of 
voltage change, the DHPR undergoes conformational changes that enable its 
allosteric activation of the RYR1, triggering Ca2+ release from the sarcoplasmic 
reticulum (SR) (Tanabe et al., 1988).  Ca2+ binds troponin which is associated 
with tropomyosin on actin filaments.  Ca2+ binding triggers a conformational 
change in troponin, altering its interaction with tropomyosin and exposing 
myosin binding sites on the actin filament.  The globular head of myosin, bound 
to adenosine diphosphate (ADP) and an inorganic phosphate (Pi), binds actin 
and forms a cross-bridge.  The power stroke occurs whereby myosin pulls actin 
towards the M line and shortens the sarcomere, releasing ADP.  Binding of an 
adenosine triphosphate (ATP) molecule to myosin, and its subsequent 
hydrolysis to ADP and Pi, releases myosin from actin, enabling it to bind to 
another site providing Ca2+ levels are sufficient (Hopkins, 2006). 
4 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 – Schematic of the excitation contraction coupling mechanism 
1) Action potentials are propagated along the sarcolemma (orange arrows) 2) Cav1.1 (DHPRs are shown as a single complex rather 
than a tetrad for simplicity) detects the voltage change and undergoes a conformational change 3) The RYR1 is allosterically activated 
and Ca2+ (blue arrows) released from the SR 4) Ca2+ binds troponin, enabling muscle contraction via the interaction of actin and 
myosin 5) Excess Ca2+ from the sarcoplasm is transported into the SR by SERCA. 
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1.3.2.1 The dihydropyridine receptor 
The dihydropyridine receptor (DHPR) is composed of 5 subunits (α1s: 176 kD, 
α2: 147 kDa, δ: 24 kDa, β1a: 56 kDa and γ: 34 kDa) (Catterall, 2011).  The 
complex is arranged in tetrads that oppose alternate RYR1s on the SR 
membrane - an arrangement dependent on the presence of the β1a subunit 
(Schredelseker et al., 2005) (Figure 1.1).  Historically, structural resolution of 
the DHPR has been limited, with progress hindered by its membrane-bound 
localisation (Hu et al., 2015).  Nonetheless, a number of attempts have 
produced consistent observations with regard to the function of each subunit.  
To date, the DHPR has been resolved to 15 Å and the α1s subunit to 3.6 Å (Hu 
et al., 2015; Wu et al., 2016).    
 
The α1s subunit (hereafter referred to as Cav1.1) is the main component of the 
DHPR, forming the ion-conducting channel and voltage sensor (Tanabe et al., 
1987).  It comprises four repeat units (I, II, III and IV), each with six 
transmembrane domains (S1-S6) (Hu et al., 2015).  It has been postulated that, 
due to DHPR similarity to voltage gated Na+ and K+ channels, transmembrane 
domains S1-S4 are involved in voltage sensing whereas S5-S6 form the ion 
conducting channel (Samso, 2015).  The Cav1.1 repeat units are connected via 
linkers known as loops.  The I-II loop contains the alpha-1 interacting domain 
(AID) motif which binds the β1a subunit (Almagor et al., 2012).  This interaction 
is thought to enable the transmission of conformational changes from the 
voltage-sensing domains (VSDs) to the β1a subunit.  The II-III loop physically 
interacts with the RYR1 (Tanabe et al., 1990), an interaction that has been 
postulated to occur via β1a docking onto the RYR1, bringing the II-III loop into 
proximity with its RYR1 interaction site (Hu et al., 2015).  Residues 1083-1094 
of the III-IV loop interact with the C-terminal domain of Cav1.1. to realise a 
globular structure, although the significance of this not fully understood (Wu et 
al., 2016).   
 
The γ subunit comprises four transmembrane domains (TM1-TM4) with TM2 
and TM3 mediating its interaction with S3 and S4 of Cav1.1 (Wu et al., 2016). 
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The γ subunit has been shown to act as a Ca2+ antagonist, maintaining the 
integrity of the inactive DHPR state (Andronache et al., 2007). 
The α2 and δ subunits are encoded by one gene and are separated by a single 
disulphide bond.  Through its transmembrane domain, the δ subunit tethers α2 
to the membrane (Samso, 2015).  The role of the α2/δ subunit is not fully 
elucidated, with proposed functions in excitation-coupled calcium entry 
(ECCE) and muscle cell development (Gach et al., 2008; Weiss and Ivanova, 
2008). 
 
1.3.2.2 Ryanodine receptor 1 
The RYR1 is a large, homotetrameric complex that, at ~2.2 megadaltons 
(MDa), is the largest known ion channel (Lai et al., 1988).  It comprises four 
~565 kilodalton (kDa) protomers that assemble to form a number of functional 
domains.  Recent advances in the structural resolution of rabbit RYR1 by 
cryogenic electron microscopy (cyro-EM) have begun to elucidate how the 
coordinated actions of these domains enable the propagation of conformational 
signals (Zalk et al., 2015; Efremov et al., 2015; Yan et al., 2015; Samso, 2017).  
Simplistically, the RYR1 consists of a ligand-sensing sarcoplasmic region and a 
central domain which relays conformational signals to the pore forming 
transmembrane domain.   
 
Within the sarcoplasmic region, SPRY domains act as sites of protein-protein 
interaction.  SPRY1 has been shown to bind the RYR1 regulator, FKBP12 (Yan 
et al., 2015; Yuchi et al., 2015).  In some studies, the main functional region of 
the SPRY2 domain has been shown to bind the Cav1.1 II-III loop but similar 
studies using the full length SPRY2 domain failed to corroborate these results; 
nonetheless, the proximity of the II-III loop to SPRY2 makes this possibility of 
this interaction plausible (Cui et al., 2009; Lau et al., 2014; Samso, 2017).  
Helical domains 1 and 2 are highly flexible, suggesting roles in binding and the 
communication of conformational changes (Yan et al., 2015).  The central 
domain is the only part of the sarcoplasmic region that interacts with the 6-
helices transmembrane domain (S1-S6) and this occurs via the cytoplasmic 
voltage-sensor like domain (VSC) and the C-terminal domain (Yan et al., 
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2015).  The central domain contains two EF hand domains that act as Ca2+ 
sensors, presumably relaying conformational signals to the VSC that it is in 
contact with. In addition to this, Van der Waals forces between transmembrane 
domains and the central domain provide plasticity for relaying conformational 
signals (Yan et al., 2015).  Following allosteric activation of the RYR1, Ca2+ is 
released via the channel into the sarcoplasm, where it initiates contraction of 
the sarcomere. 
 
1.3.2.2.1 Retrograde RYR1/DHPR signalling 
In addition to the orthograde coupling between the DHPR and RYR1 to trigger 
Ca2+ release from the SR, experiments in dyspedic myotubes (those lacking 
the RYR1) revealed bidirectional signalling between the RYR1 and DHPR.  In 
dyspedic myotubes, L-type Ca2+ currents were greatly reduced, an effect 
reversed by the exogenous expression of the RYR1.  Thus, it has been 
postulated that the RYR1 signals in a retrograde manner to enhance DHPR L-
type currents (Nakai et al., 1996).   
 
1.3.3 Calcium reuptake into the SR 
Following muscle contraction, the sarcoplasmic/endoplasmic reticulum calcium 
ATPase (SERCA) hydrolyses ATP to transport Ca2+ from the sarcoplasm back 
into the SR (Figure 1.1).  This allows for muscle relaxation as well as the 
replenishment of SR Ca2+ stores for further muscle contraction (Periasamy and 
Kalyanasundaram, 2006).  
 
1.3.4 Store-operated calcium entry 
First described in 2001, store operated calcium entry (SOCE) is the mechanism 
by which SR Ca2+ stores are replenished following depletion (Kurebayashi and 
Ogawa, 2001).  The mechanism by which SOCE occurs and its role in skeletal 
muscle has been controversial.  Initial studies implicated conformational 
coupling of RYR1 channels with transient receptor potential cation 
(TRPC) channels; however, sustained SOCE in RYR1 null myotubes showed 
that the RYR1 is not required for SOCE (Lyfenko and Dirksen, 2008).  Further 
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studies suggested that the combined actions of inositol trisphosphate (IP3) 
receptors and TRPC3 channels contributed to SOCE but IP3 receptors are not 
enriched in the SR and TRPC3 knockdown experiments failed to show an 
effect on SOCE (Launikonis et al., 2003; Lee et al., 2006).  Following the 
identification of stromal interaction molecule 1 (STIM1) as a Ca2+ sensor in 
non-excitable cells, it is now largely accepted that SOCE occurs through 
interactions between STIM1 and the calcium release-activated calcium channel 
1 (ORAI1) (Roos et al., 2005).  In non-excitable cells, STIM1 exists as a 
monomer and acts as a Ca2+ sensor through an EF hand motif, where 
depletion of Ca2+ and its subsequent dissociation from STIM1 induces 
conformational changes in STIM1 that trigger its oligomerisation (Stathopulos 
et al., 2006).  STIM1 oligomers are able to translocate to regions of the ER 
membrane in close contact with the plasma membrane and interact with ORAI1 
tetrads, triggering Ca2+ influx (Wu et al., 2006).  In skeletal muscle cells, STIM1 
is pre-localised to the SR membrane regions in close contact with the 
sarcolemma and it is unclear whether they exist as monomers or oligomers 
(Stiber et al., 2008).  Interestingly, a splice variant of STIM1, STIM1L, is 
enriched in skeletal muscle cells and is permanently coupled with ORAI1 
tetrads on the sarcolemma membrane (Darbellay et al., 2011; Launikonis et al., 
2010).  This association increases the rate at which SOCE can occur in 
skeletal muscle cells (Launikonis et al., 2010).   
 
1.3.5 Excitation-coupled calcium entry 
Sustained depolarisation of the sarcolemma initiates another extracellular Ca2+ 
entry mechanism known as excitation-coupled calcium entry (ECCE), 
irrespective of Ca2+ store depletion (Cherednichenko et al., 2004).  The channel 
responsible for Ca2+ influx via ECCE remains unidentified; however, it is likely 
that the DHPR at least contributes to Ca2+ entry (Bannister et al., 2009) 
 
1.3.6 SH3 and cysteine rich domain 3 protein 
SH3 and cysteine rich domain 3 (STAC3), almost exclusively expressed in 
skeletal muscle, has recently been realised as a player in ECC.  Genetic 
screens in zebrafish have identified a defect in the STAC3 gene that reduces 
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Ca2+ transients in ECC (Horstick et al., 2013).  Further studies have shown that 
STAC3 is required for the appropriate trafficking of Cav1.1 to membranes 
(Nelson et al., 2013).  Indeed, fluorescently tagged STAC3 and Cav1.1 were 
found to co-localise to the plasma membrane in non-muscle cells which, 
without STAC3, have poor or no Cav1.1 expression (Polster et al., 2016). 
 
1.4 RYR1 regulatory proteins 
1.4.1 Calsequestrin-1 
Calsequestrin-1 (CASQ1) is a ~44 kDa Ca2+ binding protein localised to the SR 
where it acts as a Ca2+ buffer and sensor.  CASQ1 does not contain an EF-
hand domain that is characteristic of other CASQ1 binding proteins (Kumar et 
al., 2013), but confers its Ca2+ binding capacity by numerous acidic glutamate 
and aspartate residues that are responsible for CASQ1’s highly electronegative 
surface.  In the absence of Ca2+, CASQ1 exists as a disordered monomer and 
undergoes compaction upon Ca2+ binding (Sanchez et al., 2012).  At low Ca2+ 
levels of ~10 μM, CASQ1 is monomeric and increasing Ca2+ to in vivo SR 
levels towards ~1mM triggers CASQ1 polymerisation (Royer and Rios, 2009).  
CASQ1 consists of three almost identical domains that each comprise a 5-
stranded beta sheet and four alpha-helices (Wang et al., 1998).  Hydrophobic 
residues are packed within the CASQ1 core and acidic, Ca2+ binding residues 
populate the exterior (Sanchez et al., 2012).  Polymerisation of CASQ1 begins 
with the self-association of CASQ1 monomers in a front-to-front configuration.  
The disordered N terminal arm of domain 1 in one monomer is inserted into a 
groove between beta sheets in domain 2 of the partner monomer (Wang et al., 
1998).  These dimeric CASQ1 proteins then associate in a back-to-back 
manner to form linear polymers (Sanchez et al., 2012).  Studies have 
suggested that CASQ1 monomers are able to bind up to 50-80 Ca2+ ions; 
however, the number of acidic residues in the CASQ1 protein sequence do not 
account for this high capacity binding.  Further studies have shown that the 
polymerisation of CASQ1 induces the formation of clusters of acidic residues, 
generating additional Ca2+ binding sites, accounting for the ability of CASQ1 to 
bind Ca2+ with high capacity (Sanchez et al., 2012).  Ca2+ binding-induced 
polymerisation of CASQ1 is dependent on the C-terminal tail which contains a 
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string of acidic amino acids and ablation of this region abolishes the self-
association of CASQ1 monomers (Beard and Dulhunty, 2015).  CASQ1 is the 
only CASQ isoform expressed in fast-twitch muscle fibres; however, in slow 
twitch fibres, CASQ1 is co-expressed with the cardiac CASQ, calsequestrin 2 
(CASQ2). 
1.4.1.1 The complex role of CASQ1 
CASQ1 had long been considered to function only as Ca2+ buffer, providing a 
store of Ca2+ ions for release by the RYR1; however, elucidation of its 
interactions with a number of SR proteins provided evidence of a complex role 
in calcium handling.  Namely, CASQ1 has been implicated in the regulation of 
RYR1 activity.  Early experiments indicated that addition of CASQ1 to purified 
heavy SR vesicles within an artificial lipid bilayer activates RYR1s (Kawasaki 
and Kasai, 1994).   Conversely, more recent studies indicate that CASQ1 
inhibits native RYR1 channels but activates purified RYR1 channels (Beard et 
al., 2002).  It was postulated that these conflicting reports arose from the 
requirement of further proteins for CASQ1-mediated regulation that were 
present only in native preparations.  Indeed, it has since been demonstrated 
that, at low Ca2+ levels (~20 μM), CASQ1 inhibits RYR1 activity in the presence 
of two additional proteins, junctin and triadin (Györke et al., 2004).  The 
interaction of CASQ1 with junctional SR protein 45, JP45, suggests a role for 
CASQ1 in relaying information regarding Ca2+ levels in the SR to Cav1.1.  JP45 
is a transmembrane protein that interacts with Cav1.1 on the sarcolemma and 
CASQ1 inside of the SR.  In mice lacking both JP45 and CASQ1, repeated 
depolarisation results in a massive Ca2+ influx from extracellular stores, 
suggesting that the JP45 and CASQ1 complex is a negative regulator of 
ECCE.  Furthermore, this Ca2+ influx is thought to be via the Cav1.1 channel, 
since it is prevented by the known Cav1.1 blocker, nifedipine (Mosca et al., 
2016).   
CASQ1 has also been implicated as a component in SOCE.  CASQ1 knock-
down has been shown to increase SOCE in skeletal muscle fibres, although 
the mechanism by which this occurs is unclear (Zhao et al., 2010).  
Experiments in non-muscle cells have shown that CASQ1 colocalises with 
STIM1, suggestive of binding, preventing STIM1 oligomerisation and its 
interaction with ORAI1 (Wang et al., 2015).  
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1.4.1.2 The role of CASQ1 in MH 
The implication of CASQ1 in RYR1 regulation and Ca2+ handling makes the 
CASQ1 gene an interesting candidate for a role in MH.  Indeed, mice lacking 
CASQ1 exhibit an MH-like phenotype in response to halothane exposure 
(Dainese et al., 2009).  Male CASQ1-null mice exposed to 2% halothane had a 
mortality rate of 80%, compared to 15% for female CASQ1-null mice and 0% 
for wild-type mice.  In addition, an exertional heat-illness (EHI)-like phenotype 
was observed following exposure to 41oC heat in an environmental chamber.  
17 out of 24 CASQ1-null male mice underwent sudden death following heat 
exposure compared to 1 wild-type male mouse.  In contrast, the increased 
sudden death in female CASQ1-null mice was not significantly different to 
wildtype.  Notably, dantrolene was found to have a protective effect against 
both halothane and heat exposure.  This suggests that variants in the human 
CASQ1 gene could also be implicated in EHI, which has considerable clinical 
overlap with MH (Hopkins et al., 1991; Hopkins, 2007).  Interestingly, an 
increase in voltage-sensitive Ca2+ release was observed in CASQ1-null mice, 
possibly due to loss of CASQ1 inhibition of the RYR1 (Dainese et al., 2009).  
The observed increase in susceptibility to MH in male mice in this study is 
mirrored in human MH cases.  Whilst the reason behind the increased 
incidence of MH in males is not entirely understood, recent studies have shown 
that oestrogens protect against lethal MH-like episodes in CASQ1-null mice.  
This is an effect perhaps achieved by regulating the activity of enzymes 
involved in the production of reactive oxygen species (ROS) and reactive 
nitrogen species (RNS) (Michelucci et al., 2017). 
To date, no variants in the CASQ1 gene have been definitively linked to MH in 
humans (Lewis et al., 2015).  The relevance of CASQ1 variants identified in 
MHS individuals will be addressed in this research project. 
 
1.4.2 Junctin and triadin 
Junctin and triadin are both embedded in the SR membrane at the triad region, 
where they interact with the RYR1 and CASQ1 (Figure 1.1).  The presence of 
both proteins has been shown to permit CASQ1-mediated inhibition of the 
RYR1; however, their individual roles are not fully understood (Gyorke et al., 
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2004; Wei et al., 2009).  In-vitro studies using artificial lipid bilayers have shown 
that in the absence of CASQ1, both junctin and triadin activate the RYR1 and 
this occurs at different sites on the RYR1 for each protein, suggesting that they 
have distinct roles (Wei et al., 2009). Indeed, CASQ1-mediated inhibition of the 
RYR1 can occur in the presence of junctin alone in artificial bilayers, an effect 
intensified by low Ca2+ levels, suggesting that junctin is the main contributor to 
CASQ1-mediated RYR1 inhibition (Wei et al., 2009).  Furthermore, knockdown 
of junctin in C2C12 mouse skeletal muscle myotubes resulted in reduced SR 
Ca2+ stores, seemingly consistent with reduced RYR1 inhibition (Wang et al., 
2009).  Conversely in this study, triadin knockdown resulted in reduced Ca2+ 
release following K+ induced depolarisation (Wang et al., 2009).   
The generation of triadin and junctin null mice has enabled studies of the 
structural effects of triadin/junctin ablation on muscle fibres.  Triadin null muscle 
fibres have been shown to lack ‘anchors’ that connect CASQ1 polymers to the 
junctional SR membrane, resulting in a disordered and reduced network of 
CASQ1; however, junctin null fibres had a structural arrangement comparable 
to wild-type (Boncompagni et al., 2012).  This seems to contrast data that has 
shown junctin alone is able to permit CASQ1-mediated inhibition of the RYR1 
(Wei et al., 2009).  These discrepancies may be due to the presence of 
additional proteins in myotubes that are absent from cell-free models. 
Functional Ca2+ release studies on myotubes derived from triadin/junctin null 
mouse models have shown that triadin null myotubes have a reduced Ca2+ 
release in response to depolarisation, corroborating observations made in 
triadin knockdown myotubes (Wang et al., 2009).  Ca2+ release following 
caffeine stimulation of junctin null myotubes was comparable to wild-type; 
however, triadin null myotubes had reduced Ca2+ release and reduced 
sensitivity to caffeine (Boncampagni et al., 2012).  In contrast to studies of 
junctin knockdown in myotubes, junctin-null myotubes did not have reduced SR 
Ca2+ stores but triadin-null myotubes did, which is inkeeping with Ca2+ release 
data.  To date, the exact roles of triadin and junctin are not fully understood and 
conflicting literature surrounding their functions emphasises the complexity of 
Ca2+ handling in skeletal muscle. 
 
  
13 
 
1.4.3 FKBP12 
FKBP12, sometimes referred to as calstabin 1, is a sarcoplasmic protein 
constitutively bound to the RYR1 (Samso, 2006).  FKBP12 is thought to 
regulate the RYR1 by stabilising its open and closed states (Gaburjakova et al., 
2001).  In artificial bilayer studies, the interaction of the RYR1 with the II-III loop 
of Cav1.1 increases the RYR1 open probability dramatically, an effect that is 
not seen upon the removal of FKBP12 (O’Reilly et al., 2002).  Interestingly, 
FKBP12 is proposed to stabilise the closed state of the RYR1 via its interaction 
with triadin (Eltit et al., 2010).  The over-expression of FKBP12 in triadin null 
myotubes restored SR Ca2+ levels and reduced resting sarcoplasmic Ca2+ 
levels; however, it did not restore the abnormal RYR1 sub-conductance states 
observed, suggesting other proteins may be involved in the FKBP12-mediated 
closed-state stabilisation of the RYR1 (Eltit et al., 2010). 
1.5 Regulation of RYR1 by Mg2+ 
In addition to protein ligands, small molecules mediate the activity of the RYR1.  
Mg2+ exerts an inhibitory effect on the RYR1 via two mechanisms.  Firstly, Mg2+ 
competes with Ca2+ for a binding site that triggers activation of the RYR1 and 
secondly, Mg2+ binds to a low-affinity site that inhibits RYR1 activity (Meissner 
et al., 1986; Laver et al., 1997).  Studies have shown that Mg2+ inhibition of the 
RYR1 is reduced in the presence of the C-terminal residues of Cav1.1 and 
increases in SR Ca2+ may reduce the affinity of Mg2+ to activation sites on the 
RYR1, thus preventing its competition for binding (Haarmann et al., 2005; 
Laver et al., 2004).  Given the potential for a greater role in the regulation of 
ECC, it has been postulated that Mg2+ contributes to the aetiology of MH 
(Steele and Duke, 2007).  Indeed, Mg2+ inhibition of Ca2+ release is reduced in 
muscle fibres derived from MHS individuals (Steele and Duke, 2007). 
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1.6 Mitochondrial function in muscle contraction 
The skeletal muscle sarcoplasm is rich in mitochondria that generate ATP 
required during muscle contraction, primarily by oxidative phosphorylation 
(OXPHOS).  OXPHOS takes place in the mitochondrial inner membrane 
whereby the electron carrier NADH transfers electrons through a series of 
electron carriers embedded in the membrane, in a process termed the electron 
transport chain (ETC).  As electrons are transferred, energy is released and is 
used to drive a proton (H+) gradient across the membrane – the two processes 
are said to be in coupling.  Energy within the H+ gradient is used by ATP 
synthase, which phosphorylates ADP, converting it to ATP.  Having passed 
through a series of donors and acceptors, electrons combine with O2 and H+ to 
form water (Alberts et al., 2008, p. 98-100).  The reduction of O2 to H2O can 
lead to the formation of superoxide anions (O2•−) and subsequently hydrogen 
peroxide (H2O2), which can form highly reactive oxygen species (ROS) such as 
hydroxyl radicals (•OH) (Görlach et al., 2015).  Whilst ROS are required as 
signalling molecules in normal cellular processes such as cell proliferation and 
migration, high levels cause damage to DNA and proteins (Martindale and 
Holbrook, 2002). 
   
1.6.1 Ca2+, ATP and ROS 
Ca2+ is thought to be transported to the mitochondrial matrix via the voltage-
dependent anion channel (VDAC) on the outer membrane and the 
mitochondrial Ca2+ uniporter (MCU) located on the inner membrane (Gincel et 
al., 2001; Kirichock et al., 2004).  It is well established that Ca2+ primarily 
activates OXPHOS in the mitochondria, enabling increased ATP synthesis in 
response to elevated Ca2+ levels (Das and Harris, 1990).  In turn, this can lead 
to increased ROS production due to a higher metabolic rate and increased 
ETC leakage.  In addition to this, elevated Ca2+ is also postulated to contribute 
to mitochondrial dysfunction by potentiating the response of the cell death-
associated permeability transition (PT) pore on the outer mitochondrial 
membrane to ROS (Brookes and Darley-Usmar, 2004).  
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1.6.2 Reactive nitrogen species 
In addition to ROS, reactive nitrogen species (RNS) are a biproduct of 
OXPHOS.  Ca2+ has been shown to activate the nitric oxide synthase (NOS) 
enzyme which catalyses the production of nitric oxide (NO·) (Alderton et al., 
2001).  Interestingly, NO· has inhibitory effects on a complex within the ETC, 
complex IV.  Inhibition of this complex leads to increased ROS production from 
another complex, complex III, suggesting a role for NO· in relaying redox 
signals (Brookes and Darley-Usmar, 2004).   
 
1.6.3 Mitochondrial function in MH 
Numerous reports have suggested that mitochondrial structure and function in 
impaired in MHS muscle.  Electron microscopy of muscle samples obtained 
from mice with the MH RYR1 p.Y522S variant, revealed that a proportion of 
mitochondria are larger than wild-type, swollen and damaged (Boncompagni et 
al., 2009).  Structural abnormalities are corroborated in studies of MHS human 
muscle, where the density of some mitochondrial matrices is altered and some 
mitochondria fragmented (Lavorato et al., 2016).  Muscles from mice with the 
MH RYR1 p.R163C variant have increased levels of ROS, reduced glucose 
uptake (indicative of reduced OXPHOS) and mitochondrial uncoupling leading 
to reduced ATP production (Giulivi et al., 2011).  ATP production via OXPHOS 
has also been shown to be reduced in MHS human muscle samples 
(Thompson et al., 2017).  Recently, MHS human muscle samples have been 
shown to have reduced OXPHOS despite increased mitochondrial mass 
compared to wild-type.  Furthermore, this reduced OXPHOS capacity is 
thought to be due to a deficiency in complex II of the ETC.  Interestingly, 
complex II is also involved in glycolysis, which could present an area of future 
research with regard to mitochondrial function in MHS muscle (Chang et al., 
2019) 
 
1.6.3.1 Redox modifications of RYR1 
The interplay between Ca2+ and ROS/RNS is bidirectional, that is, whilst Ca2+ is 
known to affect ROS/RNS production, ROS/RNS also alter Ca2+ homeostasis.  
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The addition of an NO· group to a free thiol group on cysteine residues (S-
nitrosylation) occurs primarily when oxygen levels are low and has been 
implicated in the pathogenesis of the MH RYR1 p.Y522S variant.  Y522S mice 
have increased sensitivity to caffeine and the inhalational anaesthetic, 
isofluorane.  In addition to this, exposure to heat triggers rhabdomyolysis and 
sudden death (Durham et al., 2008).  Ca2+ leak from the SR leads to increased 
RNS production and initiates S-nitrosylation of the RYR1, increasing its activity 
(Sun et al., 2006).  Progressive mitochondrial damage due to elevated Ca2+ 
and RNS ultimately leads to myopathy in Y522S mice (Durham et al., 2008).  
 
As oxygen levels increase, oxidation overtakes nitrosylation as the primary 
redox modification.  S-oxidation activates the RYR1 by enabling the formation 
of disulphide bonds between RYR1 subunits, thus coordinating their actions 
(Hamilton and Reid, 2000).  Like other forms of regulation of the RYR1, redox 
modifications are complex, and it is likely that the alteration of these fine-tuned 
mechanisms in MH could contribute its pathogenesis.  
1.7 Genetics of MH 
1.8 The ryanodine receptor 1 gene 
The ryanodine receptor 1 gene (RYR1), which is ~15 kilobases (kb) and 
encoded on chromosome 19q, was linked to MH in the 1990s when linkage 
studies showed the co-segregation of RYR1 markers with the MH phenotype in 
an autosomal dominant fashion (Maclennan et al., 1990).  To date, over 200 
RYR1 missense variants have been associated with MH and 48 are currently 
accepted as diagnostic variants by the European Malignant Hyperthermia 
Group (EMHG), illustrating the allelic heterogeneity of MH.   In humans, RYR1 
variants are found in a heterozygous form; however, homozygosity of the 
p.R614C diagnostic variant has been reported in humans and homozygosity 
causes an MH-like reaction in pigs in response to halothane, heat and stress 
(Rueffert et al., 2001; Fujii et al., 1991).  Understanding the genetic basis of MH 
is complex and a single MHS individual may harbour multiple RYR1 variants 
(Monnier et al., 2002; Fiszer et al., 2015).  Approximately 76% of MH cases in 
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the UK are attributed to defects in the RYR1 gene and ~50% of these are 
attributed to the c.7300G>A p.G2434R variant (Miller et al., 2018; Robinson et 
al., 2006).  
 
1.9  The alpha-1 subunit of the dihydropyridine receptor gene 
In addition to the RYR1, heterozygous missense variants in the CACNA1S 
gene, encoding the α1 subunit of the DHPR (Cav1.1) have been explicitly 
linked to MH.  The search for additional MH loci followed the exclusion of RYR1 
linkage to MH in multiple pedigrees (Levitt et al., 1991; Fagerlund et al., 1992; 
Ruebsam et al., 1993; Iles et al., 1992). A genome-wide linkage study provided 
evidence of locus linked to MH being located at chromosome 1q, the site of the 
CACNA1S gene (Robinson et al., 1997).  To date, CACNA1S remains the only 
gene other than the RYR1 with accepted MH diagnostic variants (Weiss et al., 
2004; Eltit et al., 2012).  The p.R1086H and p.R174W variants are found in 
1.7% of UK MH cases and in some cases, are found alongside a diagnostic 
RYR1 variant, further demonstrating the complexity of elucidating the genetic 
basis of MH (Miller et al., 2018). 
 
1.9.1 The role of RYR1/CACNA1S variants in the pathogenesis of 
MH 
RYR1 variants identified in MHS individuals are gain of function.  They cause 
RYR1 hypersensitivity to agonists, increasing the likelihood of channel 
activation, an observation first made in p.R615C pigs (Fill et al., 1991; Yang et 
al., 2003).  Experiments using muscle fibres derived from MHS humans and 
mice, in addition to mouse myotubes expressing RYR1 variants have shown 
that sarcoplasmic resting Ca2+ levels are higher compared to wild-type (Yang et 
al., 2007; Feng et al., 2011).  This is speculated be the result of a chronic, 
passive SR Ca2+ leak via variant RYR1s.   
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The mechanism of pathogenesis of the RYR1 p. R163C variant has been 
extensively studied.  The p.R163C variant is the fourth most common variant 
within the UK population (Miller et al., 2018).  Hyperactivity of RYR1 p.R163C 
channels has been postulated to occur through aberrant post-translational 
modifications of the cysteine residue or the formation of disulphide bonds that 
disrupt interactions between intra or inter molecular domains, although this has 
not been ascertained (Voss et al., 2004; Tung et al., 2010; Feng et al., 2011).  
Other attempts to explain the hyperactivity of RYR1 variant channels include 
the disruption of interactions with negative regulators of the RYR1, such as 
FKBP12, through phosphorylation.  Increased phosphorylation of the serine at 
position 2844 in RYR1 p.R163C channels has been observed; however, 
western blotting of RYR1 p.R163C sample preparations showed no difference 
in the amounts of FKBP12 compared to wild-type (Feng et al., 2011).  In recent 
years, multiple Ca2+ pathways have been implicated in the pathogenesis of MH.  
Partial depletion of SR Ca2+ stores by leaky RYR1 p.R163C channels leads to 
an increased level of Ca2+ influx via SOCE, an observation previously seen in 
human MHS muscles (Eltit et al., 2013; Duke et al., 2010).  In addition to Ca2+, 
p.R163C muscle fibres have increased levels of sarcoplasmic Na+, which may 
occur through the actions of a non-selective Ca2+/Na+ channel, thought to be 
the transient receptor potential channels 3 or 6 (TRPC3/6) on the sarcolemma 
membrane (Eltit et al. 2013).  RYR1 p.R163C myotubes also show increased 
ECCE which can be suppressed by dantrolene treatment (Cherednichenko et 
al., 2008)  
 
Whilst the full pathogenic mechanism of RYR1 variants remains to be 
elucidated, advances in the resolution of the RYR1 structure are likely to shed 
light on this complex series of events. Indeed, mapping of MH variants onto 
structural and functional domains of the RYR1 has been made possible in 
recent years (Figure 1.2; Yan et al., 2015).  The majority of MH variants have 
been identified in the ligand-sensing N-terminal domain and the flexible helical 
domain 1; however, this is likely due to DNA sequencing bias.  
  
  
19 
 
The Cav1.1 p. R1086H variant is positioned within the III-IV linker.  Residues 
1083-1094 of this linker interact with III S6 and form a helix that, when 
interacting with a helix in the Cav1.1 C-terminal domain, complete a globular 
structure (Wu et al., 2016).  In myotubes expressing Cav1.1 R1086H channels, 
Ca2+ release from the SR occurs at a lower voltage than in myotubes 
expressing wild-type Cav1.1s and RYR1 R1086H sensitivity to caffeine is 
increased.  This is thought to be due to the dual effect of raised sarcoplasmic 
Ca2+ levels, in addition to the lack of negative regulatory effect thought to be 
exerted by the DHPR on the RYR1 (Weiss et al., 2004).  The role of the DHPR 
in negatively regulating RYR1 activity is corroborated by studies of the 
functional effect of the Cav.1.1 p.R174W variant, which is positioned at a highly 
conserved gating charge residue in repeat I of the S4 transmembrane domain.  
Unlike the p. R1086H variant, p. R174W does not cause Ca2+ release from the 
SR to occur at lower voltages; however, its ability to prevent RYR1 Ca2+ leak at 
rest is impaired and RYR1 sensitivity to caffeine is increased (Eltit et al., 2012) 
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Figure 1.2 – MH variants mapped to RYR1 domains 
Major domains of rabbit RYR1 according structures resolved in Yan et al., 2015.  Amino acid positions are shown beneath the domain 
names and MH variants shown in red text.  NTD, N-terminal domain. Adapted from Yan et al., 2015.
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1.10 SH3 and cysteine-rich domain-containing protein 3 gene 
In recent years, the homozygous p.W284S variant in the STAC3 gene has 
been implicated in Native American Myopathy (NAM) (Horstick et al., 2013).  
NAM, an autosomal recessive disorder, features symptoms including 
congenital myopathy and skeletal abnormalities, in addition to MH susceptibility 
(Bailey and Bloch, 1987).  Next generation sequencing (NGS) efforts of mainly 
European Caucasian MH families in recent years have failed to identify any 
novel, potentially pathogenic STAC3 variants (Miller et al., 2018).  Currently, no 
STAC3 variants are accepted as diagnostic MH variants according to the 
EMHG (available at www.emhg.org, accessed August 2019).  
1.11 Role of other genes in MH 
Since a proportion of MH cases are not attributed to defects in the 
RYR1/CACNA1S/STAC3 genes, variants in genes yet unassociated with MH 
may be implicated in up to ~25% of MH cases (Miller et al., 2018).  Variants in 
genes encoding gene products that regulate the RYR1, such as CASQ1, are 
promising candidates for MH susceptibility (Protasi et al., 2009).  In an effort to 
identify MH variants at novel loci, the Leeds MH unit performs NGS of fifty 
genes associated with calcium handling, in MH families with no diagnostic 
RYR1/CACNA1S/STAC3 variant. 
1.12 MH link to exertional heat illness 
Exertional heat illness (EHI) is a complex disorder arising from interactions 
between environmental and physiological factor, leading to temperature 
dysregulation and hypermetabolism (Muldoon et al., 2004).  Symptoms of an 
EHI reaction may be mild, ranging from exhaustion to muscle cramps but 
severe cases can progress to exertional heat stroke (EHS).  EHS is life 
threatening and symptoms include rhabdomyolysis, tachycardia and 
hyperthermia, which can lead to multi-organ failure and death (Capacchione 
and Muldoon, 2009).  EHI occurs primarily in young, healthy males performing 
strenuous exercise in hot environments such as military training exercises; 
however, it is also more likely to occur in people who are obese, unfit or 
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suffering a viral infection (Hopkins et al., 1991; Hopkins, 2015).  Due to their 
significant clinical overlap, it has been postulated that there is a link between 
MH and EHI.  A number of reports describe the diagnosis of MH in individuals 
who had previously had EHI episodes (Hopkins et al., 1991; Thomas and 
Crowhurst, 2013).  More recently, Thomas and Crowhurst (2013) described an 
EHI episode in an otherwise healthy 25-year-old male running a 10 km race.  
The proband and a further 5 family members were diagnosed as MHShc.  The 
availability of genetic testing has led to a number of reports in which individuals 
who have suffered EHI episodes have been found to harbour diagnostic MH 
variants.  For example, in 2001, Tobin et al., published a case study of an 
anaesthesia-induced MH reaction and subsequent EHI episode whilst playing 
football in a 12-year-old child.  It was later revealed that the child and their 
father harboured the RYR1 p.R163C variant (Tobin et al., 2001).  In more 
recent years, NGS of individuals who have experienced EHI episodes has 
revealed a number of rare, potentially pathogenic variants in the RYR1 and 
other genes implicated in Ca2+ handling that could act to influence susceptibility 
to EHI; however, the functional significance of these variants remains to be 
determined (Fiszer et al., 2015).   
 
1.13 Diagnosis of MH 
MH susceptibility is diagnosed using the in vitro contracture test (IVCT) – an 
assay based on the increased contractile sensitivity of MH susceptible (MHS) 
skeletal muscle to caffeine and halothane compared to MH normal (MHN) 
skeletal muscle (Kalow et al., 1970; Ording et al., 1997).  The IVCT protocol is 
standardised and used as the gold-standard across diagnostic centres within 
the European Malignant Hyperthermia Group (EMHG).  Muscle biopsies from 
the vastus medialis or vastus lateralis are maintained in physiological buffer 
and electrically stimulated to demonstrate viability.  A baseline measurement of 
tension (measured in grams) is taken prior to exposure of the muscle sample to 
increasing concentrations of caffeine and halothane.  An increase in tension of 
≥0.2 g from baseline, following exposure to 2% halothane or 2 mM caffeine is 
deemed a positive response (Figure 1.4).  
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susceptible to halothane and caffeine (MHShc), MH susceptible to halothane 
only (MHSh), MH susceptible to caffeine only (MHSc) or MHN.  Since the IVCT 
procedure is highly invasive, in recent years, a DNA-level diagnostic approach 
has been implemented where appropriate but this is limited due to an 
incomplete understanding of the genetic basis of MH (Figure 1.5; Hopkins et 
al., 2015). 
1.14 Discordancy in MH 
The implementation of a DNA-level diagnostic approach is hindered by reports 
of discordancy between the IVCT phenotype and RYR1/CACNA1S genotype.  
That is, individuals with a positive IVCT phenotype (MHShc or MHSh) and a 
negative RYR1/CACNA1S genotype or individuals with a negative IVCT 
phenotype and a positive RYR1/CACNA1S genotype – the latter of which is 
less common, likely due to bias as individuals with negative IVCT phenotypes 
are not routinely offered DNA screening.  Discordancy in MH has been widely 
reported in the past two decades - the G1021A mutation in the RYR1 gene was 
shown not to fully co-segregate with MH within families (Adeokun et al., 1997) 
and MHN individuals were reported to harbour the C1840T mutation (Deufel et 
al., 1995).  Currently, discordancy has been reported in 26.2% of UK MH 
families (Miller et al., 2018).  These observations emphasise the complexity of 
MH and suggest that multiple variants could act to determine MH susceptibility 
(Robinson et al., 2000; Robinson et al., 2002).  Indeed, a threshold effect has 
been proposed whereby ‘stronger’ RYR1 variants (i.e. those associated with 
strong IVCT phenotypes) may be sufficient to cause MH susceptibility but 
‘weaker’ RYR1 variants may only cause MH susceptibility in the presence of 
other variants (Carpenter et al., 2009).  Interestingly, within the UK MH cohort, 
genotype-phenotype discordancy is distributed equally across RYR1 variants; 
however, no discordancy has been observed for the p.R2435H variant which is 
associated with strong IVCT phenotypes (Miller et al., 2018). 
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Figure 1.3 – IVCT traces of a negative and positive response to halothane 
Representative traces of a negative (A) and positive (B) response to halothane.  Electrical stimulation is applied to biopsied muscle 
samples causing it to twitch, as a measure of viability.  An initial tension is applied and the muscle sample allowed to relax prior to 
application of halothane – the point at which tension is lowest is called the pre-dose and acts as a baseline for measurement of 
subsequent increases in tension.  Halothane is applied incrementally, at 0.5%, 1% and 2% and tension recorded.
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Figure 1.4 – Leeds MH unit strategy for the diagnosis and investigation of MH  
Suspected probands in the UK are referred to the Leeds MH unit for diagnosis.  The Leeds Genetics Laboratory (St James’ University 
Hospital, Leeds) performs NGS of the coding regions of the RYR1/CACNA1S genes and genotyping of the STAC3 p. W284S variant.  
Identification of a diagnostic variant allows for confirmation of MH status without the need for IVCT.  If a diagnostic variant is not 
identified, probands are referred for an IVCT to determine MH status.  MHS individuals are candidates for further research.
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1.15 Functional characterisation of RYR1 and CACNA1S 
variants 
The development of a genetic diagnostic panel for MH would alleviate the 
necessity for invasive IVCT diagnosis; however, progress in this field has been 
hindered in part due to the allelic and genetic heterogeneity of MH – a result of 
the complex Ca2+ handling mechanisms implicated in it.  To date, despite the 
association of over 200 variants in the RYR1 with MH, only 48 have been 
added to a diagnostic list of MH variants and only 2 CACNA1S variants are 
diagnostic (EMHG, available at www.emhg.org, accessed August 2019).  
Furthermore, up to ~25% of MH cases cannot be attributed to defects in the 
RYR1 or CACNA1S genes (Miller et al., 2018).  Past and present methods of 
variant characterisation will be discussed below, highlighting the need for a 
novel characterisation process for MH associated variants.  
 
1.15.1 Criteria for the assignment of diagnostic MH variants 
The EMHG have published guidelines for the characterisation of variants 
associated with MH (Hopkins et al., 2015).  These guidelines are in line with 
those set out by the American College of Medical Genetics and Genomics 
(ACMG; Richards et al., 2015).  As such, all variants must be fully described at 
a genetic and protein level, using the A residue of the ATG start codon as 
position 1.  In addition, the reference sequence used should be cited.  The 
minor allele frequency (MAF) should be ascertained using a population 
database and in the case of MH, the EMHG anticipates that pathogenic 
variants will have a MAF of less than 0.001 (0.1%).  The EMHG also 
recommends that the conservation status of a variant across species is 
reported and the ACMG recommends this is reported along with whether the 
variant is located in any critical domains (Richards et al., 2015).  Previously, it 
had been a requirement that the variant must have been identified in multiple 
MH families but since the majority of variants are unique to single families, this 
criterion has since been removed (Robinson et al., 2006; Miller et al., 2018).  
The ACMG recommends that in-silico tools can be used to aid the 
interpretation of variants, especially when multiple programmes are used in 
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parallel; however, these interpretations cannot be used soley to make clinical 
decisions (Richards et al., 2015).  In addition to a full genetic description, the 
EMHG requires that variants undergo functional characterisation for effects 
consistent with the pathogenic mechanism of MH (Hopkins et al., 2015).   
 
1.15.2 Methods of characterisation for MH associated variants 
 
1.15.2.1 Primary ex-vivo patient samples 
IVCT biopsies have provided a convenient means to derive primary myoblasts 
from patient samples for functional characterisation.  Following differentiation 
into myotubes, cells can be loaded with Ca2+ indicating dyes and stimulated 
with RYR1 agonists such as caffeine to measure Ca2+ release from the SR – a 
mechanism that is perturbed in MHS muscle fibres (Brinkmeier et al., 1999; 
Wehner et al., 2002).  Whilst myotubes offer a balance between physiological 
relevance (i.e. they express muscle-specific genes and structures) and ease of 
isolation, primary cells have a limited replicative potential (Hayflick and 
Moorhead, 1961).  Further to this, the contamination of myoblast preparations 
with fibroblasts means that repeated pre-plating procedures are required to 
obtain a pure myoblast population, increasing the passage number of the cells 
further (Chowdhury et al., 2015).  Whilst there has been limited success in 
immortalising human myoblasts through retroviral-mediated delivery of human 
telomerase reverse transcriptase (hTERT) and cyclin dependent kinase 4 
(CDK4) (Mamchaoui et al., 2011), replication of this procedure in our group has 
proved challenging and there are no reports of the use of immortalised human 
myoblasts for the characterisation of variants in MH.  To overcome issues with 
the immortalisation of human myoblasts, some groups have isolated B-
lymphocytes, which express the RYR1 but not all functional components of the 
ECC mechanism, from patient blood samples and immortalised them with 
Epstein-Barr virus (EBV) prior to Ca2+ release studies (Girard et al., 2001; Sei 
et al., 2002).   
 
Despite this, the main limitation of using any primary patient samples is the 
unknown genetic background of the patient.  That is, the presence of additional 
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unknown variants may alter Ca2+ handling making it difficult to determine that 
the observed effect is attributed to the variant in question.  Ultimately, this 
provides only corroboration of MH status previously determined by IVCT.  In 
efforts to address concerns regarding genetic background, it has been 
recommended that functional characterisation in this manner must be 
performed on multiple MH families; however, it has been postulated that high-
risk MH haplotypes exist which could ultimately lead to functional 
characterisation of the incorrect variant (Carpenter et al., 2009).  Furthermore, 
since the majority of MH variants are unique to individual families, a large 
proportion of variants could not be characterised this way (Miller et al., 2018). 
 
1.15.2.2 Heterologous RYR1 expression in HEK293 cells and dyspedic 
myotubes 
The predominant system for functional characterisation of MH associated 
variants is the heterologous expression of variant rabbit or human RYR1 
cDNAs in human embryonic kidney (HEK293) cells that inherently lack RYR1 
expression (Nakai et al., 1996).  Tong et al., (1997) introduced this method for 
the functional characterisation of 15 variants associated with MH.  Following 
site-directed mutagenesis of an RYR1 construct, it is transiently transfected 
into HEK293 cells and Ca2+ release in response to RYR1 agonists is measured 
(Tong et al., 1999a; Lynch et al., 1999).  In contrast to the use of primary 
myoblasts derived from ex-vivo patient samples, the HEK293 system offers a 
constant genetic background meaning that differences in Ca2+ release can be 
attributed to the variant present in the cDNA.  Nonetheless, the HEK293 
system does not come without limitations.  Firstly, most site directed 
mutagenesis protocols rely on the amplification of the entire plasmid which is 
problematic for large vectors.  Indeed, the RYR1 coding sequence alone is ~15 
kb.  To overcome this, subcloning of fragments of the RYR1 coding sequence 
is required which can prove time consuming and laborious (Merritt et al., 2017).  
Dramatic reductions in transfection efficiencies are observed with large vectors, 
making confirmation of heterologous RYR1 expression by western blotting 
challenging and data obtained from Ca2+ release studies highly variable 
between cells (Kreiss et al., 1999; Merritt et al., 2017).  Another point of 
contention when using HEK293 cells is that they do not express ECC 
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machinery such as the DHPR, nor do they form muscle-specific structures such 
as triad regions or SR that ensures efficient Ca2+ storage, release and 
reuptake.   
 
Dyspedic 1B5 skeletal myotubes, those that lack RYR1 channels, provide an 
appealing means to overcome the limitations associated with primary samples 
and HEK293 cells.  Indeed, a number of MH variants have been characterised 
whereby modified type 1 herpes simplex virus (HSV-1) vectors were co-
transfected alongside a vector encoding the RYR1 variant, enabling the study 
of RYR1 channels in the presence of muscle-specific structures and the ECC 
machinery (Yang et al., 2003).  Despite this, heterologous expression of 
RYR1s in any cell type requires the mutagenesis and transfection or 
transduction of the large RYR1 cDNA.  Ultimately, a novel variant 
characterisation process that allows for the study of variants in a muscle cell 
line and circumvents issues with laborious cloning and transfection of the 
RYR1 gene is needed to overcome the bottleneck associated with RYR1 
variant characterisation.  The development of such a pipeline will extend the 
availability of DNA-level diagnostics in MH and allow for an individualised, 
stratified medicines approach to anaesthesia. 
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1.16 CRISPR-Cas9 as a functional characterisation system 
1.16.1 History of engineered nucleases 
The ability to introduce mutations at any location in any genome has been a 
long sought-after objective.  In the 1990s, the development of zinc finger 
nucleases (ZFNs) saw introduction of double stranded breaks (DSBs) at 
targeted DNA sequences (Kim and Chandrasegaran, 1994).  The DNA-binding 
ZF domains, that each recognise a 3 base pair (bp) sequence, are assembled 
together to produce a large complex with specific DNA targeting capacities 
(Klug and Rhodes, 1987).  Following designation of the target DNA sequence, 
fusion to a modified, recognition-inactive Fok I endonuclease enables cleavage 
of both DNA strands (Kim and Chandrasegaran, 1996).  DSBs can be repaired 
by two major mechanisms, non-homologous end joining (NHEJ) and homology 
directed repair (HDR) (reviewed in Gupta and Musunuru, 2014).  NHEJ results 
in the incorporation of random insertions or the deletion of bases flanking the 
cleavage site, leading to knockout of the targeted gene through frameshift or 
the insertion of a stop codon.  HDR enables the introduction of specific 
mutations via the presence of a repair template that has the mutation to be 
introduced flanked by several bases of homology to the sequence flanking the 
cleavage site (Figure 1.5).  Despite the widespread use of ZFNs, their use 
presents two major limitations.  Firstly, the engineering and assembly of ZF 
domains has proved challenging, typically taking months to complete (Gupta 
and Musunuru, 2014).  Secondly, since ZFNs target 3 bp, sequence specificity 
may be limited.  More recently, a class of nucleases known as transcription 
activator-like effector nucleases (TALENs) have been utilised.  TALENs 
comprise an array of repeat amino acids, of which just two confer specificity to 
a single nucleotide, expanding the scope for sequence specificity engineering 
compared to ZFNs (Bogdanove and Voytas, 2011).  Furthermore, since just 
two amino acid residues determine nucleotide specificity, engineering TALENs 
is less time consuming and laborious.  Nonetheless, the use of TALENs is 
limited by their large size.  With a coding sequence of ~3 kb (compared to 1 kb 
for ZFNs), their delivery into cell lines has proved challenging (Gupta and 
Musunuru, 2014).  In addition, the preferred method of delivery into cell lines is 
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using viruses; however, the tandem array present in TALENs is prone to 
recombination in viral vectors (Holkers et al., 2013). 
 
 
 
  
Figure 1.5 – Double stranded break repair outcomes 
Following target recognition (1) and cleavage of the target site by a nuclease 
(2), DSBs can be repaired by two main mechanisms – NHEJ and HDR (3).  
NHEJ results in the insertion of random nucleotides or deletion of the 
sequences flanking the cleavage site.  HDR requires a repair template which 
contains a specific mutation to be introduced flanked by homology to the 
regions encompassing the cleavage site.  Homologous recombination between 
the genome and the repair template results in the introduction of the desired 
mutation.  
 
1.16.2 CRISPR-Cas system 
 
1.16.2.1 The CRISPR-Cas9 type II system 
In 2013, the exploitation of a bacterial acquired immunity system revolutionised 
genome editing (Cong et al., 2013; Ran et al., 2013a).  The Clustered 
Regularly Interspaced Short Palindromic Repeats (CRISPR) array and its 
CRISPR associated proteins (Cas) comprise an RNA-guided mechanism by 
which invading bacteriophage DNA is cleaved to prevent re-infection (Mojica et 
al., 1993; Mojica et al., 2005; Jansen et al., 2002; Figure 1.6).  CRISPR 
systems are divided into two main categories – type I systems which require 
the actions of multiple Cas proteins and type II systems which rely only upon 
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the activity of the Cas9 nuclease (Brouns et al., 2008; Jinek et al., 2012).  The 
most widely characterised and implemented system is the Streptococcus 
pyogenes (S. pyogenes) type II system which will be described here. Sections 
of the invading DNA called protospacers lie immediately upstream of the 
protospacer adjacent motif (PAM).  The PAM consists of a dinucleotide repeat 
(NGG – where N is any nucleotide) and acts as a recognition sequence for 
Cas9 (Bolotin et al., 2005).  Following infection, protospacers are incorporated 
into the CRISPR array in the bacterial genome - a cluster of repeats that lie 
downstream of the Cas genes.  Following incorporation of the protospacers into 
the CRISPR array, the CRISPR locus is transcribed, producing immature, 
precursor CRISPR RNAs (crRNAs).  These long RNAs are cleaved into their 
mature form that comprise a single protospacer sequence.  Following re-
infection of the bacterial cell, the crRNAs form a duplex with a small RNA 
unique to the type II system – the transactivating CRISPR RNA (tracrRNA) 
(Deltcheva et al., 2011).  The RNA duplex binds Cas9 and guides it to the 
invading DNA where the crRNA binds to its complementary sequence and 
Cas9 introduces a double stranded break.  The mechanism by which Cas9 
recognises the PAM and cleaves DNA is partially understood.  Cas9 has two 
nuclease domains – HNH and RuvC.  The HNH domain cleaves the DNA 
strand that is complementary to the crRNA sequence and the RuvC domain 
cleaves the opposite strand (Jinek et al., 2012; Gasiunas et al., 2012).  
Importantly, the recognition of the PAM sequence is critical to the ability of 
Cas9 to cleave.  It is postulated that PAM recognition triggers a conformational 
change in the Cas9-RNA complex into an active form, enabling the formation of 
an R-loop (Nishimasu et al., 2014)  
 
The CRISPR-Cas9 system provides a programmable, sequence specific 
genome editing tool.  For exploitation in mammalian cells, the system requires 
only the Cas9 nuclease, a short RNA sequence comprising the target 
sequence (which must lie upstream of a PAM) and a tracrRNA which can be 
fused to the sequence specific guide RNA (gRNA) (Jinek et al., 2012).  Unlike 
ZFNs and TALENs, the sequence specificity of the CRISPR-Cas9 system is 
conferred by a short RNA sequence and does not require protein engineering.  
Thus, the system is more rapidly programmable. 
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Figure 1.6 – CRISPR-Cas mechanism 
Invading bacteriophage DNA enters the cell (1) and is incorporated into the CRISPR array through association with Cas proteins (2).  
Following transcription of the CRISPR locus, a pre crRNA transcript is formed (3) which is cleaved by Cas genes into mature crRNAs 
(4).  Following reinfection, the crRNAs are able to associate with the Cas genes and guide a Cas nuclease to the invading DNA 
through base pair complementarity.  Here, the crRNA binds its complementary site and a Cas nuclease introduces a double-stranded 
break (5). 
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1.17 Thesis aims 
This thesis aims to investigate the molecular mechanisms of calcium 
dysregulation in malignant hyperthermia susceptibility.  This will be achieved 
through developing a novel CRISPR-Cas9 pipeline for the introduction MH-
associated RYR1 variants into a skeletal myoblast cell line, overcoming the 
existing limitations of variant characterisation.  Since a growing body of 
evidence suggests a role of CASQ1 in conferring MH susceptibility, this thesis 
also aims to develop systems for the characterisation of human CASQ1 
variants identified in patients referred to the Leeds MH unit, through the 
generation of a Casq1 knockout C2C12 cell line and characterisation of the 
Ca2+ binding and polymerisation capacities of three CASQ1 variant proteins 
using in-vitro biochemical assays.  This work will contribute to the 
understanding of the mechanisms underlying calcium dysregulation in MH and 
ultimately, provide a biologically relevant characterisation process of MH-
associated variants that broadens the availability of DNA diagnostics in MH. 
 
1.18 Thesis objectives 
1.18.1 Develop a novel characterisation process of RYR1 variants 
identified in MHS individuals 
The main objective of this thesis is to develop a novel characterisation pipeline 
for rare, missense RYR1 variants identified in MHS individuals.  Candidate 
variants will be selected from data generated through NGS of fifty genes 
associated with calcium handling, already performed by the Leeds MH unit.  
CRISPR-Cas9 genome editing will be used to engineer candidate variants into 
immortalised human myoblasts and C2C12 mouse myoblasts.  The functional 
effects of these variants on Ca2+ release from the SR will be investigated by 
fluorescence Ca2+ imaging upon stimulation of Ca2+ release by caffeine.  
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1.18.2 Investigate the functional and biochemical effects of CASQ1 
variants identified in MHS individuals 
CRISPR-Cas9 genome editing will be used to knockout out of expression of the 
endogenous Casq1 gene in C2C12 mouse myoblasts and the consequence of 
Casq1 ablation determined by Ca2+ imaging.  This cell line will provide a vehicle 
for the re-introduction of human CASQ1 cDNAs encoding variants of interest in 
the future, for the determination of the functional effect of the variants on Ca2+ 
release.  In addition, wild-type human CASQ1 and cDNAs encoding three pre-
selected CASQ1 variants will be cloned into expression vectors, for 
heterologous protein expression and purification in Escherichia coli (E. coli).  
The effect of the variants on CASQ1 polymerisation and Ca2+ binding will be 
investigated using a range of biochemical and biophysical techniques. 
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Chapter 2 - Materials and Methods 
2.1 General cell culture methods 
2.1.1 Immortalised human myoblast culture 
Immortalised human myoblasts (Mouley group, Institut de Myologie, Paris) 
were cultured in growth medium consisting of Hams-F10 (Gibco®) 
supplemented with 20% (v/v) heat inactivated fetal bovine serum (FBS; 
Gibco®),1X penicillin/streptomycin (50 units/ml penicillin, 50 μg/ml 
streptomycin), and human fibroblast growth factor (hFGF) to a final 
concentration of 2.5 ng/ml.  The human immortalised myoblasts were, for some 
experiments, cultured in PromoCell Skeletal Muscle Growth Medium 
supplemented with 25% (v/v) fetal calf serum, 50 μg/ml bovine fetuin, 10 ng/ml 
human epidermal growth factor (hEGF), 1 ng/ml hFGF, 10 μg/ml insulin and 0.4 
μg/ml dexamethasone (PromoCell).  Where each growth media was used is 
clearly indicated in section 3.2.  Tissue culture flasks were coated in entactin-
laminin-collagen (ECL) cell attachment matrix (Merck Millipore).  A 20 μg/ml 
stock solution of ECL was made in serum-free Hams-F10 media) and added to 
culture vessels to a final concentration of 5 μg per cm2 by incubation at 37oC 
for 1 hour prior to plating.  Cells were incubated at 37oC with 5% CO2.   
 
2.1.2 C2C12 mouse myoblast culture 
C2C12 mouse myoblasts were cultured in growth medium consisting of DMEM 
GlutaMAXTM high glucose, high pyruvate media (Gibco®) supplemented with 
10% (v/v) heat inactivated FBS (Gibco®) and 1X penicillin/streptomycin.  Cells 
were incubated at 37oC with 5% CO2.  
 
2.1.3 HEK293 FT culture 
HEK293 FT cells were cultured in growth medium consisting of DMEM 
GlutaMAXTM high glucose, high pyruvate media (Gibco®) supplemented with 
10% (v/v) FBS, 1X penicillin/streptomycin and 500 μg/ml GeneticinTM for 
maintenance of cells transformed with the SV40 enhancer.  Cells were 
incubated at 37oC with 5% CO2.      
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2.1.4 Cell passage 
To passage, media was aspirated and 4ml 0.25% trypsin-EDTA (Gibco®) 
added to the cells in a T-75 flask prior to incubation at 37oC for ~4 min (trypsin 
volumes were appropriately scaled for different culture vessels).  The detached 
cells were added to 20ml phosphate buffered saline (PBS; Gibco®), 
centrifuged at 400 x g for 6 min and the cell pellet resuspended in warm growth 
media. 
 
2.1.5 Cryostorage of cell lines 
Cells were pelleted as described in 2.1.4 and resuspended in 900 μl growth 
media.  The cells were transferred to a 2 ml cryovial containing 100 μl dimethyl 
sulfoxide (DMSO) and mixed by inversion.  The cells were cooled slowly by 
transfer to a freezing container and placed in the -80oC freezer.  After at least 
24 hours in the -80oC freezer, cells were transferred to liquid nitrogen storage 
at ~ -200oC. 
 
2.1.6 Myoblast differentiation 
Aliquots of Extracellular Matrix (ECM) Gel from Engelbreth-Holm-Swarm 
murine sarcoma (Sigma) were thawed on ice overnight and diluted 1:1 in 
serum-free DMEM.  Black, clear bottom 96-well plates (Greiner) and pipette 
tips were pre-chilled at -20oC and 30 μl of the diluted gel added to the desired 
wells in a chilled 96-well plate.  The plate was placed on a rocking device for 30 
min at room temperature to ensure an even layer of the gel was dispersed on 
the well surface.  The plate was then incubated at 37oC, 5% CO2 for 1 hour.  
Myoblasts were plated on ECM gel-coated wells at 2 x 104 cells per well of a 
black, clear bottom 96-well plate (Greiner) in growth media.  The following day, 
when cells had reached ~90% confluency, growth media was aspirated and 
replaced with 200 μl differentiation media.  Differentiation media consisted of 
DMEM GlutaMAXTM high glucose, high pyruvate media (Gibco®)  
supplemented with 2% (v/v) horse serum (Sigma), 1 μM insulin (Sigma) and 1X 
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penicillin/streptomycin, was added to myoblasts and changed every other day 
for 5-6 days.   
 
2.1.7 Cell counting and cell viability analysis 
Cells were detached, pelleted and resuspended, as described previously, in 
1ml media.  Ten μl of trypan blue (Gibco®) was added to 10 μl cells and 10 μl 
of the mixture loaded onto a haemocytometer for counting.  
 
2.1.8 Fluorescence activated cell sorting 
Transfected cells were detached, pelleted and resuspended at ~1.5 x 106/ml in 
growth media, as described previously.  Resuspended cells were filtered 
through a 70 μm cell strainer and transferred to FBS-coated 5 ml polypropylene 
fluorescent activated cell sorting (FACS) tubes.  To prevent cell aggregation, 
FACS tubes were and kept on ice prior to cell sorting.  FACS was performed 
using the BD InfluxTM Cell Sorter (BD Biosciences) and was provided as a 
service by Dr Adam Davison and Mrs Liz Straszynski at Leeds Institute of 
Medical Research at St James’ Hospital (Leeds, UK).  Gates were drawn to 
exclude non-viable cells from the sort.  For all cell sorts, a non-transfected 
control population of cells was provided to enable the determination gating 
boundaries for the OFP/GFP-expressing cells.  OFP-expressing cells were 
detected using the 561 nm laser and 585/30 bandpass filter.  GFP-expressing 
cells were detected using the 488 nm laser and 530/40 bandpass filter. Cells 
were collected in 1 ml growth media or a 1:1 ratio of conditioned media to 
growth media to a final volume of 200 μl for cell sorting into an ECL-coated 96 
well plate.   
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2.2 General DNA methods 
2.2.1 DNA extraction from mammalian cells 
Cell pellets were resuspended in lysis buffer (25 mM 
ethylenediaminetetraacetic acid (EDTA) and 2% (w/v) sodium dodecyl sulfate 
(SDS)) at 1ml per 1 x 106 cells and agitated by pipetting up and down.  One 
third volume of 10 M ammonium acetate was added and the sample mixed by 
inversion.  The samples were centrifuged at 3200 x g for 15 min and the 
supernatant transferred to a clean Falcon tube.  For large samples (>1 ml), 1 
volume of 100% isopropanol was added.  For smaller samples, 2.5 volumes of 
cold 100% ethanol was added.  For isopropanol precipitation, the sample was 
mixed by inversion until DNA was visible.  For ethanol precipitation, the sample 
was incubated overnight at -20oC.  Precipitated DNA was pelleted by 
centrifugation at 3200 x g for 15 min.  The supernatant was discarded and the 
cell pellet washed in 70% (v/v) ethanol for a total of 2 washes.  The pellet was 
left to air dry for 10 min at room temperature before being resuspended in 
nuclease-free water (Ambion) and quantified using the NanoDropTM 1000 
spectrophotometer (ThermoFisher). 
 
Where contaminants were present, indicated by 260/230 and 260/280 ratios,  
samples were further purified by adding an equal volume of 
phenol:chloroform:isoamyl alcohol (24:25:1) and mixing thoroughly to form an 
emulsion.  The sample was separated by centrifugation at 13,200 x g for 5 min.  
The aqueous layer was transferred to a clean tube and an equal volume of 
chloroform added.  The sample was mixed and centrifuged at 13,200 x g for 5 
min.  The aqueous layer was transferred to a new tube and 0.1 volumes of 3 M 
sodium acetate (pH 5.2) was added.  DNA was precipitated and resuspended 
as described previously.  
 
2.2.2 PCR 
Primers for PCR were designed using Primer Blast (Ye et al., 2012) and 
commercially synthesised by Integrated DNA Technologies (IDT).  Lyophilised 
primers were resuspended to 10 μM in nuclease-free water.  Where PCR 
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products were used in Gibson cloning applications, the Q5® hot start high-
fidelity polymerase (NEB) was used in a 50 μl reaction comprising 1X Q5® 
reaction buffer (NEB), 0.2 mM dNTPs, 0.2 μM forward primer, 0.2 μM reverse 
primer, 10-200 ng template DNA, 1 unit Q5® hot start high fidelity DNA 
polymerase and nuclease-free water to 50 μl.  For all other PCR applications, 
DreamTaq polymerase (ThermoFisher) was used in a 50 μl reaction.  The 
composition of the reaction was the same as described previously, but with 
1.25 units DreamTaq polymerase.  For difficult to amplify PCR reactions, 
DMSO was added to a final concentration of 5%. 
 
To visualise PCR products, 2 μl 6X purple gel loading dye (NEB; 1X 
components: 2.5% (w/v) Ficoll®-400, 10 mM EDTA, 3.3 mM Tris-HCl, 0.08% 
(w/v) SDS, 0.02% (w/v) Dye 1 and 0.0008% (w/v) Dye 2) was added to 10 μl 
PCR product.  10 μl sample was loaded onto a 1% (w/v) agarose gel made with 
1X Tris-acetate-EDTA (TAE) buffer (40 mM Tris, 20 mM acetic acid and 1 mM 
EDTA) containing 0.5 μg/ml ethidium bromide.  PCR products were separated 
by gel electrophoresis at 120 V for 40 min.  Gels were visualised using 
ultraviolet (UV) light in the UGenius gel imaging system (Syngene).   
 
2.2.3 Direct PCR 
2.2.3.1 Mammalian cells 
Cells were trypsinised and 10 μl of the detached cells transferred to a PCR 
tube containing 15 μl nuclease-free water.  Cells were centrifuged at 4000 x g 
for 6 min, the supernatant discarded and the cells resuspended in 200 μl 
nuclease-free water.  Cells were heated at 99oC for 10 min before adding 
proteinase K to a final concentration of 200 μg/ml and the reaction incubated at 
56oC for 30 min.  Proteinase K was inactivated by incubation at 96oC for 10 min 
and the reaction cooled on ice for 5 min.  2.5 μl of the cell lysate was added to 
a 50 μl PCR. 
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2.2.3.2 Bacterial colonies 
A PCR was set up as described in 2.2.2.  A sterile pipette tip was used to pick a 
single bacterial colony on an agar plate and the pipette tip swirled into the PCR 
mixture. 
 
2.2.4 PCR product purification 
Where necessary, PCR products were purified using AMPureXP beads 
(Beckman Coulter) according to manufacturer’s instructions.  PCR products 
were pooled and 1.8 volumes of room-temperature beads added and mixed by 
pipetting up and down 10 times.  The mixture was incubated at room 
temperature for 10 min to allow for binding of DNA to the beads before transfer 
to a magnetic rack for 5 min to separate the beads from solution.  The 
supernatant was removed and the DNA-bound beads washed with 800 μl 70% 
(v/v) ethanol for a total of two washes.  The DNA-bound beads were allowed to 
air dry at room temperature for 10 min before being removed from the magnetic 
rack and resuspended in 40 μl nuclease-free water.  The reaction was 
transferred to a magnetic stand for 5 min to separate the beads from the 
solution and the solution carefully transferred to a new tube.       
   
2.2.5 Restriction digest 
 
Restriction digest reactions comprised 0.5-1 μg plasmid DNA, 1 μl of each 
restriction enzyme and the corresponding buffer to a final concentration of 1X 
and made up to 20 μl with nuclease-free water.  FastDigest enzymes 
(ThermoFisher) and High-Fidelity HF® enzymes (NEB) were incubated at 37oC 
for 10 min and inactivated at 80oC for 20 min (unless manufacturer 
recommended alternative temperatures).  Ten μl of the sample was loaded 
onto a 1% (w/v) agarose gel made with 1X TAE buffer containing 0.5 μg/ml 
ethidium bromide.  The gel was electrophoresed at 120 V for 40 min to 1 hour 
and the products visualised using the UV UGenius gel imaging system 
(Syngene).   
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2.2.6 Sanger sequencing 
Where Sanger sequencing was performed at the Leeds Institute of Medical 
Research at St James’ University Hospital, unincorporated dNTPs and primers 
were removed by incubating 2 μl IllustraTM ExoProStarTM (GE Healthcare) with 
5 μl PCR product for 30 min at 37oC and then for 15 min at 80oC for 
deactivation.  Cycle sequencing was performed using 1 μl BigDyeTM Terminator 
(Applied Biosystems) , 1 μl half BDTM reagent (Merck Millipore), 1 μl of primer 
to a final concentration of 3.2 μM, 2 μl sample and was made up to 10 μl with 
nuclease-free water.  The DNA template was denatured at 96oC for 5 min prior 
to 30 cycles of 96oC for 30 seconds, 68oC for 20 seconds and 60oC for 4 min. 
The resultant products were precipitated in ethanol as described previously and 
air-dried at room temperature for 20 min.  The air-dried pellets were stored at -
20oC.   At least one hour prior to Sanger sequencing, pellets were resuspended 
in 10 μl Hi-Di Formamide (Applied Biosystems).  Sanger sequencing was 
provided as a service at Leeds Institute of Medical Research at St James’ 
University Hospital (Leeds, UK) using the ABI3130xl Genetic Analyser (Applied 
Biosystems).  Where sequencing was outsourced, un-purified PCR products 
and 3.2 μM primers were sent by post to SourceBioscience (Cambridge, UK) 
for clean-up and Sanger sequencing.  Sanger sequencing reads were analysed 
using 4Peaks software (Nucleobytes). 
2.3 General bacterial methods 
 
2.3.1 Transformation 
Escherichia.coli  (E. coli) cells were thawed on ice for 15 min prior to 
transformation.  Two μl of the DNA product was added to 50 μl of cells and 
mixed gently by flicking the bottom of the tube.  The tube was incubated on ice 
for 30 min.  The cells were heat shocked at 42oC for 45 seconds using a 
heated block or water bath and incubated on ice for 2 min.  Five-hundred μl 
Super Optimal broth with Catabolic repressor (SOC) medium (InvitrogenTM; 2% 
tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM 
MgSO4, and 20 mM glucose) was added to the cells and the mixture incubated 
at 37oC with shaking at 200 rpm for 1 hour.  Depending on the expected 
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transformation efficiency, between 100 μl and 500 μl of the transformation 
reaction was plated on a Lysogeny Broth (LB) agar (Invitrogen; 1% (w/v) 
SELECT peptone 140, 0.5.% (w/v) SELECT yeast extract, 0.5% (w/v) NaCl, 
1.2% (w/v) SELECT agar) plate containing ampicillin at 100 μg/ml. 
 
For XL10-gold® ultracompetent cells, (Agilent) cells were thawed on ice for 20-
30 min.  Four μl beta-mercaptoethanol was added to 100 μl cells and the 
mixture incubated on ice for 10 min, swirling periodically.  The cells were heat 
shocked at 42oC for 30 seconds using a heated block and incubated on ice for 
2 min.  Five-hundred μl SOC medium was added to the cells and the mixture 
incubated at 37oC with shaking at 200 rpm for 1 hour.  The entire 
transformation reaction was plated onto an LB agar plate containing ampicillin 
at 100 μg/ml, 40 μl 100 mM IPTG and 120 μl 20 mg/ml X-gal spread onto the 
surface of the plate. 
 
2.3.2 Bacterial culture for plasmid prep 
Following transformation, single colonies were picked from LB agar plates 
using a pipette tip and the tip transferred to 5 ml LB media (1% (w/v) SELECT 
peptone 140, 0.5% (w/v) SELECT yeast extract, 0.5% (w/v) NaCl) containing 
the appropriate antibiotic(s) concentration in Falcon tubes.  Overnight cultures 
or starter cultures for utilisation in downstream maxi-preps were grown at 37oC 
with shaking at 200 rpm. 
 
2.3.3 Plasmid mini prep 
5ml overnight cultures were pelleted by centrifugation at 4000 x g for 10 min at 
4oC.  Plasmid isolation was performed using the QIAGEN QIAprep® spin 
miniprep kit according to manufacturer’s instructions.   The pellet was 
resuspended in 250 μl Buffer P1 (50 mM Tris-HCl pH 8.0, 10 mM EDTA, 100 
μg/ml RNaseA) by vortexing and transferred to a microcentrifuge tube.  Cells 
were lysed by the addition of 250 μl Buffer P2 (200 mM NaOH, 1% SDS) and 
the tube inverted multiple times to mix.  The lysis solution was neutralised by 
adding 350 μl Buffer N3 (4.2 M Gu-HCl, 0.9 M potassium acetate pH 4.8) and 
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mixed immediately by inversion.  The solution was centrifuged at maximum 
speed in a table-top centrifuge for 10 min.  The resultant supernatant was 
applied to a QIAprep 2.0 spin column, centrifuged for 60 seconds and the flow-
through discarded.  Any trace nuclease activity was removed by the addition of 
500 μl Buffer PB (5 M Guanidine-HCl, 30% v/v isopropanol) to the spin column 
and centrifugation at maximum speed for 60 seconds.  The flow-through was 
discarded and 750 μl Buffer PE (10 mM Tris-HCl pH 7.5, 80% v/v ethanol)  was 
applied to the spin column to remove contaminants.  The flow through was 
discarded and the spin column centrifuged for 60 seconds to remove any 
residual Buffer PE.  Finally, spin columns were placed into clean 
microcentrifuge tubes and 50 μl nuclease-free water was added to the spin 
column.  The spin column was left to stand at room temperature for 5 min prior 
to centrifugation for 1 min to elute the plasmid DNA.  Plasmid DNA was 
quantified using the NanoDropTM 1000 spectrophotometer. 
 
2.3.4 Plasmid maxi prep 
Maxi prep cultures were generated by using 200 μl of starter culture to 
inoculate 200 ml of LB media containing 100 μg/ml ampicillin.  The culture was 
incubated overnight at 37oC with shaking at 200 rpm.   Plasmid isolation was 
performed using the QIAGEN-Tip 500 plasmid maxi kit or QIAGEN HiSpeed 
plasmid maxi kit according to manufacturer’s instructions.  Plasmid DNA was 
resuspended in TE buffer (QIAGEN; 10 mM Tris·Cl, pH 8.01 mM EDTA) and 
quantified using the NanoDropTM 1000 spectrophotometer. 
 
2.3.5 Establishment of glycerol stocks 
Glycerol stocks were established for long term storage of plasmids.  500 μl 
overnight culture was added to 500 μl 50% (v/v) glycerol and vortexed briefly to 
mix.  The stocks were stored at -80oC. 
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2.4 In-silico pathogenicity prediction methods 
2.4.1 Pathogenicity prediction tools 
Three tools were used to predict pathogenicity of the selected MH-associated 
VUS.  Sorting Intolerant From Tolerant (SIFT) predicts whether a missense 
variant will affect protein function based on the conservation of the residue or 
the conservation of the class of amino acid at that position, that is, its charge 
state and polarity (Ng and Henikoff, 2003; Sim et al., 2012).  SIFT scores were 
generated using SIFT 4G (2018) available at https://sift.bii.a-star.edu.sg/sift4g/.  
Polymorphism Phenotyping 2 (PolyPhen-2) predicts whether a missense 
variant is likely to be damaging based on its predicted effect on protein 
structure and function (Adzhubei et al., 2010).  PolyPhen2 scores were 
generated using PolyPhen-2 v2 (2018) available at 
http://genetics.bwh.harvard.edu/pph2/.  The combined annotation dependent 
depletion tool (CADD) combines 63 in-silico pathogenicity prediction 
annotations to compute a CADD score (C score) (Kircher et al., 2014).  C 
scores were generated using CADD v1.4 (2018) available at 
https://cadd.gs.washington.edu/score. 
 
2.4.2 Conservation analysis 
The entire human RYR1 amino acid sequence (P21817.3) and human CASQ1 
amino acid sequence (NP_001222.3) were entered into The ConSurf Server 
(Ashkenazy et al., 2016; Celniker et al., 2013; Asheknazy et al., 2010; Berezin 
et al., 2004) available at http://consurf.tau.ac.il.  CSI-BLAST (Angermuller et al., 
2012) was used to search for homologues in the UniRef90 database (Suzek et 
al., 2015) and MAFFT L-INS-i version 7.392 (Katoh et al., 2002; Katoh and 
Standley, 2013) was used to create a multiple sequence alignment using the 
Bayesian calculation method.  To limit the analysis to RYR1 homologues and 
CASQ1 homologues (excluding other RYR/CASQ isoforms), ConSurf was 
programmed to search only for sequences with >70% homology to the human 
RYR1 sequence and >50% homology to the human CASQ1 sequence.  
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2.4.3 PyMOL mutagenesis 
The rabbit RYR1 (PDB ID: 3J8H; Yan et al., 2015) human CASQ1 (PDB ID: 
5CRD; Lewis et al., 2015) protein structures were opened in PyMOL Molecular 
Graphics System version 2.0 (Schrödinger, LLC).  Sequences were displayed 
and the residue of interest was selected.  From the action panel, polar contacts 
to any atom excluding the solvent were found and displayed.  From the wizard 
panel, mutagenesis was selected and the desired residue substitution 
introduced.  Polar contacts to any atom excluding the solvent were re-selected 
with the substituted residue. 
2.5 CRISPR-Cas9 methods 
Unique sequences designed for gRNAs and HDR templates are reported as 
results in sections 3.2.4, 4.2.4 and 5.2.2.  As such, specific oligonucleotide 
sequences of gRNAs (with and without appended overhangs for pSpCas9(BB)-
2A-GFP and pGCS cloning), gRNA specific primers for in-vitro gRNA synthesis, 
and HDR templates are detailed there. 
 
2.5.1 gRNA design and off-target prediction 
2.5.1.1 RYR1/Ryr1 gRNA design for human immortalised myoblasts and 
C2C12 myoblasts 
A 100 bp sequence flanking the base to be edited (human RYR1 reference 
sequence: NG_008866.1; mouse Ryr1 reference sequence: NC_000073.6; 
was entered into CRISPR/Cas9 Target Online Predictor  (CCTOP; Stemmer et 
al., 2015) available at https://crispr.cos.uni-heidelberg.de/.  CCTOP was 
programmed to search for gRNAs in the GRCh38 and GRCm38/mm10 
genomes using the Streptococcus pyogenes (S. pyogenes) PAM of NGG 
(where N is any nucleotide), that were 20 nt in length and unique sequences in 
the genome.  CCTOP ranks gRNAs based on the number and location (i.e. 
whether they are located in introns, exons or intergenic regions) of predicted 
off-target sites.  The top three ranked gRNA sequences that had Cas9 cut sites 
within 30 bp of the base to be edited were selected for testing of gene-editing in 
the appropriate cell line.  Within CCTOP, an efficacy prediction was made by 
CRISPRater (Labuhn et al., 2017) based on the analysis of molecular features 
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associated with highly active gRNAs such as PAM-distal GC content.  The 
gRNAs with efficacy values <0.56 are deemed low efficacy, gRNAs with 
efficacy values ≥0.56 but ≤0.74 are deemed medium efficacy and gRNAs with 
efficacy values >0.74 are deemed high efficacy 
 
The same 100 bp sequence was entered into CRISPOR (Haeussler et al., 
2016) available at  http://crispor.tefor.net/ to confirm the off-target predictions 
made by CCTOP and identify any others.  CRISPOR was programmed to 
search for gRNAs and associated off-targets using the same parameters as 
CCTOP (20 bp gRNA and the NGG PAM).  Following gRNA selection, the top 
10 predicted off-target sites from each tool were selected for primer design 
(Table 2.1) and subsequent Sanger sequencing in the resultant cell lines. 
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Table 2.1 – Primers used to sequence Ryr1 p.D3986E and p.S1728F off-
target sites 
Where multiple primer sets were tested, the underlined primer sequences show 
the primer set that generated successful PCR amplification and Sanger 
sequencing reads. 
Variant and off 
target site 
Forward primer 5’-3’ Reverse primer 5’-3’ 
p.D3986E; 
Ptpn14 
CCCTAATGTCACACTCCGCT GCGTGACAATCACGATCCCT 
p.D3986E; Bcat1 TGTGCAACCATGAGAGCCTG AGCACACACTTGCTGACCTT 
p.D3986E; 
RP23-267G12.1 
TTTGCAGGGTAGCTGGTCAA AGCTGTGGTCAGGCAAATCT 
p.D3986E; 
Med23 
TGCTTTTTGAGATGGGTCTTGC AAAGACGGGGTGACTCACAC 
p.D3986E; Nrros ATAGGCAAGGTTGAGACGCC CCTGTGGAACCATTCCCTCC 
p.D3986E; 
Gm4889-Dusp4 
TTTTCAGGGCTGATTGGCAC ACTGCTTACTCCCACTTGCC 
p.D3986E; 
Gm23796-
Gm23831 
TGTGGAGGTGAGTCTCTGCT CACCCAAGTCCAGACTGAGC 
p.D3986E; 
Zmiz1 
TCCCCTTGTTAGGAGGCAGA ACAGACACACGGAGAACGAC 
p.D3986E; 
Pabpc6-Qk 
GCCATCCTACCAGAACCCTG AGAGGAAGCAGCAGTTTGCT 
p.D3986E; Optn AGTCCATCTCAGGGACGACA TCCAGATTCTTTGCCGTGGT 
p.D3986E; 
Gm3898 
1 TGGCAGAACGATTGAGCAGA 
2 GACCACGTGTATGGCTCCAA 
3 GCTGTTGTATCTTCGGCTGC 
1 GGGATCTTGTGTGGAACCCA 
2 TCTGTAACCACACCTGGGGA 
3 TGGGTAGCAGGTGCTCAGTA 
p.D3986E; 
Rreb1 
1 ATCCTTCCAACGGTCAAGGC 
2 GGACCAGAGCCTCAGACTTC 
1 CAAGGACCTGATGGGCTACC 
2 CTGATGGGCTACCCTCTGTG 
p.D3986E; Nkx6 1 GTAGACACCTGCAGACGAGG 
2 GCCCGAAGTAGACACCTGC 
1 GTCCTCTCGCTTTCCCGTAG 
2 CTGCCTTCTCTCTGACCGC 
p.D3986E; 
6030407O03Rik 
1 AGAGCCTCTGCAAATTCCGA 
2 AGAAGCCACACCGCTGTTAT 
1 GGCTCTGTAAGAGGGAAGCC 
2 GGTCCTGTGAAGACACCTGG 
p.D3986E; 
Smtnl2-Ggt6 
1 TGGTTGCACAGATGAACACT 
2 CCACCTGGAGGCAAAGTAGG 
3 GCACCTCTAAAATCTGTCAGGGA 
4 GTGAAGAACGTTGCCTGATTGA 
1 CTGGAGGGGGAAGGAACAAC 
2 TGAGTAGGCAGCAGGTAATGG 
3 GAGGGGGAAGGAACAACGAA 
4 GGAAGGAACAACGAAGCCC 
p.S1728F; Zhx2 ACATCAGTGTGACGGGCATT TGGAAGCAAGGATGAACGCT 
p.S1728F; 
Rpgrip1l 
AAAAGGCAGAGTGGGCACAT GGGCAAGGAAGAGTGTGGTT 
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p.S1728F; 
Cenph 
GCAAAGGCCATTGGACACAG TAGCAAAGCAACTCGGCTCA 
p.S1728F; Ptprs 1 CCTGTTGTCCCTGTGGTCC 
2 CTGTTGTCCCTGTGGTCCG 
1 CGCCATCATCAAGTACACGG 
2 CTTCCCGCAGATCTTGGGC 
p.S1728F; 
2310022B05Rik 
CAGGGTCACTGCATTCCACT CTTCCTACCGCTGAGAGCAG 
p.S1728F; Adcy1 AGCCTGGACAGACCCTACAT GCAGACTGAGGCTCAAGGAG 
p.S1728F; 
Dusp26 
GGAGTGAGCAGATCCGCTAC GGTCTTGGGGCTCTTCACTC 
p.S1728F; 
Gm5464 
CAATGGAGGGGTGATCGTCC TAGATCTGCAAGCGCCACAA 
p.S1728F; 
A930001A20Rik-
Gm9733 
GAGCTCTTTGACCTGACCCC AAGCCTCACAACATGCAGGT 
p.S1728F; 
Tnfrsf25 
GGACATAGCCCCTCAGCTTC TAGGTCGCCGGTGAAGACTA 
p.S1728F; 
Gm12604-Mllt3 
ATTAGCTCTTCCACGTGGGC CCCAAAGCAATGCCTCTGAC 
p.S1728F; 
Gm23892-
Gm25382 
GAGGTTGGAAGGGGAAAGCA AGGCTGGCAGTTCAAAGTCC 
p.S1728F; Aqp9-
Aldh1a2 
GCCCACAAGATTCCCCCTTT GACCTTTTGCCCTGCTTGTG 
p.S1728F; 
Gm25665-
Gm24469 
CCCTTAGCCACATGATTGCC CCTCACCTCACTGTGTCACC 
p.S1728F; 
Hmcn2 
GAGATGGGCACCGTGAAGAA GCTCTGAGCTGTGTCTCCAG 
p.S1728F; 
Scara5 
 
CACCTCTTCCACAGTGTCCC GGAGTCACTCTGCTGTCCTG 
2.5.1.2 Casq1 knockout in mouse C2C12 myoblasts 
The Casq1 knock out gRNA sequences were designed as described for the 
RYR1/Ryr1 gRNAs; however, a 450 bp sequence beginning at base 1 of exon 
1 in the mouse Casq1 coding sequence (NM_009813.2) was entered into 
CCTOP and CRISPOR for gRNA design and off-target prediction.  Two of the 
top gRNA sequences were selected for testing in C2C12 myoblasts.  Following 
gRNA selection, all of the off-target sites were selected for primer design (Table 
2.2) and Sanger sequencing in the resultant cell lines. 
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Table 2.2 – Primers used to sequence Casq1 off-target sites 
Where multiple primer sets were tested, the underlined primer sequences show 
the primer set that generated successful PCR amplification and Sanger 
sequencing reads. 
Off-target site Forward primer 5’-3’ Reverse primer 5’-3’ 
Gm24444 CCCCCGATGGAAGAAAAGCA GATAGAGGCAGAGGCAGCAA 
Dpep AAGGGGTCCCGGAGTGC GATTCCAGGCAGTAGGTCCC 
Col15A CACTGGATGGATGCCTTGGT GAGCCTTATGTAACCCGCGA 
Serpin TGATTCCCCCTCTCCCCTTT AACCTCATATGTACTACAAAGTCCT 
pGap TGTCCCTGCTGGAATTGCTT 
AATCTCTCCTGTTCCTGCCC 
TGGAGAGATGAGCCCACTGA 
CCAGCCTCTTTAGTCCAGCT 
Gypc GAGGCATCAAGAGTTTTCGAA 
 
CCTAGTGCCACTGTTATAGCCT 
 
 
The gRNA sequences for human RYR1-targetting gRNAs are detailed in 3.2.4, 
the gRNA sequences for mouse Ryr1-targetting gRNAs are detailed in 4.2.4, 
the gRNA sequences for mouse Casq1-targetting gRNAs are detailed in 5.2.2. 
 
2.5.2 HDR repair template design for RYR1/Ryr1 variant 
introduction 
HDR repair templates were designed manually from genomic DNA reference 
sequences (NG_008866.1; NC_000073.6).  The HDR arms were designed as 
160 nt single stranded oligonucleotides (ssODNs), with 80 nt of 
complementarity to the sequences flanking the cut site.  Silent mutations were 
introduced within either the PAM or seed region of the gRNA to prevent re-
cleavage following incorporation of the HDR template.  The ssODNs were 
commercially synthesised by Integrated DNA Technologies (IDT).  HDR 
template sequences are detailed in 3.2.5 and 4.2.5. 
 
2.5.3 Cloning of gRNAs into pSpCas9(BB)-2A-GFP  
Cloning of gRNAs into the pSpCas9(BB)-2A-GFP vector (Figure 2.1) was 
performed as described in Ran et al., 2013a.  The pSpCas9(BB)-2A-GFP 
vector was a gift from Feng Zhang  (Addgene #48138).  The desired gRNA 
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sequences were synthesised as single stranded HPLC purified 
oligonucleotidies by IDT.   
Overhangs complementary to the resulting overhangs following digestion of 
pSpCas9(BB)-2A-GP with FastDigestTM BbsI (ThermoFisher) were added to 
the 5’ of the forward and reverse gRNA sequences (Figure 2.2).  The appended 
sequences on the forward and reverse gRNA sequences were 5’-CACC-3’ and 
5’-ACCC-3’, respectively.  The forward and reverse single stranded DNA 
oligonucleotides comprising the gRNA sequences were resuspended in 
nuclease-free water (Ambion) to a final concentration of 100 μM.  The forward 
and reverse oligonucleotides were phosphorylated and annealed in a reaction 
comprising each oligonucleotide at a final concentration of 10 μM, 1X T4 
ligation buffer (NEB), 10 units of T4 polynucleotide kinase (NEB) and nuclease-
free water to a final volume of 10 μl.  In a thermocycler, the reaction was 
incubated at 37oC for 30 min, 95oC for 5 min and ramped down to 25oC at a 
rate of 5oC per min.  The phosphorylated and annealed oligonucleotides were 
diluted 1:200 and added to a simultaneous digestion-ligation reaction consisting 
of 100 ng of pSpCas9(BB)-2A-GFP, 2 μl diluted oligonucleotides, 1X tango 
buffer (ThermoFisher; 33 mM Tris-acetate pH 7.9, 10 mM magnesium acetate, 
66 mM potassium acetate, 0.1 mg/ml bovine serum albumin (BSA), 
dithiothreitol (DTT) to a final concentration of 0.5 mM, ATP to a final 
concentration of 0.5 mM, 1 μl FastDigest BbsI (ThermoFisher), 1500 units of T7 
DNA ligase (NEB) and nuclease-free water to a final volume of 20 μl.  The 
reaction was incubated at 37oC for 5 min followed by 21oC for 5 min for a total 
of 6 cycles. 
 
The reaction was incubated with PlasmidSafe ATP-dependent DNase 
(Epicentre) to remove remaining linear DNA.  Two μl of the product was 
transformed into OneShot® chemically competent Stbl3TM cells (InvitrogenTM), 
as described in 2.3.1.  Four colonies per vector were picked and plasmid was 
isolated by mini prep as described in 2.3.3. 
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Figure 2.1 – Vector map of pSpCas9(BB)-2A-GFP 
The pSpCas9(BB)-2A-GFP vector was purchased from Addgene (Addgene 
code PX458) where it had been deposited by Feng Zhang.  Following the pUC 
origin of replication, the vector encodes the human U6 promoter for 
transcription of the tracrRNA-gRNA fusion.  The Cas9 gene, flanked by two 
nuclear localisation signals (NLS), a 5’ 3x FLAG peptide and a 3’ T2A self 
cleaving peptide sequence, is transcribed by the hybrid chicken β-
actin promoter (CBh).  Downstream of the T2A cleavage site is the GFP coding 
sequence, the bovine growth hormone (bGH) poly A signal for transcript 
stability and an inverted terminal repeat which is required for packaging if 
generating adeno-associated virus (AAV).  Vector maps were taken from 
Addgene (www.addgene.org/48138; accessed August 2019) and modified in 
SnapGene®. 
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Figure 2.2 – Cloning into pSpCas9(BB)-2A-GFP 
In pSpCas9(BB)-2A-GFP (Panel A), there are two BbsI sites within close proximity.  Digestion with BbsI in these vectors leads to the 
excision of a small fragment of DNA and yields a bottom strand overhang of 3’ GTGG 5’ and a top strand overhang of 5’ GTTT 3 
(Panel B)’.  Appendage of 5’ CACC 3’ to the 5’ top strand gRNA and 5’ AAAC 3’ to the 5’ of the bottom strand gRNA facilitates cloning 
into both vectors (Panel C).  Adapted from www.addgene.org/crispr/zhang; accessed August 2019. 
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2.5.4 Cloning of gRNAs into pGCS 
The GeneArtTM genomic cleavage selection kit (InvitrogenTM) was used to 
select for cells that had successfully been transfected with Cas9 nuclease and 
in-vitro transcribed gRNAs.  Oligonucleotides were designed that contained the 
gRNA sequence and the PAM sequence.  To the top strand oligonucleotide, a 
5’ AATT overhang was appended and to the bottom strand oligo, a 5’ CTAG 
overhand was appended.  These overhangs are complementary to the 
overhang sequence on the linearised pGCS vector (Figure 2.3).  
Oligonucleotide sequences were synthesised by IDT and are detailed in 3.2.4. 
 
The oligonucleotides were annealed and ligated into pGCS according to 
manufacturer’s instructions.  To anneal the oligonucleotides, each 
oligonucleotide to a final concentration of 5 μM, 1X ligation buffer 
(ThermoFisher; 50 mM Tris-Hcl, pH 7.6, 10 mM MgCl2, 1 mM ATP, 1 mM DTT 
and 5% w/v polyethylene glycol (PEG) and nuclease-free water to 20 μl were 
added to a PCR tube and heated at 95oC for 5 min.  The reaction was ramped 
down from 95oC to 85oC at a rate of -2oC/second and then from 85oC to 25oC 
at a rate of -0.1oC per second to anneal the forward and reverse 
oligonucleotides.  The double-stranded oligonucleotides were diluted to 50 nM 
in nuclease-free water.  A ligation reaction was performed by mixing 1X ligation 
buffer (ThermoFisher), 30 ng linearised pGCS, double stranded 
oligonucleotides to a final concentration of 5 nM, 1 unit T4 DNA ligase 
(ThermoFisher) and nuclease-free water to 20 μl.  The reaction was incubated 
for 2 hours at room temperature and transformed into OneShotTM chemically 
competent Stbl3TM cells as described in 2.3.1.  Single colonies were picked and 
used to inoculate 5 ml cultures of LB broth containing 100 μg/ml ampicillin.  
After ~ 8 hours of growth, samples of the cultures were taken and later used to 
as starter cultures for maxiprep, described in 2.3.4.  The remaining sample was 
further incubated for up to 24 hours and used to isolate plasmid DNA by 
miniprep, described in 2.3.3. 
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Figure 2.3 – Vector map of the GeneArt® Genomic Cleavage Selection 
vector, pGCS  
The pGCS vector is provided linearised with the overhangs shown above the 
vector map.  The vector contains a pUC origin of replication (ori).  The 
cytomegalovirus promoter transcribes the V5 epitope, the OFP sequences for 
FACS-based selection, the CD4 coding sequence which can be used for bead-
based enrichment or fluorescent labelling with an anti-CD4 fluorescently 
labelled antibody.  A T2A cleavage site separates the OFP and CD4 
sequences.  Neomycin coding sequence allows for selection of the vector in 
mammalian cells while ampicillin allows for selection in bacterial cells.  A 
polyomavirus simian virus 40 (SV40) polyadenylation signal terminates 
transcription.  Vector map was taken from the User Guide: GeneArt® Genomic 
Cleavage Selection Kit (Life Technologies, 2015). Available at 
http://tools.thermofisher.com/content/sfs/manuals/GeneArt_Genomic_Cleavage
_Selection_Kit_UG.pdf (Accessed August 2019).   
 
2.5.5 In-vitro transcription of gRNAs 
The GeneArtTM gRNA synthesis kit (InvitrogenTM) was used to generate gRNAs 
from DNA templates according to manufacturer’s instructions.  Briefly, a 
forward primer (containing a region of complementarity to the T7 promoter 
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sequence and a 5’ portion of the gRNA specific sequence) and primer 2 (with a 
region of complementarity to the tracrRNA and the 3’ gRNA sequence that 
partially overlaps with the gRNA specific sequence on the forward primer) were 
designed (exact sequences are detailed in 3.2.4) and commercially synthesised 
as PAGE-purified single stranded DNA oligonucleotides by IDT.  Primers were 
added to a PCR containing the tracr fragment sequence, the T7 forward primer 
and the tracr reverse primer.  This yielded a ~ 100 bp PCR product which was 
used as the DNA template for in-vitro transcription (IVT) of the gRNA-tracr RNA 
sequence.  The IVT reaction comprised 6 μl of the DNA template, 160 mM 
nucleoside-triphosphate (NTP) mix, 1X TranscriptAidTM reaction buffer and 2 μl 
TranscriptAidTM enzyme mix containing the T7 RNA polymerase made to 20 μl 
with nuclease-free water.  The reaction was incubated at 37oC for 3 hours. The 
DNA template was removed by DNAse I digestion at 37oC for 15 min and the 
RNA purified using the gRNA clean up kit GeneJETTM RNA purification micro 
columns (InvitrogenTM) according to manufacturer’s instructions.   
 
2.5.6 RNA agarose gel electrophoresis 
1 μl sample was diluted in 4 μl nuclease-free water and mixed with RNA 
loading dye to a final concentration of 1X (NEB; 47.5% formamide, 0.01% SDS, 
0.01% bromophenol blue, 0.005% xylene cyanol, 0.5mM EDTA).  The sample 
was heated at 99oC for 10 min before electrophoresis on a 1% agarose-TAE 
gel at 100V for 1 hour. 
 
2.5.7 RNA quantification 
In-vitro transcribed RNA was diluted 1:10 and quantified using the QuBit® 
Broad Range (BR) RNA assay kit (ThermoFisher) according to manufacturer’s 
instructions.  Prior to starting, the kit was allowed to reach room temperature.  
Working solution was prepared by diluting the Qubit® RNA BR reagent (200X 
concentrate in DMSO) 1:200 in Qubit® RNA BR buffer, 190 μl working solution 
was added to 10 μl of Qubit® standard 1 (0 ng/μl in TE buffer) and Qubit® 
standard 2 (100 ng/μl in TE buffer) and mixed by vortexing.  RNA samples 
were diluted 1:10 in nuclease-free water and 199 μl working solution added to 1 
μl RNA sample.  All tubes were incubated at room temperature for 2 min.  On 
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the Qubit® fluorometer 2.0, RNA broad range was selected as the assay type.  
The tube containing Qubit® standard 1 was inserted into the sample chamber 
and the fluorescence read.  This was repeated with Qubit® standard 2, 
followed by the RNA samples.  The stock concentration of the RNA samples 
was calculated using the ‘Calculate Stock Conc’ function on the fluorometer 
and the value multiplied by 10 to account for the original 1:10 dilution.   
 
2.5.8 Transfection of pSpCas9(BB)-2A-GFP and HDR templates 
Plating densities and LipofectamineTM 3000 reagent (Life Technologies) 
volumes for each cell line are shown in Table 2.3.  Immediately prior to 
transfection, cells were plated in a 6-well plate in 1 ml growth media.  
Lipofectamine® 3000 reagent was diluted in 125 μl Opti-MEM media (Gibco®).  
Plasmid DNA, p3000 reagent at 2 μl/μg plasmid DNA  and, where needed, a 
total of 5 μl of the 10 μM HDR template stock, were diluted in 125 μl Opti-MEM 
media and the mixture added to the diluted Lipofectamine mixture.  Lipid:DNA 
complexes were incubated at room temperature for 15 minutes before being 
added drop-wise to the cells.  Cells were incubated at 37oC with 5% CO2 for 24 
hours prior to FACS/viability analysis.  Following 24 hours incubation, 
transfection efficiencies were estimated using the cell counting tool on the 
EvosTM FL Imaging System (ThermoFisher).  Cells within 12 4mm2 grids were 
counted and averages taken.   
Table 2.3 – Volumes used for LipofectamineTM 3000 transfection of human 
immortalised myoblasts and C2C12 myoblasts 
All cell densities and volumes are for transfection in one well of a 6-well plate. 
 Human immortalised 
myoblasts 
C2C12 myoblasts 
Plating density ~1.5 x 105 ~2.5 x 105 
LipofectamineTM 3000 3.75 μl 7.5 μl 
P3000 reagent 5 μl 10 μl 
Plasmid DNA 2.5 μg 5 μg 
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2.5.9 Transfection of pGCS, Cas9 protein and HDR templates 
Cells were plated at 1.5 x 105 cells per well in a 6-well plate immediately prior to 
transfection.  6.25 μg Cas9 nuclease (ThermoFisher), 1.2 μg gRNA, 2.5 μg 
pGCS (ThermoFisher), 12.5 μl LipofectamineTM Cas9 plusTM reagent and, 
where needed, a total of 5 μl of a 10 μM stock of HDR templates were diluted in 
125 μl Opti-MEM.  7.5 μl LipofectamineTM CRISPRMAXTM reagent was diluted 
in 125 μl.  The diluted complexes were mixed 1:1 and incubated at room 
temperate for 10 min before being added drop-wise to cells.  Cells were 
incubated at 37oC with 5% CO2 for 24 hours prior to FACS/viability analysis.   
 
2.5.10 T7 endonuclease I assay 
A T7 endonuclease 1 assay (T7 assay) was performed to estimate gene-editing 
efficiencies (Figure 2.4).  PCR was performed to amplify a region surrounding 
the predicted Cas9 cut site (primer sequences for amplification are shown in 
Table 2.4).  The PCR products were purified using Agencourt AMPureXP 
beads (Beckman Coulter). Purified products were quantified using the 
Nanodrop 1000.  600 ng DNA, 2 μl NEBuffer 2 and nuclease-free water to a 
final volume of 19.25 μl was added to a PCR tube.  DNA was denatured by 
incubation for 5 min at 95oC and renatured by ramping down to 85oC at -
2oC/sec, followed by ramp down to 25oC at -0.1oC/sec, 0.25 μl T7 
endonuclease I was added and incubated at 37oC for 5 min.  The reaction was 
terminated by adding EDTA to a final concentration of 2.5 mM, 20 μl of the 
reaction separated by electrophoresis on a 1% agarose-TAE gel as described 
in 2.2.2.    
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Table 2.4 – Primer sequences for amplification of the gRNA region for T7 
assay 
Editing 
event 
Forward primer 5’-3’ Reverse primer 5’-3’ Size (bp) 
p.D3986E 
human 
GAGCAGGGCAAGAGGAACTT CTCGGGTGACAAACTGACCA 388 
p.D3986E 
mouse 
ACTGGTATTACTCGGGCAAGG CAATTCAGAAGGGGTTTGGGC 449 
p.S1728F 
mouse 
CTACAGCGCTTCCACTCACA CCAACATTCTCAGCGCCTTG 475  
Casq1 
knockout 
mouse 
CCCAGAAGGTGTCGTCCTTG GCTCTTAAGCTAGCCCCCAC 1005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 – Schematic of T7 endonuclease 1 assay 
Transfected cells are enriched by FACS/antibiotic selection and pooled. 2. 
Genomic DNA is extracted from these cells and a PCR performed to amplify a 
region (500 bp – 1 kb) around the Cas9 cut site.  This results in the 
amplification of a multitude of editing events.  3. PCR amplicons are denatured. 
4. PCR amplicons are renatured slowly, using a ramp-down protocol, to 
encourage the formation of heteroduplex DNA.  That is, PCR amplicons 
containing different editing events are encouraged to anneal.  5. The renatured 
amplicons are incubated with the T7 enzyme which recognises the mismatched 
editing events and cleaves at the heteroduplex DNA. 6. Gel electrophoresis of 
the T7 assay is performed and cleavage products produced by the T7 enzyme 
are revealed. Expected sizes of cleavage products can be calculated from the 
number of bases into the amplicon the cut site lies.  
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2.5.11 TaqManTM genotyping 
Custom TaqManTM genotyping assays were designed using the ThermoFisher 
Custom Assay Design Tool (CADT) to detect the presence of the D3986E and 
S1728F variants in C2C12 myoblasts.  The custom assays were designed to 
avoid the silent mutations introduced into the PAM/seed regions of the HDR 
templates, allowing for allele-specific detection of the variant of interest.  To 
confer single-base specificity, genotyping assays comprise two allele-specific 
probes each bound to either VICTM or FAMTM reporter dyes.  The probes also 
contain a 3’ minor groove binder (MGB) that stabilises binding and a non-
fluorescent quencher (NFQ) that quenches fluorescence of the probes whilst in 
solution, reducing background signal.  Binding of the probe to the 
complementary template sequence allows Taq polymerisation and the 5’ 
nuclease activity of the Taq polymerase degrades the probe sequence, 
enabling separation of the reporter dye from the quencher and subsequent 
fluorescence emission.  As such, the end-point levels of fluorescence of each 
dye indicates the genotype of the sample.  The assay ID for the D3986E 
genotyping assay was ANNKVVX  and the assay ID for the S1728F genotyping 
assay was ANYMNZR.  Primer and probe sequences are shown in Table 2.5. 
Each genotyping reaction contained 20 ng DNA, 1X TaqManTM universal 
master mix, 0.25 μl of the assay and was made up to 10 μl with nuclease-free 
water.  Real-time PCR was performed using the QuantStudio 3 Real-Time PCR 
System (Applied Biosystems) and data was analysed in the Genotyping Module 
on the ThermoFisher cloud. 
Table 2.5 – Custom TaqManTM genotyping assay primer and probe 
sequences 
 p.D3986E p.S1728F 
Forward primer  CCGGAAACCAGCAGAGTCT 
 
TCAGCATCCACCTCGAAAGC 
 
Reverse primer  ATCATCATGTGCGCGAACAC 
 
GGTCTCCGGCGTGAGT 
 
Wild-type probe ACCACGGCATCCCA 
 
AGAGAGCATGGAGCGAC 
 
Variant probe  ACCACGGCCTCCCA 
 
AGAGCATGAAGCGAC 
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2.5.12 TA cloning  
TA cloning was performed using the pGEM®-T vector system (Promega).  
Primers were designed to amplify a ~500 bp region around the Cas9 cut site by 
PCR (Table 2.6) and PCR products were purified using AMPureXP beads as 
described in 2.2.4.  Purified PCR products were phosphorylated by incubation 
of approximately 3 μg DNA with 1X T4 polynucleotide kinase (PNK) buffer 
(NEB; 70 mM Tris-HCl pH 7.6, 10 mM MgCl2, 5mM DTT), 1 mM ATP and 10 
units of T4 PNK (NEB).  The reaction was incubated at 37oC for 30 min and 
enzymes inactivated at 65oC for 20 min.  The linearised pGEM®-T vector was 
dephosphorylated to prevent self-ligation using recombinant Shrimp Alkaline 
Phosphatase (rSAP; NEB).  The vector was incubated with 1X CutSmart® 
buffer (NEB; 50 mM potassium acetate, 20 mM Tris-acetate, 10 mM 
magnesium acetate, 100 μg/ml BSA, pH 7.9) and 1 unit of rSAP per 1 μg 
plasmid DNA.  Reaction volumes were made to 20 μl with nuclease-free water.  
The reaction was incubated at 37oC for 30 min and enzymes inactivated by 
incubation at 65oC for 20 min.  Phosphorylated PCR products and 
dephosphorylated pGEM®-T vector were incubated at a 5:1 molar ratio with 1X 
rapid ligation buffer (Promega; 30 mM Tris-HCl pH 7.8, 10 mM MgCl2, 10 mM 
DTT, 1 mM ATP, 10% w/v PEG), 5 units T4 DNA ligase (Promega) per 100 ng 
vector and made to 20 μl in nuclease-free water.  Ligation reactions were 
incubated overnight at 4oC.  Following incubation, the reactions were 
immediately transformed into OneShot® TOP10 chemically competent E. coli 
cells (InvitrogenTM) as described in 2.3.1.  Transformation reactions were plated 
on LB agar plates with ampicillin at 100 μg/ml and 40 μl 100mM IPTG and 120 
μl 20 mg/ml X-gal spread onto the surface of the plate.  White colonies were 
picked and used to inoculate miniprep cultures and plasmid DNA isolated as 
described in 2.3.3.  Isolated plasmid DNA was subjected to Sanger sequencing 
as described in 2.2.6.  A summary of the number of TA clones picked per cell 
line used in this project is provided in Table 2.7. 
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Table 2.6 – Primers used for amplification of templates for TA cloning 
Editing 
event 
Forward primer 5’-3’ Reverse primer 5’-3’ Size 
(bp) 
p.D3986E 
mouse 
ACTGGTATTACTCGGGCAAGG CAATTCAGAAGGGGTTTGGGC 449 
p.S1728F 
mouse 
CTACAGCGCTTCCACTCACA CCAACATTCTCAGCGCCTTG 475 
Casq1 
knockout 
mouse 
GAGAGCTACCGACAGGATGGG 
 
TAGCCCCCACCCTCAGACTC 
 
330 
 
Table 2.7 – Number of TA clones processed for sequencing for each cell 
line 
Cell line No. TA clones 
Ryr1 p.D3986E 8G6 28 
Ryr1 p.D3986E 2G7 17 
Ryr1 p.D3986E 9H12 18 
Ryr1 p.D3986E 1E6 27 
Ryr1 p.D3986E 1C5 27 
Ryr1 p.D3986E 10G5 27 
Ryr1 p.S1728F 6F12 10 
Ryr1 p.S1728F 6B4 10 
Casq1 knockout 8E10 18 
Casq1 knockout 3B9 20 
Casq1 knockout 7E5 19 
2.6 Calcium release assay methods 
 
2.6.1 Preparation of imaging buffer 
A 10X concentrated stock of imaging buffer (1X components: 10 mM HEPES 
pH 7.4, 133 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 5.5 mM glucose) 
was prepared without glucose, CaCl2 and MgCl2 and was stored at 4oC.  The 
1X imaging buffer was prepared on the day of imaging or the evening before 
(stored at 4oC overnight) with glucose, CaCl2 and MgCl2 added and the solution 
corrected to pH 7.4.  Imaging buffer was pre-warmed to 37oC prior to cell 
loading and Ca2+ imaging. 
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2.6.2 Cell loading with Fluo-8 AM and Pluronic® F-127 
Pluronic® F-127 (Sigma) was used to improve cell loading by facilitating the 
dispersal of the acetoxymethyl ester (AM) group on Fluo-8 AM.  The AM esters 
render ion indicators membrane permeable by neutralising their negative 
charge.  A Pluronic® F-127 stock solution was prepared by dissolving 
Pluronic® F-127 in DMSO to a final concentration of 20% (w/v) at 40oC with 
shaking at 200 rpm for at least 30 minutes.  Once dissolved, the Pluronic® F-
127 stock solution was stored at room temperature.  Stock solutions of Fluo-8 
AM (Abcam, UK) were prepared in DMSO to a final concentration of 10 mM.  5 
μl aliquots of the stock Fluo-8 AM solution were stored at -20oC. 
 
Myotubes were differentiated for 5-6 days in black, clear-bottom 96-well plates 
coated with ECM Gel from Engelbreth-Holm-Swarm murine sarcoma (Sigma) 
as described in 2.1.6.  Differentiation media was removed and the cells washed 
twice with 200 μl imaging buffer pre-warmed to 37oC.  To generate a working 
dye solution, the 20% (w/v) stock of Pluronic® F-127 was mixed 1:1 with 10 
mM Fluo-8 AM and diluted in imaging buffer to give a final concentration of 
0.04% (v/v) Pluronic® F-127 and 10 μM Fluo-8 AM.  80 μl of the working dye 
solution was added to each well and incubated for 30 min at 37oC, 5% CO2.  
Following loading, cells were washed twice with imaging buffer and allowed to 
equilibrate at room temperature for 20 min in the dark.   
2.6.3 Preparation of the caffeine series for Ca2+ imaging  
Whilst cells were equilibrating at room temperature for 20 min, a caffeine series 
was prepared in imaging buffer to final concentrations of 0.1 mM, 1 mM, 3 mM, 
5 mM, 10 mM and 20 mM.   
 
2.6.4 Fluorescence microscopy Ca2+ imaging data acquisition 
Caffeine solutions were loaded onto a multivalve perfusion system connected 
to a Nikon TE2000 inverted microscope for the measure of caffeine-induced 
Ca2+ transients.  Myotubes in 96-well plates that had been loaded with Fluo-8 
AM were transferred to the stage of the microscope. 
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The multivalve perfusion system (Automate Scientific Inc.) comprised 8 x 35 ml 
syringes that were computer controlled using the ValveBank controller 
(Automate Scientific Inc.), allowing for the automated opening and closing of 
stop valves located at the bottom of the syringes.  One syringe was reserved 
for imaging buffer and a faulty stop valve on one of the syringes prevented its 
use, hence 6 caffeine concentrations were used.  Pressure at 1 pound per 
square inch (psi) was applied to the syringes using the Bambi BB24V air 
compressor (Air SuppliesTM).  Each syringe was connected to a single inflow 
port via Tygon® plastic tubing that enabled the delivery of solutions to a 
myotubes in a well of a 96-well plate (Figure 2.5).  Previous experiments 
performed by Dr Xiaochen Liu showed that at 1 psi, solutions were delivered at 
a rate of 100 μl per second.  Solutions were removed from the well into a waste 
container using an outflow port connected to a vacuum pump.  For dose 
response experiments, a program was created using the ValveBank controller 
whereby myotubes were perfused with imaging buffer for 10 seconds, caffeine 
at the desired concentration for 10 seconds and imaging buffer for a further 10 
seconds.  Myotubes were allowed to recover for approximately 60 seconds 
prior to the next application of caffeine to allow replenishment of SR Ca2+ 
stores and avoid cell death.  A single dose-response experiment, defined by 
the application of all 6 caffeine concentrations, was performed per well. 
Caffeine-induced Ca2+ transients were detected using the Nikon TE2000 
inverted microscope and a 40x oil immersion objective.  Fluo-8 AM was excited 
at 494 nm using the X-cite 120 metal halide arc lamp (EXFO) and a 480/20 nm 
excitation filter.  Emission was filtered using a 540/40 nm emission filter.  The 
intensity of the light source was adjusted to the lowest level possible whilst 
allowing detection of a robust fluorescent signal, to avoid cell damage. The 
data were collected using an intensified charge-coupled device (CCD) camera 
at 20 frames per second (fps).  Piper ControlTM Acquisition Software (Stanford 
Photonics) was used to draw regions of interest (ROIs) around myotubes.    
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Figure 2.5 – Schematic of the multivalve perfusion system for live-cell 
Ca2+ imaging 
The multivalve perfusion system comprised 8 syringes under pressure of 1 psi.  
Six of the syringes contained caffeine solutions and one contained imaging 
buffer.  One of the syringes was faulty and unable to be used.  Stop valves 
located at the bottom of the syringes were controlled by the ValveBank 
automated controller.  As such, syringes were automatically opened and 
closed, allowing the automated delivery of solutions to the cells via tubing and 
the inflow port.  The outflow port removed excess liquid using a vacuum pump 
into a waste container. 
 
2.6.5 Imaging schedule, exclusion criteria and n numbers 
Due to differences in cell growth and myoblast differentiation, Ca2+ imaging was 
not always able to be performed for all genotypes being compared on the same 
day.  The days on which the data were collected for each genotype is 
summarised in Table 2.8.  Myotubes were removed from the analysis if they did 
not show a dose dependent increase in fluorescence in response to caffeine.  
Furthermore, cells that did not show a response following 3 mM caffeine 
perfusion were also removed.  Finally, myotubes with particularly low (<50) or 
high (>600) baseline fluorescence units (FUs) were excluded from the analysis.  
The total n numbers for each genotype are summarised in Table 2.9. 
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Table 2.8 – Data collection for all cell lines 
An X indicates where data were collected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.9 – Total n numbers for all cell lines 
Total n numbers included in the analysis following application of exclusion 
criteria. 
 
 
 
 
 
 
 
 
Experiment WT 3E1 8G6 10G5 3B9 8E10 7E5 5F2 
1 X  X X     
2 X    X  X  
3   X X     
4 X   X X    
5     X X X  
6      X X X 
7   X   X   
8   X    X  
9        X 
10  X     X X 
11      X X  
12         
13  X X      
14        X 
15     X    
16     X    
         
Cell line n 
WT 45 
3E1 33 
8G6 44 
10G5 46 
3B9 59 
8E10 55 
7E5 49 
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2.6.6 Fluorescence microscopy imaging data analysis 
The raw fluorescence values of each pixel within a ROI were averaged and 
imported into Prism 8 (GraphPad) for analysis.  Half maximal effective 
concentration (EC50) values were generated from two separate analyses - area 
under the curve (AUC) measurements and peak height measurements. 
For both analyses, baseline measurements for each caffeine-induced peak 
were calculated by averaging fluorescence values for 20 frames (1 second) 
prior to caffeine application.  The built-in AUC analysis function on Prism 8 was 
used to calculate the total area of each peak (AUC analysis) and the maximum 
peak fluorescence value (peak height analysis).  Peaks were ignored that were 
less than 10% of the distance from baseline to maximum fluorescence.  For 
peak height analysis, the change in fluorescence from baseline was calculated 
by subtracting the baseline measurement from the maximum peak 
measurement.  For both analyses, AUC measurements and peak height 
measurements were normalised to the maximum response of that myotube at 
20 mM caffeine.  The resultant values were plotted against caffeine 
concentration on a logarithmic scale and a non-linear regression analysis 
performed to derive EC50 values.  EC50 values are expressed as the mean of all 
myotubes for each genotype (standard deviation; 95% confidence interval).  
Statistical analysis was performed to determine whether the EC50 values 
differed between genotypes using a one-way analysis of variance (ANOVA) 
followed by Tukey’s post hoc test for multiple pair-wise comparisons, correcting 
for multiple testing.  EC50 values were considered significantly different when 
p<0.05. 
2.7 Western blot methods for Casq1, myosin and GAPDH 
detection 
2.7.1 Mammalian whole cell lysate preparation 
C2C12 cells and CASQ1 knockout C2C12 derivatives were differentiated for 6 
days as described in 2.1.6.  Cells were pelleted as described in 2.1.4 and 
resuspended in an appropriate volume of ice cold RIPA buffer (ThermoFisher; 
25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% (v/v) NP-40, 1% (w/v) sodium 
deoxycholate and 0.1% (w/v) SDS).  The resuspended cells were incubated on 
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ice for 15 min.  Lysates were clarified by centrifugation at 13,000 x g for 30 min 
at 4oC.  The supernatant was transferred to a clean tube for quantification.  
Lysates were stored at -20oC. 
 
2.7.2 BCA assay 
Cell lysates were diluted 1:10 and quantified using the detergent-compatible 
PierceTM protein BCA assay kit (ThermoFisher) according to manufacturer’s 
instructions.  A series of BSA (provided  at 2 mg/ml in 0.9% saline and 0.05% 
sodium azide) standards were prepared in RIPA buffer ranging from 2000 
μg/ml to 0 μg/ml.  Twenty-five μl of each standard was transferred to a well of a 
96-well plate for a total of 2 replicates.  Twenty-five μl of each lysate sample 
was transferred to a well of the same 96-well plate for a total of 2 replicates.  
200 μl of working reagent, consisting of a 50:1 ratio of reagent A (sodium 
carbonate, sodium bicarbonate, bicinchoninic acid and sodium tartrate in 0.1M 
sodium hydroxide) to reagent B (containing 4% cupric sulfate) was added to 
each standard and each sample.  The plate was incubated at 37oC for 30 min 
and absorbance at 540 nm measured using the SpectraMax plate reader 
(Molecular Devices).  Averaged blank values were subtracted from all standard 
and sample measurements.  The blank-corrected standard measurements 
were plotted against their concentration in μg/ml and a linear trendline fitted to 
the graph to generate a calibration curve.  This was used to calculate the 
concentrations of the unknown samples.   
2.7.3 SDS-PAGE 
For western blots, where visualisation of CASQ1 (~42 kDa), GAPDH (~ 25 
kDa) and myosin heavy chain (~ 223 kDa) was needed, precast Mini-
PROTEAN TGXTM 8-16% gradient gels were purchased from BioRad.  In the 
first lane of each gel, 10 μl prestained colour protein standard (NEB) was 
loaded.  Samples were heated to 95oC for 5 min with an equal volume of 2X 
protein loading dye (2% (w/v) SDS, 10% (v/v) glycerol, 5% (v/v) beta-
mercaptoethanol, 60 mM Tris-HCl pH 6.8, 0.1 % (w/v) bromophenol blue) prior 
to loading.  Fifty μg total protein was loaded per lane.  Electrophoresis was 
performed in Tris-glycine SDS buffer (250 mM Tris pH 8.3, 1.92 M glycine and 
1% (w/v) SDS) at 180 V for 1 hour.   
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2.7.4 Western blot 
Following SDS-PAGE, proteins were transferred onto 0.45 μm mini PVDF 
membranes using the Trans-Blot® TurboTM transfer system (BioRad).  The 
Trans-Blot® TurboTM ready-to-assemble transfer kit was used according to 
manufacturer’s instructions.  Briefly, filter paper stacks were equilibrated in 1X 
transfer buffer (BioRad; 25 mM Tris-HCl pH 8.3, 192 mM glycine, 20% (v/v) 
methanol) and PVDF membranes were equilibrated in 100% ethanol for 2-3 
min.  The stack was assembled in the following order: filter paper stack, 
membrane, gel and filter paper stack.  Proteins were transferred at 2.5 A for 30 
min.  The PVDF membrane was placed in 5% skimmed milk powder in Tris-
buffered saline with 0.1% Tween® (Sigma) (TBST; 25 mM Tris-HCl pH 7.5, 
0.15 M NaCl, 0.1% w/v Tween®20) for 1 hour at room temperature before 
being washed with TBST for a total of 3 washes, each lasting 5 minutes. 
Antibodies were diluted in 1% skimmed milk powder in TBS according to Table 
2.10.  For re-probing with the GAPDH loading control, membranes were 
washed 3 times in TBST, blocked and re-probed.  Primary antibodies were 
incubated with the membrane overnight at 4oC and secondary antibodies 
incubated for 1 hr at room temperature, washing between the use of each 
antibody.  To visualise proteins by enhanced chemiluminescence, the 
membrane was incubated for 5 min with  SuperSignal West Femto Maximum 
Sensitivity Substrate (ThermoFisher) and images captured using the Gel DocTM 
XR+ Gel Documentation System (BioRad). 
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Table 2.10 – Antibodies used and working dilutions 
Antibodies were used to detect proteins within C2C12 myotube lysates. 
Antibody Host 
species 
Supplier Working 
dilution 
Expected 
band 
(kDa) 
Anti-casq1 
EPR15227(B) 
Rabbit 
(IgG) 
Abcam 
(ab191564) 
1:2000 50 
MF-20  
anti-myosin heavy 
chain 
Mouse 
(IgG2b) 
Deposited to 
the DSHB by 
D.A. Fischman. 
0.5 ug/ml 220 
Anti-GAPDH Mouse  
(IgG2b) 
Abcam 
(ab9484) 
1:2000 37 
Anti-rabbit IgG 
(HRP) 
Goat Abcam 
(ab6721) 
1:2000 N/A 
Anti-mouse IgG 
(HRP) 
Rabbit ThermoFisher 
(A16160) 
1:2000 N/A 
 
2.8 Heterologous CASQ1 expression and purification 
methods 
2.8.1 Cloning into pOPINF 
The expression vector, pOPINF (a gift from Ray Owens; Addgene #26042) was 
used for heterologous expression of human CASQ1 wild-type, CASQ1 E364K, 
CASQ1 F186Y and CASQ1 I138T (Figure 2.6).  This vector incorporates an N-
terminal hexa-histidine tag followed by a 3C cleavage site onto translated 
proteins.  The pOPINF vectors containing the CASQ1 cDNAs without the 34 
amino acid signal peptide, were assembled by Gibson assembly, as described 
in the Oxford Protein Production Facility (OPPF) manual (Gibson et al., 2009; 
OPPF pOPIN vector suite, 2016).  The pOPINF vector was linearised in a 
restriction digest reaction consisting of 10 μl pOPINF vector (200 ng/μl), 1 μl 
KpnI-HF® (NEB), 1 μl HindIII-HF® (NEB), 2 μl 10X Green CutSmart Buffer 
(NEB) and nuclease-free water to a final volume of 20 μl.  The reaction was 
incubated at 37oC for 30 min and the enzymes inactivated by heating at 80oC 
for 20 min.  Five μl of the reaction was electrophoresed for 40 min at 120 V as 
described in 2.2.2 .   
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Figure 2.6 – Vector map of pOPINF 
The pOPINF vector was developed by the Oxford Protein Production Facility 
(Oxford, UK) and deposited on Addgene (#26042).  The vector allows for 
heterologous protein expression in insect cells (via baculovirus recombination 
regions and the p10 promoter), mammalian cells (via the cytomegalovirus 
enhancer and chicken beta actin promoter) and bacterial cells (via the T7 
promoter).  The lac operator allows for IPTG induction and ampicillin allows for 
the selection of transformed E. coli clones.  A beta-globin poly(A) signal is 
located downstream of the POI cDNA sequence for mRNA stabilisation and the 
T7 terminator terminates transcription.  Proteins expressed from pOPINF 
contain an N-terminal hexa-histidine tag (6xHis tag).  Vector maps were taken 
from Addgene (www.addgene.org/26042; accessed August 2019) and modified 
in SnapGene®. 
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Figure 2.7 – pOPINF Gibson assembly schematic 
Primers with appendages complementary to the pOPINF vector (green) were 
used to amplify the CASQ1 coding region (blue) without the N-terminal signal 
peptide. Bases were added to complete the 3C cleavage site (bold text) and a 
stop codon was added to the reverse primer (red). 2) the PCR product was 
digested with a 5’ exonuclease to generate large overhangs. 3) The pOPINF 
vector was digested with KpnI (yellow) and HindIII (purple) restriction enzymes 
to linearise the vector. 4) The linearised vector was digested with 5’ 
exonuclease prior to ligation with the digested insert (5).  
 
The CASQ1 cDNAs without the signal peptide were amplified by PCR from 
vectors already containing the cDNAs.  A 21-22 nt sequence was appended to 
the 5’ of the forward primer consisting of 15 nt complementarity to the pOPINF 
vector and a 5 nt sequence which completed the 3C cleavage site.  An 18 nt 
sequence was appended to the 5’ of the reverse primer consisting of 15 nt 
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complementarity to the pOPINF vector and a 3 nt stop codon.  A ligation 
reaction was assembled consisting of 1 μl digested pOPINF vector (~200 ng), 
600 ng purified insert, 10 μl 2X Gibson assembly master mix (NEB) and 
nuclease-free water to a final volume of 20 μl.  The ligation reaction was 
incubated at 50oC for 1 hour and immediately transformed into XL10-gold® 
cells (Agilent) as described in 2.3.1.  Four white colonies per vector were 
picked and plasmid was isolated by mini prep as described in 2.3.3.  To confirm 
successful cloning, a series of overlapping sequencing primers spanning the 
entire CASQ1 insert within the pOPINF backbone were designed and Sanger 
sequencing was outsourced to Source Bioscience (Cambridge, UK).  The 
Sanger sequencing chromatograms were analysed using 4Peaks software and 
assembled manually.  
Table 2.11 – pOPINF-CASQ1 assembly primers 
Green text shows the sequences complementary to pOPINF.  Bold black text 
shows the sequence added to complete the 3C cleavage site.  Red text shows 
the stop codon sequence.  Blue text shows the primer sequence 
complementary to the CASQ1 cDNA. 
Primer name Sequence 5’-3’ 
pOPINF_CASQ1_ 
Forward 
AAGTTCTGTTTCAGGGCCCGCAGGAAGGGCTGGACTTCCCTG 
 
pOPINF_CASQ1_ 
Reverse 
CTGGTCTAGAAAGCTTTAGTCATCATCATCATCGTCATC 
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2.8.2 Induction of his-tagged CASQ1 expression 
The pOPINF-CASQ1 vectors were transformed into BL21(DE3) RosettaTM E. 
coli cells (Novagen®) as described in 2.3.1.  Single colonies were picked using 
a sterile toothpick and used to inoculate 100 ml LB media containing the 
ampicillin at 100 μg/ml and chloramphenicol at 25 μg/ml.  The 100 ml culture 
was incubated overnight at 37oC with shaking at 200 rpm.  The following day, 
the 100 ml culture was used to inoculate 1 L LB media containing the 
appropriate antibiotics.  The 1 L culture was grown for ~4 hours at 37oC with 
shaking at 200 rpm until the optical density at 600 nm (OD600) reached 0.4-0.6.  
IPTG was added to a final concentration of 0.4 mM and the culture incubated 
overnight at 18oC.   
 
2.8.3 Preparation of lysates protein purification 
Cultures were decanted into 1 L containers and centrifuged at 7,500 x g for 15 
min at 4oC.  The supernatant was removed and pellets resuspended on ice in 
40 ml resuspension buffer (0.01M phosphate buffered saline (PBS; 0.01M 
phosphate buffer, 0.0027M KCl, 0.137M NaCl; pH 7.4; tablets were purchased 
from Fisher Bioreagents) with 0.1% (v/v) Triton® X-100 (Fisher Bioreagents), 
200 µg/ml lysozyme from chicken egg white (Sigma) and one tablet of 
cOmpleteTM EDTA-free, EASYpack, protease inhibitor cocktail tablets (Roche)).  
The cells were lysed by sonication on ice using the Fisherbrand™ Model 120 
Sonic Dismembrator (Fisher Scientific).  Lysates were clarified by centrifugation 
at 25,000 x g for 30 min at 4oC followed by filtration through a 0.22 μM syringe-
driven filter.  Clarified lysates were kept on ice here onwards.  
 
2.8.4 Nickel affinity chromatography 
Nickel affinity chromatography was performed using an AKTA Pure FPLC 
system (GE Healthcare) and HisTrapTM HP 1 ml columns (GE Healthcare).  All 
buffers used on the AKTA system were filtered through a vacuum driven 0.22 
μM filter (Nalgene) and degassed.  The AKTA system and column were pre-
equilibrated with low salt wash buffer (50 mM Tris-HCl pH 7.6, 300 mM NaCl, 
20 mM imidazole, 5% (v/v) glycerol, 0.075% (v/v) beta-mercaptoethanol) for 5 
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column volumes (CV).  Samples were loaded onto the column using a sample 
pump at a rate of 1 ml/min.  The column was washed with 5 CV of low salt 
wash buffer, high salt wash buffer (50 mM Tris-HCl pH 7.6, 500 mM NaCl, 20 
mM imidazole, 5% (v/v) glycerol, 0.075% (v/v) beta-mercaptoethanol) and then 
low salt wash buffer again.  Bound protein was eluted using a linear gradient 
from 0% elution buffer (50 mM Tris-HCl pH 7.6, 300 mM NaCl, 300 mM 
imidazole, 5% glycerol (v/v), 0.075% (v/v) beta-mercaptoethanol) to 70% 
elution buffer over 15 CV and elution monitored by absorbance at 280 nm.  
Elution at 70% elution buffer was maintained for 5 CV before a step to 100% 
elution buffer was applied for a further 5 CV to remove remaining protein bound 
to the column.  Flow-through from sample application and washes were 
collected in Falcon tubes and eluate was collected in 1 ml fractions in a 96-well 
deep well plate.  Fractions that displayed a peak of absorbance at 280 nm were 
analysed by SDS-PAGE along with the pellet, flow through and washes.  
Columns were stored in 20% ethanol. 
 
2.8.5 SDS-PAGE for confirmation human CASQ1 purification 
To determine the masses of proteins within the eluted fractions that showed a 
peak of absorbance at 280 nm, SDS-PAGE was performed.  SDS-PAGE gels 
comprised of 12% acrylamide resolving gels with a 5% acrylamide stacking 
layer were prepared using the BioRad mini-PROTEAN apparatus.  10 ml 
resolving gels were prepared by mixing 3.3 ml distilled, deionised water 
(ddH2O), 4 ml 30% (w/v) acrylamide-bis solution (19:1) (Severn Biotech), 2.5 ml 
1.5 M Tris pH 8.8, 100 μl 10% (w/v) ammonium persulfate, 100 μl 10% (w/v) 
SDS and 4 μl N,N,N',N'-tetramethylethane-1,2-diamine (TEMED).  A layer of 
water saturated butanol was added to the top of the resolving gel and the gel 
left to set for 30 min.  The water saturated butanol was removed and 5 ml 5% 
stacking gel prepared by mixing 3.4 ml ddH2O, 830 μl 30% (w/v) acrylamide-bis 
(19:1), 630 μl 1M Tris pH 6.8, 50 μl 10% (w/v) ammonium persulfate, 50 μl 10% 
(w/v) SDS and 5 μl TEMED.  The stacking gel was layered on top of the 
resolving gel and a comb inserted.  The stacking gel was left to set for 20 min.  
Electrophoresis was performed as described in 2.7.3. 
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2.8.6 Coomassie staining 
Gels were incubated with InstantBlueTM Coomassie protein stain (Expedeon) 
for 30 min and images were captured using the G:BOX Chemi XX6/XX9 imager 
(Syngene).  Densitometry was performed using ImageJ software to determine 
the percentage purity of purified CASQ1 protein fractions. 
 
2.8.7 Protein concentration 
Purified protein samples were concentrated using PierceTM protein 
concentrators with a polyethersulfone (PES) membrane and 10 kDa molecular 
weight cut off (MwCO) (ThermoFisher).  Samples were pipetted into the upper 
chamber and centrifuged at 4000 x g at 4oC in 5 minute increments until the 
desired concentration had been achieved.     
 
2.8.8 Preparative size exclusion chromatography 
Samples prepared by nickel affinity chromatography were further purified by 
preparative size exclusion chromatography using an AKTA Pure FPLC system 
(GE Healthcare) and a HiLoad 26/600 Superdex 200 prep grade (pg) column 
(GE Healthcare).  Buffer exchange was performed prior to preparative size 
exclusion chromatography (SEC) using Sephadex G-25 PD-10 desalting 
columns (GE Healthcare) according to manufacturer’s instructions.  Briefly, 
columns were equilibrated with 25 ml of SEC buffer (10 mM HEPES pH 7.5, 
500 mM NaCl), 2.5 ml protein sample was loaded onto the column and the flow 
through discarded before protein was eluted with 3.5 ml SEC buffer and 
collected in a bijou container.  The HiLoad 26/600 Superdex 200 pg column 
SEC column was pre-equilibrated with 1 CV SEC buffer at a rate of 1 ml/min.  
Samples were loaded onto the column manually by injecting into a 5 ml sample 
loop using a syringe.  Isocratic elution was performed at a rate of 2 ml/min and 
elution was monitored by absorbance at 280 nm.  The first 64 ml of eluate was 
discarded and the remaining eluate collected in 2 ml fractions in a 96-well deep 
well plate.  Fractions that displayed a peak in absorbance at 280 nm were 
analysed by SDS-PAGE.  Fractions containing purified CASQ1 were pooled 
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and concentrated as described in 2.8.7 and then buffer exchanged into 
experimental buffer (10 mM HEPES pH 7.5, 300 mM KCl). 
 
2.8.9 Protein quantification 
Purified CASQ1 was quantified using the QubitTM protein assay kit and QubitTM 
3.0 fluorometer (InvitrogenTM) according to manufacturer’s instructions.  Briefly, 
the fluorescent dye was diluted 1:200 in protein assay buffer to prepare the 
working solution.  Pre-made BSA standards were diluted 1:20 in working 
solution used to plot a calibration curve.  Protein samples were diluted 1:100 in 
working solution and concentration derived from the calibration. 
 
2.8.10 Protein storage 
Purified proteins in experimental buffer were snap frozen using liquid nitrogen 
and stored in 50 μl aliquots at -80oC. 
2.9 Biomolecular interactions methods 
2.9.1 Mass spectrometry 
All mass spectrometry was performed as a service by the Mass Spectrometry 
facility in the Astbury Centre for Structural and Molecular Biology, by Dr James 
Ault and Dr Rachel George.  Briefly, samples for protein identification by 
peptide mass fingerprinting were submitted as 10 μg protein on an SDS-PAGE 
gel stained with InstantBlueTM Coomassie stain (Expedeon).  Proteins extracted 
from the gel were subject to tryptic digestion and peptides separated by liquid 
chromatography using the ACQUITY M-Class UPLC system prior to tandem 
mass spectrometry (MS/MS).  Data were processed with PEAKS Studio 
(Bioinformatic Solutions Inc, Waterloo, Ontario, Canada) and searched against 
a Uniprot database for CASQ1. 
 
Samples for native and denatured mass spectrometry were supplied at 10 μM-
20 μM in experimental buffer, with or without 1 mM CaCl2.  Denatured samples 
were separated by liquid chromatography as described previously and the 
eluant directed into the Xevo QToF G2-XA mass spectrometer via a Z-spray 
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electrospray source.  MS was operated in positive TOF mode.  Data were 
analysed using MassLynx v4.1 (Waters).  For native mass spectrometry, 
CASQ1 proteins were provided in experimental buffer with or without 1 mM 
CaCl2.  Native samples without Ca2+ were buffer exchanged into 200 mM 
ammonium acetate using ZebaTM spin 7K MWCO columns (ThermoFisher).  
Native samples with calcium were buffer exchanged into 200 mM ammonium 
acetate with 1 mM calcium acetate.  For samples with EGTA, EGTA was added 
to experimental buffer at 1 mM by dialysis overnight at 4oC using Slide-A-
LyzerTM 10 MwCO cassettes (ThermoFisher) prior to dialysis back into 
experimental buffer.  Native MS was performed using either the ESI-MS Synapt 
G2 high definition mass spectrometer (Waters) and data analysed in MassLynx 
v4.1 (Waters) or the Q-Exactive Plus mass spectrometer (ThermoFisher) and 
data analysed in UniDec v2.7.1 (Marty et al., 2015). 
 
2.9.2 Microscale thermophoresis  
Purified proteins were diluted to 20 uM in PBS and incubated for 1 hour at 
room temperature with a 4.5X molar excess of fluorescein isothiocyanate 
(FITC).  Excess dye was removed using NAP-5 columns (GE Healtchare) 
according to manufacturer’s instructions and the labelled proteins eluted into 10 
mM HEPES pH 7.5, 150 mM NaCl.  To confirm sufficient labelling, samples of 
each protein were diluted 10- to 320-fold with 2-fold iterations in between and 
transferred to NT.115 standard treated capillaries (NanoTemper Technologies) 
and each dilution scanned for fluorescence with blue LED at 15% power using 
the Monolith NT.115 (NanoTemper Technologies).  LED power was decreased 
if fluorescence values were greater than 1500 fluorescence units (FUs) for all 
dilutions. The optimal dilution was chosen for the experiment based on what 
one would provide sufficient FUs following subsequent 2-fold dilution in a CaCl2 
titration. A 2-fold CaCl2 titration ranging from 200 mM to ~6 uM was prepared in 
10 mM HEPES pH 7.5, 150 mM NaCl, mixed 1:1 with labelled protein (final 
concentration of the CaCl2 gradient 100 mM – 5 uM), and allowed to equilibrate 
for 10 min at room temperature.  A protein sample diluted 1:1 in experimental 
buffer with no CaCl2 as a control.  MST was performed at MST intensity 20, 40 
and 80%.  Fluorescence values from two experiments averaged and plotted 
against CaCl2 concentration in GraphPad Prism. 
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2.9.3 Dynamic light scattering 
CASQ1 proteins at 0.5 mg/ml in experimental buffer were prepared in 2 x 250 
μl aliquots per protein.  1 M CaCl2 was prepared in experimental buffer and 2.5 
μl added to the 250 μl protein aliquots to generate a final concentration of 10 
mM CaCl2.  Samples with Ca2+ were allowed to equilibrate at room temperature 
for 10 min.  Due to practical limitations, all samples were prepared at the same 
time and incubated on ice prior to experiments.  The 250 μl samples were 
injected into the Wyatt miniDawn Treos® system attached to the WyattQELS 
module for DLS measurements at 135o.  Baselines were measured before and 
after sample injection for 5 min, using filtered (0.22 μm) experimental buffer 
that was kept on ice.  After each sample, the flow cell was washed with 1 ml 
1M nitric acid followed by ddH2O prior to re-equilibration with 2 ml experimental 
buffer. Correlation curves were analysed using the ASTRA® 6.0.3 software by 
regularisation, using a 3 minute sample window.  
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Chapter 3 - CRISPR-Cas9 mediated knock in of the RYR1 
p.D3986E variant in human immortalised myoblasts 
3.1 Introduction 
3.1.1 Complications of existing characterisation methodologies 
Despite the association of >200 RYR1 variants with MH, since the 
implementation of the EMHG guidelines for variant characterisation, only 48 
have been functionally characterised (EMHG, available at www.emhg.org, 
accessed August 2019).  Functional characterisation is currently performed, 
predominantly, by two imperfect methods – primary patient myoblast or B-
lymphocyte isolation and heterologous rabbit or human RYR1 expression in 
HEK293 cells.  Primary myoblasts have limited replicative potential and despite 
some success, predominantly from the Institut de Myologie in Paris, France 
(Zhu et al., 2007; Mamchaoui et al., 2011), myoblast immortalisation has 
proved a challenge in the field.  Indeed, to date, no MH variants have been 
functionally characterised in human immortalised myoblasts and attempts in 
our group to generate human immortalised myoblasts that retain their ability to 
proliferate and differentiate have been with limited success (Vikas Kaura, pers. 
comms).  B-lymphocytes from patient blood samples can be immortalised with 
relative ease and express the RYR1; however, they do not express other ECC 
apparatus (Levano et al., 2009; Girard et al., 2001).  Furthermore, the unknown 
genetic background of patient samples means that it is difficult to ascertain that 
any observed effect on Ca2+ release is attributed to the variant in question.  The 
HEK293 system is plagued by the need for laborious site directed mutagenesis 
and sub-cloning to introduce the variant of interest, followed by the inefficient 
transfection of large constructs into cells (Kreiss et al., 1999).  Indeed, the 
RYR1 coding sequence is ~15 kb in length.  Fundamental physiological 
differences between HEK293 cells and myotubes has made obtaining 
consistent resting Ca2+ data difficult (Tong et al., 1999b).   Despite these 
discrepancies, variants characterised in both HEK293 cells and myotubes thus 
far appear to show consistent results with regard to sensitivity to caffeine, 
halothane and 4-chloro-m-cresol (4-CmC; Yang et al., 2003).  In contrast, 
challenges with existing methods of functional characterisation are highlighted 
by numerous conflicting reports of functional relevance following 
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characterisation in HEK293 cells and B-lymphocytes.  Expression of the RYR1 
p.R2336H variant in HEK293 cells showed that the p.R2336H variant had a 
significantly lowered EC50 to caffeine compared to wild-type RYR1 (Merritt et 
al., 2017).  In contrast, characterisation of the same variant in B-lymphocytes 
did not show a significant difference in response to caffeine compared to wild-
type, but did show a significant abnormal Ca2+ response following perfusion 
with 4-CmC (Levano et al., 2009).  Merritt et al., (2017) also showed increased 
sensitivity of the p.V4849I variant to caffeine in HEK293 cells; however, 
characterisation in B-lymphocytes showed no difference compared to wild-type 
in response to either caffeine or 4-CmC (Ducreux et al., 2006).   
 
3.1.2 Selection of the p.D3986E variant 
The p.D3986E variant is an aspartate (D) to glutamate (E) substitution at 
position 3986 in the RYR1 coding sequence (P21817.3) resulting from a C>G 
transition at cDNA position 11958 (c.11958C>G; NM_000540.2), changing the 
amino acid codon from GAC to GAG.  Within the rabbit RYR1 structure, the 
p.D3986 residue is located in the central domain – the only cytoplasmic 
structure that interacts with the channel domain (Yan et al., 2015).   
 
The p.D3986E variant was selected for introduction into immortalised human 
myoblasts due to its identification in MHShc/MHSh individuals in multiple 
families.  The p.D3986E variant has been identified in 6 MH families referred to 
the Leeds MH unit (Table 3.1).  Across these families, p.D3986E has been 
identified in a total of 7 MHShc individuals, 3 MHSh individuals and no MHN 
individuals (Table 3.1).  Discordancy was detected in one family, whereby an 
MHSh individual did not harbour the p.D3986E variant, suggesting that an 
undetected variant in another gene could influence the MH response in addition 
to the p.D3986E variant; however, no further variants were identified in the 4 
MHShc individuals that were subject to NGS of 50 genes associated with Ca2+ 
handling.  The p.D3986E variant is rare, with no occurrences in the Exome 
Aggregation Consortium (ExAC, 2019; Lek et al., 2016) or the Genome 
Aggregation Database (gnomAD, 2019; Karczewski et al., 2019).  Analysis of 
the relative strength of contracture during IVCT of 22 variants associated with 
MH (including some diagnostic variants) showed that samples harbouring the 
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p.D3986E variant produced significantly stronger contractures in response to 
caffeine during IVCT compared to the most common UK MH variant, p.G2434R 
and probands harbouring p.D3986E variant had significantly increased creatine 
kinase (CK) levels (suggestive of increased Ca2+ turnover in normal 
conditions); however, probands did not have an increased onset time to a 
clinical reaction nor did p.D3986E samples produce significantly increased 
responses to halothane (Carpenter et al., 2009).  The power of this study to 
draw phenotype-genotype associations with the p.D3986E variant is likely 
limited by the small sample size of 2.  The Leeds MH Unit has shown no 
significant difference in the EC50 to caffeine in HEK293 cells expressing the 
p.D3986E variant compared HEK293 cells expressing wild-type RYR1 (Merritt 
et al., 2017).  In HEK293 cells, the p.D3986E variant did have a significantly 
reduced EC10 compared to wild-type, but this is unlikely to account for the 
strong IVCT reaction observed in individuals harbouring the variant.  Functional 
characterisation of a p.D3986E B-lymphocyte cell line showed a significantly 
increased sensitivity to 4-CmC compared to wild-type controls (sensitivity to 
caffeine was not measured; Gonsalves, 2014).  Furthermore, CK levels in the 
p.D3986E B-lymphocyte cell line were significantly higher (1,271 units per litre 
(U/L)) than both the wild-type control (78 U/L) and the diagnostic variant 
p.R614C positive control (194 U/L), corroborating observations made by 
Carpenter et al. (2009).  Nonetheless, it is important to emphasise that the 
studies in B-lymphocytes were performed on samples derived from a single 
individual and thus the results may not reflect genuine differences attributed to 
the p.D3986E variant (Gonsalves, 2014).  Further exploration of the effect of 
the p.D3986E variant in a myoblast cell line is necessary to provide clarification 
of its role in MH.     
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Table 3.1 – Prevalence of p.D3986E variant in Leeds MH Unit referrals 
The 6 MH families in which the p.D3986E variant has been detected have been anonymised and assigned codes from D1-D6 (column 
1).  Since not all family members have been subject to DNA sequencing, the genetic analysis column refers to the number of family 
members who have had their DNA sequenced to determine the presence of the p.D3986E variant.  The p.D3986E + column refers to 
the number of family members determined to harbour the p.D3986E variant after DNA sequencing was performed. 
 
 No. MHShc No. MHSh No. MHN 
Family Total MHShc Genetic analysis p.D3986E 
+ 
Total MHSh Genetic analysis p.D3986E 
+ 
Total MHN Genetic analysis p.D3986E 
+ 
D1 1 1 1 1 1 0 1 1 0 
D2 3 3 3 1 1 1 3 3 0 
D3 8 1 1 2 0 - 9 0 - 
D4 7 1 1 1 0 - 4 0 - 
D5 1 1 1 2 2 2 0 - - 
D6 1 1 0 0 0 0 - - - 
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3.1.3 Chapter aims and strategy 
This primary aim of this chapter is to develop a novel, robust CRISPR-Cas9 
methodology by which MH-associated variants of unknown significance (VUS) 
can be introduced into a human immortalised myoblast cell line and to explore 
the feasibility of this strategy for MH variant characterisation.  In addition, in-
silico tools will be used to gain insight into the potential pathogenicity of the 
p.D3986E variant.  
Establishment of a CRISPR-Cas9 pipeline for the introduction of MH-
associated VUS will overcome existing issues with variant characterisation by 
providing a constant genetic background, overcoming issues with the limited 
proliferative capacity of primary cells and providing characterisation in a 
physiologically relevant environment with all components of the ECC 
machinery expressed and muscle-specific structures such as the SR.  Previous 
attempts at functional characterisation of the p.D3986E variant in HEK293 cells 
affords the opportunity to determine the consistency in caffeine dose-response 
data between the HEK293 system and CRISPR-Cas9 system in myotubes.  
Due to difficulties in generating an immortalised human myoblast line in our 
group, the cell line for editing was obtained from the Institut de Myologie 
courtesy of Prof. Vincent Mouly (Paris, France) from a male patient undergoing 
surgery for hip fracture with no known muscle disorders (Anne Bigot, pers. 
comms.).   
Two CRISPR-Cas9 strategies will be employed in this chapter (Figure 3.1).  In 
recent years, dramatic increases in gene-editing efficiency and on-target 
activity have been observed using purified Cas9 protein in complex with the 
gRNA:tracrRNA fusion (Dewari et al., 2018; Mason et al., 2018; Xu et al., 
2018).  Thus, commercially available Cas9 will be co-transfected alongside the 
gRNA:tracrRNA fusion, HDR templates and a commercially available vector to 
detect functionality of the transfected reagents (pGCS) (Figure 3.1; panel A).  
The pGCS vector contains two partially overlapping orange fluorescent protein 
(OFP) coding sequences separated by a cloning site for the gRNA and PAM.  
Following introduction of all reagents into target cells, Cas9 is able to cleave 
not only target cell DNA but also the gRNA sequence in pGCS.  Introduction of 
a double-stranded break in pGCS allows for recombination between the 
overlapping partial OFP sequences, restoring full OFP expression which can 
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be detected by fluorescent activated cell sorting (FACS).  In addition, the more 
widely-used plasmid-based system will be executed in parallel (Ran et al., 
2013a).  The pSpCas9(BB)-2A-GFP vector encodes Cas9, the tracrRNA, a 
cloning site for the gRNA and the green fluorescent protein (GFP) coding 
sequence for selection of transfected cells.  The vector will be transfected 
alongside HDR templates to incorporate p.D3986E (Figure 3.1; panel B).  For 
the introduction of base changes by HDR, it is recommended that the Cas9 cut 
site lies as close to the base to be changed as possible – ideally 0-20 bp away 
(Ran et al., 2013a).  Since gene-editing could produce undesired editing events 
such as the incorporation of random indels at the Cas9 cut site (Peng et al., 
2015) or aberrant incorporation of the HDR template (Boel et al., 2018), the 
isolation of polyclonal cells for use in determining the effect of the p.D3986E 
variant is not appropriate.  As such, transfected cells will be FACS-sorted into 
single cells and propagated to obtain a monoclonal cell line which will be 
validated by genotyping and Sanger sequencing.   
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Figure 3.1 – CRISPR-Cas9 strategy for p.D3986E introduction into human 
immortalised myoblasts 
Commercially supplied purified Cas9 protein will be transfected into human 
immortalised myoblasts alongside the gRNA:tracrRNA fusion, pGCS containing 
the gRNA sequence and PAM and the HDR templates (panel A).  Transfected 
cells, and those in which gene-editing has occurred can be selected by OFP 
expression. In a parallel strategy, the pSpCas9(BB)-2A-GFP vector which 
encodes Cas9, GFP, tracrRNA and a cloning site for the gRNA will be 
transfected into human immortalised myoblasts alongside the HDR template 
(panel B).  Transfected cells can be selected by GFP expression. 
3.2 Results 
3.2.1 p.D3986E in-silico pathogenicity prediction 
A number of bioinformatics tools were used to predict the pathogenicity of the 
p.D3986E missense variant. Using Sorting Intolerant From Tolerant (SIFT), the 
p.D3986E variant was predicted to be ‘damaging’ with a SIFT score of 0.03 – 
where a score of 0 is damaging and a score of 1 is tolerated (SIFT 4G, 2018; 
Ng and Henikoff, 2003; Sim et al., 2012).  Using PolyPhen-2, the p.D3986E 
variant was determined to be ‘probably damaging’ with a score of 0.999 – 
where a score of 1 is damaging and a score of 0 is benign (PolyPhen-2 v2, 
2018; Adzhubei et al., 2010).  Finally, the combined annotation dependent 
depletion (CADD) tool generated a CADD score (C-score) of 24.1, indicating 
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that it is in the top 1% of predicted deleterious variants (CADD v1.4, 2018; 
Kircher et al., 2014). 
 
3.2.2 p.D3986E residue conservation and in-silico mutagenesis 
ConSurf (Ashkenazy et al., 2016; Celniker et al., 2013; Asheknazy et al., 2010; 
Berezin et al., 2004) was used to identify highly conserved regions within the 
human RYR1 protein and create a multiple sequence alignment (MSA).  The 
search returned 75 results and the 40 are shown for reference in a random 
order (Figure 3.2).  At position 3986 (accession number P21817.3), the D 
residue is highly conserved with a ConSurf conservation score of 8, where 
ConSurf scores from 1-9.  The residue is predicted to be exposed on the folded 
protein and have a functional role.  Of all the homologues included in the 
search, 74 had a D residue at position 3986.  Furthermore, the sequence 
surrounding the p.D3986E residue appears highly conserved across 
homologues.  The mutagenesis wizard on PyMOL Molecular Graphics System 
version 2.0 (Schrödinger, LLC) was used to investigate the effect of the D to E 
substitution on local hydrogen bonding and Van der Waals (VdW) interactions 
using the rabbit RYR1 structure (PDB: 3J8H; Yan et al., 2015; Figure 3.3).  The 
substitution is shown in its PyMOL-assigned most likely rotamer formation 
based on the prevalence of the rotamer found in proteins within the PyMOL 
library (21%).  A number of mild (green discs) and severe (red discs) VdW 
clashes occur in this rotamer conformation and all other 18 potential 
conformations.  
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Figure 3.2 – Multiple sequence alignment of p.D3986E residue across 40 
RYR1 homologues 
CSI-BLAST was used to search for homologues with at least 70% homology to 
the human RYR1 protein and MAFTT was used to create a multiple sequence 
alignment.  ConSurf was used to determine and colour code the conservation 
of residues across homologues.  The region surrounding the p.D3986E residue 
is shown in panel A.   Predictions made regarding the exposure and role of the 
residue are shown in panel B.  Mammalian species are indicated by underlining 
and an asterisk highlights the residue of interest. 
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Figure 3.3 – PyMOL mutagenesis of rabbit RYR1 p.D3986E resiude 
The mutagenesis tool on PyMOL was used to model the effect of the p.D3986E 
variant on hydrogen bonding and VdW interactions, within the rabbit RYR1 
structure (Protein data bank (PDB ID: 3J8H).  The ancestral residue is shown 
in green and the variant is in pink.  Hydrogen bonds are shown by yellow 
dashes and VdW clashes are shown by green (less severe) and red (more 
severe) disks.  
 
3.2.3 Cell line validation 
Prior to genome-editing, DNA was extracted from the human immortalised 
myoblasts used in this project and primers were designed to amplify regions 
around all diagnostic MH variants that had been functionally characterised at 
the time this work was performed.  Sanger sequencing was performed on the 
regions around each variant to confirm the absence of them in the cell line.  
Indeed, no variants were detected. 
 
3.2.4 gRNA design 
For the introduction of the p.D3986E variant, all gRNAs were designed using 
CCTOP (Stemmer et al. 2015) and off-targets predicted by CCTOP were 
confirmed using CRISPOR (Haeussler et al., 2016).  Within CCTOP, 
CRISPRater generates a predicted efficacy score (Labuhn et al., 2017).  The 
gRNAs with efficacy values <0.56 are deemed low efficacy, gRNAs with 
efficacy values ≥0.56 but ≤0.74 are deemed medium efficacy and gRNAs with 
efficacy values >0.74 are deemed high efficacy.  Inputting a 100 bp sequence 
flanking the base to be edited returned 14 gRNA results.  Within the top 5 
ranked gRNAs, three were of medium to high quality and were deemed 
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suitable distances away from the desired based change (Table 3.2).  The first 
human p.D3986E-targeting gRNA (Hs_D3986E_gRNA1) had a cut site 8 bp 
from the desired base change.  Hs_D3986E_gRNA1 had an efficacy score of 
0.82 and 8 off-targets of which 1 was exonic, 5 were intronic and 2 were 
intergenic.  Hs_D3986E_gRNA2, with a cut site 9 bp from the target, had an 
efficacy score of 0.76 and 27 off-targets of which 2 were exonic, 15 were 
intronic and 10 were intergenic.  Hs_D3986E_gRNA3, with a cut site 20 bp 
from the target, had an efficacy score of 0.68 and 43 off-targets of which none 
were exonic, 12 were intronic and 31 were intergenic.  Hs_D3986E_gRNA1 
and 2 target the coding strand whereas Hs_D3986E_gRNA 3 targets the non-
coding strand.   
 
Table 3.2 – Human p.D3986E-targeting gRNA sequences and their PAM 
gRNA name Sequence PAM 
Hs_D3986E_gRNA1 CCTGGCGCACAGTCGCCTAT GGG 
Hs_D3986E_gRNA2 GCCTGGCGCACAGTCGCCTA TGG 
Hs_D3986E_gRNA3 TCATGTGGGCGAACACGTGC AGG 
 
The gRNAs were commercially synthesised as single-stranded 
oligonucleotides with appropriate overhangs to facilitate in-vitro transcription 
(Table 3.3), cloning into pGCS (Table 3.4) and cloning into pSpCas9(BB)-2A-
GFP (Table 3.5).  To confirm that there were no single nucleotide 
polymorphisms (SNPs) within the intended gRNA region in the target cells, 
DNA was extracted from human immortalised myoblasts by salting-out and 
used as a PCR template to amplify a 400 bp region around the intended gRNA 
site. The resultant amplicons were prepared for Sanger sequencing.  No SNPs 
were identified within any of the intended gRNA sequences (Figure 3.4). 
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Table 3.3 – Human RYR1 p.D3986E-targeting gRNA primer sequences for in-vitro transcription 
Sequences in black text show the partial gRNA sequence (primer 1 is a partial forward sequence and primer 2 is a partial reverse 
complement sequence).  Sequences in green text show the T7 promoter sequence to enable in-vitro transcription and sequences in 
blue text show the partial tracrRNA sequence. 
Primer name Primer 1 5’-3’ Primer 2 5’-3’ 
Hs_D3986E_IVT_gRNA1 TAATACGACTCACTATAGCCTGGCGCACAGTCGC TTCTAGCTCTAAAACATAGGCGACTGTGCGCCAG 
Hs_D3986E_IVT_gRNA2 TAATACGACTCACTATAGGCCTGGCGCACAGTCG TTCTAGCTCTAAAACTAGGCGACTGTGCGCCAGG 
Hs_D3986E_IVT_gRNA3 TAATACGACTCACTATAGTCATGTGGGCGAACAC TTCTAGCTCTAAAACGCACGTGTTCGCCCACATG 
 
 
Table 3.4 – Human RYR1 p.D3986E-targeting gRNA sequences for cloning into pGCS 
Sequences in black text show the gRNA sequences and their complements, with PAM sequences shown in orange.  Sequences in 
green text show the overhangs to facilitate cloning into linearised pGCS. 
Oligonucleotide name Forward sequence 5’-3’ Reverse sequence 5’-3’ 
Hs_D3986E_pGCS_gRNA1 AATTCCTGGCGCACAGTCGCCTATGGG CTAGCCCATAGGCGACTGTGCGCCAGG 
Hs_D3986E_pGCS_gRNA2 AATTGCCTGGCGCACAGTCGCCTAGGG CTAGCCCTAGGCGACTGTGCGCCAGGC 
Hs_D3986E_pGCS_gRNA3 AATTTCATGTGGGCGAACACGTGCGGG CTAGCCCGCACGTGTTCGCCCACATGA 
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Table 3.5 – Human RYR1 p.D3986E-targeting gRNA sequences for cloning into pSpCas9(BB)-2A-GFP 
Sequences in black show the gRNAs and their complements.  Sequences in green show the overhangs needed to facilitate cloning into 
linearised pSpCas9(BB)-2A-GFP and blue text shows the additional G residue added to gRNA sequences of which the first base is not 
G.  This additional G base facilitates transcription from the U6 promoter present on the pSpCas9(BB)-2A-GFP vector. 
Oligonucleotide name Forward sequence 5’-3’ Reverse sequence 5’-3’ 
Hs_D3986E_pSp_gRNA1 CACCgCCTGGCGCACAGTCGCCTAT AAACATAGGCGACTGTGCGCCAGGc 
Hs_D3986E_pSp_gRNA2 CACCGCCTGGCGCACAGTCGCCTA AAACTAGGCGACTGTGCGCCAGGC 
Hs_D3986E_pSp_gRNA3 CACCgTCATGTGGGCGAACACGTGC AAACGCACGTGTTCGCCCACATGAc 
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Figure 3.4 – Human p.D3986E-targeting gRNA sequences in the human 
immortalised myoblast genome 
Sanger sequencing was performed to confirm the presence or absence of 
SNPs within the intended gRNA regions.  The gRNA sequences for 
Hs_D3986E_gRNA1, 2 and 3 (panels A, B and C, respectively) are indicated 
and their PAMs labelled in orange.  Note that Hs_D3986E_gRNA3 targets the 
reverse strand but the sequence shown is the forward, coding strand.  
Sequencing chromatograms were viewed in 4Peaks software (Nucleobytes). 
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3.2.5 HDR template design 
Following confirmation that the gRNA regions were free of SNPs, the genomic 
human RYR1 reference sequence, NG_008866.1, was retrieved and used to 
manually design HDR templates that would introduce the variant of interest.  
HDR templates were designed as single stranded oligonucleotides that had 80 
base pairs of homology to the target sequence flanking the Cas9 cut site (Table 
3.6).  For Hs_D3986E_gRNA3, a silent mutation in the PAM site was 
introduced to prevent re-cleavage following successful incorporation of the 
HDR arms.  For Hs_D3986E_gRNA1 and Hs_D3986E_gRNA2, it was not 
possible to introduce a silent mutation in the PAM without affecting the amino 
acid coding sequence, so a number of silent mutations were added to the 12 nt 
seed region of the gRNA (Figure 3.5).  To facilitate the production of 
heterozygotes following transfection, two HDR templates were designed per 
gRNA – one which contained the edited p.D3986E variant plus the PAM/seed 
region silent mutations and one which contained the wild-type D3986 residue 
plus the PAM/seed region silent mutations. 
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Table 3.6 – Human RYR1 p.D3986E-targeting HDR template sequences 
HDR template sequences used to introduce the RYR1 p.D3986E variant into human immortalised myoblasts.  The gRNA sequences 
are shown in orange and edited bases in purple.  PAMs are shown in green and the base to be changed is shown in red.  The Cas9 cut 
site is indicated by a /.  
HDR template Sequence 5’-3’ 
Hs_D3986E_
HDR_gRNA1 
GATTCCCTTCCCCCCCACACGGCACTCTGCCTCCCAGGGTCCCTGCACCGGGAACCAGCAGAGCCTGGCGCACTCCAGGT/
TGTGGGAGGCAGTGGTGGGATTCCTGCACGTGTTCGCCCACATGATGATGAAGCTCGCTCAGGTTCGAGCCCCTCTGGTC 	
Hs_D3986E_
HDR_gRNA2 
GGATTCCCTTCCCCCCCACACGGCACTCTGCCTCCCAGGGTCCCTGCACCGGGAACCAGCAGAGCCTGGCGCACTCCAGG/
TTGTGGGAGGCAGTGGTGGGATTCCTGCACGTGTTCGCCCACATGATGATGAAGCTCGCTCAGGTTCGAGCCCCTCTGGT 	
Hs_D3986E_
HDR_gRNA3 
GCCTCCCAGGGTCCCTGCACCGGGAACCAGCAGAGCCTGGCGCACAGTCGCCTATGGGAGGCAGTGGTGGGATTTCTGCA/
CGTGTTCGCCCACATGATGATGAAGCTCGCTCAGGTTCGAGCCCCTCTGGTCTCCATCCACCTGCTTCCGGGCGTCCCCC 	
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Figure 3.5 – Human RYR1 p.D3986E-targeting HDR templates 
HDR arms were designed to include 80 bp of homology upstream and downstream of the Cas9 cut site. HDR templates were modified 
from the original target sequence to prevent re-cleavage by Cas9 following insertion into the genome, by introducing silent mutations 
into either the PAM sequence (panel C) or the seed region (panels A and B).  The gRNA sequences are shown in orange text, PAMs in 
green text, the base to be edited in blue text, the edited base in red and the silent mutations in purple.  Beneath the DNA sequences 
are the amino acid single letter codes.  
 
 
 
97 
 
3.2.6 Preparation of reagents for use in Cas9 protein system 
For the introduction of purified Cas9 in complex with the gRNA:tracrRNA 
duplex and pGCS, the gRNA:tracrRNA fusion was produced by in-vitro 
transcription (IVT) and the gRNA sequences (including their PAMs) were 
cloned into pGCS. 
 
3.2.6.1 In-vitro transcription of gRNAs 
Using the Precision gRNA synthesis kit (InvitrogenTM), the gRNA:tracrRNA 
fusion DNA template for IVT was produced by PCR using primers shown in 
Table 3.3.  Primer 1 contained a region of complementarity to the T7 promoter 
sequence and a 5’ portion of the gRNA specific sequence.  Primer 2 had a 
region of complementarity to the tracrRNA and the 3’ gRNA sequence that 
partially overlaps with the gRNA specific sequence on the forward primer 
(Figure 3.6).  Incubation of each primer in a PCR with the company-provided 
universal T7 primer, tracrRNA sequence and tracrRNA reverse primer would 
yield a full DNA template for gRNA synthesis. 
 
Figure 3.6 – PCR assembly schematic of the T7 promoter:gRNA:tracrRNA 
fusion 
Primer 1 was designed to include 16 nt of the gRNA sequence with the T7 
promoter sequence appended to the 5’.  Primer 2 was designed to include 19 
nt of the reverse complement gRNA sequence and 15 nt of the reverse 
complement tracrRNA sequence. Adapted from Thermo Fisher Scientific, 2016. 
Available at: 
https://tools.thermofisher.com/content/sfs/manuals/geneart_precision_gRNA_s
ynthesis_kit_man.pdf (accessed April 2017).   
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Successful assembly of the PCR template was determined by agarose gel 
electrophoresis of the resultant DNA fragment, to confirm its size.  Indeed, a 
~120 bp product was formed comprising the 18 nt T7 promoter sequence, 20 nt 
gRNA sequence and 80 nt tracrRNA sequence (Figure 3.7). 
Figure 3.7 – Confirmation of IVT template assembly 
IVT template assembly was confirmed by agarose gel electrophoresis on a 1% 
TAE-agarose gel.  Lane 1 contains the 100 bp plus ladder (NEB), lane 2 
contains the entire PCR reaction minus the gRNA specific primers, lanes 3, 4 
and 5 contain the Hs_D3986E_IVT_gRNA 1, 2 and 3 reactions, respectively.  
Lane 6 contains the reaction using company-provided positive control primers. 
 
 
Following confirmation of the correct template assembly, the templates were 
added to an IVT reaction containing NTPs and the T7 RNA polymerase and 
incubated at 37oC for 3 hours to synthesise the gRNA:tracrRNA fusion.  
Successful production of each gRNA:tracrRNA fusion by IVT was confirmed by 
RNA agarose gel electrophoresis of the resultant products (Figure 3.8).  
Indeed, a 100 nt band corresponding to the gRNA:tracrRNA fusion was 
observed in all samples.  The RNA was purified from the reaction using an 
RNA-binding spin column in preparation for complex formation with Cas9 and 
transfection into human immortalised myoblasts. 
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Figure 3.8 – Confirmation of IVT RNA product assembly 
RNA generation by IVT was confirmed by electrophoresis on a 1% TAE-
agarose gel.  Lane 1 shows the CenturyTM-Plus RNA marker (Ambion), lanes 2, 
3 and 4 show IVT reaction products from incubation with the 
Hs_D3986E_IVT_gRNA1, 2 and 3 templates, respectively.  Lane 5 shows the 
IVT reaction products from incubation with the template made using company-
provided positive control primers. 
 
3.2.6.2 Cloning into pGCS 
Oligonucleotides containing the gRNAs were designed to include overhangs to 
facilitate ligation into the pre-linearised pGCS vector (Table 3.4).  The forward 
and reverse oligonucleotides were annealed and incubated with pre-linearised 
pGCS in a ligation reaction.  Ligation reactions were transformed into 
OneShotTM chemically competent Stbl3TM cells (InvitrogenTM) and plated onto 
LB agar plates containing ampicillin at 100 μg/ml.  5 single colonies per gRNA 
were picked and used to inoculate LB media for plasmid isolation by miniprep.  
Isolated DNA was prepared for Sanger sequencing to confirm successful 
cloning (Figure 3.9).  All of the selected colonies contained the desired 
insertion.   
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Figure 3.9 – Sanger sequencing traces of human RYR1 p.D3986E-
targeting gRNAs in PGCS 
Following plasmid isolation, Sanger sequencing was used to confirm the 
insertion of Hs_D3986E_gRNA, 1 (panel A), 2 (panel B) and 3 (panel C) into 
pGCS.  The pGCS overhangs are shown in green, gRNA sequences in blue 
and the PAM is in orange.  Sequencing chromatograms were viewed in 4Peaks 
software (Nucleobytes).   
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3.2.7 Preparation of reagents or use in pSpCas9(BB)-2A-GFP 
plasmid system 
 
3.2.7.1 Cloning into pSpCas9(BB)-2A-GFP 
Prior to cloning, a restriction digest using BbsI and AgeI was used to confirm 
plasmid integrity and expected size and digestion products.  As expected, 
digestion with BbsI and AgeI resulted in the generation of 2 fragments of ~8 kb 
and ~1 kb.  Digestion of pSpCas9(BB)-2A-GFP with BbsI, results in the 
generation of overhangs.  The forward and reverse gRNA sequences designed 
with complementary overhangs to facilitate cloning into pSpCas9(BB)-2A-GFP 
(Table 3.5) were annealed to form double stranded DNA.  The duplexes were 
incubated with digested pSpCas9(BB)-2A-GFP in a ligation reaction before 
treatment with PlasmidSafe ATP-dependent DNase (Epicentre) to remove any 
residual linearised DNA that could affect transformation efficiency.  Ligation 
reactions were transformed into OneShotTM chemically competent Stbl3TM cells 
(InvitrogenTM) and colonies allowed to grow on LB agar plates containing 
ampicillin.  Four single colonies were picked per gRNA and used to inoculate 5 
ml LB broth for miniprep cultures and for use as starter cultures for maxipreps 
at a later date, as described previously.  Isolated plasmid DNA was screened 
for gRNA insertions by digestion with BbsI and AgeI – insertion of the gRNA 
removes the AgeI restriction site, thus the digest produces only a single band in 
successfully cloned plasmids. For all gRNAs, restriction digest showed that 
100% of the clones analysed contained the insert (Figure 3.10).  One colony 
per gRNA was selected for Sanger sequencing confirmation of the insertion 
(Figure 3.11).  The desired insertion was confirmed for each of the gRNAs. 
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Figure 3.10 - Restriction digest screening of pSpCas9(BB)-2A-GFP clones 
containing gRNAs 
Plasmid DNA was prepared by miniprep from 4 single colonies per gRNA and 
500-1000 ng added to a restriction digest with FastDigest BbsI and AgeI 
(Thermo Scientific).  The entire reaction was loaded onto a 1% TAE-agarose 
gel for electrophoresis.  For each image, lanes 1, 2 and 3 show the 1 kb Plus 
Extension DNA Ladder (InvitrogenTM), a no DNA negative control and a no 
insert pSpCas9(BB)-2A-GFP control, respectively.  Subsequent lanes show the 
pSpCas9(BB)-2A-GFP vector with the gRNA inserts. 
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Figure 3.11 - Sanger sequencing traces of human RYR1 p.D3986E-targeting gRNAs in pSpCas9(BB)-2A-GFP 
Sanger sequencing was used to confirm the insertion of Hs_D3986E_gRNA1, 2 and 3 into pSpCas9(BB)-2A-GFP.   The gRNA 
sequences are shown in blue and pSpCas9(BB)-2A-GFP overhangs are in green, with additional pSpCas9(BB)-2A-GFP sequence 
flanking the insertions shown in black.  Sequencing chromatograms were viewed in 4Peaks software (Nucleobytes). 
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3.2.8 Determining gene-editing capacity of gRNAs 
The T7 endonuclease I assay (T7 assay) detects and cleaves at mismatches in 
heteroduplex DNA caused by gene editing.  Due to their rapid growth and ease 
of transfection, human embryonic kidney (HEK)293 FT cells were plated in 6-
well plates and used to perform the T7 assay.  The pSpCas9(BB)-2A-GFP 
system was used to detect gene-editing due to the simplicity of transfection, 
relative ease of plasmid regeneration and cost effectiveness compared to the 
commercially supplied purified Cas9 protein.  The HEK293 FT cells were 
transfected with the pSpCas9(BB)-2A-GFP plasmids containing each gRNA 
using the Lipofectamine3000TM transfection reagent.  Importantly, no HDR 
templates were transfected alongside the plasmids at this stage.  Twenty four 
hours following transfection, GFP-expressing (i.e. transfected) cells were 
enriched by FACS using a 488 nm blue laser and 530/40 bandpass filter.  
Gates were drawn to exclude non-viable cells from the sort.  Cell viability was 
determined using the forward and side scatter profiles whereby non-viable cells 
tend to have lower forward scatter measurements (as a measure of size) and 
higher side scatter measurements (as a measure of granularity).  The 
transfected HEK293 FT cells had an overall viability of 95.94%, comparable to 
96.57% for non-transfected HEK293 FT cells (Figure 3.12; panels A and B).  
As expected, non-transfected cells showed low fluorescence values between 
100 and 101.  In contrast, the fluorescence values of transfected HEK293 FT 
cells are more broadly distributed across the fluorescence intensity spectrum, 
up to 104, indicating that GFP was being expressed in the transfected cells.  
Using the non-transfected cells as a reference, gates were drawn to define and 
collect the proportion of cells with GFP expression – this was 51.02% of the 
total population (Figure 3.12; panels C and D). 
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Figure 3.12 – FACS traces for HEK293 FT cells transfected with the 
pSpCas9(BB)-2A-GFP plasmid 
Transfected HEK293 Cells were incubated for 24 hours at 37oC, 5% CO2 prior 
to FACS.  Panels A and B show the side scatter profile (SSC; X axis) and 
forward scatter profile (FSC; Y axis) of HEK293 FT cells transfected with 
pSpCas9(BB)-2A-GFP and non-transfected HEK293 FT cells, respectively. 
Panels C and D show the cell count (Y axis) and fluorescence intensity count in 
arbitrary units (X axis) of GFP positive HEK293 FT cells and non-transfected 
HEK293 FT cells, respectively.  Non-transfected cells were used as a control to 
assist the drawing of GFP positive gates in the transfected sample.  The 
number of events corresponds to the number of cells detected by the laser and 
is usually measured between 10,000-200,000 cells dependent on the sample 
size, to give a snapshot of the profile of the cells. 
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For each gRNA, the GFP-expressing cells were pooled and genomic DNA 
extracted.  A 388 bp region around the gRNA cut site was amplified by PCR 
and purified using AMPureXP magnetic beads (Beckman CoulterTM).  The 
purified PCR product was denatured by heating and slowly reannealed, to 
encourage the formation of heteroduplex DNA. The heteroduplex products 
were incubated with T7 endonuclease I and separated by agarose gel 
electrophoresis (Figure 3.13).  Successful gene-editing by the gRNA-Cas9 
complex is indicated by the presence of cleavage products derived from the 
388 bp amplicon.  The size of the expected cleavage products was determined 
by the location of the Cas9 cut site within the amplicon.  Indeed, the T7 assay 
from HEK293 FT cells transfected with Hs_D3986E_gRNA 1, 2 and 3 yielded 
products corresponding to ~157 bp and 231 bp, 156 bp and 232 bp and 129 bp 
and 259 bp, respectively.  Furthermore, no cleavage products arose from the 
T7 assay from non-transfected cells. 
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Figure 3.13 – T7 assay to determine gene editing capacity of 
Hs_D3996E_gRNA 1, 2 and 3 in HEK293 FT cells. 
Products from T7 assay were separated by gel electrophoresis on a 1% TAE-
agarose gel.  Lane 1 shows the 100 bp DNA ladder (NEB), lane 2 shows the 
T7 assay from cells transfected with the Hs_D3986E_gRNA1 plasmid without 
the T7 enzyme, lane 3 shows the T7 assay from cells transfected with the 
Hs_D3986E_gRNA1 plasmid with the T7 enzyme, lane 4 shows the T7 assay 
from cells transfected with the Hs_D3986E_gRNA2 plasmid without the T7 
enzyme, lane 5 shows the T7 assay from cells transfected with the 
Hs_D3986E_gRNA2 plasmid with the T7 enzyme, lane 6 shows the T7 assay 
from cells transfected with the Hs_D3986E_gRNA3 plasmid without the T7 
enzyme, Lane 7 shows the T7 assay from cells transfected with the 
Hs_D3986E_gRNA3 plasmid with the T7 enzyme, lane 8 shows the T7 assay 
from non-transfected cells without the T7 enzyme and lane 9 shows the T7 
assay from non-transfected cells with the T7 enzyme. 
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ImageJ was used to quantify the relative intensity (which is proportional to DNA 
quantity) of each band by 2D densitometry.  The percentage of product cleaved 
for Hs_D3986E_gRNA1, 2 and 3 was 62.6%, 31.5% and 23.0%, respectively.  
Gene-editing efficiency was calculated using Equation 1, where the fraction 
cleaved is the sum of the cleaved fragments divided by the sum of all 
fragments (Guschin et al., 2010). 
 
Equation 1. %	#$%$	&'()*)+,-)'% = /00 × 2/ − (/ − *5,+-)'%	+6$,7$() / 9: ;				 
 
The percentage gene modifications of Hs_D3986E_gRNA1, 2 and 3 were 
39.2%, 17% and 12.3%, respectively.  Since Hs_D3986E_gRNA1 had the 
highest predicted gene-editing efficiency and had the shortest distance 
between the base to be edited and the Cas9 cut site, this gRNA was selected 
for future work. 
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3.2.9 Transfection of human immortalised myoblasts 
Following the determination that all gRNAs induced gene-editing in HEK293 FT 
cells, progress was made towards implementing both the Cas9 protein system 
and pSpCas9(BB)-2A-GFP plasmid system in human immortalised myoblasts. 
 
3.2.9.1 Transfecting Cas9, pGCS and gRNA:tracrRNA  
Prior to full transfection of the Cas9:tracrRNA:gRNA complex alongside pGCS, 
human immortalised myoblasts were treated with 
LipofectamineTMCRISPRMAXTM reagent to determine whether any cell toxicity 
could be observed from the lipid reagent.  Human immortalised myoblasts were 
plated in 6-well plates and treated with the reagent for 24 hours in triplicate.  
Following treatment, images were captured of the cells to observe cell 
morphology using the EVOSTM FL microscope (Figure 3.14).  Cell viability was 
estimated by trypan blue staining and counting using a haematocytometer; the 
estimated cell viability before treatment was 98.6% and 95.5% following 
treatment, suggesting that there is no significant detrimental effect on the use 
of CRISPRMAXTM reagent on human immortalised myoblast viability.  Both 
before and after treatment, cells appeared spindle-like in shape, characteristic 
of healthy human myoblasts and adhered to the surface of the cell culture flask 
(Figure 3.14). 
 
Figure 3.14 – Human immortalised myoblasts treated with CRISPRMAXTM 
reagent 
Human immortalised myoblasts were plated at 1.5 x 105 cells per well in a 6-
well plate with 1 ml growth media.  3 wells were maintained in growth media 
(panel A) and 3 were treated with 250 μl OptiMEM media, 7.5 μl 
CRISPRMAXTM and 5 μl Cas9 plus reagent (panel B).  Cells were incubated for 
24 hours at 37oC, 5% CO2 prior to analysis.  Images were captured using the 
EVOSTM FL microscope using the x10 objective.  The scale bar shows 1000 
μM. 
 
 
 
110 
Following confirmation that the CRISPRMAXTM reagent was not detrimental to 
cell viability, a full transfection of Cas9, pGCS, the tracrRNA:gRNA fusion and 
the HDR templates was performed in triplicate.  Human immortalised 
myoblasts were plated in 6-well plates and transfected with all reagents using 
CRISPRMAXTM transfection reagent.  Following incubation for 24 hours, a 
marked increase in cell death was observed, with 78.5% of the cells rounded in 
shape and detached from the surface of the plate (Figure 3.15).  Despite this, 
the remaining cells were obtained for FACS to confirm OFP expression and 
separate transfected cells from non-transfected cells into a single cell per well 
in a 96-well plate for cell line propagation (Figure 3.16).  In total, FACS for bulk 
OFP enrichment was attempted 4 times and single-cell collection was 
attempted 2 times.  FACS was performed using a 561 nm laser and 585/30 
bandpass filter.  Gates were drawn to exclude non-viable cells from the sort as 
described previously.  Despite significant cell death following transfection, the 
mean viability of the remaining cells was 88.46% (cf. 95.94% for HEK293 FT 
plasmid transfection) and for non-transfected cells the mean viability was 
97.752%.  The mean proportion of OFP positive cells within the population was 
26.0%.   
 
Figure 3.15 – Human immortalised myoblasts following full transfection 
of Cas9, gRNA:tracrRNA, pGCS and HDR templates 
Human immortalised myoblasts were plated at 1.5 x 105 cells per well in a 6 
well plate with 1 ml growth media (2 full 6-well plates were used per 
transfection).  250 μl OptiMEM media, 7.5 μl CRISPRMAXTM, 12.5 μl Cas9 plus 
reagent, 1.2 μg gRNA:tracrRNA, 6.25 μg Cas9, 2.5 μg pGCS and 5 μl of 10 μM 
HDR templates were added to 3 wells and incubated for 24 hours at 37oC, 5% 
CO2.  Images were captured using the EVOSTM FL microscope using the x10 
objective.  The scale bar shows 1000 μM. 
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Figure 3.16 – FACS traces of human immortalised myoblasts following 
transfection with Cas9, tracrRNA:gRNA, pGCS and HDR templates. 
Transfected human immortalised myoblasts (between doubling number 51 and 
60) were incubated for 24 hours at 37oC, 5% CO2 prior to FACS.  Panels A and 
B show the side scatter (SSC; X axis) and forward scatter (FSC; Y axis) 
profiles for transfected and non-transfected cells, respectively.  Panels C and D 
show the cell counts (X axis) and fluorescence intensity in arbitrary units (Y 
axis) for OFP positive and OFP negative cells, respectively.  The number of 
events corresponds to the number of cells detected by the laser and is usually 
measured between 10,000-200,000 cells dependent on the sample size, to 
give a snapshot of the profile of the cells.  A representative trace of a bulk cell 
collection FACS sort has been shown for reference; however, bulk enrichment 
was attempted 4 times and single cell collection was attempted twice. 
 
Promising levels of OFP expression were achieved in human immortalised 
myoblasts transfected with all components of the Cas9 protein system, 
indicating that the system was functional and gene-editing had occurred; 
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however, cells isolated for both single cell propagation and bulk cell storage 
failed to survive.  For the optimisation of bulk cell collection, collection media 
was provided in different ratios of conditioned:fresh media – 0:1, 1:1, 1:2 and 
1:4 and cells were added to ECL-coated flasks.  Despite this, cells failed to 
attach to the surface of the plate.  For single cell collection, two ratios of 
conditioned:fresh media were used – 1:1 and 1:2 and 96-well plates were 
coated with ECL.  Unfortunately, no single cells appeared to show signs of 
growth.  Since transfection of the Cas9 protein system resulted in significant 
cell death, the pSpCas9(BB)-2A-GFP system was implemented and optimised 
in an attempt to limit cell death following transfection and encourage cell 
survival following FACS. 
 
3.2.9.2 Transfecting pSpCas9(BB)-2A-GFP 
To ensure that the LipofectamineTM 3000 reagent did not have obvious 
cytotoxic effects on human immortalised myoblasts, the cells were plated in 6-
well plates and treated with the reagent for 24 hours in triplicate.  Images were 
captured and cell viabilities estimated as described previously.  The estimated 
cell viabilities of non-treated cells and treated cells were 98.6% and 97.7%, 
respectively.  Both before and after treatment, cells remained spindle-like in 
shape and adhered to the surface of the cell culture flask (Figure 3.17).  Thus, 
like the CRISPRMAXTM reagent, Lipofectamine 3000TM did not appear to have 
any significant effect on cell viability. 
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Figure 3.17 – Human immortalised myoblasts following treatment with 
LipofectamineTM 3000 reagent 
Human immortalised myoblasts were plated at 1.5 x 105 cells per well with 1 ml 
growth media in a 6-well plate.  250 μl OptiMEM media, 7.5 μl LipofectamineTM 
3000 and 5 μl p3000 reagent were added to the cells and incubated overnight 
at 37oC, 5% CO2.  Images were captured using the EVOSTM FL microscope 
using the x40 objective.  The scale bar shows 1000 μM. 
 
3.2.9.2.1 Viability of human immortalised myoblasts following transfection of 
pSpCas9(BB)-2A-GFP 
Following the determination that LipofectamineTM 3000 does not cause any 
obvious cell toxicity, the transfection of pSpCas9(BB)-2A-GFP containing 
Hs_D3986E_gRNA1 alongside HDR templates was performed.  To determine 
optimal conditions for the transfection, a range of DNA:LipofectamineTM 3000 
ratios and volumes were tested in triplicate.  Transfection efficiency was 
estimated by counting the proportion of GFP expressing cells within a given 
area using the EVOSTM FL counting tool.  The estimated transfection 
efficiencies of cells transfected with 0.5 μg DNA and 0.75 μl LipofectamineTM 
3000 (1:1.5 ratio; Figure 3.18 panel A), 0.5 μg DNA and 1.5 μl LipofectamineTM 
3000 (1:3 ratio; Figure 3.18 panel B), 1 μg DNA and 0.75 μl LipofectamineTM 
3000 (1.3:1 ratio, Figure 3.18 panel C) and 1 μg DNA and 1.5 μl 
LipofectamineTM 3000 (1:1.5 ratio; Figure 3.18 panel D) were 2.5%, 4.8%, 7.1% 
and 7.7%, respectively).   
 
With all LipofectamineTM 3000 doses, cell death was observed with cells 
forming ball-shaped structures (as opposed to healthy spindle-like myoblasts) 
that detached from the surface of the plate (Figure 3.18).  The average 
estimated viabilities of cells transfected with 0.5 μg DNA and 0.75 μl 
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LipofectamineTM 3000 (1:1.5 ratio; Figure 3.18 panel A), 0.5 μg DNA and 1.5 μl 
LipofectamineTM 3000 (1:3 ratio; Figure 3.18 panel B), 1 μg DNA and 0.75 μl 
LipofectamineTM 3000 (1.3:1 ratio, Figure 3.18 panel C) and 1 μg DNA and 1.5 
μl LipofectamineTM 3000 (1:1.5 ratio; Figure 3.18 panel D) were 81.1%, 64.7%, 
68.1% and 60.11%, respectively.  The estimated viability of non-transfected 
cells was 84.7%. 
  
 
Figure 3.18 - Human immortalised myoblasts transfected with 
pSpCas9(BB)-2A-GFP 
Human immortalised myoblasts were plated at 3 x 104 cells per well in a 24-
well plate and treated with a range of DNA:LipofectamineTM 3000 ratios and 
volumes - with 0.5 μg DNA and 0.75 μl LipofectamineTM 3000 (panel A), 0.5 μg 
DNA and 1.5 μl LipofectamineTM 3000 (panel B), 1 μg DNA and 0.75 μl 
LipofectamineTM 3000 (panel C) and 1 μg DNA and 1.5 μl LipofectamineTM 
3000 (panel D).  2 μl p3000 reagent was added per μg of DNA.  Lipid 
complexes were incubated at room temperature for 20 min before being added 
dropwise to cells.  Cells were incubated for 24 hours at 37oC, 5% CO2 prior to 
image capture using the EVOSTM FL microscope with a x40 objective.  The 
scale bar shows 400 μM. 
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The conditions resulting in the highest cell viability (0.5 μg, 0.75 μl 
Lipofectamine 3000) were selected for future use in transfections.  FACS was 
performed using the 488 nm blue laser and 530/40 bandpass filter to isolate 
GFP-expressing cells and sort into single cells per well of 96-well plates.  
Unlike the Cas9 protein system, GFP expression using the pSpCas9(BB)-2A-
GFP plasmid system is not necessarily indicative of gene-editing and acts as a 
marker of transfection only.  Gates were drawn as described previously to 
exclude non-viable cells from the sort and to enrich GFP positive cells.  A 
representative trace of human immortalised myoblasts transfected with 
Hs_D3986E_gRNA1 prior to single cell sorting is shown for reference (Figure 
3.19); however, bulk GFP-cell enrichment and single-cell collection were each 
attempted twice.  In this instance, the percentage of GFP positive cells in the 
sample was 5.68%.  Of the cells that remained following detachment from the 
surface of the plate after transfection, the viability was 96.15%.  The viability of 
non-transfected cells was 97.44%.  Across repeated sorts, the percentage of 
GFP positive cells varied with a mean of 7.11% (range 1.42%-15.31%).  The 
mean viability of transfected cells was 97.54% and the mean viability of non-
transfected cells was 97.0%.  Despite encouraging viabilities of the remaining 
cells following transfection, similarly to human immortalised myoblasts 
transfected with the Cas9 protein system, FACS-sorted cells failed to 
propagate following collection in filtered conditioned media:fresh media at a 
ratio of 0:1 or 1:1.   
 
The immortalised human myoblasts used in this project were routinely cultured 
in Hams-F10 Nutrient Mix (GibcoTM) supplemented with 20% FBS and 2.5 
ng/ml as per routine myoblast culture protocols (Rezniczek et al., 2016); 
however, since the use of PromoCell Skeletal Muscle Growth media has been 
reported elsewhere (Lattanzi et al., 2017), a batch of human immortalised 
myoblasts were cultured in this media and subject to transfection and FACS for 
bulk cell enrichment as described previously.  No clear improvements in cell 
viability, transfection efficiency or cell survival were observed.  After gating, 
non-transfected cells had a viability of 76.32% and cells transfected with 
Hs_D3986E_gRNA1 had a cell viability of 84.17%.  The proportion of GFP-
positive cells after gating was 5.49%.  Whilst the cell viabilities were lower here 
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than in previous sorts, it cannot be determined whether this is due to a change 
in media since transfection and FACS in PromoCell Skeletal Muscle media was 
performed once.  Unfortunately, FACS-sorted cells did not survive bulk cell 
enrichment following collection in a 1:1 ratio of conditioned:fresh PromoCell 
Skeletal Muscle Growth media.   
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Figure 3.19 – FACS traces of human immortalised myoblasts transfected 
with pSpCas9(BB)-2A-GFP 
Transfected human immortalised myoblasts (between doubling number 51 and 
60) were incubated for 24 hours at 37oC, 5% CO2 prior to FACS.  Panels A and 
B show the side scatter (SSC; X axis) and forward scatter (FSC; Y axis) 
profiles for transfected and non-transfected cells, respectively.  Panels C and D 
show the cell counts (X axis) and fluorescence intensity in arbitrary units (Y 
axis) for GFP positive and GFP negative cells, respectively.  The number of 
events corresponds to the number of cells detected by the laser and is usually 
measured between 10,000-200,000 cells dependent on the sample size, to 
give a snapshot of the profile of the cells.  A representative trace of a cell 
population prior to single cell sorting has been shown for reference.  In total, 
bulk cell enrichment was attempted 2 times in Hams-F10 media and once in 
PromoCell Skeletal Muscle media.  Single cell collection was attempted 2 times 
in Hams-F10 media. 
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3.3 Discussion and future directions 
The results presented in this chapter demonstrate significant progress towards 
implementing CRISPR-Cas9 in human immortalised myoblasts for a novel 
method of functional characterisation of MH-associated VUS, namely, 
p.D3986E.   
 
CRISPR-Cas9 genome-editing was selected for use in this project as it 
overcomes the requirement for the laborious site directed mutagenesis, cloning 
and transfection of large RYR1 constructs that has been considered a 
bottleneck in MH-associated VUS characterisation.  Furthermore, it allows 
functional characterisation to take place in the context of a muscle cell with a 
constant genetic background, where ECC machinery is expressed following 
differentiation into myotubes (Park et al., 1998).  For targeting of the human 
p.D3986E variant, medium to high quality gRNAs targeting the region of 
interest were designed with relative ease.  Using CCTOP, a search for gRNAs 
with the sequence flanking 50 bp either side of the base to be edited returned 
14 gRNAs (Stemmer et al., 2015).  The gRNAs for use were selected based on 
their ranking by CCTOP (determined by the number and location of off-targets 
and efficacy score) and proximity to the desired base change, since increased 
gene editing efficiencies are observed when the base to be edited is located as 
close as possible to the Cas9 cleavage site (Ran et al., 2013a).  In this case, 
the requirement of a PAM did not hinder the design of gRNAs, since the NGG 
dinucleotide repeat was located frequently within the region of interest; 
however, it is important to consider that gRNAs targeting in such close 
proximity to the base to be edited may not be possible for all MH associated 
VUS.  Indeed, on average, GG dinucleotide repeats are located every 42 bp in 
the human genome (Scherer, 2008). 
 
For Hs_D3986E_gRNA1 and 2, it was not possible to introduce a silent 
mutation in the PAM to prevent re-cleavage following incorporation into the 
genome.  The final G base of the PAM for Hs_D3986E_gRNA1 (GGG, 
encoding glycine) was also the first base of the GAC codon to be edited.  The 
alternative codons for glycine are GGA, GGC and GGT.  Mutation of the final G 
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base in the glycine codon to A, C or T would have changed the aspartate 
codon at position 3986 to AAC (asparagine), CAC (histidine) or TAC (tyrosine), 
respectively.  For Hs_D3986E_gRNA2, the PAM was TGG, the only codon that 
encodes tryptophan so could not be mutated silently.  In both cases, it was 
possible to introduce silent mutations in the 10-12 nt ‘seed region’ proximal to 
the PAM, which is essential for sequence specific targeting of Cas9 (Wu et al., 
2014).  In most cases, the presence of just two mismatches within the seed 
region abolishes Cas9 activity so the inability to silently mutate the PAM in 
other MH-associated VUS targeting gRNAs is unlikely to hinder gRNA/HDR 
template design (Anderson et al., 2015).  Since all MH diagnostic variants and 
VUS are found in the heterozygous form (with the exception of STAC3 
p.W284S variant), generation of both homozygote cells and heterozygote cells 
would be optimal for functional studies. To facilitate this, HDR arms containing 
both the edited base and wild-type base were designed for introduction into 
human immortalised myoblasts.  Another method for the generation of 
heterozygotes is optimisation of the cut-to-mutation distance.  For the 
introduction of Alzheimer’s disease associated point mutations, a cut-to-
mutation distance of 23 nt produced ~50% heterozygotes compared to 100% 
homozygotes with a cut-to-mutation distance of 2 nt (Paquet et al., 2016).   
 
Off-target activity is a major concern in any CRISPR-Cas9 genome-editing 
experiment.  Hs_D3986E_gRNA 1, 2 and 3 were predicted to have 8, 27 and 
43 off-targets, respectively.  For comparison, the lowest ranking p.D3986E-
targeting gRNA generated by CCTOP had 205 off-targets.  Since no edited 
human immortalised myoblast lines were obtained, it is not possible to 
comment on the off-target activity of the specific gRNAs designed in this 
chapter; however, high-throughput screening of 380 gRNAs showed that 96% 
do not function when they contain 2 mismatches to the target.  Since all gRNAs 
designed in this chapter had at least 2 mismatches and, in most cases, 4 
mismatches to the in-silico predicted off-target sites, it is likely that the gRNAs 
function with specificity to the desired target (Anderson et al., 2015).  MiSeq 
deep sequencing performed on iPSC-derived myogenic cell lines edited in the 
DMPK gene to correct myotonic dystrophy defects showed 0 to 0.3% off-target 
activity at the two most probable off-target sites (as predicted using the 
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Optimised CRISPR Design Tool formerly available at http://crispr.mit.edu) 
(Dastidar et al., 2018).  Despite this, it is important to consider that off-target 
activity may occur at locations other than those predicted by computational 
algorithms and ultimately, genome-wide profiling is necessary to rule out all off-
target activity (Tsai et al., 2015). 
 
Two strategies to introduce the p.D3986E into human immortalised myoblasts 
were implemented in this chapter.  At the time of starting the work, significantly 
more literature was available utilising the pSpCas9(BB)-2A-GFP system; 
however, an emerging body of evidence indicated that increased gene-editing 
efficiencies and reduced off-target activities were achieved with the Cas9 
protein system in conjunction with a purified gRNA:tracrRNA fusion (Ran et al., 
2013a; Dewari et al., 2018; Mason et al., 2018; Xu et al., 2018).  The human 
immortalised myoblasts used in this chapter were sensitive to both plasmid and 
protein transfection, with the protein system resulting in the largest reductions 
in cell viability following transfection.  Nonetheless, sufficient numbers of cells 
survived for use in FACS and both systems resulted in moderate transfection 
efficiencies determined by FACS of ~7% for the plasmid system and ~26% for 
the protein system which are comparable to myoblast transfection efficiencies 
reported in the literature (Jackson et al., 2013). 
 
Alternatives to fluorescence were available for the selection of 
transfected/edited cells.  The pSpCas9(BB)-2A-GFP was available with a 
puromycin resistance marker rather than GFP (Addgene plasmid PX459, 
deposited by Feng Zhang) and the pGCS vector contains partial overlapping 
sequences for the CD4 gene in addition to the OFP coding sequence, allowing 
enrichment of edited cells using Dynabeads® CD4 antibody conjugated 
magnetic beads (InvitrogenTM).  Fluorescence-based enrichment was deemed 
optimal for several reasons.  Firstly, selection by FACS retains lower passage 
numbers in transfected cells, since antibiotic selection would need to be 
performed over several days.  Secondly, FACS allows for the automated 
sorting of single cells into wells of a 96-well plate for the propagation of 
monoclonal cell populations.  An alternative procedure for the isolation of single 
cells in cell populations that are sensitive to FACS is to perform a limiting 
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dilution of enriched cells.  Whilst this method would overcome issues 
associated with FACS, it is important to consider that results generated 
elsewhere in this project suggest that myoblast propagation from single cells is 
inefficient, with only a proportion showing growth (sections 4.2 and 5.2).  As 
such, a vast number of dilutions may need to be performed to obtain sufficient 
number of cell lines for screening.  Nonetheless, it is a promising alternative to 
FACS that should be explored for future development of CRISPR-Cas9 in 
human immortalised myoblasts. 
 
The reasons for lack of cell survival following FACS observed in this chapter 
are undetermined, since average cell viabilities of cells subjected to FACS 
were relatively high for both systems and HEK293 FT cells consistently 
survived FACS.  Since FACS involves the movement of cells through narrow 
tubing under pressure and the application of an electric charge to the cells prior 
to collection, it is likely that the process is inherently damaging to more 
sensitive cell types (Herzenberg et al., 1976).   
 
CRISPR-Cas9 genome-editing has previously been performed on human 
immortalised myoblasts obtained from the Institut de Myologie (Paris, France).  
The CRISPR-Cas9 system was used to correct mutations associated with 
Duchenne muscular dystrophy (DMD), namely the targeted deletion of 
duplicated exon 2 in the DMD gene and myotonic dystrophy type 1 (DM1) by 
the targeted deletion of (CTG⋅CAG)n-repeats in the DMPK gene (Ousterout et 
al., 2015; Lattanzi et al., 2017; Van Agtmaal et al., 2017).  Unlike the work 
presented in this chapter, none of these studies used HDR templates to 
introduce a specific variant but delivered gRNAs to induce a knock-out by 
NHEJ.  Lattanzi et al., (2017) used lentiviral vectors to transduce myoblasts 
with higher efficiencies than lipid-based transfections.  Van Agtmaal et al., 
(2017) used nucleofection to introduce purified Cas9 protein alongside a 
gRNA:tracrRNA fusion RNA inot the cells and FACS was performed to enrich 
GFP-expressing cells two days post transfection (cf. 24 hours as used in this 
chapter).  Ousterout et al., (2015) utilised a plasmid-based system to introduce 
the gRNA:tracrRNA and Cas9 into cells by electroporation followed by 
enrichment of GFP-expressing cells using FACS.  The exploitation of the 
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CRISPR-Cas9 system for the correction of disease-causing mutations provides 
a promising insight into feasibility of using CRISPR-Cas9 to introduce MH-
associated VUS into human immortalised myoblasts.  Nonetheless, the work 
presented here shows that genetic manipulation of human myoblasts remains 
difficult and optimisation of the CRISPR-Cas9 pipeline is required. 
 
As illustrated in this chapter, the Cas9 protein system is more laborious than 
the pSpCas9(BB)-2A-GFP system, requiring the cloning of gRNAs into pGCS 
and the generation of gRNAs by IVT and their subsequent purification.  Another 
practical consideration is that the Cas9 protein reagents used in this chapter 
were all commercially supplied meaning that unlike the pSpCas9(BB)-2A-GFP 
plasmid, they were not easily nor cost-effectively regenerated.  The ease of 
regeneration of the pSpCas9(BB)-2A-GFP plasmid was the reason for its use 
in the T7 assay in HEK293 cells and HEK293 cells were chosen for use due to 
their rapid growth and ease of transfection.  The T7 assay determined gene 
editing efficiencies of Hs_D3986E_gRNA1, 2 and 3 to be 39.2%, 17% and 
12.3%, respectively.  These values show the same hierarchy in efficiency as 
the efficacy prediction by the in-silico CRISPRater tool which for 
Hs_D3986E_gRNA1, 2 and 3 were 82, 76 and 68, respectively, potentially 
allowing a single gRNA to be designed in the future if CRISPRater efficacy 
predictions are supported by more functional work.  Since no edited cell lines 
were obtained, the accuracy or sensitivity of the T7 assay in this case cannot 
be commented on. 
3.3.1 In-silico investigations of p.D3986E pathogenicity 
Whilst the determination of functional significance of the p.D3986E variant in 
myotubes was beyond the scope of this chapter, in-silico pathogenicity tools 
and investigation of the levels of conservation across species of the residue 
have provided insight into the potential pathogenicity of the variant.   
Three in-silico predictors of pathogenicity were used in this chapter because 
they each use different parameters to predict the effect of a variant.  In a study 
addressing the sensitivity and specificity of these tools for prediction of MH-
associated variant pathogenicity, SIFT identified three diagnostic MH RYR1 
variants as ‘tolerated’ and PolyPhen-2 identified one as ‘benign’; however, both 
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tools correctly identified all true negatives when common sequence variants 
were tested.  CADD identified all diagnostic MH RYR1 variants as being 
potentially pathogenic but predicted half of the common RYR1 sequence 
variants tested to be potentially pathogenic using a user-defined cut-off score 
of 15 (Schiemann and Stowell, 2016).  Whilst this study clearly demonstrates 
bioinformatic data cannot be relied upon alone for determination of functional 
significance, it can at least provide a screening tool for MH-associated VUS in 
combination with segregation data and MAF.  In this chapter, SIFT, PolyPhen-2 
and CADD all identified p.D3986E as potentially pathogenic or an equivalent 
annotation.  SIFT predicts makes predictions on a protein level whereby 
residue conservation and amino acid class are considered (Ng and Henikoff, 
2003; Sim et al., 2012).  The transition from D to E results in the addition of a 
CH2 group to the amino acid side chain but the amino acid retains its acidic 
property.  The SIFT tool classified p.D3986E as damaging, despite the 
relatively mild D to E substitution.  Indeed, a number of functionally 
characterised MH variants result from amino acid changes that do not affect 
the charged state or polarity such as p.R530H and p.V4849I (EMHG, available 
at www.emhg.org, accessed August 2019).   
 
Across all homologues analysed, the p.D3986 residue was highly conserved, 
suggesting that it could have an important structural or functional role.  Using 
ConSurf, p.D3986 was predicted to be an exposed residue and therefore likely 
to have a functional role.  Indeed, exploration of the rabbit RYR1 3D structure 
using PyMOL (Schrödinger, LLC) indicated that the p.D3986 was exposed on 
the surface of the protein (Yan et al., 2015).  Such advances in resolving the 
rabbit RYR1 structure have revealed that the p.D3986 residue is located within 
the central domain of RYR1 – the only cytoplasmic domain that interacts with 
the channel domain and forms part of the activation module, presumably 
relaying conformational signals between the ligand sending cytoplasmic 
domain and pore forming channel domain (Yan et al., 2015; des Georges et al., 
2016).  Using the PyMOL mutagenesis wizard, mutagenesis of D to E does not 
disrupt normal hydrogen bonding but does result in the generation of VdW 
clashes in all possible rotamer conformations.  VdW clashes occur when VdW 
radii overlap and produce repulsion effects.  Since VdW clashes are not 
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physically allowed, the p.D3986E would likely result in an alteration in local 
protein structure at this position; however, in-silico mutagenesis does not allow 
one to determine whether this alteration in structure would be tolerated or not. 
Nonetheless, the co-segregation of the p.D3986E variant with the MH 
phenotype in multiple MH families referred to the Leeds MH Unit, in conjunction 
with bioinformatic data, make p.D3986E a promising candidate for a role in MH.  
Previous studies in our group have shown that HEK293 cells expressing 
p.D3986E RYR1 channels do not have a significantly reduced EC50 to caffeine 
compared to wild-type RYR1 channels (Merritt et al., 2017).   It is possible that 
an effect of p.D3986E depends upon the expression of other ECC apparatus 
that are absent in HEK293 cells or depends upon the presence of an additional 
variant that has not been yet been identified; however, without functional data 
for p.D3986E in myotubes, its role remains to be elucidated and this will be 
addressed in Chapter 4. 
 
3.3.2 Future directions 
 
In the first experiments of their kind in the Leeds MH Unit and the wider MH 
field, this chapter has provided significant insight into the development of a 
CRISPR-Cas9 methodology for the introduction of MH-associated VUS into 
human immortalised myoblasts and highlighted some key considerations to be 
made for future use which are detailed below. 
 
3.3.2.1 Selection of the cell line for genome-editing 
One of the major benefits of using CRISPR-Cas9 to introduce MH-associated 
VUS is that it is performed in a single cell line with a constant genetic 
background.  The work presented in this chapter has highlighted the 
importance of using a robust cell line for editing.  Whilst optimisation of several 
factors could improve the survival of the human immortalised myoblasts used 
here, alternative cell types should be considered for future work.  A growing 
number of reports detail the use of induced pluripotent stem cells (iPSCs) 
programmed into myogenic lines (Dastidar et al., 2018; Young et al., 2016); 
however, to the best of my knowledge iPSCs have not been used in the wider 
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MH field and are likely to require optimisation of differentiation protocols that 
would hinder immediate progress in the functional characterisation of MH-
associated VUS.  Alternative cell types include primary mouse cells, 
immortalised mouse cells and C2C12 cells – an immortal mouse myoblast cell 
line generated from the serial passage of cells derived from C3H mouse 
muscle (Yaffe and Saxel, 1977).   
 
3.3.2.2 Consideration of the feasibility of the Cas9 protein system in its 
current form 
The pSpCas9(BB)-2A-GFP plasmid system is easily regenerated and 
comprises a single cloning step followed by transfection of a single plasmid.  In 
contrast, the Cas9 protein system is more laborious, requiring the IVT, 
purification and quantification of gRNAs and cloning into pGCS, followed by the 
transfection of Cas9, the gRNA and pGCS into cells.  The Cas9 protein used in 
this chapter was commercially supplied (GeneArt Platinum Cas9 Nuclease, 
InvitrogenTM), limiting its ease of regeneration.  For future work using the Cas9 
protein system, in-house heterologous expression and purification of Cas9 
would be advantageous. 
 
3.3.2.3 FACS alternatives 
Alternative strategies that circumvent the need for FACS sorting such as the 
use of a pSpCas9(BB)-2A vector encoding puromycin would enable enrichment 
of transfected cells by puromycin selection and single cell isolation by limiting 
dilution; however, as mentioned previously, the feasibility of performing limiting 
dilutions to obtain sufficient cell lines for screening would need to be explored. 
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Chapter 4 – Exploration of the utility of CRISPR-Cas9 in the 
functional characterisation of MH-associated variants in 
C2C12 myoblasts 
4.1 Introduction 
Previous attempts to introduce the RYR1 p.D3986E variant into human 
immortalised myoblasts highlighted challenges in the utilisation of CRISPR-
Cas9 genome editing to introduce MH-associated variants for downstream 
functional characterisation.  To address the difficulties that were associated 
with the use of human immortalised myoblasts, CRISPR-Cas9 gene-editing will 
be performed using C2C12 mouse myoblasts for the introduction of the RYR1 
p.D3986E and p.S1728F variants.  The C2C12 myoblast line is a subclone of 
cells generated by the isolation of satellite cells following repeated crush injury 
of C3H mouse thigh muscle (Yaffe and Saxel, 1977; Blau et al., 1983).  C2C12 
cells are not bound by the limited replicative potential associated with primary 
cells and they form multinucleated myotubes following cell culture in conditions 
that promote differentiation.  As such, they have been used extensively in the 
study myogenesis.  For example, recently, a small interfering RNA (siRNA) 
screen of 100 genes previously uncharacterised with regard to their function in 
myogenesis, revealed 13 novel genes implicated in differentiation, providing 
candidates for further in-vivo studies (Alwan et al., 2017).  In another study, the 
Stac3 gene, which has recently been implicated in MH, was shown to act as a 
negative regulator of C2C12 cell differentiation (Ge et al., 2014).   As such, 
studies in C2C12 cells have contributed to our understanding of the complex 
mechanisms governing myogenesis that will, ultimately, facilitate the 
development of regenerative medicine approaches to the treatment of 
myopathies.   
 
The same characteristics that have validated C2C12 cells for the study of 
myogenesis also make them a promising candidate for use in MH-associated 
VUS characterisation via CRISPR-Cas9 genome editing.  The majority of 
reports of CRISPR-Cas9 genome editing in C2C12 cells are in the context of 
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NHEJ.  Xu et al., (2016) performed proof-of-principle in-frame deletion of DMD 
gene exons 21-23 to overcome a pathogenic nonsense mutation in exon 23, 
prior to post-natal editing in the mdx DMD mouse model, Wang et al., (2017) 
used CRISPR-Cas9 to explore the effect of MyoD ablation in C2C12 cells and 
Kim et al., (2019) used CRISPR-Cas9 to knockout the STIM2β splice variant in 
C2C12 cells that revealed a role for STIM2β in myogenesis.  To date, C2C12 
cells have not been utilised in the characterisation of MH-associated VUS since 
they express the Ryr1 following differentiation and current strategies rely on 
heterologous expression of variant Ryr1 cDNAs into Ryr1 null cells e.g. 
dyspedic myotubes or more commonly, HEK293 cells. 
 
4.1.1 Selection of the p.S1728F variant 
Whilst it is important to emphasise that any results observed in mouse cells 
may not directly recapitulate the response in human cells, the mouse RYR1 
protein and human RYR1 protein share 96% homology at the amino acid level.  
The human RYR1 variant p.S1728F comprises a serine (S) to phenylalanine 
(F) substitution resulting from a C to T variant at cDNA position 5183, changing 
the codon from TCC to TTC.  Both the amino acid residue and codon are 
conserved in the mouse genome.  In contrast, the p.D3986E variant that results 
from a GAC to GAG codon change in humans results from a GAT to GAG 
alteration in the mouse genome, whilst the D residue is conserved at an amino 
acid level.   
 
The p.S1728F variant was selected for characterisation due to its enrichment in 
in MHShc/MHSh individuals across multiple MH families.  In total, p.S1728F 
has been identified in 12 MHShc individuals and 15 MHSh individuals across 8 
families referred to the Leeds MH unit (Table 4.1).  Discordance was observed 
in one family (family S5), with the variant being detected in one MHN individual 
and one MHSh individual not harbouring the variant.  No further variants were 
detected in the 9 MHShc/MHSh individuals referred for NGS of 50 genes 
associated with Ca2+ handling.  The p.S1728F variant is rare, with a MAF of 
0.000004064 in the gnomAD browser (gnomAD, 2019; Karczewski et al., 
2019).   
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Recent advances in the resolution of the rabbit RYR1 structure by cryo-EM 
revealed that the p.S1728F variant lies within the handle domain, which in 
conjunction with the central and helical domains, provides a scaffold for the 
ligand binding and the propagation of conformational signals (Yan et al., 2015).  
Analysis of the relative contracture strength in samples derived from patients 
harbouring specific MH-associated variants revealed individuals harbouring the 
p.S1728F variant produced weak contractures upon IVCT compared to the 
most common variant in the UK population, p.G2434R.  The p.S1728F variant 
has not been characterised using the HEK293 system; however, one study has 
shown increased sensitivity of a B-lymphocyte cell line containing the p.S1728F 
variant to 4-CmC compared to wild-type controls, in addition to increased 
resting Ca2+ (Gonsalves, 2014).  These experiments were performed on a cell 
line obtained from a single individual and the contribution of genetic 
background to the results is unknown.
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Table 4.1 – Prevalence of the p.S1728F variant in the Leeds MH Unit referrals 
The 8 MH families in which the p.S1728F variant has been detected have been anonymised and assigned codes from S1-S8 (column 
1).  Since not all family members have been subject to DNA sequencing, the genetic analysis column refers to the number of family 
members who have had their DNA sequenced to determine the presence of the p.S1728F variant.  The p.S1728F + column refers to 
the number of family members determined to harbour the p.S1728F variant after DNA sequencing was performed. 
 
 
 No. MHShc No. MHSh No. MHN 
Family Total MHShc Genetic analysis p.S1728F 
+ 
Total MHSh Genetic analysis p.S1728F 
+ 
Total MHN Genetic analysis p.S1728F 
+ 
S1 4 1 1 6 4 4 13 0 - 
S2 1 1 1 2 2 2 3 0 - 
S3 8 4 4 4 2 2 4 0 - 
S4 0 - - 1 1 1 0 - - 
S5 6 3 3 4 4 3 4 3 1 
S6 2 2 2 1 1 1 3 0 - 
S7 1 1 1 2 0 - 4 0 - 
S8 1 0 - 4 2 2 5 0 - 
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4.1.2 Chapter aims and strategy 
The primary aim of this chapter is to introduce the RYR1 p.D3986E and 
p.S1728F variants into C2C12 myoblasts and determine the sensitivity of the 
resultant cell lines to caffeine by Ca2+ imaging.  In addition, the karyotype of 
C2C12 cells will be confirmed and in-silico tools will be used to gain insight into 
the potential pathogenicity of the p.S1728F variant. 
 
Since traditional HDR is inefficient and resultant cell lines can contain a number 
of NHEJ events, recent developments in CRISPR-Cas9 gene-editing 
technologies will be explored as alternatives to traditional HDR for the 
introduction of MH-associated VUS (Ran et al., 2013a; Liu et al., 2019).  In 
particular, an analysis of the feasibility of using cytidine deaminase base 
editors for the introduction of MH-associated VUS will be conducted.  Cytidine 
deaminase base editors are comprised of a Cas9 nuclease that is inactive in 
one of its catalytic domains, resulting in the introduction of single stranded DNA 
breaks (Cas9 D10A) fused to a cytidine deaminase and uracil glycosylase 
inhibitor (BE3) (Komor et al., 2016).  The Cas9 D10A-BE3 system enables the 
introduction of C>T base substitutions when gRNAs are designed to target the 
forward strand, and the introduction of G>A substitutions when gRNAs are 
designed to target the reverse strand.  As such, the potential for using this tool 
will be analysed for all MH-associated VUS identified in at least one family that 
occur due to a C>T or G>A substitution.  Importantly, the bases to be edited 
must be located within positions 1-8 bp of the PAM-distal end of the gRNA, with 
maximum base editing efficiencies observed within positions 4-8 bp (Komor et 
al., 2016).  Since the p.D3986E variant is a result of a G>T substitution, it is not 
amenable to Cas9 D10A-BE3 editing and traditional HDR will be performed for 
this variant.  For the introduction of variants by traditional HDR, the plasmid 
system (pSpCas9(BB)-2A-GFP encoding gRNAs) will be used.  In contrast to 
the purified Cas9 protein system detailed in Chapter 3, the plasmid system 
boasts the benefit easy regeneration of the vector, increased tolerance for 
transfection of a single plasmid compared to the components of the purified 
Cas9 protein system and encouraging plasmid transfection efficiencies of up to 
60% for C2C12 cells reported in the literature (Balci and Dinçer, 2009). 
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Development of a robust CRISPR-Cas9 gene-editing platform in the widely 
used C2C12 cell line will overcome limitations of the existing characterisation 
methodologies for MH-associated VUS and will address the challenges 
identified in using CRISPR-Cas9 gene-editing on immortalised human 
myoblasts. 
4.2 Results 
4.2.1 p.S1728F in-silico pathogenicity prediction, conservation 
analysis and mutagenesis 
The following in-silico pathogenicity predictions were made for p.D3986E in 
Chapter 3, section 3.2.1.  Three bioinformatics tools were used to predict the 
pathogenicity of the p.S1728F variant. The p.S1728F variant was predicted to 
be ‘tolerated’ by SIFT with a score of 0.2 – where a score of 0 is damaging and 
a score of 1 is tolerated (SIFT 6.2.1, 2019; Ng and Henikoff, 2003; Sim et al., 
2012).  Conversely, PolyPhen-2 categorised the p.S1728F variant as ‘possibly 
damaging’ with a score of 0.756 – where a score of 1 is damaging and a score 
of 0 is benign (PolyPhen-2 v2, 2019; Adzhubei et al., 2010).  The CADD tool 
generated a CADD score (C-score) of 24, indicating that it is in the top 1% of 
predicted deleterious variants (CADD v1.4, 2019; Kircher et al., 2014). 
 
ConSurf (Ashkenazy et al., 2016; Celniker et al., 2013; Asheknazy et al., 2010; 
Berezin et al., 2004) was used to investigate the conservation of the RYR1 
p.S1728F residue (sequence accession number P21817.3) across RYR1 
homologues.  This returned 75 results, of which the first 40 are shown for 
reference to show a sample of the results (Figure 4.1).  The p.S1728F residue 
was predicted to be exposed; however, no functional or structural prediction 
was made by ConSurf.  The p.S1728F residue was not highly conserved 
across all homologues analysed, with a ConSurf score of 1 meaning that the 
residue is ‘variable’.  Across all homologues, 37.736% had a serine residue at 
position 1728, 26.415% had a glycine residue, 18.868% had a methionine, 
13.208% had a threonine and both alanine and leucine accounted for the 1728 
residue in 1.887% of sequences. Despite this, the p.S1728F residue was 
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conserved in all mammalian RYR1 protein sequences.  The conservation of the 
sequence surrounding p.S1728F varied, with some residues (p.R1728) being 
highly conserved and some (p.S1725) being variable.  None of the homologues 
analysed have an F residue at position 1728.  The PyMOL Molecular Graphics 
System version 2.0 mutagenesis wizard (Schrödinger, LLC) was used to 
explore the effect of the S to F substitution on local hydrogen bonding and VdW 
interactions using the rabbit RYR1 structure (PDB: 3J8H; Yan et al., 2015; 
Figure 4.2).  Substitution of the S residue to F generated four potential rotamer 
conformations, all of which showed varying degrees of VdW clashes.  The most 
likely rotamer conformation (57% probability) showed mild VdW clashes (green 
disks; Figure 4.2; Panel B), as did the third rotamer conformation (11.0%; 
Figure 4.2, Panel D).  In contrast, the second and fourth rotamer conformations 
(29.8% and 1.3%, respectively) showed severe VdW clashes (red disks; Figure 
4.2, panels C and E). 
 
 
 
 
 
 
 
 
 
133 
 
Figure 4.1 – Multiple sequence alignment of the p.S1728 residue across 
40 RYR1 homologues 
CSI-BLAST was used to search for homologues with at least 70% homology to 
the human RYR1 protein and MAFTT was used to create a multiple sequence 
alignment.  ConSurf was used to determine and colour code the conservation 
of residues across homologues.  The region surrounding the p.S1728 residue 
is shown here in panel A.   Predictions made regarding the exposure and role 
of the residue are shown in panel B.  Mammalian species are indicated by 
underlining and an asterisk highlights the residue of interest. 
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Figure 4.2 – PyMOL mutagenesis of rabbit RYR1 p.S1728F residue 
The mutagenesis tool on PyMOL was used to model the effect of the p.S1728F 
variant on hydrogen bonding and VdW interactions, within the rabbit RYR1 
structure (PDB: 3J8H).  The ancestral residue is shown in green and the 
variant residue is in pink.  Hydrogen bonds are shown by yellow dashes and 
VdW clashes are shown by green (less severe) and red (more severe) disks. 
Black arrows are used to highlight VdW clashes that are difficult to see.  Panel 
A shows the S residue at position 1728 and panels B, C, D and E show each 
rotamer conformation in order of decreasing probability of occurrence.  Panel F 
shows the probabilities of occurrence of each rotamer conformation. 
 
4.2.2 Exploration of the use of the cytidine deaminase vector for 
MH-associated VUS 
Developments in genome-editing technologies at the time of these experiments 
were investigated as potential alternatives to traditional HDR for the 
introduction of point mutations; namely Cas9 D10A-BE3 (Komor et al., 2016).  
Since p.D3986E results from a G>T variant, the use of Cas9 D10A-BE3 was 
not possible.  To design potential gRNAs Cas9 D10A-BE3-mediated base 
editing of the p.S1728F variant, a region around the variant was entered into 
CCTOP (Stemmer et al., 2015) and gRNAs 20 nt in length, with at least 4 
mismatches to any other sequence in the mouse (GRCm38/mm10) genome.  
Only one gRNA result was returned that targeted the forward strand and thus 
would produce C>T variants.  The variant to be edited lay 12 bp downstream of 
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the PAM, thus it did not meet the positional criteria for C>T editing (Figure 4.3); 
as such, a traditional HDR strategy was implemented for the introduction of 
p.S1728F.  In fact, out of all MH-associated VUS that occur as a result of a 
C>T or G>A variant and are found in more than one family (a total of 19), only 
5 produced gRNAs that could potentially edit the variant of interest (Table 4.2).  
Of the 14 variants for which no gRNAs were designed, 5 were excluded due to 
codon differences between human and mouse that prevented substitution of 
the correct amino acid (Table 4.2).  The arginine residue of p.R177C is 
comprised of the codon CGC, whilst in mouse the codon is CGA.  Thus, editing 
of the C base would result in AGA which also encodes arginine.  The threonine 
residue of p.T214M is comprised of the codon ACG but in mouse, it is 
comprised of the codon ACT.  Editing of the C base would result in the 
formation of ATT which encodes isoleucine, not methionine.  The arginine 
residue of p.R1469W is comprised of CGG but in mouse the codon is AGG, 
thus there is no C base available for editing.  The arginine residue of 
p.R2676W is comprised of CGG but in mouse the codon is CGC.  Editing of the 
C bases in this instance could produce either TGT, TGC or CGT which encode 
cysteine (TGT and TGC) and arginine (CGT).  Finally, the threonine residue in 
p.T3711M is encoded by ACG but in mouse the codon is ACT.  Editing of the C 
base at this position would result in the formation of ATT, which also encodes 
threonine.  The remaining variants failed to produce gRNAs where the base to 
be edited was within positions 1-8 bp of the PAM-distal site (Table 4.2).   
 
 
Figure 4.3 – gRNA design for cytidine deaminase-mediated editing of the 
p.S1728F variant 
CCTOP (Stemmer et al., 2015) was used to design gRNAs using the mouse 
(Mm10) genome for targeting of the p.S1728F variant with Cas9 D10A-BE3.  
The p.S1728 codon is shown in blue with the base to be edited in red.  The 
PAM sequence is shown in green. 
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Table 4.2 – Potential for genome-editing using cytidine deaminase Cas9 
across MH-associated VUS 
All MH-associated VUS that occur due to a C>T or G>A variant that were found 
in at least two independent families were included for an analysis of the utility 
of Cas9 D10A-BE3.  The base to be edited is underlined.  No. IF refers to the 
number of independent families the variant has been identified in. 
 
 
 
Variant Human codon Mouse codon No. IF Result 
p.R177C CGC CGA 10 Excluded 
p.T214M ACG ACT 4 Excluded 
p.R1469W CGG AGG 2 Excluded 
p.S1728F TCC TCC 9 No suitable gRNAs 
p.P1787L CCT CCA 8 No suitable gRNAs 
p.E2362K GAG GAG 2 No suitable gRNAs 
p.V2627M GTG GTG 5 Potential gRNAs 
p.R2676W CGG CGC 3 Excluded 
p.R3051H CGC CGC 2 No suitable gRNAs 
p.R3366H CGT CGT 2 Potential gRNAs 
p.R3539H CGT CGC 7 No suitable gRNAs 
p.T3711M ACG ACT 3 Excluded 
p.R3772Q CGG CGG 6 No suitable gRNAs 
p.R3903Q CGG CGG 2 No suitable gRNAs 
p.A4295V GCG GCG 4 Potential gRNAs 
p.G4638D GGC GGC 3 Potential gRNAs 
p.R4737Q CGG CGG 7 No suitable gRNAs 
p.R4893Q CGG CGG 3 Potential gRNAs 
p.P4973L CCG CCA 3 No suitable gRNAs 
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The five variants potentially amenable to cytidine deaminase editing were 
p.V2627M, p.R3366H, p.A4295V, p.G4638N and p.R4893Q which produced 1, 
3, 3, 1 and 1 potential gRNAs, respectively (Figure 4.4).  All of the gRNAs for 
p.V2627M, p.A4295V, p.G4638N and p.R4893Q contained additional C 
residues within positions 1-8 in the PAM-distal gRNA region and would likely be 
subject to deamination resulting in the introduction of undesired amino acid 
changes (Table 4.3).  Two gRNAs targeting p.R3366H, gRNAs 2 and 3, did 
contain an additional C base within the 1-8 bp PAM-distal region; however, 
substitution of a C>T in these cases did not alter the original amino acid, 
leucine.  Thus, whilst Cas9 D10A-BE3 could be used to base-edit p.R3366H, 
its scope for use as a tool to characterise MH-associated VUS in murine cells 
was limited.  Since the use of cytidine deaminase Cas9 was not feasible for the 
introduction of the two candidate variants in this project, p.S1728F and 
p.D3986E, traditional HDR was used to introduce these variants into C2C12 
myoblasts. 
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Figure 4.4 – gRNAs designed for base-editing with Cas9 D10A-BE3 
CCTOP was used to design gRNAs for the introduction of MH-associated 
variants that result from a C>T or G>A variant – p.V2627M (A), p.R3366H (B), 
p.A4295V (C), p.G4638D (D) and p.R4893Q (E).  The codon to be edited is 
shown in blue, with the base to be edited shown in red.  The PAM is shown in 
green and additional C residues with the potential for editing shown in purple.  
Numbers beneath the PAM-distal end of the gRNA sequence show the position 
of the bases within the 1-8 bp PAM-distal region. 
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Table 4.3 – Potential variant substitution for gRNAs designed for use with 
Cas9 D10A-BE3 
The base position refers to the position of the base within the 1-8 bp PAM distal 
end.  
Variant and gRNA Base position Codon Amino acid 
p.V2627M gRNA 1 
1 GAT>AAT ASP>ASN 
5 GTG>GTA VAL>VAL 
5 and 7 GTG>ATA VAL>ILE 
7 GTG>ATG VAL>MET* 
8 CTG>CTA LEU>LEU 
p.R3366H gRNA1 
1 CGG>CGA ARG>ARG 
2 CGG>CAG ARG>GLN 
1 and 2 CGG>CAA ARG>GLN 
4 AAG>AAA LYS>LYS 
8 CGT>CAT ARG>HIS* 
p.R3366H gRNA2 
3 CGT>CAT ARG>HIS* 
5 TTG>TTA LEU>LEU 
p.R3366H gRNA3 
4 CGT>CAT ARG>HIS* 
6 TTG>TTA LEU>LEU 
p.A4295V gRNA1 
2 ACT>ATT THR>ILE 
5 GCG>GTG ALA>VAL* 
p.A4295V gRNA2 
3 ACT>ATT THR>ILE 
6 GCG>GTG ALA>VAL* 
p.A4295V gRNA3 
1 GCG>GTG ALA>VAL 
4 ACT>ATT THR>ILE 
7 GCG>GTG ALA>VAL* 
p.G4638D gRNA 1 
6 GGC>GAC GLY>ASP* 
7 GGC>AGC GLY>SER 
6 and 7 GGC>AAC GLY>ASN 
p.R4893Q gRNA 1 
1 GCC>ACC ALA>THR 
2 CGG>CGA ARG>ARG 
2 and 3 CGG>CAA ARG>GLN* 
3 CGG>CAG ARG>GLN* 
7 GTC>ATC VAL>ILE 
* Intended variant substitution
 
 
 
140 
4.2.3 C2C12 cell line karyotyping 
Due to conflicting reports in the literature regarding the ploidy of C2C12 cells, 
(Hardeman et al., 1988; Fischer et al., 2016), cells at passage number 11 (cells 
resuscitated from liquid nitrogen storage were labelled as passage 0 at the 
outset of this project) were outsourced for karyotyping by Cell Guidance 
Systems (Cambridge, UK).  Three populations of karyotypes were identified, 
with C2C12s appearing predominantly tetraploid (Figure 4.5).  The mouse Ryr1 
gene is located on chromosome 7, of which there are three copies in all 
karyotypes.  The first karyotype, hereafter referred to as karyotype A (Figure 
4.5; panel A) had 81 chromosomes in total.  Karyotype A had four copies of 
chromosomes 1, 2, 4 (with one chr.4 showing additional material notated as 
add(4)), 5, 6, 8, 11, 12, 14, 17, 19 and X.  Three copies of chromosomes 7, 9, 
13, 16 and 18 were identified and five copies of chromosome 15 were 
identified.  In addition, three marker chromosomes of unknown origin were 
detected (Figure 4.5; panel A).  The second karyotype identified, hereafter 
referred to as karyotype B (Figure 4.5; panel B), had 80 chromosomes in total.  
Four copies of chromosomes 1, 2, 3, 4, 5, 6 (with 2 derivatives of chromosome 
6 and 15, notated as der (6;15)), 8, 9, 16, 17, 19 and X were identified.  Three 
copies of chromosomes 7, 12, 13, 14 and 18 were identified within karyotype B 
and five copies of chromosomes 11 and 15 (with one der(15;15)) were 
identified.  Finally, six copies of chromosome 10 were identified within 
karyotype B and an additional marker chromosome of unknown origin was 
detected (Figure 4.5; Panel B).  The third karyotype, hereafter referred to as 
karyotype C (Figure 4.5; panel C) had 83 chromosomes in total.  Four copies of 
chromosomes 1, 3, 4, 5, 6, 8, 9, 10, 11, 13, 16, 17, 18, 19 and X were 
identified.  Three copies of chromosomes 7 and 14 were identified, five copies 
of chromosomes 2 and 12 were identified and six copies of chromosome 15 
were identified.  Finally, an additional marker chromosome was detected, the 
origin of which is unknown (Figure 4.5; Panel C).   
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Figure 4.5 – C2C12 cell karyotyping 
C2C12 cells at passage number 11 were outsourced to Cell Guidance Systems 
(Cambridge, UK) for karyotyping.  The three populations identified are shown in 
panels A, B and C.  Chromosome number is depicted in green text beneath 
chromosome images.  A tabular summary of chromosomal copy number is 
provided to the right of each karyotype image. 
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4.2.4 gRNA design 
Three gRNAs were designed per variant for testing in C2C12 myoblasts (Ran 
et al., 2013a).  The gRNAs were designed using CCTOP (Stemmer et al., 
2015).  Within CCTOP, an extension called CRISPRater (Labuhn et al., 2017) 
was used to predict the efficacy of the gRNAs.  Using the Mus musculus 
(GRCm38/mm10) genome, CCTOP was used to search for gRNAs 20 nt in 
length and upstream of an S. pyogenes PAM (NGG).  For p.D3986E-targetting 
gRNAs, inputting a sequence of 101 bp with 50 bp flanking both upstream and 
downstream of the base to be edited returned 13 gRNA results.  The top 3 
gRNAs (ranked on number of off-targets, distribution of mismatches to off-
targets and location of off-targets i.e. whether they are exonic, intronic or 
intergenic) were selected for use in this chapter.   
 
The first gRNA, named Mm_D3986E_gRNA1 (Table 4.4) had a cut site 21 bp 
from the desired base change, an efficacy score of 0.68 (deemed medium 
efficacy) and 11 off-targets, of which 1 was exonic, 4 were intronic and 6 were 
intergenic.  The second gRNA, Mm_D3986E_gRNA2 (Table 4.4) had a cut site 
8 bp away from the desired base change, a high efficacy score of 0.82 and 42 
off-targets, of which 3 were exonic, 15 were intronic and 24 were intergenic.  
The third gRNA, Mm_D3986E_gRNA3 (Table 4.4) had a cut site 6 bp away 
from the desired base change, a medium efficacy score of 0.69 and 41 off-
targets, of which 6 were exonic, 16 were intronic and 19 were intergenic 
Mm_D3986E_gRNA1 targets the reverse DNA strand, whereas 
Mm_D3986E_gRNA2 and 3 target the forward strand.  An additional gRNA 
design tool, CRISPOR v4.4 was used to confirm predicted off-targets and 
identify those that had not been predicted by CCTOP (Haeussler et al., 2016).  
CRISPOR predicted 31 off-targets for Mm_D3986E_gRNA, including the 11 
were identified by CCTOP.  Mm_D3986E_gRNA 2 was predicted to have 63 
off-targets by CRISPOR, including the 42 predicted by CCTOP and 
Mm_D3986E_gRNA3 was predicted to have 56 off-targets by CRISPOR, 
including the 41 predicted by CCTOP. 
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For the p.S1728F-targetting gRNAs, inputting a 101 bp sequence with 50 bp 
flanking the base to be edited into CCTOP returned 8 results.  The first gRNA, 
Mm_S1728F_gRNA1 had a cut site 24 bp away from the base to be edited, a 
high efficacy score of 0.75 and 26 off-targets, of which none were exonic, 9 
were intronic and 17 were intergenic.  The second gRNA, Mm_S1728F_gRNA2 
had a cut site 13 bp from the base to be edited, a high efficacy score of 0.79 
and 29 off-targets, of which 15 were exonic, 10 were intronic and 4 were 
intergenic.  The third gRNA, Mm_S1728F_gRNA3 had a cut site 9 bp from the 
base to be edited, a high efficacy score of 0.79 and 54 off-targets, of which 6 
were exonic, 25 intronic and 23 intergenic.  All p.S1728F-targetting gRNAs 
target the reverse strand.  As described for p.D3986E-targeting gRNAs, 
CRISPOR was used to confirm and identify additional potential off-target sites 
not predicted by CCTOP.  For Mm_S1728F_gRNA1, CRISPOR predicted 60 
off-target sites including the 26 identified by CCTOP.  For 
Mm_S1728F_gRNA2, CRISPOR predicted 66 off-target sites including the 29 
predicted by CCTOP.  Finally, for Mm_S1728F_gRNA3, CRISPOR predicted 
166 off-target sites, including the 54 predicted by CCTOP. 
 
Table 4.4 - Mouse Ryr1 p.D3986E and p.S1728F-targeting gRNA 
sequences and their PAM 
gRNA Sequence PAM 
Mm_D3986E_gRNA1 TCATGTGCGCGAACACGTGC AGG 
Mm_D3986E_gRNA2 TCTGGCGCACAGTCGCCTCT GGG 
Mm_D3986E_gRNA3 CGCCTCTGGGATGCCGTGGT GGG 
Mm_S1728F_gRNA1 GGCTGCGGCAGGCGCTTTCG AGG 
Mm_S1728F_gRNA2 CATGGAGCGACGGCTGCGGC AGG 
Mm_S1728F_gRNA3 AGAGCATGGAGCGACGGCTG CGG 
 
Prior to gRNA synthesis, DNA was extracted from C2C12 myoblasts and a 400 
bp region around each gRNA of interest was amplified by PCR and processed 
for Sanger sequencing, to confirm that no SNPs were located within the gRNA 
sequence that could affect targeting.  Indeed, all gRNA sites in the C2C12 
genome were wild-type (Figure 4.6). 
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Figure 4.6 – Sanger sequencing traces of p.D3986E and p.S1728F gRNAs 
in C2C12 myoblasts 
Sanger sequencing was performed to exclude the possibility of SNPs being 
present within the intended gRNA sequences.  Traces for p.D3986E gRNAs 1 
(A), 2 (B) and 3 (C) and p.S1728F gRNAs 1 (D), 2 (E) and 3 (F) are shown in 
4Peaks software (Nucleobytes, Amsterdam, Netherlands).  gRNA sequences 
are underlined in black and the PAM is underlined in orange. 
 
Following confirmation that all intended gRNA sequences were free of SNPs in 
C2C12 myoblasts, gRNAs and their reverse complements were outsourced for 
synthesis as HPLC-purified single stranded oligonucleotides by Integrated DNA 
Technologies (IDT).  For gRNAs that did not have a G as the first base, an 
additional G nucleotide was added to facilitate transcription from the hU6 
promoter.  To facilitate cloning into pSpCas9(BB)-2A-GFP, a 5’-CACC 
overhang was added to the forward sequence and a 5’-AAAC overhang was 
added to the reverse sequence (Table 4.5; Table 4.6). 
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Table 4.5 – Mouse Ryr1 p.D3986E- targeting gRNAs for cloning into pSpCas9(BB)-2A-GFP 
Sequences in black text show the gRNAs and their complements.  Sequences in green text show the overhangs to facilitate cloning 
into pSpCas9(BB)-2A-GFP and the additional G nucleotide to enhance transcription from the U6 promoter is shown in blue text.   
 
 
 
 
 
 
Table 4.6 – Mouse Ryr1 p.S1728F-targeting gRNAs for cloning into pSpCas9(BB)-2A-GFP 
Sequences in black text show the gRNAs and their complements.  Sequences in green text show the overhangs to facilitate cloning 
into pSpCas9(BB)-2A-GFP and the additional G nucleotide to enhance transcription from the U6 promoter is shown in blue text.   
gRNA name Forward sequence 5’-3’ Reverse sequence 5’-3’ 
Mm_S1728F_gRNA1 CACCGGCTGCGGCAGGCGCTTTCG AAACCGAAAGCGCCTGCCGCAGCC 
Mm_S1728F_gRNA2 CACCgCATGGAGCGACGGCTGCGGC AAACGCCGCAGCCGTCGCTCCATGc 
Mm_S1728F_gRNA3 CACCgAGAGCATGGAGCGACGGCTG AAACCAGCCGTCGCTCCATGCTCTc 
gRNA name Forward sequence 5’-3’ Reverse sequence 5’-3’ 
Mm_ D3986E_gRNA1 CACCgTCATGTGCGCGAACACGTGC AAACGCACGTGTTCGCGCACATGAc 
Mm_D3986E_gRNA2 CACCgTCTGGCGCACAGTCGCCTCT AAACAGAGGCGACTGTGCGCCAGAc 
Mm_D3986E_gRNA3 CACCgCGCCTCTGGGATGCCGTGGT AAACACCACGGCATCCCAGAGGCGc 
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4.2.5 HDR template design 
HDR templates were designed as described previously (3.2.5), with single 
stranded oligonucleotides containing 80 bp homology to the sequence flanking 
the gRNA cut site.  To prevent re-cleavage of the gRNA if successfully 
incorporated into the C2C12 genome, silent mutations were introduced either 
into the PAM or 12 nt gRNA seed region.  For Mm_D3986E_gRNA1, the PAM 
sequence spanned 2 amino acid codons – TTC (phenylalanine, F) and CTG 
(leucine, L).  Substituting the C base of the TTC codon to produce TTT 
removed the PAM site without altering the amino acid (Figure 4.7; panel A).  
For Mm_D3986E_gRNA2, it was not possible to introduce a silent mutation into 
the PAM sequence; however, 8 silent mutations were able to be introduced into 
the 12 nt PAM seed region (Figure 4.7; panel B).  Introduction of a silent 
mutation within the PAM of Mm_D3986E_gRNA3 was also not possible and 
only 2 silent mutations were able to be introduced within the 12 nt seed region.  
Since reports show that up to 2 mismatches within the seed region may be 
tolerated (Hsu et al., 2013), 2 additional silent mutations were introduced 
towards the PAM-distal end of Mm_D3986E_gRNA3 in an attempt to further 
prevent re-cleavage (Figure 4.7; panel C).  For all of the p.S1728F-targetting 
gRNAs, introduction of a silent mutation in the PAM was possible.  For 
Mm_S1728F_gRNA1, the PAM was comprised of 2 amino acids codons, CAC 
(histidine, H) and CTC (leucine, L).  Substitution of the CAC codon for CAT 
abolished the PAM site without altering the histidine residue (Figure 4.8; panel 
A).  For Mm_S1728F_gRNA2, the PAM spanned 2 amino acid codons, GCC 
(alanine, A) and TGC (cysteine, C).  Substitution of GCC for GCA removes the 
PAM site but does not alter the alanine residue at that position (Figure 4.8; 
panel A).  The PAM of Mm_S1728F_gRNA3 also spanned two amino acid 
codons, TGC (cysteine, C) and CGC (arginine, R).  Substitution of the TGC 
codon for TGT removed the PAM site without affecting the cysteine residue at 
that position (Figure 4.8; panel C).   
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Table 4.7 – HDR template sequences for mouse Ryr1 p.D3986E and p.S1728F-targeting gRNAs. 
Single stranded HDR template sequences were used to introduce the RYR1 p.D3986E and RYR1 p.S1728F variants into C2C12 
myoblasts.  The gRNA sequences are shown in orange and edited bases in purple.  PAMs are shown in green and the base to be 
changed is shown in red.  The Cas9 cut site is indicated by a /.  
HDR template Sequence 5’-3’ 
Mm_D3986E_H
DR_gRNA1 
GTTCCCCAGGGACCCTGCACCGGAAACCAGCAGAGTCTGGCGCACAGTCGCCTCTGGGAGGCCGTGGTGGGCTTTCTGCA/CGTGTTCGCGCAC
ATGATGATGAAGCTGGCTCAGGTTTGAGTTCGTCTGAGAACAGCTCTTTCCCTCCAGCCATCCCCTA 
Mm_D3986E_H
DR_gRNA2 
CTCCTGCTGAGGCTTCAGGCCACCCTTTGTTCCCCAGGGACCCTGCACCGGAAACCAGCAGAGTCTGGCGCATTCAAGAT/TATGGGAGGCCGT
GGTGGGCTTCCTGCACGTGTTCGCGCACATGATGATGAAGCTGGCTCAGGTTTGAGTTCGTCTGAGA 
Mm_D3986E_H
DR_gRNA3 
TTCAGGCCACCCTTTGTTCCCCAGGGACCCTGCACCGGAAACCAGCAGAGTCTGGCGCACAGTAGACTATGGGAGGCAGT/AGTGGGCTTCCTG
CACGTGTTCGCGCACATGATGATGAAGCTGGCTCAGGTTTGAGTTCGTCTGAGAACAGCTCTTTCCC 
Mm_S1728F_H
DR_gRNA1 
TTGCATGCGCTGGAGGATGCGCGCTTGCCAGGTCCTCTGCGAGCAGGCTACTACGACCTCCTCATCAGCATCCATCTCGA/AAGCGCCTGCCGC
AGCCGTCGCTTCATGCTCTCTGAGTACATCGTGCCACTCACGCCGGAGACCCGCGCCATCACGCTTT 
Mm_S1728F_H
DR_gRNA2 
GGAGGATGCGCGCTTGCCAGGTCCTCTGCGAGCAGGCTACTACGACCTCCTCATCAGCATCCACCTCGAAAGCGCATGCC/GCAGCCGTCGCTT
CATGCTCTCTGAGTACATCGTGCCACTCACGCCGGAGACCCGCGCCATCACGCTTTTCCCACCTGGG 
Mm_S1728F_H
DR_gRNA3 
GATGCGCGCTTGCCAGGTCCTCTGCGAGCAGGCTACTACGACCTCCTCATCAGCATCCACCTCGAAAGCGCCTGTCGCAG/CCGTCGCTTCATG
CTCTCTGAGTACATCGTGCCACTCACGCCGGAGACCCGCGCCATCACGCTTTTCCCACCTGGGCGAA 
148 
 
 
 
 
Figure 4.7 – Mouse Ryr1 p.D3986E-targeting repair templates 
HDR arms were designed to include 80 bp of homology upstream and downstream of the Cas9 cut site. HDR templates were modified 
from the original target sequence to prevent re-cleavage by Cas9 following insertion into the genome, by introducing silent mutations 
into either the PAM sequence (panel A) or the seed region (panels B and C).  The gRNA sequences are shown in orange text, PAMs in 
green text, the base to be edited in blue text, the edited base in red and the silent mutations in purple.  Beneath the DNA sequences 
are the amino acid single letter codes.
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Figure 4.8 - Mouse Ryr1 p.S1728F-targeting repair templates 
HDR arms were designed to include 80 bp of homology upstream and downstream of the Cas9 cut site. HDR templates were modified 
from the original target sequence to prevent re-cleavage by Cas9 following insertion into the genome, by introducing silent mutations 
into either the PAM sequence.  The gRNA sequences are shown in orange text, PAMs in green text, the base to be edited in blue text, 
the edited base in red and the silent mutations in purple.  Beneath the DNA sequences are the amino acid single letter codes 
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4.2.6 Cloning into pSpCas9(BB)-2A-GFP 
Forward and reverse gRNA sequences with 5’-CACC and 5’-AAAC overhangs, 
respectively, were annealed incubated in a ligation reaction with pSpCas9(BB)-
2A-GFP that had be linearised with BbsI.  Following incubation, ligation 
reactions were transformed into OneShotTM chemically competent Stbl3TM cells 
(InvitrogenTM) and colonies allowed to grow on LB agar plates containing 
ampicillin.  Four single colonies were picked per gRNA and used to inoculate 5 
ml LB broth.  Cultures were used for plasmid DNA extraction by miniprep and 
also as starter cultures for maxipreps, to isolate transfection-grade plasmid 
DNA.  Isolated plasmid DNA was prepared for Sanger sequencing to confirm 
that the gRNAs had been inserted successfully.  All colonies picked contained 
the gRNA insert and were confirmed by Sanger sequencing (Figure 4.9).
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Figure 4.9 – Sanger sequencing traces of mouse Ryr1 p.D3986E and p.S1728F-targeting gRNAs in pSpCas9(BB)-2A-GFP 
Sanger sequencing was used to confirm the insertion of gRNAs in pSpCas9(BB)-2A-GFP.  At the top of the figure is the pSpCas9(BB)-
2A-GFP cloning schematic.  Sanger sequencing traces show the presence of Mm_D3986E_gRNA1 (panel A), 2 (panel B) and 3 (panel 
C) and Mm_S1728F_gRNA1 (panel D), 2 (panel E) and 3 (panel F) in pSpCas9(BB)-2A-GFP.  On each trace, the vector sequence is 
underlined in black, the BbsI-induced overhangs are underlined in green and the gRNA sequence is underlined in blue. 
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4.2.7 Viability of C2C12 myoblasts following Lipofectamine TM  3000 
treatment 
To investigate whether LipofectamineTM 3000 had an adverse effect on C2C12 
cell viability, C2C12 cells were plated in 6-well plates and incubated with 
LipofectamineTM 3000 for 24 hours. Viability was estimated by trypan blue 
staining and cell counting using a haematocytometer.  The average viabilities 
across 4 wells of non-treated C2C12 and 4 wells of LipofectamineTM 3000 
treated cells were 89.0% and 90.4%, respectively.  No obvious cell death was 
observed in treated C2C12 cells compared to non-treated control C2C12 cells 
(Figure 4.10).  Thus, LipofectamineTM 3000 was deemed not to have a 
detrimental effect on C2C12 cell viability. 
 
 
Figure 4.10 – Non-transfected C2C12 cells and LipofectamineTM 3000 
treated C2C12 cells. 
C2C12 cells were maintained in growth media (panel A) and another well was 
treated with 125 μl Opti-MEM medium containing 7.5 μl LipofectamineTM 3000 
and 5 μl p3000 reagent (panel B).  The cells were incubated for 24 hours 
(37oC, 5% CO2) prior to analysis.  Images were captured using the EVOSTM FL 
microscope using the x40 objective.  The scale bar indicates 400 μM. 
 
4.2.8 Viability of C2C12 myoblasts following transfection with 
pSpCas9(BB)-2A-GFP 
To investigate parameters for C2C12 myoblast transfection, a range of 
volumes and ratios of LipofectamineTM 3000:plasmid DNA were used for an 
initial transfection in triplicate.  Cell viabilities and transfection efficiencies were 
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estimated as described previously.  Transfection was well tolerated in C2C12 
myoblasts, with cell viabilities for cells transfected with 0.5 μg plasmid DNA and 
0.75 μl LipofectamineTM 3000, 0.5 μg plasmid DNA and 1.5 μl LipofectamineTM 
3000, 1 μg plasmid DNA and 0.75 μl LipofectamineTM 3000 and 1 μg plasmid 
DNA and 1.5 μl LipofectamineTM 3000 of 94.0%, 93.6%, 91.8% and 91.3%, 
respectively.  Non-transfected C2C12 myoblasts had a cell viability of 93.5%.  
Estimates of transfection efficiencies for 0.5 μg plasmid DNA and 0.75 μl 
LipofectamineTM 3000 (Figure 4.11; panel A), 0.5 μg plasmid DNA and 1.5 μl 
LipofectamineTM 3000 (Figure 4.11; panel B), 1 μg plasmid DNA and 0.75 μl 
LipofectamineTM 3000 (Figure 4.11; panel C) and 1 μg plasmid DNA and 1.5 μl 
LipofectamineTM 3000 (Figure 4.11; panel D) were 8.8%, 9.5%, 12.0% and 
17.0%, respectively.  Since conditions using 1 μg plasmid DNA and 1.5 μl 
LipofectamineTM 3000 produced the highest transfection efficiency in this initial 
experiment, these volumes and reagent:DNA ratio were used for subsequent 
transfections. 
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Figure 4.11  - C2C12 cells transfected with pSpCas9(BB)-2A-GFP plasmid. 
C2C12 cells in 24-well plates were treated with varying volumes of 
LipofectamineTM 3000 and ratios of LipofectamineTM 3000 to plasmid DNA in 
triplicate – 0.5 μg plasmid DNA and 0.75 μl LipofectamineTM 3000 (panel A), 
0.5 μg plasmid DNA and 1.5 μl LipofectamineTM 3000 (panel B), 1 μg plasmid 
DNA and 0.75 μl LipofectamineTM 3000 (panel C) and 1 μg plasmid DNA and 
1.5 μl LipofectamineTM 3000 (panel D).  2 μl p3000 reagent was added per 1 μg 
plasmid DNA.  Cells were incubated for 24 hours (37oC, 5% CO2) prior to 
analysis.  Images were captured using the EVOSTM FL microscope 
(ThermoFisher). The scale bar indicates 400 μM. 
 
4.2.9 Determining gene-editing capacity of gRNAs 
T7 endonuclease assays were performed to determine whether the gRNAs 
induced double stranded breaks at the desired location within the genome.  
The gene-editing efficiencies of each gRNA for p.D3986E and p.S1728F were 
estimated to inform what gRNA would be used for editing, in conjunction with 
positional information regarding the distance of the Cas9 cut site from the base 
to be edited.  C2C12 cells were plated at 2.5 x 105/well of a 6-well plate 
immediately prior to transfection of all pSpCas9(BB)-2A-GFP vectors 
containing Mm_D3986E_gRNA1, 2 and 3 and Mm_S1728F_gRNA1, 2 and 3.  
For the purpose of illustration, representative traces of cells transfected with 
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pSpCas9(BB)-2A-GFP containing Mm_D3986E_gRNA1 and 
Mm_S1728F_gRNA1 are shown (Figure 4.12).  As described previously, gates 
were drawn to exclude non-viable cells from the sort based on their SSC and 
FSC measurements.  Non-transfected cells were used as a control to 
determine where to place GFP positive gates.  An example FACS trace has 
been shown for refeence (Figure 4.12).  In this instance, the proportion of intact 
cellular bodies, a measure of cell viability, of non-transfected C2C12 cells was 
98.07%.  The cell viabilities of C2C12 cells transfected with 
Mm_D3986E_gRNA1 and Mm_S1728F_gRNA1 were 96.90% and 94.89%, 
respectively.  The proportions of GFP-expressing cells collected for 
Mm_D3986E_gRNA1 and Mm_S1728F_gRNA1 were 24.11% and 33.35%, 
respectively.  In total, two FACS experiments per vector were performed to 
obtain cells for DNA extraction and T7 assay optimisation.  Across 
experiments, the mean cell viability for non-transfected cells was 97.38%.  The 
mean cell viabilities for C2C12 cells transfected with the pSpCas9(BB)-2A-GFP 
vectors containing p.D3986E and p.S1728F gRNAs were 96.10% and 95.44%, 
respectively.  The proportion of GFP positive cells collected varied across 
experiments with a mean of 25.02% (range 6.37%-52.74%) for p.D3986E 
vectors and 25.25% (range 5.57%-53.48%) for p.S1728F vectors. 
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Figure 4.12 – FACS traces of C2C12 myoblasts transfected with 
pSpCas9(BB)-2A-GFP 
Transfected.C2C12 cells were incubated at 37oC, 5% CO2 for 24 hours prior to 
FACS.  Panels A, D and G show the side scatter (Y axis) and forward scatter 
(X axis) profiles of non-transfected cells, Mm_D3986E_gRNA1 transfected 
cells and Mm_S1728F_gRNA1 transfected cells, respectively.  Panels B, E and 
H show the cell count (Y axis) and relative fluorescence intensity in arbitrary 
units (X axis) of non-transfected cells, Mm_D3986E_gRNA1 transfected cells 
and Mm_S1728F_gRNA1 transfected cells, respectively.  Panels C, F and I 
show the proportion of intact cellular bodies (red), GFP positive cells (green) 
and GFP negative cells (blue) of non-transfected cells, Mm_D3986E_gRNA1 
transfected cells and Mm_S1728F_gRNA1 transfected cells, respectively.  The 
number of events (black) corresponds to the number of cells detected by the 
laser and is usually measured between 10,000-200,000 cells dependent on the 
sample size, to give a snapshot of the profile of the cells.  
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Following FACS enrichment, DNA was extracted from each pool GFP-
expressing cells.  A region around the Cas9 cut site was amplified by PCR and 
purified using AMPure XP magnetic beads (Beckman Coulter).  For the 
p.D3986E gRNAs, the amplified region was 449 bp.  For Mm_D3986E_gRNA1, 
the expected products following Cas9 cleavage were 268 bp and 181 bp.  For 
Mm_D3986E_gRNA2, the expected products were 241 bp and 208 bp.  Finally, 
for Mm_D3986E_gRNA3, the expected products were 255 bp and 194 bp.  
Indeed, separation of each T7 reaction on an agarose gel yielded distinct 
bands corresponding to the expected cleavage products for each gRNA (Figure 
4.13).  The cleavage products for Mm_D3986E_gRNA2 were observed as a 
single band, due to resolution limitations of agarose gel electrophoresis.  No 
cleavage products were observed in the non-transfected cell sample.  The 
proportion of cleaved products was quantified by 2D densitometry.  The 
proportion cleaved for Mm_D3986E_gRNA1, 2 and 3 was 41.13%, 29.06% and 
36.81%, respectively.  Gene editing efficiencies were estimated using Equation 
1 (detailed in 3.2.8; Guschin et al., 2010); Mm_D3986E_gRNA1, 2 and 3 had 
estimated gene-editing efficiencies of 23.27%, 15.75% and 20.50%, 
respectively. 
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Figure 4.13 – T7 assay to determine the gene-editing efficiency of 
Mm_D3986E_gRNA, 2 and 3. 
The T7 assay was loaded onto 1% TAE-agarose gel and products separated 
by gel electrophoresis.  Lane 1 shows the 100 bp DNA ladder (NEB) and lane 2 
shows all components of the T7 reaction minus DNA.  Lanes 3 and 4 show the 
T7 assay from C2C12 cells transfected with Mm_D3986E_gRNA1 without and 
with the T7 enzyme.  Lanes 5-10 show the same for Mm_D3986E_gRNA2, 
_D3986E_gRNA3 and non-transfected cells. 
 
For the p.S1728F gRNAs, the amplified region for the T7 assay was 475 bp.  
The expected Cas9 cleavage products for Mm_S1728F_gRNA1 were 188 bp 
and 287 bp.  For Mm_D3986E_gRNA2, the expected cleavage products were 
199 bp and 275 bp.  For Mm_D3986E_gRNA3, the expected cleavage 
products were 203 bp and 272 bp.  Whilst the T7 assay for p.S1728F gRNAs 
did not produce bands as distinct as those for the p.D3986E gRNAs, cleavage 
products were separated from the main amplicon following agarose gel 
electrophoresis that corresponded to the expected sizes (Figure 4.14).  No 
cleavage products were observed in the non-transfected cell sample.  The 
fractions cleaved for Mm_S1728F_gRNA1, 2 and 3 were 5.89%, 13.78% and 
8.33%, respectively.  The estimated gene-editing efficiencies were 2.98%, 
7.15% and 4.26%, respectively.   
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Figure 4.14 – T7 assay to determine the gene-editing efficiency of 
Mm_S1728F_gRNA1, 2 and 3. 
The T7 assay was loaded onto a 1% TAE-agarose gel and products separated 
by gel electrophoresis.  Lane 1 shows the 100 bp DNA ladder (NEB), lane 2 
shows all components of the T7 reaction minus DNA, lanes 3 and 4 show the 
T7 assay from C2C12 cells transfected with Mm_S1728F_gRNA1 without and 
with the T7 enzyme.  Lanes 5-10 show the same for Mm_S1728F_gRNA2 and 
gRNA3. 
 
Following confirmation that all gRNAs for p.D3986E and p.S1728F were 
functional in C2C12 myoblasts, gRNAs to be used for subsequent variant 
introduction were selected.  The gRNAs were selected based a combination of 
data on gene-editing efficiency, off-target ranking by CCTOP and the Cas9 cut 
site distance from the base to be edited.  For the p.D3986E gRNAs, 
Mm_D3986E_gRNA1 was not used due to the 23 bp distance between the 
base to be edited and the Cas9 cut site.  The base to be edited was <10 bp 
away from the Cas9 cut site for both Mm_D3986E_gRNA2 and 
Mm_D3986E_gRNA3.  While Mm_D3986E_gRNA3 demonstrated slightly 
higher gene-editing efficiencies, Mm_D3986E_gRNA2 was selected for use 
due to its higher CCTOP ranking.  For p.S1728F, Mm_S1728F_gRNA1 was 
excluded based on the 24 bp distance of the base to be edited from the Cas9 
cut site.  Whilst Mm_S1728F_gRNA3 Cas9 cut site was 9 bp from the base to 
be edited, in contrast to 13 bp for Mm_S1728F_gRNA2, Mm_S1728F_gRNA3 
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had wide-spread predicted off-targets.  Consequently, Mm_D3986E_gRNA2 
and Mm_S1728F_gRNA2 were used for HDR. 
 
4.2.10 Single cell isolation and propagation 
FACS was used to isolate single cells from C2C12 cells transfected with the 
Mm_D3986E_gRNA2 and Mm_S1728F_gRNA2 vectors that showed GFP 
expression.  The passage number of C2C12s used for this transfection was 10 
(C2C12 cells resuscitated from liquid nitrogen at the outset of this project were 
labelled as passage 1; however, no information was available regarding the 
history of these cells prior to the start of this project).  A single FACS sort was 
performed for each vector for the collection of single cells.  For p.D3986E, 10 
96-well plates of single cells were collected and for p.S1728F, 8 plates were 
collected.  Cells were collected in a 1:1 ratio of fresh:filtered, conditioned 
growth media and were incubated for one week at 37oC with 5% CO2.  After 
one week, all 960 wells for p.D3986E and 768 wells for p.S1728F were 
manually inspected using a light microscope for signs of cell growth.  Cells that 
had grown were transferred to a 6-well plate for cell line propagation (at this 
stage, 2 96-well plates worth of p.D93986E cells were each given to laboratory 
technicians Catherine Daly and Xiaochen Liu for their assistance in culturing 
the cell lines, the remainder were cultured by me).  Cells were cultured until two 
T-75 flasks were ~60% confluent. One flask was processed for liquid nitrogen 
storage and the other used for DNA extraction.  Throughout the propagation 
process, some cell lines were discarded due to contamination or lack of cell 
growth.  In total, 160 cell lines were obtained for p.D3986E and 74 for 
p.S1728F. 
 
4.2.11 Validation of edited p.D3986E and p.S1728F cell lines 
 
4.2.11.1 TaqManTM SNP genotyping to detect the presence of variants 
DNA extracted from the single-cell derived lines was genotyped using a custom 
TaqManTM SNP genotyping assay to detect the presence of the p.D3986E and 
p.S1728F variants.  Custom probes were designed to detect only the single 
nucleotide variants, and not the silent mutations inserted in the PAM/seed 
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region.  Genotyping data were analysed using the Genotyping Module on the 
Thermo Fisher Cloud (Applied Biosystems).  For p.D3986E, an initial screening 
experiment was performed whereby single replicates of each sample were 
genotyped.  Out of the 160 p.D3986E lines screened, 6 were identified by the 
genotyping assay to contain the variant of interest (3.75%) – cell lines 8G6, 
2G7, 9H12, 1E6, 1C5 and 10G5.  Variants were confirmed by repeating the 
genotyping assay and the 6 samples were tested in triplicate alongside a wild-
type C2C12 control.  The allelic discrimination plot produced three distinct 
genotype clusters of allele 2/allele 2, allele 1/allele 2 and allele 1/allele 1 
(Figure 4.15).  
 
Figure 4.15 – TaqManTM SNP genotyping of p.D3986E cell lines 
Allelic discrimination plot generated by the Genotyping Module on the Thermo 
Fisher Cloud (Applied Biosystems) showing the genotypes of p.D3986E cell 
lines 8G6, 2G7, 9H12, 1E6, 1C5 and 10G5.  The X axis shows deltaRn (dRn) 
values for allele 1 (wild-type) and the Y axis shows the dRn values for allele 2 
(p.D3986E variant).  The dRn values refer to the change in fluorescence from 
baseline, normalised to the passive reference dye, ROX.  DNA was extracted 
from each cell line, quantified using the NanoDropTM 1000 spectrophotometer 
(ThermoFisher) and diluted to 20 ng/ul, with 20 ng added to each reaction.  Cell 
lines were genotyped in triplicate and genotypes were automatically called as 
either Allele1/ Allele 1 (red dots), Allele1/ Allele 2 (green dots) or Allele 2/ Allele 
2 (blue dots).  For autocalling, use of the Hardy-Weinberg equilibrium equation 
was removed from the analysis. 
 
 
 
162 
 
Cell lines 8G6 and 2G7 were called as allele 2/allele 2, while 9H12, 1E6, 1C5 
and 10G5 were called as allele 1/allele 2.  Within these clusters, there were so-
called vector clusters, whereby the 8G6 and 2G7 clusters were diverged within 
the allele2/allele2 cluster and the 9H12 diverged from 1C5, 1E6 and 10G5 in 
the allele1/allele2 cluster.  Since autocalling analyses the ratios of dRn values 
to determine genotype, dRn ratios were manually compared between cell lines 
within each cluster to infer the copy number of wild-type and variant alleles in 
the triploid Ryr1 genes of each cell line (Table 4.8).  Cell line 8G6 appears to 
have 2 copies of the p.D3986E variant and 1 wild-type sequence, with the dRn 
value for allele 2 roughly double those for allele 1 (1:1.99).  The dRn ratios of 
cell line 2G7 were less clear.  Whilst the 2G7 cell line was called as allele 
2/allele 2, the ratio of allele 2 to allele 1 was 1.5:1.  Cell line 9H12 was called 
as allele 1/allele 2; however, it formed a distinct group from cell lines 1E6, 1C5 
and 10G5.  The dRn ratios of 2G7 and 9H12 may be indicative of equal copies 
of allele 1 and allele 2, with dRn values at an almost 1:1 ratio (1:1.5 and 1:1.3, 
respectively).  The dRn values for 1E6, 1C5, 10G5 indicate that each cell line 
has 1 copy of the p.D3986E variant and 2 copies of the wild-type sequence, 
with a roughly 2:1 ratio of allele 1 to allele 2 (1E6 = 2.13:1; 1C5 = 2.51:1; 10G5 
= 2.40:1).  No amplification of the p.D3986E allele 2 was observed in wild-type 
C2C12 cells.  For use as a control in downstream caffeine sensitivity 
experiments, an un-edited cell line that had been subjected to transfection, 
FACS and propagation from a single cell was selected (cell line 3E1).  Cell line 
3E1 had average dRn values comparable to wild-type (allele 1 = 1.997, allele 2 
= 0.085) and Sanger sequencing of the p.D3986E region showed a wild-type 
sequence (Figure 4.16).  
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Table 4.8 – TaqManTM SNP genotyping dRn values for p.D3986E cell lines 
Each cell line was genotyped in triplicate and dRn values for allele 1 and allele 
2 averaged.  For reference, dRn values from the initial screening genotyping 
run are shown in brackets – these values were obtained from a single replicate.  
Cell line dRn wild-type allele 1 dRn p.D3986E allele 2 
8G6 0.418 (0.495) 0.833 (1.077) 
2G7 0.730 (0.893) 1.107 (1.332) 
9H12 1.297 (1.597) 0.948 (1.142) 
1E6 1.346 (1.383) 0.632 (0.640) 
1C5 1.222 (1.282) 0.486 (0.587) 
10G5 1.496 (1.416) 0.622 (0.595) 
WT C2C12 1.565 0.048 
 
 
Figure 4.16 – Mm_D3986E_gRNA2 region in cell line 3E1 
Sanger sequencing was performed on DNA extracted from cell line 3E1.  The 
gRNA sequence is underlined in orange and the PAM in green.  The T>G base 
to be edited is shown in blue.  Chromatograms were viewed in 4Peaks 
(Nucleobytes). 
 
For p.S1728F, 74 cell lines were screened.  The initial genotyping screening 
assay identified 1 cell line, 6B4, as having the p.S1728F variant.  Two 
additional cell lines, 6F12 and 6H6 were autocalled as ‘undetermined’ with low 
confidence flags.  For this genotyping assay, all dRn values were low (>0.7 for 
allele 1 and >0.4 for allele 2; Table 4.9).  While 6H6 was autocalled as 
‘undetermined’, the amplification plot for allele 2 closely resembled that of 
background amplification (Figure 4.17).  Indeed, following repetition of the 
genotyping of 6B4, 6E6 and 6F12 alongside wild-type C2C12s, it was 
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confirmed that only cell lines 6B4 and 6F12 contained the p.S1728F variant 
(2.7% of the 74 cell lines screened; Figure 4.18).   
 
 
Figure 4.17 – p.S1728F TaqManTM SNP genotype screening assay 
amplification plot 
DNA extracted from GFP-expressing cells transfected with the pSpCas9(BB)-
2A-GFP p.S1728F gRNA vector was used in a TaqManTM genotyping assay to 
detect the presence of the variant.  Amplification plots for each cell line were 
generated showing the change in fluorescence (dRn; Y axis) over cycle 
iterations (X axis).  The amplification plot for the 6H6 cell line is indicated by an 
arrow. 
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Figure 4.18 – TaqManTM SNP genotyping of p.S1728F lines 
Allelic discrimination plot generated by the Genotyping Module on the Thermo 
Fisher Cloud (Applied Biosystems) for p.S1728F cell line genotyping.  The X 
axis shows dRn values for allele 1 (wild-type) and the Y axis shows the dRn 
values for allele 2 (p.S1728F variant).  The dRn values refer to the change in 
fluorescence from baseline, normalised to the passive reference dye, ROX.  
DNA was extracted from each cell line, quantified using the NanoDropTM 1000 
spectrophotometer (ThermoFisher) and diluted to 20 ng/ul, with 20 ng added to 
each reaction.  Each cell line was genotyped in triplicate and genotypes were 
automatically called as either Allele1/ Allele 1 (red dots) or Allele1/ Allele 2 
(green dots). For autocalling, use of the Hardy-Weinberg equilibrium equation 
was removed from the analysis. 
 
Genotypes of the p.S1728F lines were estimated as described for p.D3986E 
cell lines, by comparing the ratios between dRn values for allele 1 (wild-type) 
and allele 2 (variant) (Table 4.9).  Cell line 6F12 had a 2:1 ratio of allele 1 to 
allele 2, suggesting 2 copies of allele 1 and a single copy of allele 2.  Cell line 
6B4 had a 1.5:1 ratio of allele 1 to allele 2.  
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Table 4.9 – TaqManTM SNP genotyping dRn values for p.S1728F cell lines 
Each cell line was genotyped in triplicate and dRn values for allele 1 and allele 
2 averaged.  For reference, dRn values from the initial screening genotyping 
run are shown in brackets – these values were obtained from a single replicate. 
 
Cell line dRn allele 1 wild-type dRn allele 2 p.S1728F 
6B4 0.489 (0.318) 0.334 (0.243) 
6F12 0.411 (0.295) 0.212 (0.170) 
6H6 0.419 (0.290) 0.067 (0.119) 
WT C2C12 0.544 0.033 
 
Since C2C12 cells have 3 copies of chromosome 7, the power of Sanger 
sequencing to confirm variant insertions was limited.  To overcome this, a 
region encompassing the gRNA site was amplified by PCR and amplicons 
were ligated into the commercially available pGEM®-T vector (Promega) by TA 
cloning.  Ligation reactions were transformed into TOP10 chemically competent 
cells (InvitrogenTM) and plated on LB agar plates containing ampicillin at 100 
μg/ml, 40 μl 100mM IPTG and 120 μl 20 mg/ml X-gal spread onto the surface 
of the plate.  In theory, picking sufficient numbers of colonies would enable the 
detection of variants or indels within the 3 Ryr1 genes for each cell line.  The 
total numbers of colonies processed for Sanger sequencing for cell lines 8G6, 
2G7, 9H12, 1E6, 1C5 and 10G5 were 28, 17, 18, 27, 27 and 27, respectively.  
A proportion of the Ryr1 TA clones picked for Sanger sequencing either did not 
contain the insert (8%), produced Sanger sequencing reads too short in length 
to detect the region of interest (17%), produced poor sequencing 
chromatograms from which the sequence could not be derived (34%) or the 
same editing events were detected multiple times (Table 4.10).  As such, not all 
modifications on each of the 3 Ryr1 genes across all cell lines were detected.  
The modifications that were detected revealed successful incorporation of the 
variant alleles, in addition to a range of mutational events that occurred due to 
gene-editing (Table 4.10).  In cell line 2G7, a 7 bp ‘CAGTCGC’ deletion was 
detected that occurred 1 bp upstream of the Cas9 cut site and a near wild-type 
sequence was detected that contained a 1 bp C residue deletion at the Cas9 
cut site (Figure 4.19; panel A and panel B).  In cell line 9H12, another 7 bp 
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‘AGTCGCC’ deletion was detected that occurred directly at the Cas9 cut site 
(Figure 4.19; panel C).  In addition, the same deletion was detected with an 
undesired G>A substitution 9 bp downstream of the Cas9 cut site (Figure 4.19; 
panel C).  Complex editing events were detected in the 10G5 cell line, whereby 
2 bp upstream and 5 bp downstream of the Cas9 cut site had been deleted.  A 
partial p.D3986E HDR template had been inserted downstream of these 
deletions and upstream of the endogenous wild-type base to be edited (Figure 
4.21).  Consequently, this allele contained both the wild-type and edited base.  
A 37 bp deletion was also detected in cell line 10G5 that occurred directly at 
the Cas9 cut site (Figure 4.19; panel E).  Finally, a 5 bp ‘GCCTC’ deletion was 
detected at the Cas9 cut site (Figure 4.19; panel G).  The same 1 bp C residue 
deletion that was detected in cell line 2G7 was also detected in cell line 1E6 
(Figure 4.19; panel B).  In addition, cell line 1E6 contained a successfully 
incorporated p.D3986E HDR template and a wild-type unedited Ryr1 (Figure 
4.19; panel D and panel H).  Cell line 1C5 contained the 1 bp C residue 
deletion, a successfully incorporated p.D3986E HDR template and a 
successfully incorporated wild-type HDR template (Figure 4.19; panel B, D and 
F).  The same 37 bp deletion detected in 10G5 was detected in cell line 8G6 
(Figure 4.19; panel E).  In addition, a complex editing event was detected in 
8G6 whereby a partial HDR fragment was present downstream of the Cas9 cut 
site and downstream of a 5 bp insertion (Figure 4.20).  
 
Eight colonies were processed for Sanger sequencing for each of the 
p.S1728F cell lines.  Cell line 6B4 had a successfully incorporated p.S1728F 
variant HDR template (Figure 4.22; panel A) and a 2 bp ‘AC’ insertion that 
occurred directly at the Cas9 cut site (Figure 4.22; panel B). 
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Table 4.10 – Summary of editing events detected in p.D3986E and p.S1728F cell lines 
The number of times the editing event was detected in that cell line is shown in brackets. 
Cell line Allele 1 Allele 2 Allele 3 
8G6 p.D3986E HDR fragment 
insertion* and T>C substitution 
(4) 
37 bp deletion (5) Not detected 
2G7 7 bp deletion (1) 1 bp deletion (1) Not detected 
9H12 7 bp deletion and G>A 
substitution (1) 
7 bp deletion (7) Not detected 
1E6 1 bp deletion (3) p.D3986E variant** (7) Wild-type unedited (4) 
1C5 p.D3986E variant** (3) 1 bp deletion (6) Wild-type HDR template *** (3) 
10G5 5 bp deletion (1) 37 bp deletion (5) p.D3986E HDR fragment 
insertion upstream of wild-type* 
(3) 
6B4 p.S1728F variant* (1) 2 bp insertion (2) Not detected 
6F12 Not detected Not detected Not detected 
* HDR template inserted erroneously. 
** successful recombination and incorporation of the variant HDR template. 
*** successful recombination and incorporation of the wild-type HDR template.
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Figure 4.19 – Graphical representation of editing events detected in 
p.D3986E cell lines 
The nature of the editing event and the cell lines in which it has been detected 
is shown above the diagrams.  Wild-type sequences are shown in black, gRNA 
sequences are shown in orange, PAM sites are shown in green, silent 
mutations within the p.D3986E HDR template are shown in purple, the desired 
base change for introduction of the p.D3986E variant is shown in red and 
undesired substitutions are shown in pink.  The Cas9 cut site is indicated by /.  
The 7 bp deletion in 9H12 (panel C) was also detected without the G>A 
substitution. 
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Figure 4.20 – Graphical representation of the HDR template insertion 
detected in p.D3986E cell line 8G6 
Sanger sequencing of an 8G6 cell line TA clone revealed a partial insertion of 
the p.D3986E HDR template (shown in black, bold text), with a T>C 
substitution (pink) near the Cas9 cut site.  Wild-type sequences are shown in 
black (not bold), gRNA sequences are shown in orange, silent mutations within 
the HDR template are shown in purple, the PAM site is shown in green and the 
desired base change is shown in red. 
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Figure 4.21 – Graphic representation of the partial HDR template insertion 
detected in the p.D3986E 10G5 cell line 
Sanger sequencing of a 10G5 cell line TA clone revealed an insertion of a 
partial p.D3986E HDR template.  Endogenous wild-type sequences are shown 
in black text (not bold).  The gRNA sequences are shown in orange, the silent 
mutations within the p.D3986E HDR template are shown in purple, PAM 
sequences are shown in black.  The partial HDR template insertion is shown in 
bold black text.  The endogenous wild-type base to be edited is shown in blue 
and the edited variant base is shown in red.  1. Two bases upstream of the 
Cas9 cut site (indicated by an arrow and /) had been deleted in addition to 5 bp 
downstream of the Cas9 cut site. 2. A 22 bp deletion at the start of the 
p.D3986E HDR template was detected. 3. The final 10 bp of the HDR template 
were also deleted.  The remaining fragment of the p.D3986E HDR template 
was inserted upstream of the endogenous C2C12 wild-type sequence (wild-
type base is shown in blue).   
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Figure 4.22 – Editing events detected in the p.S1728F 6B4 cell line 
The nature of the editing event is shown above the diagrams.  Wild-type 
sequences are shown in black, gRNA sequences are shown in orange, PAM 
sites are shown in green, silent mutations within the p.S1728F HDR template 
are shown in purple, the desired base change for introduction of the p.S1728F 
variant is shown in red and insertions are shown in blue.  The Cas9 cut site is 
indicated by /.   
 
4.2.11.2 Sanger sequencing of in-silico predicted off-target sites for 
p.D3986E and p.S1728F cell lines 
The top 10 off-target sites predicted by CCTOP and CRISPOR were selected 
for PCR amplification and Sanger sequencing to detect off-target activities 
within the resultant cell lines.  All p.D3986E cell lines with the exception of 
9H12 (which did not survive liquid nitrogen resuscitation) were sequenced at 
selected off-target sites.  For Mm_D3986E_gRNA2, CCTOP and CRISPOR 
shared 2 (Smtnl-Ggt6 and Nkx6-2) off-target sites within the top 10 predicted 
off-targets.  Of the 18 off-target sites to be sequenced, PCR primers were 
unable to be designed for 3 (Hspg2; GC content of the surrounding region was 
75%), Gm5385; surrounding region was repetitive and Pfdn1-Hbergf; 
surrounding region was repetitive), 1 (SmtnI-Ggt6; surrounding region was 
repetitive) failed to produce amplicons despite repeated attempts and the use 
of alternative primers and 2 (RP23-267G12.1 and Gm3898; both within highly 
repetitive regions) did not produce clear Sanger sequencing traces despite 
repeated attempts.  All of the remaining 12 off-target sites that were sequenced 
across the 1C5, 1E6, 2G7, 8G6 and 10G5 cell lines showed wild-type 
sequences (all p.D3986E off-target Sanger sequencing traces can be found in 
Appendix A), with the exception of the Optn and 6030407O03Rik sites for 
which the 2G7 sequencing reactions failed.  For the Med23 off-target site, dye 
blobs at ~70 bp were present within the off-target sequences; however, the 
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wild-type sequences were still distinguishable beneath the dye blob (Figure 
4.23). 
 
Figure 4.23 – Example of dye blob present within the Med23 off-target 
sequence 
DNA was extracted from each of the p.D3986E cell lines.  A region around the 
in-silico predicted Med23 off-target site was amplified by PCR and the amplicon 
processed for Sanger sequencing.  The sequencing chromatogram was 
analysed in 4Peaks (Nucleobytes, Amsterdam, Netherlands).  The off-target 
sequence is shown within a black box and the presence of a dye blob at ~70 bp 
indicated by an arrow. 
 
As described for Mm_D3986E_gRNA2 off-targets, the top 10 off-target sites for 
Mm_S1728F_gRNA2 from CCTOP and CRISPOR were selected for 
sequencing.  The two programs shared 4 off-target sites within their respective 
top 10 predicted sites (Zhx2, Rpgrip1I, 2310022B05Rik and Dusp26).  Primers 
were unable to be designed for CCTOP-predicted sites Grm4 (GC content 
77%) and Asmt (GC content 78% and the sequence downstream of the target 
site was incomplete in the GRCm38/mm10 genome).  Since there was 
considerable overlap within the top 10 sequences, an additional 2 off-target 
sequences were selected from the 11th and 12th predicted sites by CRISPOR 
(Hmcn2 and Scara5).  All off-target sites that were sequenced for cell lines 6B4 
and 6F12 were wild-type, with the exception of Ptprs for both cell lines which 
failed to produce clear Sanger sequencing traces (GC content 77%).  
Sequencing traces for the Aqp9-Aldh1a2 site in cell line 6B4 had a dye blob 
between 130 and 140 bp; however, the wild-type sequence was still 
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distinguishable (all p.S1728F off-target Sanger sequencing traces can be found 
in Appendix B).   
 
4.2.11.3 Differentiation of single cells into myotubes 
Cells were plated at ~2 x 104 cells per well of a 96-well plate coated with 
Extracellular Matrix (ECM) Gel from Engelbreth-Holm-Swarm murine sarcoma 
(Sigma Aldrich).  The following day, media was changed to differentiation 
media and replaced every other day for 5-6 days.  Of the 6 p.D3986E single-
cell derived lines obtained, only 10G5 and 8G6 formed myotubes following 5 
days of differentiation (Figure 4.24).  Myotube diameter and length was 
generally comparable between all cell lines; however, there appeared to be a 
greater proportion of smaller myotubes in cell lines 3E1 and 8G6. 
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Figure 4.24 – C2C12 and p.D3986E derivative cell lines following 5 days of 
differentiation 
Polyclonal wild-type C2C12 cells (panel A), monoclonal wild-type C2C12 3E1 
cells (panel B) and the p.D3986E derivatives (panels C and D) were plated on 
ECM Gel (Sigma Aldrich) coated plates and differentiated for 5-6 days with 
media replaced every other day.  Images were captured using the EVOSTM FL 
imaging system (ThermoFisher) with a 10x objective.  The scale bar (bottom 
right) indicates 400 uM. 
 
Neither of the p.S1728F cell lines differentiated in a manner comparable to 
wild-type C2C12 cells.  At 5 days post differentiation, following plating at 2 x 
104 cells per well of a 96-well plate, both 6B4 and 6F12 became confluent and 
it was difficult to distinguish between individual cells.  No elongated structures 
were observed for the 6B4 cell line.  For 6F12, elongated cells were observed 
(Figure 4.25; panel A and C); however, these did not appear to be 
multinucleated and were considerably smaller than myotubes observed for 
other cells (Figure 4.24).  Since plating at 2 x 104 resulted in overly confluent 
cells, plating at 5 x 103 prior to differentiation was attempted.  Again, cell line 
 
 
 
176 
 
6B4 showed no evidence of myotube formation and the elongated cells 
observed in the 6F12 cell line were smaller than those observed for other cell 
lines in both length and diameter (Figure 4.25; panel B and D).   
 
 
Figure 4.25 – p.S1728F cell lines following 5 days of differentiation 
The p.S1728F cell lines 6B4 and 6F12 were plated at 2 x 104 cells (panels A 
and C) and 5 x 103 (panels B and D) per well of a ECM Gel (Sigma Aldrich) 
coated 96-well plate.  Cells were incubated for 24 hours (37oC, 5% CO2) prior 
to the replacement of growth media with differentiation media.  Differentiation 
media was changed every other day for up to 5 days. An arrow indicates where 
an elongated structure was observed for 6F12 cells plated at a density of 2 x 
104 (panel C).  Images were captured using the EVOSTM FL imaging system 
(ThermoFisher) with a 10x objective.  The scale bar (bottom right) indicates 
400 uM. 
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4.2.12 Determination of caffeine sensitivity of edited cell lines 
 
4.2.12.1 p.D3986E cell lines caffeine EC50 analysis 
Wild-type C2C12 myoblasts and the 3E1, 8G6 and 10G5 cell lines were plated 
at 2 x 104 cells per well of ECM Gel from Engelbreth-Holm-Swarm murine 
sarcoma-coated black, clear bottom 96-well plates.  The following day, with 
myoblasts at ~90% confluency, growth factors were depleted by replacing 
growth media with differentiation media to encourage the formation of 
myotubes (Clegg et al., 1987).  On days 5 or 6, myotubes were loaded with 
Fluo-8 AM (Abcam) to a final concentration of 10 μM with 0.04% Pluronic® F-
127 acid.  Following loading, cells were equilibrate at room temperature in 
imaging buffer for 20 min prior to experiments.  The washes and equilibration 
step at room temperature allow for the removal of extracellular dye and 
redistribution of compartmentalised dye within the cell (Paredes et al., 2008).  
Prior to Ca2+ imaging, a caffeine series was prepared in imaging buffer to final 
concentrations of 0.1 mM, 1 mM, 3 mM, 5 mM, 10 mM and 20 mM and 
warmed, along with calcium imaging buffer, to 37oC.  Caffeine-induced Ca2+ 
release was observed as transient increases in fluorescence following 
perfusion, detected using the Nikon TE2000 inverted microscope attached an 
intensified CCD camera (Figure 4.26).  Cells were allowed to rest for 1 min 
between caffeine doses.   
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Figure 4.26 – Example of a caffeine-evoked Ca2+ transient trace 
Cells loaded with Fluo-8 AM (Abcam) were perfused for 10 seconds with 
imaging buffer, 10 seconds with caffeine at the desired concentration and 10 
seconds with imaging buffer (total of 30 seconds perfusion).  Increases in Ca2+ 
are observed as increases in raw fluorescence values measured in arbitrary 
fluorescence units (Y axis).  Recordings were made at a rate of 20 frames per 
second (the number of frames is shown on the X-axis).  Cells were allowed to 
equilibrate in imaging buffer for approximately 60 seconds following caffeine 
exposure.  The fluorescence light source was turned off after fluorescence had 
reached baseline again following caffeine exposure to avoid photobleaching, 
hence fluorescence values decreased to 0 between application of each 
caffeine concentration.  Recordings were made using Piper ControlTM 
Acquisition Software (Stanford Photonics, Inc). 
  
The sensitivity of each cell line to caffeine was determined by the half maximal 
effective concentration (EC50).  EC50 values were generated by performing two 
separate analyses.  Baseline measurements of fluorescence prior to each 
application of caffeine in the dose response experiment were taken by 
averaging fluorescence values for 20 frames (1 second) prior to caffeine 
application.  The first analysis measured the increase in fluorescence from 
baseline, determined by the maximum peak height for each caffeine-induced 
peak.  The second analyses utilised area under the curve (AUC) 
measurements for each caffeine-induced peak.   
 
To account for variability in the magnitude of fluorescence response between 
individual myotubes, peak height and AUC measurements for each caffeine-
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induced peak were normalised to the maximal response at 20 mM caffeine of 
that myotube.  For both analyses, cells that did not show a dose-dependent 
increase in fluorescence and/or did not respond to concentrations ≥3 mM were 
excluded from the analysis.  Furthermore, cells showed a minor, yet significant, 
negative correlation of baseline fluorescence values and EC50 values 
(correlation coefficient (r) -0.2125; 95% CI -0.2889 to -0.1334; p<0.0001), 
whereby cells with lower and higher baseline fluorescence values were 
correlated with higher and lower EC50 values, respectively (Figure 4.27).  The 
negative correlation was more pronounced at fluorescence values <50 and 
>600, with cells between these values showing less variation in EC50 values.  A 
small number of cells (7) with fluorescence values between 50 and 100 
clustered at higher EC50s (9-12 mM) alongside cells with fluorescence values 
<50; however, these cells accounted for a small proportion of the total cells in 
the correlation analysis (588).  Thus, cells with initial baseline fluorescence 
values <50 and >600 were also excluded from the analysis.  Determination of 
statistical significance was performed using one-way analysis of variance 
(ANOVA) and Tukey’s test for multiple comparisons (Tukey, 1949).    
 
 
Figure 4.27 – Correlation of baseline fluorescence values and EC50 values 
A Pearson correlation test was performed using EC50 (Y axis) and average 
baseline fluorescence values (X axis) for 588 myotubes that showed dose 
dependent increases in fluorescence.  The correlation co-efficient (r) was 
significant (p<0.0001).  Cells outside of the dashed red lines were excluded 
from the analysis and the dashed blue line shows the mean EC50 value (SD; 
95% CI).  
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Analysis of peak height data showed that polyclonal wild-type C2C12 cells had 
a mean EC50 of 5.388 mM (SD 2.328; 95% confidence interval (CI) 5.094 to 
5.697) (Figure 4.28; panels A and B).  The monoclonal wild-type 3E1 cell line 
was similar to wild-type C2C12 cells, with an EC50 of 5.009 mM (SD 1.627; 
95% CI 4.744 to 5.288).  There was no significant difference between the 
polyclonal wild-type C2C12s and the monoclonal wild-type 3E1 line (p=0.6185).  
The p.D3986E 8G6 cell line had an EC50 of 3.776 (SD 0.8779; 95% CI 3.599 to 
3.96) and the p.D3986E 10G5 cell line had an EC50 of 3.311 (SD 1.943; 95% 
CI 3.085 to 3.543).  The EC50 values for 8G6 and 10G5 were both significantly 
reduced compared to polyclonal wild-type C2C12 cells (p<0.0001) and the 
monoclonal wild-type 3E1 cell line (8G6 p=0.0043; 10G5 p=0.001).  While the 
EC50 of 8G6 was greater than that of 10G5, this was not statistically significant 
(p=0.9721).   
 
The EC50 values generated from AUC analysis followed a similar pattern to 
those generated in the peak height analysis (Figure 4.28; panels C and D).  
Wild-type C2C12 cells had an EC50 of 6.232 mM (SD 2.386 ; 95% CI 5.9 to 
6.582) and the 3E1 cell line had an EC50 of 6.283 mM (SD 1.538; 95% CI 6.01 
to 6.568) with no statistically significant difference between the EC50 values for 
the two cell lines (p=0.9732).  The p.D3986E cell line 8G6 had an EC50 of 
5.092 mM (SD 1.04; 95% CI 4.857 to 5.337) and the 10G5 cell line had an 
EC50 of 4.04 mM (SD 1.839; 95% CI 3.813 to 4.276).  The mean EC50 values 
for both 8G6 and 10G5 were significantly statistically different to wild-type (8G6 
p=0.0011; 10G5 p<0.0001) and 3E1 (8G6 p=0.0127; 10G5 p<0.0001) but there 
was no statistically significant difference in EC50 values between 8G6 and 
10G5 (p=1.839).  
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Figure 4.28 – Caffeine dose-response analysis of Ca2+ imaging of wild-
type C2C12 cells and p.D3986E derivatives 
Panels A and C show the peak and AUC sigmoidal dose-response analysis, 
respectively, of wild-type C2C12s (blue circles), wild-type 3E1 cells (green 
squares), 8G6 (red diamonds) and 10G5 (orange triangles).  Normalised 
fluorescence (a percentage of the maximal response at 20 mM caffeine) is 
shown on the Y axis and the caffeine concentration (mM) is on the X axis.  
Peak height data points are means of 33-46 myotubes and AUC data points 
are means of 33-45 myotubes (plated and imaged on at least 3 different days, 
with the exception of 3E1 from which data was collected on 2 different days) 
and error bars show the SD.  Panels B and D show box plots of the peak and 
AUC EC50 values, respectively.  Box plots show the median data point, upper 
and lower quartiles and the minimum and maximum data points.  Curves were 
fitted and graphs plotted using Prism 7 (GraphPad).  One-way ANOVA and 
Tukey’s test for multiple comparisons were used to determine significance. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
Values of the mean peak percentage maximal response (%MR) at each 
caffeine concentration are shown in Figure 4.29; Panel A.  Wild-type C2C12 
cells and cell line 3E1 responded to caffeine similarly at all concentrations, as 
did cell lines 8G6 and 10G5 with the exception of at 1 mM caffeine.  The %MR 
of wild-type polyclonal C2C12 cells was 7.698% at 1 mM caffeine.  In contrast, 
the %MR of cell line 3E1 was 0.7449 and was significantly different to wild-type 
C2C12 (p= 0.0046).  Cell line 8G6 had a %MR of 4.225, which was not 
significantly different to wild-type C2C12 (p=0.2654) or 3E1 (p=0.3347).  Cell 
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line 10G5 had %MR of 14.92%, which was significantly different to wild-type 
C2C12 (p=0.0006), 3E1 (p<0.0001) and 8G6 (p<0.0001).   
At 3 mM caffeine, %MR was 26.39 for wild-type C2C12 cells, 34.76 for 3E1, 
46.01 for 8G6 and 46.08 for 10G5.  There was a significant difference between 
the %MR for wild-type C2C12 cells and cell lines 8G6 (p <0.0001) and 10G5 (p 
<0.0001).  Furthermore, there was a significant difference between 3E1 and 
cell lines 8G6 (p=0.0090) and 10G5 (p=0.0058).  There was no significant 
difference between wild-type C2C12 and 3E1 at 3 mM caffeine (p=0.0808), nor 
was there a significant difference between 8G6 and 10G5 at 3 mM caffeine 
(p>0.9999). 
At 5 mM caffeine, the %MR of wild-type C2C12 cells was 44.49 and the %MR 
of 3E1 cells was 46.58, with no significant difference between the two (p= 
0.9430).  The %MR of 8G6 and 10G5 at 5 mM caffeine was 59.33 and 64.53, 
respectively.  Like 3 mM caffeine, there was no significant difference in %MR 
between 8G6 and 10G5 (p= 0.4134).  The %MR for cell line 8G6 was 
significantly different to both wild-type C2C12 (p= 0.0002) and cell line 3E1 
(p=0.0048).  Similarly, the %MR for cell line 10G5 was significantly different to 
both wild-type C2C12 (p <0.0001) and cell line 3E1 (p<0.0001). 
At 10 mM caffeine, the %MR of wild-type C2C12 cells was 73.64 and 3E1 was 
73.13, with no significant difference between the two cell lines (p=0.9987).  The 
%MR of 8G6 was 79.13, which was not significantly different to wild-type 
C2C12 cells (p=0.3031), 3E1 (p=0.2965) or 10G5 (p=0.3206).  The percentage 
release of 10G5 cells was 84.35 and this was significantly different to wild-type 
C2C12 cells (p=0.0028) and 3E1 cells (p=0.0045). 
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Figure 4.29 – Peak and AUC percentage maximal response of p.D3986E and wild-type C2C12 at 1, 3, 5 and 10 mM caffeine 
The peak (panel A) and AUC (B) percentage maximal response of each cell line at 1 mM, 3 mM, 5 mM and 10 mM caffeine.  Baseline 
fluorescence values were calculated from an average of 20 frames prior to caffeine perfusion at each dose.  Baseline was used to 
define peaks for the AUC analysis and was subtracted from the peak height increase in fluorescence for the peak height analysis.  The 
resultant values for each caffeine concentration were calculated as a percentage of the maximal response at 20 mM caffeine.  Data are 
shown as the mean (33-46 cells in the peak analysis; 33-45 cells in the AUC analysis) and error bars are the SD.  One-way ANOVA 
and Tukey’s test for multiple comparisons were used to determine significance. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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The %MR at each caffeine concentration from AUC analysis followed a similar 
pattern the data gleaned from peak height analysis (Figure 4.29; Panel B).  
Again, wild-type C2C12 cells and cell line 3E1 responded in a similar manner 
throughout the dose response experiment, as did cell lines 8G6 and 10G5, with 
the exception of at 1 mM caffeine.  At 1 mM caffeine, polyclonal wild-type 
C2C12 cells had a %MR of 4.233.  Cell line 3E1 had a %MR of 0.1552, which 
was significantly different to wild-type C2C12 (p=0.0090).  Cell line 8G6 had a 
%MR of 2.001, which was not significantly different to wild-type C2C12 or 3E1 
cells (p=0.2410).  Cell line 10G5 had a %MR of 9.296 which was significantly 
different to wild-type C2C12 (p<0.0001), 3E1 (p<0.0001) and 8G6 (p<0.0001).   
At 3 mM caffeine, wild-type C2C12 cells and cell line 3E1 had %MRs of 20.55 
and 22.13, which were not significantly different to each other (p=0.9602).  In 
contrast, cell line 8G6 had a %MR of 32.06, which was significantly different to 
3E1 (p=0.0130) and wild-type (p=0.0009).  Cell line 10G5 had a %MR of 37.54 
which was not significantly different to 8G6 (p=0.2224) but was significantly 
different to wild-type C2C12 (p<0.0001) and 3E1 (<0.0001).   
At 5 mM caffeine, wild-type C2C12 cells and 3E1 had %MRs of 38.41 and 
36.33.  As found at previous caffeine concentrations, these values were not 
significantly different (p=0.9477).  Cell line 8G6 and 10G5, with %MRs of 48.74 
and 57.45 were significantly different to both wild-type C2C12 (8G6 p.= 0.0207; 
10G5 p<0.0001) and 3E1 (8G6 p=0.0080; 10G5 p<0.0001), but not to each 
other (p=0.0541). 
At 10 mM caffeine, wild-type C2C12, 3E1, 8G6 and 10G5 had %MRs of 67.94, 
68.7, 70.44 and 76.98, respectively.  The %MR of wild-type C2C12 cells was 
not significantly different to 3E1 (p=0.9967) or 8G6 (p=0.8772) but was 
significantly different to 10G5 (p=0.0244).  Cell line 3E1 was not significantly 
different to 8G6 (p=0.9633) or 10G5 (p=0.0821).  Finally, the %MR of cell line 
8G6 was not significantly different to that of cell line 10G5 (p=0.1762). 
 
4.2.12.2 p.D3986E cell lines raw fluorescence increase from baseline 
observations 
Between myotubes, the magnitude of raw fluorescence increases from 
baseline in response to caffeine perfusion was variable.  On average, wild-type 
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C2C12 and cell line 10G5 consistently produced greater increases in raw FUs 
following caffeine perfusion than 3E1 and 8G6 (Figure 4.30).  This was 
observed at all caffeine doses.  For example, where 20 mM caffeine was 
perfused, the mean increase in raw FUs from baseline following perfusion for 
wild-type C2C12s was 648.3 (SD 252.2; 95% CI 575.1-721.5).  This was 
significantly different to cell line 8G6, which had a mean increase of 168.5 FUs 
(SD 71.27; 95% CI 144-193; p<0.0001) and cell line 3E1, which had a mean 
increase of 194.2 FUs (SD 95.96; 95% CI 161.3- 227.2; p<0.0001).  There was 
no significant difference between wild-type C2C12 and 10G5 which had a 
mean increase in raw FUs of 672.9 (SD 224.3; 95% CI 613.4- 732.4; p= 
0.9136).  The response of cell line 3E1 was not significantly different to 8G6 
(p= 0.9434) but was significantly different to 10G5 (p<0.0001).  Finally, the 
magnitude of the responses of cell lines 8G6 and 10G5 was also significantly 
different (p<0.0001).  It should be noted that the reduced response at 1 mM 
caffeine in cell lines 3E1 and 8G6 is likely a result of the low magnitude 
responses not producing peaks 10% greater than baseline; as such, these 
peaks would not have been detected during data analysis (Figure 4.29). 
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Figure 4.30 – Mean raw fluorescence increases in response to 20 mM 
caffeine for p.D3986E lines and wild-type C2C12 cells 
Baselines were calculated for each myotube by averaging fluorescence values 
for 20 frames (1 second) prior to perfusion with 20 mM caffeine.  Baseline 
measurements were subtracted from the peak height measurement for each 
myotube, to generate the raw fluorescence increase.  Raw fluorescence 
increases were averaged across 33-46 genotypes per cell line, generating the 
mean raw fluorescence increase in response to 20 mM caffeine.  The 20 mM 
caffeine dose has been used for reference; however, the pattern was the same 
across all caffeine doses.  Box plots show the median data point, upper and 
lower quartiles and the minimum and maximum data points.  One-way ANOVA 
and Tukey’s test for multiple comparisons were used to determine significance. 
****p<0.0001. 
 
The differences in the magnitude of response from baseline between 
genotypes could reflect reductions in the number of SR in cell lines 3E1 and 
8G6.  In agreement with that, it was observed that cell lines 3E1 and 8G6 
produced a greater proportion of smaller myotubes than 10G5 and wild-type 
C2C12 cells; however, these were still elongated and multinucleated (Figure 
4.24).  Furthermore, differences in magnitude of the response were not 
associated with different mean EC50 values within genotypes.  Analysis of the 
EC50 values generated when myotubes had raw baseline increase 
fluorescence values that were low (defined as <200 FU) and high (defined as 
>=200 FU) showed no significant difference in EC50 values between the low 
and high groups, in any of the genotypes (WT p>0.999 low n=5 and high n=40; 
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3E1 p=0.0884 low n=16 and high n=17; 8G6 p=0.9505 low n=24 and high 
n=20; cell line 10G5 was not included in this analysis since the low group had 
n=1).  Indeed, all responses were normalised to the maximum of that myotube 
for the EC50 analysis.   
4.3 Discussion 
The primary aim of this chapter was to introduce the p.D3986E and p.S1728F 
variants into C2C12 myoblasts with the view to determine the sensitivity of the 
resultant cell lines to caffeine by Ca2+ imaging.  Whilst a number of cell lines 
were generated that contained the variants of interest, the work presented in 
this chapter has been unable to conclusively determine the functional 
significance of the RYR1 p.D3986E and p.S1728F variants due to complex 
mutational patterns induced by the NHEJ and HDR DNA repair mechanisms.  
Nonetheless, this work provides a substantial foundation for the introduction of 
MH-associated VUS into C2C12 myoblasts using CRISPR-Cas9 gene-editing, 
in the first study of its kind within the MH field.  Importantly, this work has 
highlighted the complexity of the gene-editing events that can occur as a result 
of CRISPR-Cas9 gene-editing and the limitations associated with the use of 
myoblasts that must be considered for future work in developing a CRISPR-
Cas9 pipeline for the functional characterisation of MH-associated VUS. 
 
4.3.1 Evaluation of the CRISPR-Cas9 genome editing strategy 
In theory, the apparent polyploidy of C2C12 cells does not pose a major issue 
with regard to functional characterisation.  Successful incorporation of the 
variants of interest by HDR in varying copy numbers of 1 to 3 would provide 
insight into the gene dosage effect of the variant of interest following Ca2+ 
imaging.  Practically, the main complication of using polyploid C2C12 cells was 
the determination of editing events on each copy of the mouse Ryr1 gene.  
Whilst the TaqManTM genotyping assays utilised in this chapter provided an 
effective screening tool for the detection of cell lines containing the variant of 
interest, the utility of the assays in determining the composition of each allele 
was limited.  Unlike TaqManTM gene expression assays, the genotyping assays 
are designed to optimise single nucleotide specificity over reaction efficiency 
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(Hui et al., 2008).  As a result, cycle threshold (Ct) values cannot be used to 
determine copy number and the Genotyping Module assigns genotype calls 
based on cluster orientation and the end-point ratios of the VICTM (allele 1; wild-
type) and FAMTM (allele 2; variant) reporter dyes, measured by dRn values.  
Given this, dRn ratios were compared to infer the genotype of vector clusters 
that appeared following genotyping.  The extrapolations from the genotyping 
assay were supported by TA cloning and subsequent Sanger sequencing data. 
 
In cell line 8G6, editing events detected by Sanger sequencing account for one 
of the variant alleles detected by the genotyping assay.  The 37 bp deletion in 
8G6 would have removed the TaqManTM probe site; as such, this allele would 
not have been detected by the genotyping assay.  Further sequencing analysis 
is required to determine the composition of the third allele; however, it is 
plausible that this allele has undergone a complex editing event whereby the 
p.D3986E variant has been incorporated whilst maintaining the wild-type 
sequence, accounting for the dRn ratios observed in the genotyping assay.  
Accordingly, an editing event that resulted in the wild-type and variant 
p.D3986E sequences on a single chromosome was detected in cell line 10G5.  
Similarly to cell line 8G6, the 37 bp deletion in cell line 10G5 would have 
removed the TaqManTM probe site.  Identification of a small 5 bp deletion on 
the third Ryr1 allele in cell line 10G5 accounts for the second wild-type allele 
identified by the genotyping assay.  
 
Combining genotyping and Sanger sequencing for cell line 2G7 suggests that it 
has two copies of both the wild-type and variant alleles, since dRn ratios were 
1:1.5 wild-type allele to variant allele and two editing events that would have 
been identified as wild-type by the genotyping assay were detected.  The 
composition of the third allele was not been detected; however, it may have 
undergone a complex editing event that resulted in two copies of the p.D3986E 
variant allele.   
 
The dRn values for cell line 9H12 could be indicative of a single copy of each 
allele, with the remaining allele unable to be amplified due to the presence of 
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an additional mutation or deletion within the TaqManTM probe sequence.  TA 
cloning revealed a 7 bp deletion in cell line 9H12 that would have been 
identified as wild-type by the genotyping assay.  In one case, this deletion was 
followed by a G>A substitution within the TaqManTM probe sequence.  Since 
TaqManTM genotyping assays are designed to discriminate between a single 
base, this substitution would prevent hybridisation of the wild-type probe.  
Whilst this would account for the detection of just two alleles by the genotyping 
assay, it is important to consider that this could be an error introduced by PCR 
of the region of interest.  Further sequencing to detect the composition of the 
remaining allele(s) would determine whether this is a genuine mutation or an 
error.  If the G>A substitution was found to be a technical error, a large deletion 
that removed the TaqManTM probe sequence would account for a single copy 
of variant and wild-type alleles.  Alternatively, 9H12 could contain two copies of 
each allele that could have been introduced by complex editing events such as 
those observed in 8G6 and 10G5.  All three alleles identified by the genotyping 
assay have been accounted for by Sanger sequencing data for cell lines 1E6 
and 1C5.   
 
For the p.S1728F genotyping assay, dRn values were considerably lower than 
that of the p.D3986E assay, with allele 1 dRn values for wild-type C2C12s of 
1.565 in the p.D3986E assay and 0.544 in the p.S1728F assay.  This likely 
reflects an inherent property of the TaqManTM probe sequences in the 
p.S1728F assay, since the same wild-type DNA was used in both the 
p.S1728F and p.D3986E assays.  Since both assays were custom designed 
and non-human, they were not functionally validated by the supplier prior to this 
experiment.  Nonetheless, the p.S1728F assay detected two cell lines that 
contained the variant.  The comparison of dRn ratios and cluster orientations 
suggested that both cell lines have a single copy of the p.S1728F variant.  The 
6F12 cell line had a 2:1 ratio of allele 1 (wild-type) to allele 2 (variant); whereas 
the 6B4 cell line had a 1.5:1 ratio of allele 1 to allele 2.  Two editing events, a 
successful incorporation of the p.S1728F HDR template and a 2 bp insertion at 
the Cas9 cut site, were detected in cell line 6B4.  These editing events account 
for the variant and wild-type allele detected by the genotyping assay; however, 
there was insufficient data to conclude whether cell line 6B4 has another wild-
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type allele or whether a deletion of the TaqManTM probe sequence resulted in 
the detection of only 2 alleles by the genotyping assay.  No further information 
was obtained from Sanger sequencing of the TA clones picked from 6F12 
vectors, either due to poor sequencing quality or the clones not containing the 
insert.   
 
In conclusion, the TaqManTM genotyping assays served their function as low-
cost, moderate-throughput screening tools to robustly detect cell lines 
containing the variant of interest.  The comparisons of dRn ratios between 
alleles was largely supported by Sanger sequencing data; however, when dRn 
ratios are roughly equal, it is not possible to determine allele 1/allele 2 copy 
number without sequencing confirmation.  In addition, any gene-editing events 
outside of the TaqManTM probe sequences could not be detected.  
Consequently, wild-type alleles detected by the genotyping assay were later 
confirmed to have subtle modifications.  This highlights the importance of 
confirming the composition of Ryr1 loci by sequencing.  Whilst considerable 
progress was made using TA cloning and subsequent Sanger sequencing to 
confirm editing events on each allele, alternative sequencing technologies 
would provide increased throughput and greater sensitivity for the detection of 
gene-editing events that occurred.  Multiple reports in the literature describe the 
use of deep sequencing to detect CRISPR-induced editing events in myoblasts 
and other cell types (Dastidar et al., 2018; Min et al., 2019; Wojtal et al., 2016).  
Since Sanger sequencing can only confirm the presence of a specific editing 
event and not the copy number, deep sequencing would provide a more 
comprehensive analysis of editing events on each allele and is rapidly 
becoming the gold standard for the analysis of indel generation at the target 
site.  This technique would overcome the limitations associated with the 
polyploidy of C2C12 cells, providing a promising outlook for their utilisation in a 
CRISPR-Cas9 pipeline for the characterisation of MH-associated VUS. 
 
4.3.1.1 Mechanims of DSB repair 
The HDR efficiencies demonstrated in this study were low, with 3.75% of single 
cell colonies containing the variant of interest for p.D3986E and 2.70% for 
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p.S1728F, although the low efficiency of HDR is well documented and these 
values are similar those reported in the literature (Liu et al., 2019; Boel et al., 
2018).  HDR was used to correct a premature stop codon in exon 23 of the 
DMD gene that interferes with dystrophin expression in Duchenne Muscular 
Dystrophy (DMD), achieving HDR efficiencies of up to 9% following injection 
into DMD mouse model, mdx, zygotes (Long et al., 2014).   
 
Strikingly, a range of mutational events introduced by CRISPR-Cas9 gene-
editing were observed in this study.  The presence of small insertions and 
deletions can be explained by NHEJ – the primary mechanism by which DSBs 
are repaired in mammalian cells (Davis and Chen, 2013) .  The most common 
form, canonical NHEJ (c-NHEJ) involves the recognition of DSBs by the 
dimeric Ku70/Ku80 protein complex.  The Ku complex recruits a number of 
proteins that allow for processing of the DNA ends to render them ligatable.  
Processing of the DNA ends can result in minor resection or the introduction of 
random sequences, usually up to 10 bp (Ata et al., 2018).  Following 
processing, ligase IV acts to ligate the DSB.  Interestingly, some of the indels 
detected in this study were detected multiple times in different cell lines.  This 
suggests that, at least in some cases, preferential editing events may occur 
and this could be sequence context dependent.  Indeed, non canonical NHEJ, 
also known as microhomology mediated end joining (MMEJ) is another 
pathway implicated in the repair of DSBs (Bae et al., 2014).  MMEJ uses short 
regions of homology for the repair of double-stranded breaks, resulting in more 
homogenous editing events than canonical NHEJ (Ata et al., 2018).  
 
Resection of the 5’ ends of the DSB allows for the commitment of the cell to an 
HDR pathway.  Whilst the mechanism of single strand oligonucleotide 
integration has not been fully elucidated, it is believed to occur by a HDR 
mechanism called synthesis dependent strand annealing (SDSA; Paix et al., 
2017; Boel et al., 2018).  In SDSA, the 5’ ends of the DSB are resected to 
produce large 3’ overhangs.  The single stranded oligonucleotide template then 
binds to the complementary 3’ overhang and acts as a template for DNA 
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polymerase to extend, filling in the 5’ resection.  Finally, DNA ligase acts to 
ligate nicks in the DNA.   
 
The observation that some HDR templates were scarlessly recombined into the 
C2C12 genome was highly encouraging, ultimately providing proof of principle 
for the introduction of MH-associated VUS into a myoblast cell line for 
downstream functional characterisation.  In some instances, HDR templates 
were found to have been integrated erroneously.  Aberrant DNA synthesis 
during SDSA can occur by a mechanism referred to as template switching 
whereby the newly synthesised DNA strand binds to regions of microhomology 
elsewhere on the repair template or in the endogenous DNA.  This results in 
erroneous DNA synthesis and the incorporation of inverted, duplicated or 
fragmented repair templates (Boel et al., 2018).  As such, this work provides 
support for the role of SDSA in the integration of single stranded 
oligonucleotide HDR templates through the observation of such erroneous 
HDR template integrations.   
 
4.3.1.2 Optimisation of HDR efficiency 
In this study, attempts to improve HDR efficiency were primarily focused on the 
optimisation of the distance between the cut site and base to be edited (cut to 
base distance).  Whilst HDR efficiency is locus and cell type dependent, in 
general, reductions in HDR efficiency of ~50% are observed when the cut to 
base distance is 10 bp.  When this increased to 20 bp, a reduction of ~70% is 
observed.  HDR efficiencies of near 0% are observed with a cut to base 
distance of 35 bp (Paquet et al., 2016).  As such, the major criterion in gRNA 
design was the cut to base distance.  Furthermore, single stranded 
oligonucleotide HDR templates were used in this study due to reports of 
increased HDR efficiencies compared to vector-encoded double stranded HDR 
templates and reduced illegitimate recombination events (Ran et al., 2013a; 
Würtele et al., 2003).  HDR templates with 80 bp homology flanking the cut site 
(total length of 161 bp) were selected since each arm of homology should be 
50-100% the size of the insertion, typically 50-80 bp for small changes (Ran et 
al. 2013a; Li et al., 2014).  Recently, a growing body of literature has emerged 
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concerning the improvement of HDR efficiencies by optimisation of several 
parameters.  Firstly, since undesired editing events introduced by NHEJ are 
widespread, efforts to inhibit the mechanism using chemical inhibitors have 
been explored elsewhere.  Success has been limited in using Ligase IV 
inhibitor, SCR7 (Maruyama et al., 2015).  While Maruyama and colleagues 
found improvements in HDR efficiency by up to 19-fold in human epithelial and 
melanoma cells, others have found no improvement to HDR efficiencies using 
SCR7 in zebrafish (Boel et al., 2018).  Two proteins from the adenovirus 4 
genome, E1B55K and E4orf6, have also been used to suppress NHEJ by 
facilitating the degradation of Ligase IV (Chu et al., 2015).  Furthermore, 
modified Cas9 proteins with one inactive catalytic site, resulting in the 
introduction of single-stranded breaks, can undergo HDR with reduced NHEJ 
events (Ran et al., 2013a).  Interestingly, Guo et al., (2018a) reported 
increased ‘perfect’ HDR (that is, scarless recombination) using a cold-shock 
protocol whereby iPSCs exposed to 32oC for 24 hours following transfection 
had increased perfect HDR rates by two-fold, potentially due to temperature 
stabilisation of recombination intermediates (Guo et al., 2018a). 
 
In conclusion, despite the considered design of HDR templates, mainly 
concerning the cut to base distances, HDR efficiencies in this study were low 
and undesired NHEJ events were widespread.  Nonetheless, the nature of 
CRISPR-Cas9 as a rapidly developing technology means that there are a 
number of areas that could be explored for the improvement of HDR 
efficiencies and scarless integration.  This work highlights areas for future 
development of the CRISPR-Cas9 pipeline within the MH field for the 
characterisation of MH-associated VUS.   
 
4.3.1.3 Analysis of in-silico predicted off-target sites 
A key consideration in any gene-editing experiment is the potential for 
introduction of editing events at sites other than the target.  The CRISPOR off-
target prediction tool consistently predicted more off-target sites than CCTOP.  
Where off-target sites were predicted by both programs, they were often 
ranked at different likelihoods of binding.  These differences reflect variations in 
 
 
 
194 
 
the algorithms used by each programme to detect off-target sites.  To account 
for this, a selection of the top off-target sites predicted by both programs were 
sequenced.  Encouragingly, all off-target sites within the p.D3986E and 
p.S1728F cell lines for which sequences were successfully generated were 
wild-type.  These sequences were generated by direct Sanger sequencing of 
the sites within the C2C12 genome (as opposed to TA cloning and subsequent 
Sanger sequencing).   Detection of multiple sequences as a consequence of 
editing events would result in overlapping traces within a sequencing 
chromatogram that start near the Cas9 cut site.  Such overlapping traces were 
not observed for any of the off-target sites sequenced.  Thus, it appears that 
the Mm_D3986E_gRNA2 and Mm_S1728F_gRNA2 guides did not induce 
undesired editing events, at least at the predicted off-target sites for which 
sequences were generated.  The location of off-target sites within GC-rich and 
repetitive regions was problematic.  Primer design tool, PrimerBLAST (Ye et 
al., 2012), was unable to generate PCR primers for the sequencing of the top 2 
off-target sites predicted by CCTOP and the second off-target site predicted by 
CRISPOR for Mm_D3986E_gRNA2.  The top off-target site predicted by 
CRISPOR failed to produce PCR amplicons despite primer re-design and PCR 
optimisation with the addition of DMSO which enhances primer binding to the 
template (Mammedov et al., 2008).  Further primer re-design and optimisation 
of the PCR reaction using non-traditional parameters such as the addition of 
ethylene glycol and 1,2-propanediol could prove successful for the generation 
of amplicons from these difficult regions (Zhang et al., 2009).   
For the p.S1728F cell lines, primers were unable to be designed for the 5th and 
8th off-target site predicted by CCTOP.  Since off-target sites are ranked based 
on the likelihood of binding and only wild-type sequences were detected at 
higher ranked off-target sites, it is unlikely that gene editing occurred at the 5th 
and 8th off-target sites for which no sequences could be generated.  Whilst in-
silico tools are widely used to predict potential off-target sites, reports in the 
literature have detailed the detection of off-target editing events at sites not 
predicted by conventional in-silico tools (Zhang et al., 2015).  Consequently, 
whole-genome sequencing remains the only method by which all off-target 
activities can be ruled out; however, the feasibility of performing whole-genome 
sequencing for each cell line created is limited by the high cost and extensive 
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data analysis required to interpret genomic data.  For the use of CRISPR-Cas9 
gene-editing for the introduction of MH-associated VUS, it is more feasible to 
optimise HDR efficiency and inhibit NHEJ to increase success in generating 
cell lines that contain only the variant of interest.  Functional analysis of 
multiple lines containing different copy numbers would allow for the analysis of 
gene dosage effects, providing conclusive evidence that any effect observed is 
due to the variant in question, rather than activity at off-target sites. 
 
4.3.1.4 Gene-editing efficiencies 
The gene-editing efficiencies of the gRNAs utilised in this study, as determined 
by T7 assay, and theCRISPRater efficacy predictions did not follow a similar 
trend.  For the p.D3986E gRNAs, CRISPRater ranked them (in order of highest 
efficacy) Mm_D3986E_gRNA2, Mm_D3986E_gRNA3 and 
Mm_D3986E_gRNA1.  In contrast, the T7 assay showed the highest gene-
editing efficiencies in Mm_D3986E_gRNA1, followed by Mm_D3986E_gRNA3 
and then Mm_D3986E_gRNA2.  As such, in-silico efficacy predictions should 
not be solely relied upon for gRNA selection.   
 
4.3.2 Utilisation of C2C12 myoblasts 
The C2C12 cells used in this project tolerated transfection well, with only a 
minor reduction in cell viability following transfection and the proportion of GFP-
expressing cells following transfection reaching up to 50%, with an average of 
25%, similar to values reported in the literature (Dodds et al., 1998).  C2C12 
cells consistently survived FACS for both bulk GFP-enrichment sorts and single 
cell sorts into 96-well plates.  In total, out of the 1728 single cells collected for 
the p.D3986E and p.S1728F experiments, 234 formed cell lines that grew well 
(13.54%).  Thus, C2C12 cells provide a robust cell type in which 
characterisation of MH-associated VUS can be performed following 
improvements to HDR efficiency and NHEJ suppression.  In addition to wild-
type C2C12 cells and the 3E1 wild-type monoclonal line, only two of the edited 
cell lines formed multinucleated myotubes.  The reason for impaired myotube 
formation in some cell lines is unclear.  It has been observed here and 
elsewhere that not all myoblasts form myotubes following culture in conditions 
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that induce differentiation; however, Yoshida et al., (1998) showed that 
subcloning of these undifferentiated cells resulted in the formation of roughly 
equal ratios of differentiated and undifferentiated cells, subsequently terming 
these undifferentiated cells  ‘reserve cells’.  One explanation for the impaired 
myotube formation in some cell lines within this project is that the multiple 
doublings required for the propagation of a single cell affected the ability of 
cells to differentiate.  Impaired differentiation capacity has been observed in 
C2C12 cells that have undergone repeated passage and this is associated with 
reductions in key myogenic regulatory factors (MRFs) Myf5, MyoD, MRF4 and 
myogenin (Sharples et al., 2011; Shahini et al., 2018).  As described in 4.2.3, 
the C2C12 cells utilised in this project were labelled as passage 0 following 
retrieval from cryostorage and cells were transfected with the pSpCas9(BB)-
2A-GFP vector at passage 10; however, no information was known about 
passage number prior to freezing.  As such, it may be advisable for future work 
to obtain C2C12 myoblasts of known low passage number to improve the yield 
of differentiation competent cell lines.   
 
4.3.3 The scope for use of cytidine deaminase vectors 
Since the introduction of specific variants by HDR is largely inefficient and can 
result in undesired NHEJ events, the use of a Cas9 nickase (D10A) fused to a 
cytidine deaminase base editor and uracil glycosylase inhibitor (BE3) was 
explored as a means for the characterisation of MH-associated VUS that result 
from C>T or G>A substitutions.  Since these base editors act to modify C/G 
residues within 8 bp of the PAM-distal end of the gRNA, albeit with variable 
efficiency, base editing is not targeted to a single nucleotide; as such, if there 
are other C or G bases near the desired base to be edited, these will likely 
undergo deamination as well (Komor et al., 2016).  Given this, the Cas9 D10A-
BE3 base editor was deemed not to act with sufficient specificity to confer 
successful gene-editing for the majority of MH-associated VUS investigated.  
The only exception was the p.R3366H variant (MAF 0.0008; gnomAD).  As 
such, the Cas9 D10A-BE3 system does not provide a robust platform for the 
introduction and downstream functional characterisation of MH-associated VUS 
but it could be used to investigate the effect of the p.R3366H variant.  The 
p.R3366H variant was identified in 2 referrals to the Leeds MH Unit.  The first 
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patient, determined as MHSh by IVCT, was a central core disease (CCD) 
patient.  CCD is characterised by cores lacking mitochondria and oxidative 
enzymes in type 1 muscle fibres and the main symptom is muscle weakness.  
CCD is associated with MH susceptibility (McCarthy et al., 2000; Robinson et 
al., 2006).  Interestingly, this patient inherited the p.R3366H variant in cis 
alongside RYR1 variants p.Y3933C and p.I1571V and this haplotype has been 
reported previously (Garibaldi et al., 2019; Kraeva et al., 2015).  The second 
patient was an EHI referral determined as MHShc by IVCT.  In this patient, the 
p.R3366H, p.Y3933C, p.I1571V haplotype was identified in addition to the 
RYR1 p.T3711M variant and RYR1 p.G2050C variant.  This illustrates the 
range of complex phenotypes associated with variants in the RYR1 gene and 
the determination of the effect of the p.R3366H variant would provide insight 
into the roles of each variant present within these individuals. 
 
4.3.4 Sensitivity of resultant cell lines to caffeine 
Cell line 3E1 was selected as a control for Ca2+ imaging to ensure that any 
results observed were not due to a differential phenotype induced by 
processing of the cell line through the CRISPR-Cas9 pipeline and propagation 
from a single cell.  The sensitivity of cell line 3E1 to caffeine was not 
significantly different to wild-type polyclonal C2C12 cells, demonstrating that its 
Ca2+ handling properties had not been altered.  Plotting %MR for each cell line 
at each caffeine concentration revealed that wild-type C2C12 cells and cell line 
10G5 had a greater %MR at 1 mM caffeine than cell line 3E1 and cell line 8G6, 
despite wild-type cells having a higher EC50 than 8G6.  This result is explained 
by the observation that wild-type C2C12 cells and cell line 10G5 both 
consistently produced greater increases in raw fluorescence following caffeine 
perfusion.  As such, at 1 mM caffeine, some responses of cell lines 3E1 and 
8G6 would not have been recognised by the analysis if the increase in 
fluorescence was not >10% greater than baseline.  This criterion was included 
to ensure that any peaks identified were bona fide responses to caffeine rather 
than experimental noise.  Nonetheless, despite the reduction in magnitude of 
response in cell lines 3E1 and 8G6 (presumably due to the greater proportion 
of smaller myotubes observed in these cell lines), stratification of individual 
cells within cell lines into ‘low’ and ‘high’ responder groups did not reveal any 
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significant differences in the EC50 values generated between each group, 
giving confidence that the results observed are a consequence of the genotype 
of the cell line.  The reduced EC50 values for cell lines 8G6 and 10G5 
compared to wild-type polyclonal C2C12 cells and cell line 3E1 cannot be 
conclusively determined to result from the p.D3986E variant since both cell 
lines contained erroneous HDR integration events and NHEJ events on other 
Ryr1 alleles.  Indels that arise from NHEJ tend to introduce out-of-frame 
premature stop codons (Ran et al., 2013a).  Premature stop codon sequences 
in the mRNA are recognised by components that initiate nonsense mediated 
decay, resulting in transcript degradation (Popp and Maquat, 2016).  Given 
this, it is likely that Ryr1 expression was reduced through loss of two Ryr1 
alleles in the 10G5 cell line and at least one in the 8G6 cell line.  In both cases, 
the HDR integration events were in-frame and thus likely resulted in an Ryr1 
protein with altered function. 
Since p.S1728F cell lines did not form multinucleated myotubes, EC50 values 
were not calculated.  Although the p.S1728F cells did show a response to 
caffeine, albeit small, the drastic difference in morphology compared to 
polyclonal C2C12 cells and cell line 3E1 meant that any results observed were 
not comparable.  As such, the pathogenicity of p.S1728F remains unclear.  The 
p.S1728F variant is conserved across mammals but not all species included in 
the multiple sequence alignment.  In-silico pathogenicity prediction tools gave 
conflicting results due to the different annotations used by each program.  For 
example, SIFT, which predicts pathogenicity based on conservation, scored the 
p.S1728F variant as tolerated.  In contrast, CADD, which provides the most 
comprehensive and robust pathogenicity prediction due to its combination of 63 
annotations, assigned a C-score of 24 indicating that p.S1728F is likely a 
deleterious variant.  Whilst in-silico tools can provide a means to filter variants 
of interest in large data sets, they cannot be relied upon to confirm 
pathogenicity.  The in-silico pathogenicity prediction results could reflect the 
mild putative effect on RYR1 channel function, with patients harbouring the 
p.S1728F variant produce relatively weak contracture strength during IVCT 
(Carpenter et al., 2009).  Another in-silico pathogenicity tool that has been 
developed in recent years for variant prioritisation is The Rare Exome Variant 
Ensemble Learner (REVEL) that, like CADD, integrates scores from multiple 
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programs (Ioannidis et al., 2016).  Whilst REVEL was not utilised within this 
project, it is now being used in conjunction with CADD in the Leeds MH Unit. 
 
4.3.5 Future directions - can CRISPR-Cas9 genome editing be used 
to replace current characterisation methods? 
The work presented here provides the first report of the introduction of MH 
associated VUS into a myoblast cell line by CRISPR-Cas9 genome editing and 
provides a substantial foundation for future development of the technique.  Key 
areas for future optimisation have been highlighted and include the 
suppression of NHEJ, potentially using small molecules that inhibit Ligase IV or 
by using a Cas9 nickase nuclease that has shown reduced rates of NHEJ 
activity.  Secondly, for genome editing in C2C12 cells, deep sequencing should 
be considered for the determination of editing events on each Ryr1 allele to 
overcome the limitations associated with TA cloning.  Another consideration for 
the utilisation of CRISPR for the characterisation of MH-associated VUS is the 
ability to generate gRNAs that contain appropriate cut to base distances for all 
of the MH-associated VUS.  The introduction of the p.D3986E and p.S1728F 
variants was not hindered by design of gRNAs, with three medium to high 
quality gRNAs were designed per variant, of which 2 for each variant had cut to 
base distances of £13 bp; however, it is important to consider that this may be 
a limiting factor for some MH-associated VUS.  Ultimately, the development of 
a CRISPR-Cas9 genome editing pipeline for the characterisation of MH-
associated VUS overcomes existing limitations of variant characterisation and 
provides the potential to accelerate a DNA-level diagnostic approach to MH.  
As such, with further optimisation of the aforementioned parameters, it is likely 
that CRISPR-Cas9 genome editing will be adopted as a method of variant 
characterisation.  Indeed, recently, a similar strategy was used in human 
colonic Caco-2 cells cells for the functional characterisation of a variant 
associated with congenital chloride diarrhea.  The variant, in the SLC26A3 
gene which encodes the chloride anion exchanger, was found to affect the 
function of the epithelial barrier, providing insight into the mechanisms of the 
disease (Zhang et al., 2019).   
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Chapter 5 - Developing cellular and in-vitro systems to 
investigate the role of Calsequestrin-1 in MH and 
associated conditions 
5.1 Introduction 
5.1.1 A role for CASQ1 in MH 
The realisation of CASQ1 as a regulator of RYR1 activity and the subsequent 
generation of Casq1-null mice has led to the proposal that variants in the 
CASQ1 gene could act to influence MH susceptibility.  Indeed, Casq1-null mice 
exhibit halothane-induded MH-like responses and heat-induced EHI-like 
responses (Dainese et al., 2009; detailed in 1.4.1.2).  To date, no CASQ1 
variants have been conclusively linked to MH.  Efforts to identify CASQ1 
variants in MH susceptible individuals in the North American population 
revealed the relatively common p.M87T variant (resulting from a T to C 
substitution at cDNA position 206), which is annotated with a MAF of 0.02 (2%) 
in the gnomAD browser (Kraeva et al., 2013).  The allele frequency of p.M87T 
in MH susceptible individuals was not significantly different to the allele 
frequency of the variant in MH negative individuals nor control groups, 
suggesting that it is unlikely to represent the underlying genetic cause of MH.  
Interestingly though, out of the 15 MH susceptible individuals with the CASQ1 
p.M87T variant, 4 of them also harboured a diagnostic variant in the RYR1 
gene.  In-vitro investigations into the effect of the p.M87T on CASQ1 Ca2+ 
binding and polymerisation revealed that the variant has a reduced Ca2+ 
binding capacity, likely as a result of a diminished ability to polymerise.  Indeed, 
X-ray crystallography revealed that the p.M87T variant alters the front-to-front 
dimer interface that inhibits the linear formation of back-to-back tetramers 
(Lewis et al., 2015).  These data suggest that whilst the presence of the 
CASQ1 p.M87T may not be sufficient to induce an MH phenotype, it could act 
to modify the phenotype in the presence of an additional variant in the RYR1 
gene. 
 
5.1.2 CASQ in disease 
The heterozygous p.D244G variants in the CASQ1 gene has been linked to 
vacuolar aggregate myopathy (VAM), which is characterised by muscular 
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weakness, episodes of muscle cramps, increased CK levels, fatigue and the 
presence of cellular inclusions of aggregated CASQ1 (D’Adamo et al., 2016; 
Rossi et al., 2014).  The expression of GFP-tagged recombinant p.D244G 
CASQ1 cDNAs in rat myotubes has shown co-localisation of D244G CASQ1 
with the RYR1 and the formation of large aggregates (Rossi et al., 2014).  In-
vitro studies of the purified D244G CASQ1 protein have shown reduced Ca2+ 
binding capacity compared to wild-type (Lewis et al., 2015).  Furthermore, 
primary muscle fibres from VAM patients showed a decreased sensitivity to 
caffeine compared to unaffected control fibres (Rossi et al., 2014).  
Tubular aggregate myopathy (TAM) is characterised by the presence of 
aggregates in muscle fibres that are comprised of a number of proteins 
including SERCA, triadin and CASQ1 (Barone et al., 2017).  Symptoms include 
muscle weakness and cramps, in addition to myalgia.  Recently, 3 novel 
CASQ1 variants in patients with TAM have been characterised.  The p.D44N, 
p.G103D and p.I385T variants all showed reduced Ca2+ binding capacity in-
vitro and the p.I385T and p.D44N variants showed a reduction in CASQ1-
mediated inhibition of SOCE (Barone et al., 2017).  Interestingly, TAM is also 
associated with variants in the STIM1 and ORAI genes, which produce a more 
severe phenotype than that associated with CASQ1 variants.  VAM and TAM 
present clinical examples of how alterations in the Ca2+ binding and 
polymerisation capacity of CASQ1 can perturb normal Ca2+ handling 
mechanisms. 
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a cardiac 
condition characterised by episodes of ventricular tachycardia, causing 
syncope during strenuous exercise or periods of intense emotion.  In some 
cases, tachycardia develops into ventricular fibrillation causing sudden death 
(Behere and Weindling, 2016).  Interestingly, CPVT can be inherited in an 
autosomal dominant manner, caused by heterozygous variants in the 
ryanodine receptor 2 gene (RYR2; the RYR isoform expressed in cardiac cells) 
or the calmodulin 1 gene (CALM1; Nyegaard et al., 2012).  Alternatively, CPVT 
can be inherited as an autosomal recessive disorder, caused by homozygous 
variants in the CASQ2 gene or the triadin gene (TRDN; Faggioni et al., 2012; 
Laitinen et al., 2003).  Since CPVT results from Ca2+ dysregulation via 
premature activation of the RYR2, a mechanism analogous to MH in skeletal 
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muscle, a role for CASQ1 in MH was proposed as a corollary of this 
(MacLennan and Chen, 2009).   
 
5.1.3 CASQ1 variants identified by the Leeds MH Unit  
In an effort to identify variants in genes other than the RYR1 and CACNA1S 
that could contribute to the MH phenotype, the Leeds MH Unit uses a targeted 
gene approach to sequence the coding regions of 50 genes associated with 
Ca2+ handling by NGS.  The CASQ1 p.F186Y variant, a phenylalanine to 
tyrosine substitution as a result of a T>A transition at cDNA position 557, was 
identified in an EHI individual (IVCT result MHN).  As mentioned previously, 
EHI has significant clinical overlap with MH and whilst the pathophysiology 
underlying EHI is not fully understood, Ca2+ dysregulation has been shown to 
underly heat-induced EHI like responses in mice (Dainese et al., 2009; Lopez 
et al., 2018; Yang et al., 2006).  The CASQ1 p.F186Y variant has a MAF of 
0.000008 (gnomAD).  Out of the 50 genes sequenced, CASQ1 p.F186Y was 
identified alongside one VUS, the p.P371L c.1112C>T variant in the CHERP 
gene which encodes the calcium homeostasis endoplasmic reticulum protein.  
This variant was previously unreported and no information was available 
regarding its frequency.  Variants in the CHERP gene have not previously been 
associated with EHI or MH; as such, the relevance of this variant is not clear. 
 
The CASQ1 p.I138T variant, an isoleucine to threonine substitution as a result 
of a T>C transition at cDNA position 413, was identified in an MHSh proband.  
The variant has a MAF of 0.0002 (gnomAD).  One rare variant (MAF 0.001; 
gnomAD), the p.H80Y c.238C>T variant in the DNM2 gene, which encodes 
dynamin 2, was identified in the same individual as CASQ1 p.I138T.  Variants 
in the DNM2 gene are known to cause autosomal dominant centronuclear 
myopathy (CNM), which is characterised by muscle weakness and atrophy 
(Catteruccia et al., 2013); however, the relevance of the DNM2 p.H80Y variant 
is unknown.  Whether family members of the individual the CASQ1 p.I138T 
variant was identified in also harbor the variant remains to be determined by 
DNA sequencing.  Colleagues also identified the CASQ1 p.E364K variant in 
the Australian population, which is a glutamate to lysine substitution resulting 
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from a G>A substitution at cDNA position 1090 (Bjorksten et al., 2016).  The 
variant has a MAF of 0.00002 (gnomAD) and was identified in an MHShc 
proband.       
 
5.1.4 Chapter aims and strategy 
The primary aim of this chapter is to develop a Casq1 knockout C2C12 cell line 
that can be used for the re-introduction of CASQ1 variant cDNAs using 
lentiviral vectors for functional characterisation.  In contrast to the RYR1, the 
CASQ1 coding sequence is approximately 1 kb in length and encodes a ~44 
kDa protein.  As such, it is more amenable to site directed mutagenesis and 
cloning required for heterologous expression than the RYR1.  Since the 
HEK293 system lacks the expression of calcium handling apparatus that is 
characteristic of muscle cells, the development of a Casq1 knockout C2C12 
line affords the opportunity to functionally characterise CASQ1 variants 
identified in MH patients in a muscle specific context.  Whilst Casq1-null mice 
have been generated previously (Dainese et al., 2009), at the outset of this 
project there were no immortalised Casq1-null cells available for use.  C2C12 
cells, however, are inherently immortalised, overcoming the limitations 
associated with limited replicative potential in primary mouse cells (Shay and 
Wright, 2000).  The effect of Casq1 ablation in mice has been characterised 
previously (Dainese et al., 2009), as such, the effect of Casq1-knockout in the 
resultant C2C12 lines affords the opportunity to determine the consistency in 
the response of Casq1-null cells.  The effect of the Casq1-knockout on caffeine 
sensitivity in C2C12 cells will be determined by fluorescence Ca2+ imaging, as 
performed in 4.2.12. 
 
The secondary aim of this chapter is to perform preliminary in-vitro 
investigations into the effects of three CASQ1 variants on the Ca2+ binding and 
polymerisation properties of the CASQ1 protein, an area previously unexplored 
within the Leeds MH unit.  CASQ1 WT, CASQ1 p.I138T, p.F186Y and p.E364K 
variants will be cloned into an expression vector for heterologous expression 
and purification.  A range of in-vitro methods will be explored to aid gathering of 
this preliminary data including microscale thermophoresis (MST), mass 
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spectrometry (MS) and dynamic light scattering (DLS).  Since cell-based 
systems of functional characterisation are generally time-consuming and 
encounter limitations such as myoblast differentiation potential, the 
development of an in-vitro system could serve as a method to stratify variants 
of interest in genes other than the RYR1 for further cell-based characterisation.  
A range of in-silico tools will also be utilised to investigate the predicted 
pathogenicity of the three CASQ1 variants selected for use in this project.  
 
5.2 Results 
5.2.1 In-silico pathogenicity predictions, conservation analysis and 
mutagenesis 
As performed for the other variants explored within this project, a range of in-
silico means were employed to predict pathogenicity of the CASQ1 variants 
selected for use in this project.  The CADD tool (version 1.4) predicted C-
scores for p.I138T, p.F186Y and p.E364K of 24.9, 26.9 and 21.8, respectively, 
placing them all within the top 0.1% of potentially deleterious variants.  SIFT 
(version 6.2.1) categorised p.I138T as deleterious with a score of 0, p.F186Y 
as deleterious with a score of 0.01 and p.E364K as tolerated with a score of 
0.16.  Finally, Poly-Phen2 (version 2) categorised p.I138T as possibly 
damaging with a score of 0.935, p.F186Y as probably damaging with a score of 
0.997 and p.E364K as possibly damaging with a score of 0.672.  The ConSurf 
server (Ashkenazy et al., 2016; Celniker et al., 2013; Asheknazy et al., 2010; 
Berezin et al., 2004) was used to determine the conservation of the ancestral 
residue of each CASQ1 variant.  ConSurf was programmed to search for 100 
CASQ1 homologues with at least 50% homology to the human sequence. The I 
residue at position 183 in the CASQ1 protein sequence was scored a 
conservation score of 9 – the highest conservation score possible as 
determined by ConSurf (Figure 5.1).  It was conserved across all 99 of the 100 
homologues identified, with Poecilia formosa (Amazon molly freshwater fish) 
containing a valine residue at the same position.  The p.I183 residue was 
embedded in a cluster of highly conserved residues and was predicted to be 
buried within the protein structure with a structural role (Figure 5.1; panel B).  
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The F residue at position 186 in the CASQ1 protein sequence was also scored 
the highest possible conservation score by ConSurf and was conserved within 
all 100 homologues identified.  The p.F186 residue was predicted to be buried 
within the protein structure and to have a structural role.  Lastly, the E residue 
at position 364 in the CASQ1 protein sequence was deemed to be variable, 
with just 40% of the homologues identified having the E residue conserved at 
this position.  Aspartic acid (an amino acid with acidic properties like glutamate) 
accounted for the amino acid at position 364 in 41% of the homologues.  The 
p.E364 residue was predicted to be exposed but no prediction was made 
regarding a structural or functional role due to low conservation. 
The PyMOL (Schrödinger, LLC) mutagenesis wizard was used to explore the 
consequence of each CASQ1 variant on local hydrogen bonding and VdW 
interactions (Figure 5.2).  Substitution of the I residue with a T residue at 
position 138 in the human CASQ1 protein sequence did not affect hydrogen 
bonding nor did it produce any VdW clashes when shown in its most likely 
rotamer conformation (94.4% probability).  Two other rotamer conformations 
were suggested that both produced minor and severe VdW clashes.  
Substitution of the F residue with a Y residue at position 186 in the human 
CASQ1 protein sequence did not affect hydrogen bonding but did produce 
severe VdW clashes in its most likely rotamer conformation (53.8% probability) 
and in the 3 alternative potential rotamer conformations.  Substitution of the E 
residue to K at position 364 in the human CASQ1 protein sequence produced 
minor VdW clashes in its most likely rotamer conformation (15.9% probability), 
out of the remaining 14 alternative rotamer conformations, one of them (5.1% 
probability) did not produce any VdW clashes. 
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Figure 5.1 – Multiple sequence alignment of CASQ1 homologues  
CSI-BLAST was used to search for 100 CASQ1 homologues with at least 50% 
homology to the human CASQ1 protein and MAFTT was used to create a 
multiple sequence alignment.  The first 30 homologues identified (in a random 
order) are shown here for reference.  ConSurf was used to determine and 
colour code the conservation of residues across homologues.  Regions around 
each residue of interest are shown in panel A.  Predictions of the exposure and 
role of the residue are shown in panel B along with a key.  Mammalian species 
are indicated by underlining and an asterisk highlights the residue of interest. 
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Figure 5.2 – PyMOL mutagenesis of CASQ1 variants 
The PyMOL mutagenesis wizard was used to model the CASQ1 p.I138T, 
p.F186Y and p.E364K substitutions using the human CASQ1 protein structure 
(PBD ID: 5CRD).  The wild-type residue is shown in green and the variant 
residue is in pink.  Hydrogen bonds are shown by yellow dashes and VdW 
clashes are shown by green (less severe) and red (more severe) disks. Black 
arrows are used to highlight VdW clashes that are difficult to see.  The most 
likely rotamer conformations for each variant are shown. 
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5.2.2 gRNA design 
The gRNAs designed for the knockout of the Casq1 gene in C2C12 myoblasts 
were designed using CCTOP (Stemmer et al., 2015), searching the 
GRCm38/mm10 genome for unique sequences 20 nt in length and immediately 
upstream of an NGG PAM recognition sequence, as described in 4.2.4.  To 
search for the gRNAs, a 450 bp sequence starting at base position 1 of exon 1 
in the Casq1 gene was entered into CCTOP.  The search returned 88 results 
and two of the top-ranked gRNAs were selected for testing in C2C12 
myoblasts.  The first gRNA, hereafter referred to as Mm_Casq1_gRNA1 was 
301 bp downstream of the first base of exon 1.  Mm_Casq1_gRNA1 targeted 
the reverse DNA strand and the PAM was AGG (CCT on the reverse strand), it 
had an efficacy prediction by CRISPRater of 0.65 (medium efficacy) and 4 
predicted off-target sites, all of which were intronic (Labhun et al., 2017).  The 
CRISPOR tool predicted a further 2 off-target sites (Haeussler et al., 2016).  
The second gRNA, hereafter referred to as Mm_Casq1_gRNA2, was 402 bp 
downstream of the first base of exon 1.  Mm_Casq1_gRNA2 also targeted the 
reverse strand anf the PAM was GGG (CCC on the reverse strand), it had an 
efficacy prediction of 0.71 (medium efficacy) and 8 predicted off-target sites, of 
which 3 were in exons, 4 were in introns and 1 was intergenic.  The CRISPOR 
tool predicted 19 off-targets, including the 8 identified by CCTOP.  The gRNA 
sequences were commercially synthesised by IDT containing overhangs to 
facilitate cloning into pSpCas9(BB)-2A-GFP (Table 5.1).  
 
Table 5.1 – Mm_Casq1 gRNA sequences with pSpCas9(BB)-2A-GFP 
overhangs 
Overhangs to facilitate cloning into pSpCas9(BB)-2A-GFP are shown in green.  
The additional ‘G’ nucleotide to enhance transcription from the hU6 promoter in 
the vector is shown in blue.  Both gRNA sequences target the reverse DNA 
strand. 
gRNA Forward sequence 5’-3’ Reverse sequence 5’-3’ 
Mm_Casq1
_gRNA1 
CACCgCGGTCCACACCGTCGT
ACTC 
AAACGAGTACGACGGTGTGGA
CCGc 
Mm_Casq1
_gRNA2 
CACCGCGAGGCCTTGTCGTCC
TCG  
AAACCGAGGACGACAAGGCCT
CGC 
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5.2.2.1 Cloning into pSp(BB)-2A-GFP 
The gRNAs were cloned into the pSpCas9(BB)-2A-GFP as described in 4.2.6.  
Following transformation into Stbl3TM cells (InvitrogenTM), four single colonies 
were used to inoculate 5 ml of LB media containing 100 μg/ml ampicillin.  
Plasmid DNA was isolated by miniprep and the plasmids were digested with 
BbsI and AgeI to confirm the presence of the insertion.  As mentioned 
previously, gRNA insertion results in the excision of the AgeI cut site; as such, 
only the BbsI site is available for digest and the plasmid is linearised (Ran et 
al., 2013a).  All of the clones screened appeared to contain the insert (Figure 
5.3).  The isolated plasmid DNA was prepared for Sanger sequencing to 
confirm the insertions.  Indeed, both gRNA sequences were successfully 
ligated into pSpCas9(BB)-2A-GFP (Figure 5.4). 
 
 
Figure 5.3 – Restriction digest screen of pSpCas9(BB)-2A-GFP 
Plasmid DNA isolated from clones transformed with pSpCas9(BB)-2A-GFP and 
Mm_Casq1_gRNA ligation products was digested with BbsI and AgeI.  The 
reaction was loaded onto a 1% TAE-agarose gel and the products separated 
by gel electrophoresis.  Lane 1 shows the 1 kb extension ladder (InvitrogenTM) 
and lane 2 is a negative control comprising the reaction contents without DNA.  
Lane 3 shows the digestion products of pSpCas9(BB)-2A-GFP containing no 
insert.  Lanes 4-7 show the digestion product of Mm_Casq1_gRNA1-containing 
pSpCas9(BB)-2A-GFP vectors and lanes 8-11 show the digestion product of 
Mm_Casq1_gRNA2-containing pSpCas9(BB)-2A-GFP vectors. 
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Figure 5.4 – Sanger sequencing traces showing the insertion of 
Mm_Casq1_gRNA1 and Mm_Casq1_gRNA2 in pSpCas9(BB)-2A-GFP 
Panels A and B show the insertion of Mm_Casq1_gRNA1 and 
Mm_Casq1_gRNA2 in the pSpCas9(BB)-2A-GFP vector, respectively.  The 
gRNA sequences are underlined in blue and the 5’ CACC and 3’ GTTT (AAAC 
reverse complement) are underlined in green. 
 
5.2.3 Estimation of gene-editing efficiency 
C2C12 cells were transfected using LipofectamineTM 3000 with pSpCas9(BB)-
2A-GFP containing Mm_Casq1_gRNA1 and Mm_Casq1_gRNA2 and the GFP-
expressing cells were enriched by FACS as described in 4.2.9.  The proportion 
of GFP positive cells collected for the Mm_Casq1_gRNA1 transfection after 
gating was 10.0% and 91.32% of the cell population was viable based on SSC 
and FSC measurements.  For cells transfected with Mm_Casq1_gRNA2, the 
proportion of GFP-expressing cells after gating was 9.55% and the proportion 
of viable cells was 87.41%.  A single cell sort was sufficient to obtain cells for 
the T7 assay.  Prior to performing the T7 assay, it was uncovered that there 
was a C>T (G>A reverse strand) SNP within the gRNA site for 
Mm_Casq1_gRNA2 in the C2C12 genome (Figure 5.5; panel B), the gRNA site 
for Mm_Casq1_gRNA1 was wild-type (Figure 5.6; panel A).  Since reports in 
the literature show that at least 2 mismatches in the gRNA seed region are 
required to abolish Cas9 cleavage, the T7 assay was still performed for 
Mm_Casq1_gRNA2.  A 1005 bp region was amplified around the gRNA sites 
and a T7 assay performed for each gRNA.  The expected cleavage product 
sizes for Mm_Casq1_gRNA1 were 768 bp and 237 bp.  Mm_Casq1_gRNA1 
produced cleavage products corresponding to the expected band sizes (Figure 
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5.6).  The estimated gene-editing efficiency of Mm_Casq1_gRNA1 was 12.2%.  
As expected, Mm_Casq1_gRNA2 produced a cleavage product corresponding 
to 869 bp; however, the remaining expected 136 bp cleavage product was not 
detected.  This was presumably due to the quantity of DNA in the cleavage 
product being lower than the limit of detection of ethidium bromide.  The 
calculation of gene-editing efficiency requires the relative intensity of both 
cleavage products.  Equation 2 was used to determine the small fragment 
intensity. 
 
Figure 5.5 – Mm_Casq1_gRNA1 and Mm_Casq1_gRNA2 target sequences 
in the C2C12 genome 
DNA was extracted from C2C12 cells and a region surrounding gRNA 
sequences was amplified.  The resultant amplicon was processed for Sanger 
sequencing.  The gRNA sequences are underlined in black and the PAM 
sequences are in green.  The C>T (G>A on reverse strand) SNP present in the 
Mm_Casq1_gRNA2 sequence in shown underlined in blue.  The forward DNA 
strand is shown hence the gRNAs are shown in their reverse complement form. 
 
The estimated gene-editing efficiency of Mm_Casq1_gRNA2 was 7.5%.  The 
impact of the SNP on the gene editing efficiency of Mm_Casq1_gRNA3 is not 
known.   
Equation 2. 
!"#$$	&'#(")*+	,*+)*!,+- = 	 $#'()	&'#(")*+	,*+)*!,+-	 × 	!"#$$	&'#(")*+	!,0)	(23)$#'()	&'#(")*+	!,0)	(23) 	 
 
 
 
 
 
 
 
 
212 
 
 
Figure 5.6 – T7 assay of Mm_Casq1_gRNA1 and Mm_Casq1_gRNA2 
The T7 assay was loaded onto 1% TAE-agarose gel and products were 
separated by gel electrophoresis.  Lane 1 shows the 100 bp DNA ladder 
(NEB).  Lanes 2 and 3 show the T7 assay from non-transfected cells, without 
and with the T7 enzyme, respectively.  Lanes 4-9 show the same for cells 
transfected with the empty pSpCas9(BB)-2A-GFP vector, Mm_Casq1_gRNA1 
and Mm_Casq1_gRNA2.  Arrows show the presence of the cleavage products. 
 
Since Mm_Casq1_gRNA1 produced greater estimated gene-editing 
efficiencies than Mm_Casq1_gRNA2 and had only 6 predicted off-target sites, 
this gRNA was selected for use in generating the Casq1 knockout cells.  
Following transfection with pSpCas9(BB)-2A-GFP containing 
Mm_Casq1_gRNA1, cells were sorted into single cells in 10 96-well plates 
containing a 1:1 ratio of filtered conditioned growth media to fresh growth 
media.  Proportions of GFP-expressing cells collected range from 16.4%-
19.6% across plates, with a mean of 17.2%.  The mean proportion of viable 
cells based on FSC and SSC measurements was 99.77%.  In total, 84 cell 
lines showed growth and were propagated to T-75 flasks at ~60% confluency.  
This was 8.75% of the total single cells collected across 10 96-well plates. 
 
5.2.4 Identification and validation of edited lines 
To identify the single cell-derived lines that had been edited by CRISPR-Cas9, 
a direct PCR reaction was performed from aliquots of single-cell derived lines 
taken following trypsinisation during cell splitting.  The cells were lysed and 
treated with proteinase K before the crude lysate was added to a PCR.  The 
resultant PCR products were processed for Sanger sequencing.  Since there 
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are 4 copies of chromosome 1 on which the Casq1 gene lays, and random 
indels were expected at each Cas9 cut site, it was expected that a wild-type 
sequence would be observed until the vicinity of the Cas9 cut site, followed by 
overlapping traces there onwards reflecting different indels on each Casq1 
gene.  In the first instance, 32 single-cell derived C2C12 lines were sequenced.  
This identified 8 cell lines that had some form of editing event near the Cas9 
cut site (25%).  Out of the 8 edited cell lines detected, 3 of them consistently 
formed myotubes (cell lines 3B9, 8E10 and 7E5) and were therefore selected 
for further analysis in this project (Figure 5.7).   
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Figure 5.7 – Sanger sequencing chromatograms and differentiation 
images for cell lines 8E10, 3B9 and 7E5  
Direct PCR reactions were performed on crude lysates obtained from single 
cell-derived lines.  Amplicons were processed for Sanger sequencing to detect 
editing events in each cell line.  Editing events were evident by the presence of 
overlapping sequencing traces downstream of the gRNA sequence, reflecting 
different indels on each Casq1 allele.  Three edited cell lines that formed 
myotubes, 8E10 (panel A), 3B9 (panel B) and 7E5 (panel C) were selected for 
use and their respective Sanger sequencing chromatograms shown here.  
Above each sequencing chromatogram is the wild-type Casq1 sequence for 
comparison.  Wild-type, single peak sequences are shown in black and the 
edited, overlapping sequences are shown underlined in red.  The gRNA 
sequences are shown in orange and the PAM is in green.  The gRNAs target 
the reverse strand and the forward strand sequence is shown here, hence the 
gRNAs are shown as their reverse complement.  Images of myotubes (right) 
were taken following 6 days of differentiation on ECM from Engelbreth-Holm-
Swarm sarcoma-coated plates.  Images were captured using the EVOSTM FL 
imaging system with x20 magnification for cell lines 8E10 (panel A) and 7E5 
(panel C) and x10 magnification for cell line 3B9 (panel B). 
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As expected, the presence of overlapping sequences that occurred near the 
predicted Cas9 cut site meant it was not possible to ascertain with confidence 
the editing events on each Casq1 allele for cell lines 8E10 and 3B9.  For these 
cell lines, at least three overlapping sequences could be clearly observed 
(Figure 5.7; panels A and B).  Despite base-calling of the wild-type sequence 
until the vicinity of the Cas9 cut site, the presence of additional peaks beneath 
the wild-type sequence suggested that a larger indel had occurred on at least 
one of the Casq1 alleles in each cell line that affected the region downstream 
of the Cas9 cut site (Figure 5.7; panels A and B).  For cell line 7E5, only two 
overlapping sequences could be observed in the Sanger sequencing 
chromatogram.  Given this, it was possible to manually deconvolute the 
overlapping traces and a 5 bp CTGAG deletion and 2 bp AG deletion could be 
discerned on each trace (Figure 5.7; panel C).   
 
To elucidate the composition of each Casq1 allele within the 8E10 and 3B9 cell 
lines and to confirm the editing events observed in cell line 7E5, TA cloning and 
subsequent Sanger sequencing was performed.  DNA was extracted from each 
cell line using a salting-out method and a PCR was performed to amplify a 330 
bp region surrounding the Mm_Casq1_gRNA1 sequence.  Amplicons were 
purified using AMPure XP beads (Beckman Coulter) and phosphorylated with 
T4 PNK.  Purified, phosphorylated amplicons were incubated in a ligation 
reaction with the dephosphorylated, linearised pGEM®-T vector prior to 
transformation into OneShot® TOP10 E. coli cells.  Transformation reactions 
were plated on LB agar plates containing ampicillin at 100 μg/ml and 40 μl 
100mM IPTG and 120 μl 20 mg/ml X-gal spread onto the surface of the plate.  
White colonies were picked and used to inoculate 5 ml LB media cultures for 
plasmid isolation by miniprep.  The number of colonies processed for Sanger 
sequencing for cell lines 8E10, 3B9 and 7E5 was 18, 20 and 19, respectively.  
Three editing events were detected in cell lines 8E10 and 3B9, and the two 
editing events inferred from the sequencing chromatograms in cell line 7E5 
were confirmed (Table 5.2).  Cell line 8E10 contained a 5 bp ‘CTGAG’ deletion 
which was also detected in cell line 7E5 (Figure 5.8; panel A and panel G).  A 
single ‘T’ residue insertion was also identified in cell line 8E10 at the Cas9 cut 
site (Figure 5.8; panel C) and a large 98 bp deletion was identified (Figure 5.8; 
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panel B).  In cell line 3B9, an out of frame 9 bp ‘TCCCTGAGT’ deletion was 
detected (Figure 5.8; panel D) in addition to a 7 bp ‘AGTACGA’ deletion (Figure 
5.8; panel E) and a 19 bp ‘TACGACGGTGTGGACCGTG’ deletion at the Cas9 
cut site (Figure 5.8; panel F).  In addition to the ‘CTGAG’ deletion also detected 
in cell line 8E10, the ‘AG’ deletion in cell line 7E5 was also confirmed (Figure 
5.8; panel H).  No wild-type alleles were detected in any of the cell lines.  As 
discussed in Chapter 4, TA cloning generated some clones without inserts, 
unclear Sanger sequencing chromatograms and the same editing events were 
detected multiple times.  As such, the composition of the fourth Casq1 allele in 
cell lines 8E10 and 3B9 remains to be determined.  Only two editing events 
were detected in cell line 7E5 and only two overlapping traces were identified in 
the initial screening of single-cell derived lines (Figure 5.7).  Since the same 
editing events have been detected in multiple cell lines here and in Chapter 4, it 
is a possibility that cell line 7E5 contains two alleles with the ‘AG’ deletion and 
two alleles with the ‘CTGAG’ deletion.  An alternative explanation for the 
seemingly diploid Sanger sequencing chromatogram would be that the single 
cell from which cell line 7E5 was derived represented a rare subpopulation of 
cells within the C2C12 population that had only two copies of chromosome 1 
and its rarity within the population prevented its detection by karyotyping.  
Alternatively, it is possible that the PCR consistently preferentially amplified the 
alleles containing the AG and CTGAG deletion, meaning other alleles were not 
detected by Sanger sequencing.  All in-silico predicted off-target sites were 
sequenced in each putative Casq1 knockout cell line.  All off-target sequences 
appeared wild-type (Appendix C). 
Table 5.2 – Summary of editing events detected in edited Casq1 cell lines 
Values in brackets indicate whether the same editing event was detected in 
another cell line and the number of times the editing event was detected. 
Cell line Editing event 1 Editing event 2 Editing event 3 
8E10 5 bp del (7E5; 4) 98 bp del (1) 1 bp ins (2) 
3B9 9 bp del (3) 7 bp del (3) 19 bp del (3) 
7E5 5 bp del (8E10;4) 2 bp del (6) Not detected 
 
 
 
217 
 
 
Figure 5.8 – Graphical representation of editing events detected in edited 
Casq1 cell lines 
Panels A-C, D-F and G-H show editing events in cell lines 8E10, 3B9 and 7E5, 
respectively.  Wild-type sequences are shown in black, PAM sites are in green, 
gRNA sequences are in orange and insertions are shown in red.  The Cas9 cut 
site is indicated by /.  The forward DNA strand is shown hence gRNAs are 
shown in their reverse complement. Sanger sequencing chromatograms were 
viewed using 4Peaks software (Nucleobytes). 
 
A western blot was performed to confirm knockout of the Casq1 protein (Figure 
5.9).  Since Casq1 is expressed following the differentiation of myoblasts into 
myotubes, wild-type C2C12 cells and the edited cell lines 8E10, 3B9 and 7E5 
were plated on ECL-coated T-75 tissue culture flasks and allow to reach ~90% 
confluency (Ehrlich et al., 2016).  At this point, growth media was replaced with 
differentiation media and changed every other day for 6 days.  Total protein 
was extracted from the cells using RIPA buffer with HaltTM protease inhibitor 
cocktail (ThermoFisher) to prevent protein degradation.  The concentration of 
total protein was quantified using the PierceTM BCA assay (ThermoFisher) and 
50 μg total protein loaded onto an 8-16% gradient SDS-PAGE gel (BioRad).  
The myotubes produced by each cell line were comparable in diameter and 
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length to each other and wild-type C2C12 cells; however, since a lack of Casq1 
protein could, in theory, be due to a lesser degree of differentiation in the edited 
cell lines, the myosin heavy chain (MHC) was probed for in the western blot.  
MHC is a well-established marker of differentiation and the antibody used, MF-
20 (DSHB, deposited by D.A. Fischman), recognises all MHC isoforms (Brown 
et al., 2012; Mizunoya et al., 2008).  The expected band sizes of Casq1 and 
MHC were 50 kDa and ~223 kDa, respectively.  GAPDH was used as a loading 
control and had an expected band size of 30 kDa.  In the C2C12 wild-type 
sample, distinct bands were observed at ~200 kDa, ~ 50 kDa and ~32 kDa.  In 
the edited cell line samples, no band was observed at ~50 kDa, indicating the 
Casq1 protein was not present in these samples and successful knockouts had 
been generated.  In all samples, two bands were present at approximately 200 
kDa, potentially reflecting the separation of different MHC isoforms.  
Interestingly, cell line 7E5 appeared to have an additional high Mw band with 
increased migration compared to the MHC bands in the other samples.  The 
identity of this band was not determined but it could represent an additional 
MHC isoform or a degradation product.  Despite lysate clarification by 
centrifugation and quantification of the cell lysates, it appeared that proteins 
within the samples were not homogenously resuspended resulting in uneven 
cell loading, particularly for the 7E5 cell line sample.  Nonetheless, clear bands 
were observed at Mws corresponding to MHC and GAPDH, but not for Casq1.  
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Figure 5.9 – Confirmation of Casq1 knockout by western blot 
Wild-type C2C12 cells and the edited Casq1 derivative lines were differentiated 
into myotubes in ECL-coated flasks for 6 days.  Fifty μg total protein was 
loaded onto a 8-16% acrylamide gradient gel (BioRad).  Proteins were 
transferred to PVDF membrane using a Trans-Blot® transfer cell (BioRad).   
Blots were visualised by incubation with a HRP-conjugated secondary 
antibodies prior to development with the SuperSignal West Femto Maximum 
Sensitivity Substrate (ThermoFisher).  Blots were visualised and images 
captured using the BioRad XR+ Gel DocTM.  The first lane shows the broad 
range protein standard (NEB) and subsequent lanes show wild-type C2C12, 
3B9, 7E5 and 8E10 samples, respectively. 
 
5.2.5 Ca2+ imaging of Casq1 knockout lines 
Skeletal muscle fibres from Casq1-null mice have been reported to have 
increased sensitivity to caffeine and reductions in the amount of releasable 
Ca2+ (Dainese et al., 2009).  To determine whether this was observed in the 
C2C12 Casq1 knockout (KO) cell lines generated here, the response of cells to 
caffeine was determined by fluorescent Ca2+ imaging as described in Chapter 
4.  Briefly, cells were allowed to reach ~90% confluency on ECM-coated 96-
well plates and differentiated into myotubes for 5-6 days.  Cells were loaded 
with 10 μM Fluo-8AM at 37oC for 30 min prior to equilibration at room 
temperature for 20 min in imaging buffer.  Cells were sequentially perfused with 
caffeine solutions at 0.1 mM, 1 mM, 3 mM, 5 mM, 10 mM and 20 mM with 1 
min rest in between caffeine doses.  Transient increases in fluorescence, 
indicative of Ca2+ release, were detected and recorded using the Nikon TE2000 
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inverted microscope attached to an intensified CCD camera.  To determine 
caffeine sensitivity, EC50 values were generated for each cell line from peak 
height measurements and AUC measurements and compared to the same 
measurements from wild-type C2C12 cells and a wild-type monoclonal C2C12 
cell line, 3E1.  Cells were excluded from the analysis based on criteria detailed 
in 4.2.12. 
The peak height analysis showed that cell line 8E10 had an EC50 of 3.435 mM 
(SD 1.769; 95% CI 3.245 to 3.629; Figure 5.10; panel A).  This was significantly 
different to both wild-type C2C12 cells (p<0.0001) and cell line 3E1 (p=0.0023) 
but not cell line 3B9 (p=0.9942) or 7E5 (p=0.1894) (Figure 5.11).  Cell line 3B9 
had an EC50 of 3.726 (SD 1.559; 95% CI 3.505 to 3.955; Figure 5.10; panel B) 
which again was significantly different to wild-type C2C12 cells (p<0.0001) and 
cell line 3E1 (p=0.0107), but not cell lines 8E10 or 7E5 (p=0.4235) (Figure 
5.11).  The dose response curve for cell line 7E5 indicated that it responded 
similarly to wild-type C2C12 cells and cell line 3E1 until 10 mM caffeine at 
which the cell line responded maximally.  The normalised fluorescence value at 
10 mM was greater than that for 20 mM (i.e. greater than 100%), hence the 
data point is not shown in the dose response curve.  The EC50 for cell line 7E5 
was 4.415 (SD 1.401; 95% CI 4.205 to 4.63; Figure 5.10; panel C).  This was 
significantly different to wild-type C2C12 cells (p=0.0108) but not 3E1 
(p=0.4103), 8E10 or 3B9 (Figure 5.11). 
 
Values obtained from the AUC analysis followed a similar pattern to the peak 
height analysis.  Cell line 8E10 had an EC50 of 4.464 (SD 2.049; 95% CI 4.248 
to 4.687; Figure 5.10; panel D) which was significantly different to wild-type 
C2C12 cells (p<0.0001) and cell line 3E1 (p=0.0017) but not cell lines 3B9 
(p=0.9996) or 7E5 (p=0.7912) (Figure 5.11).  Cell line 3B9 had an EC50 of 
4.905 (SD 1.756; 95% CI 4.683 to 5.137; Figure 5.10; panel E) which was 
significantly different to wild-type C2C12 cells (p=0.0002) and cell line 3E1 
(p=0.0047) but not 8E10 or 7E5 (p=0.9011) (Figure 5.11).  Finally, cell line 7E5 
had an EC50 of 5.255 (SD 1.245; 95% CI 5.058 to 5.459; Figure 5.10; panel F) 
which was significantly different to wild-type C2C12 cells (p=0.0060) but not 
cell line 3E1 (p=0.0525), 8E10 or 3B9 (Figure 5.11). 
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Figure 5.10 – Caffeine dose-response analysis of Ca2+ imaging of wild-type C2C12 cells and Casq1 KO cells 
Panels A, B and C show the peak sigmoidal dose response analysis for cell lines 8E10 (red diamonds), 3B9 (orange upward triangles) 
and 7E5 (pink downward triangles) compared to wild-type C2C12 cells (blue circles) and cell line 3E1 (green squares).  Panels D, E 
and F show the AUC analysis.  Normalised fluorescence (a percentage of the maximal response at 20 mM caffeine) is shown on the Y 
axis and the caffeine concentration (mM) is on the X axis.  Data points are means of 33-59 myotubes (plated and imaged on at least 3 
different days, with the exception of 3E1 from which data was collected on 2 different days) and error bars show the SD.  Curves were 
fitted and graphs plotted using Prism 7 (GraphPad).   
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Figure 5.11 – Comparison of EC50 values for wild-type C2C12 cells and 
Casq1 KO cell lines 
Panels A and B show box plots of the EC50 values from the peak height 
analysis and AUC analysis, respectively.  Box plots show the median data 
point, upper and lower quartiles and the minimum and maximum data points.  
Graphs plotted using Prism 7 (GraphPad).  One-way ANOVA and Tukey’s test 
for multiple comparisons were used to determine significance. *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001. 
 
The %MR at each caffeine concentration is shown for the peak height analysis 
(Figure 5.12; panel A) and AUC analysis (Figure 5.12; panel B).  In the peak 
height analysis at 1 mM caffeine, the %MR for cell line 8E10 was 13.51 (SD 
13.41; 95% CI 9.814-17.21).  This was significantly different to cell line 3E1 
which had a %MR of 0.7449 (SD 4.279; 95% CI -0.7724-2.262; p <0.0001), cell 
line 3B9 (%MR 7.194; SD 16.83; 95% CI 2.412-11.98; p=0.0389) and cell line 
7E5 (%MR 3.393; SD 6.747; 95% CI 1.456-5.331 p <0.0001) but not wild-type 
C2C12 cells (%MR 7.698; SD 7.693; 95% CI 5.386-10.01 p=0.0848).  The 
%MR of cell line 3B9 was not significantly different to wild-type C2C12 cells 
(p=0.9995), cell line 3E1 (p=0.0834) or cell line 7E5 (p= 0.4504).  Cell line 7E5 
was also not significantly different to wild-type C2C12 cells (p=0.3483) or cell 
line 3E1 (p=0.8350). 
At 3 mM caffeine, wild-type C2C12 cells (%MR 26.39; SD 14.57; 95% CI 
22.01-30.77) responded in a similar manner with no significant differences in 
%MR to cell line 3E1 (%MR 34.76; SD 10.49; 95% CI 31.04-38.48; p=0.2646) 
and 7E5 (%MR 33.02; SD 16.28; 95% CI 28.35-37.7; p=0.3951).  There was 
also no significant difference between cell line 3E1 and 7E5 (p=0.9932).  In 
contrast, cell lines 8E10 (%MR 46.63; SD 18.64; 95% CI 41.49-51.7) and 3B9 
(%MR 43.7; SD 25; 95% CI 36.6-50.81) responded similarly to each other, with 
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no significant difference in the %MRs between the two cell lines (p=0.9252).  
The %MR of cell line 8E10 was significantly different to wild-type C2C12 cells 
(p <0.0001), cell line 3E1 (p= 0.0290), and cell line 7E5 (p=0.0019).  The %MR 
of cell line 3B9 was significantly different to wild-type C2C12 cells (p <0.0001) 
and cell line 7E5 (p=0.0309).  Whilst 3B9 did have an increased %MR than cell 
line 3E1, this was not statistically significant (p= 0.1856).    
At 5 mM caffeine, wild-type C2C12 cells (%MR 44.49; SD 19.09; 95% CI 
38.75-50.22), cell line 3E1 (%MR 46.58; SD 12.43; 95% CI 42.17-50.99) and 
cell line 7E5 (%MR 48.33; SD 19.38; 95% CI 42.77-53.9) continued to respond 
in a similar manner.  There was no significant difference in the %MR between 
wild-type C2C12 cells and 3E1 (p=0.9899) or 7E5 (p), nor was there a 
significant difference between cell lines 3E1 and 7E5 (p=0.8733).  Cell lines 
8E10 (%MR 60.9; SD 18.05; 95% CI 55.93-65.87) and 3B9 (%MR 62.51; SD 
24.37; 95% CI 55.58-69.43) continued to respond in a similar manner at 5 mM 
caffeine, with no significant difference in %MR between the two cell lines 
(p=0.9935).  The %MR of both 8E10 and 3B9 were significantly different to 
wild-type C2C12 cells (p=0.0004; p=0.0001, respectively), 3E1 (p=0.0092; 
p=0.0030, respectively) and 7E5 (p=0.0111; p=0.0032, respectively). 
At 10 mM caffeine, wild-type C2C12s (%MR 73.64;SD 18.52; 95% CI 68.07-
79.2) responded similarly to cell line 3E1 (%MR 73.13; SD 15.42; 95% CI 
67.66-78.59; p>0.9999) and cell lines 8E10 (%MR 83.31;SD 17.71; 95% CI 
78.43-88.19) and 3B9 (%MR 86.21; SD 14.65; 95% CI 82.05-90.37) continued 
to respond similarly to each other (p=0.2387).  There was no significant 
difference in %MR between wild-type C2C12 cells and 8E10 (p=0.2045); 
however, there was a statistically significant difference between wild-type 
C2C12 cells and cell line 3B9 (p=0.0498).  No significant difference was 
observed between cell line 3E1 and 8E10 (p=0.2387) or 3B9 (p=0.0695).  
Interestingly, despite responding similarly to wild-type C2C12 cells throughout 
the dose response experiment, at 10 mM caffeine cell line 7E5 responded 
maximally (%MR 111; SD 35.85; 95% CI 100.7-121.3).  This was significantly 
different to the response at 10 mM for wild-type C2C12 cells (p<0.0001), cell 
line 3E1 (p<0.0001), cell line 8E10 (p<0.0001) and cell line 3B9 (p<0.0001).   
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Values for the %MR in the AUC analysis followed the same pattern as the peak 
height analysis, with wild-type C2C12 cells, cell line 3E1 and cell line 7E5 
responding in a similar manner until 10 mM caffeine when 7E5 showed an 
increased response compared to the other cell lines (Figure 5.12; panel B).  
Cell lines 8E10 and 3B9 also responded similarly throughout the dose-
response experiment.  At 1 mM caffeine, cell line 8E10 had a %MR of 7.919 
(SD 8.994; 95% CI 5.488-10.35).  This was significantly different to cell line 
3E1 (%MR 0.1552; SD 0.8916; 95% CI -0.1609-0.4713; p<0.0001), cell line 
3B9 (%MR 3.799; SD 10.73; 95% CI 1.002-6.596; p=0.0249) and cell line 7E5 
(%MR 1.566; SD 3.785; 95% CI 0.4787-2.653; p=0.0002).  The %MR of cell 
line 8E10 was not significantly different to wild-type C2C12 cells (%MR 4.233; 
SD 4.595; 95% CI 2.852-5.613; p=0.0939) There was also no significant 
difference between wild-type and 3E1 (p=0.1119), 3B9 (p=0.9983) or 7E5 
(p=0.3987), nor was there a significant difference between cell lines 3B9 and 
7E5 (p=0.5144). 
At 3 mM caffeine, wild-type cells had a %MR of 20.55 (SD 12.68; 95% CI 
16.74-24.36) and responded in a similar manner to both cell line 3E1 (%MR 
22.13; SD 8.92; 95% CI 18.96-25.29; p) and 7E5 (%MR 23.73; SD 10.58; 95% 
CI 20.69-26.77; p).  Cell lines 8E10 (%MR 35.63; SD 17.3; 95% CI 30.96-
40.31) and 3B9 (%MR 30.48; SD 19.82; 95% CI 25.32-35.65) responded 
similarly with no significant difference in %MR between the two cell lines 
(p=0.3665).  Cell line 8E10 was significantly different to wild-type C2C12 cells 
(p<0.0001), cell line 3E1 (p=0.0006) and 7E5 (p=0.0008).  Cell line 3B9 was 
significantly different to wild-type C2C12 cells (p=0.0091) but not 3E1 
(p=0.0848) or 7E5 (p=0.1449). 
At 5 mM caffeine, wild-type cells (38.41; SD 19.82; 95% CI 32.45-44.36), cell 
line 3E1 (%MR 36.33; SD 9.33; 95% CI 33.02-39.64) and 7E5 (%MR 39; SD 
16.38; 95) continued to respond in a similar manner.  There were no significant 
differences between in the %MR wild-type C2C12 cells and 3E1 (p=0.9874) or 
7E5 (p=0.9999), nor was there significant difference between 7E5 and 3E1 
(p=0.9659).  Cell line 8E10 had a %MR of 51.46 (SD 18.64; 95% CI 46.42-
56.5) and responded similarly to cell line 3B9 (%MR 50.57; SD 21.15; 95% CI 
45.06-56.08) , with no significant difference between the two cell lines 
(p=0.9990).  The %MR for cell line 8E10 was significantly different to wild-type 
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C2C12 (p=0.0038), cell line 3E1 (p=0.0018) and cell line 7E5 (p=0.0051).  
Likewise, the %MR for cell line 3B9 was significantly different to wild-type 
C2C12 cells (p=0.0038), cell line 3E1 (p=0.0034) and cell line 7E5 (p=0.0097).  
Finally, at 10 mM caffeine, there were no significant differences in the %MR 
between wild-type C2C12 cells (% MR 67.94; SD 20.57; 95% CI 61.76-74.12) 
and cell lines 3E1 (%MR 68.7; SD 16.27; 95% CI 62.93-74.47; p=0.9999) or 
8E10 (%MR 77.17; SD 20.09; 95% CI 71.73-82.6; p=0.2284); however, cell line 
3B9 (%MR 81.76; SD 16.87; 95% CI 77.36-86.15) did have a significantly 
increased %MR compared to wild-type cells (p=0.0144)   As observed in the 
peak height analysis, cell line 7E5 responded maximally at 10 mM (%MR 
101.8; SD 31.8; 95% CI 92.63-110.9) and had a significantly increased 
response compared to wild-type C2C12 cells (p<0.0001), 3E1 (p<0.0001), 
8E10 (p<0.0001) and 3B9 (p<0.0001). 
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Figure 5.12 – Peak and AUC percentage maximal response of wild-type C2C12 cells and Casq1 KO cell lines at 1, 3, 5 and 10 
mM caffeine 
The peak (panel A) and AUC (B) percentage maximal response of each cell line at 1 mM, 3 mM, 5 mM and 10 mM caffeine.  Baseline 
fluorescence values were calculated from an average of 20 frames prior to caffeine perfusion at each dose.  Baseline was used to 
define peaks for the AUC analysis and was subtracted from the peak height increase in fluorescence for the peak height analysis.  The 
resultant values for each caffeine concentration were calculated as a percentage of the maximal response at 20 mM caffeine.  Data are 
shown as the mean (from 33-59 myotubes) and error bars are the SD.  One-way ANOVA and Tukey’s test for multiple comparisons 
were used to determine significance. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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The increase in fluorescence values from baseline following caffeine perfusion 
showed a modest, yet significant, reduction in magnitude for cell lines 8E10 
and 3B9 compared to wild-type C2C12 cells which is in agreement with data 
obtained elsewhere (Figure 5.13; Dainese et al., 2009).  Following perfusion 
with 20 mM caffeine, the mean increase in fluorescence from baseline was 
648.3 FUs (SD 252.2; 95% CI 575.1-721.5) for wild-type C2C12 cells, 420.6 
FUs (SD 251.9; 95% CI 351.9-489.4) for cell line 8E10, 437.9 FUs (SD 295.2; 
95% CI 348.1-527.6) for cell line 3B9 and 508.6 FUs (SD 291.9; 95% CI 424.8-
592.4) for cell line 7E5.  The mean increase in fluorescence for cell lines 8E10 
and 3B9 were significantly different to wild-type (p<0.0001; p=0.0009, 
respectively) but not to each other (p=0.9973) or cell line 7E5 (8E10 p=0.4016; 
3B9 p=0.6654).  The mean increase in fluorescence from baseline for cell line 
7E5 was not significantly different to wild-type C2C12 cells (p=0.4016; 
p=0.6654, respectively).  Cell line 3E1 also showed a significant reduction in 
the increase in fluorescence from baseline compared to wild-type C2C12 cells 
(p<0.0001) and all of the Casq1 KO lines (8E10 p=0.0005; 3B9 p=0.0003; 7E5 
p<0.0001); however, this was deemed to be due to reduced SR since a greater 
proportion of smaller myotubes were produced in this cell type compared to 
others in section 4.2.12.2.  In contrast, no clear difference in the proportions of 
the size of myotubes could be observed between wild-type C2C12 cells, 8E10, 
3B9 and 7E5 (Figure 5.7).  As such, the reduction in the magnitude of the 
response could be due to reduced SR Ca2+ stores in the Casq1 KO cell lines 
8E10 and 3B9, which has been shown in Casq1 null myofibres previously 
(Dainese et al., 2009).    
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Figure 5.13 – Mean raw fluorescence increases in response to 20 mM 
caffeine for wild-type C2C12 cells and Casq1 KO cell lines 
Baselines were calculated for each myotube by averaging fluorescence values 
for 20 frames (1 second) prior to perfusion with 20 mM caffeine.  Baseline 
measurements were subtracted from the peak height measurement for each 
myotube, to generate the raw fluorescence increase.  Raw fluorescence 
increases were averaged across 33-59 genotypes per cell line, generating the 
mean raw fluorescence increase in response to 20 mM caffeine.  The 20 mM 
caffeine dose has been used for reference; however, the pattern was the same 
across all caffeine doses.  Box plots show the median data point, upper and 
lower quartiles and the minimum and maximum data points.  One-way ANOVA 
and Tukey’s test for multiple comparisons were used to determine significance. 
****p<0.0001. 
 
5.2.6 Cloning CASQ1 cDNAs into pOPINF 
To investigate the effect of three CASQ1 variants on the Ca2+ binding and 
polymerisation abilities of the CASQ1 protein, CASQ1 cDNAs were cloned into 
an expression vector for heterologous expression and purification, and 
subsequent downstream in-vitro studies.  Gibson cloning was used to insert the 
human CASQ1 cDNAs for CASQ1 WT, CASQ1 p.I138T, CASQ1 p.F186Y and 
CASQ1 p.E364K into the expression vector, pOPINF (a gift from Ray Owens, 
addgene plasmid 26042).  The CASQ1 cDNAs were amplified without their 102 
bp (34 amino acid) N terminal signal peptides from pre-existing vectors.  The 
forward primer used for amplification was designed to contain a 5’ overhang 
with a region of complementarity to the pOPINF vector and a sequence for the 
completion of the 3C cleavage site upstream of the CASQ1 cDNA and 
downstream of the N terminal 6His-tag.  The reverse primer contained a 5’ 
overhang containing a region of complementarity to the pOPINF vector and a 
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stop codon downstream of the CASQ1 cDNA.  Digestion of pOPINF with KpnI 
and HindIII and the subsequent 5’ exonuclease digestion of the PCR amplicon 
and linearised vector yielded large 3’ overhangs that annealed via 
complementary base pairing in a ligation reaction (see Methods for a schematic 
of the cloning reaction).  Ligation reactions were transformed into XL10-gold® 
ultracompetent E. coli cells (Agilent) and plated on LB agar plates containing 
100 μg/ml ampicillin with 40 μl 100 mM IPTG and 120 μl 20 mg/ml X-gal spread 
onto the surface of the plate.  Four single colonies (with the exception of 
CASQ1 p.E364K transformants for which only 3 white colonies were 
generated) were used to inoculate 5 ml LB media and cultures were incubated 
overnight at 37oC with shaking at 200 rpm.  Plasmid DNA was isolated by 
miniprep.  The resultant plasmid DNA was linearised with EagI and the 
products separated by gel electrophoresis to confirm the size of the vector.  
Insertion of the 1086 bp CASQ1 cDNA increased the size of the 5.5 kb vector 
to approximately 6.5 kb (Figure 5.14).  With the exception of CASQ1 WT 
colony 4, all colonies appeared to contain the CASQ1 cDNA insert.  A series of 
overlapping primers were designed across the entire CASQ1 insert within 
pOPINF for Sanger sequencing confirmation of the insertion.  All variants were 
confirmed and plasmids were selected for use that had no additional point 
mutations introduced by erroneous PCR (Figure 5.15). 
 
 
Figure 5.14 – EagI digest of pOPINF to confirm CASQ1 cDNA insertion 
Plasmid DNA from putative recombinant CASQ1 expression vectors was 
digested with EagI and reaction products were separated by gel 
electrophoresis.  Lane 1 shows the 1 kb ladder (NEB), lane 2 shows a DNA 
negative control reaction and the subsequent lanes show the linearised vectors 
from colonies picked for CASQ1 WT, CASQ1 p.I138T, CASQ1 p.F186Y and 
CASQ1 p.E364K ligation reactions. 
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Figure 5.15 – Sanger sequencing confirmation of CASQ1 variants in 
pOPINF 
Plasmids confirmed to contain the CASQ1 cDNA insertion were processed for 
Sanger sequencing using a series of overlapping primers to enable sequencing 
of the entire insert.  Wild-type sequences are underlined in black, the edited 
codon is shown in red and the wild-type codon is shown in blue. 
 
5.2.7 Purification of CASQ1 WT and CASQ1 variant proteins 
Plasmids containing CASQ1 WT and variant cDNA sequences were 
transformed into BL21(DE3) RosettaTM E. coli cells (Novagen) that supply 
transfer RNAs (tRNAs) for eukaryotic codon optimisation.  DE3 denotes that 
the strain contains the λDE3 lysogen which encodes the T7 RNA polymerase 
for high level transcription of the CASQ1 cDNA sequence following induction 
with IPTG.  The culture was incubated overnight at 18oC with shaking prior to 
centrifugation, cell lysis and lysate clarification.  Samples of the pellet following 
centrifugation to clarify lysates were retained for analysis by SDS-PAGE to 
ensure that CASQ1 proteins were not within the insoluble fraction.  Proteins 
were initially purified from the clarified cell lysates by nickel affinity 
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chromatography using nickel-charged HisTrapTM HP 1 ml columns (GE 
Healthcare) on the AKTA Pure FPLC system (GE Healthcare).  The elution of 
proteins was monitored using ultraviolet (UV) absorbance at 280 nm in 
UNICORN software (GE Healthcare) (Figure 5.16).  The application of the 
sample to the column and its subsequent flow-through resulted in an increase 
in UV absorbance at 280 nm, as was observed for wash steps.  Samples from 
the flow-through and wash steps were retained for analysis by SDS-PAGE 
along with selected fractions within the elution peak starting at 60 ml to confirm 
the presence of the CASQ1 proteins (Figure 5.17).   
 
 
Figure 5.16 – Nickel affinity chromatogram for CASQ1 purification 
Proteins eluted from the column were measured by UV absorbance at 280 nm 
(blue line) and this is shown as milli absorbance units (mAU).  Changes in 
conductance throughout the run are shown by an orange line and the 
concentration of elution buffer is shown by a green line indicating the linear 
gradient to 70% and followed by a step up to 100% elution buffer.  Numbers 
above the peaks in absorbance at 280 nm show the number of mls at which the 
peak is present.  For reference, an example trace following nickel affinity 
purification of the CASQ1 WT protein is shown.  In total, 2 batches of each 
CASQ1 protein were used for the collection of data presented in this chapter.  
Chromatograms were generated in UNICORN software (GE Healthcare).   
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Figure 5.17 – SDS-PAGE analysis of nickel affinity purification of CASQ1 
WT and variant proteins 
The CASQ1 WT (panel A), CASQ1 p.I138T (panel B), CASQ1 p.F186Y (panel 
C) and CASQ1 p.E364K (panel D) proteins were initially purified by nickel 
affinity chromatography using the AKTA Pure FPLC system and the eluted 
proteins analysed by SDS-PAGE on 12% gels.  Lane 1 shows the Broad 
Range Colour Prestained Protein Standard (NEB).  Lane 2 shows the sample 
of the cell pellet following centrifugation prior to cell lysis.  Lane 3 shows the 
flow through upon sample loading i.e sample that did not bind to the HisTrapTM 
1 ml column.  Lanes 4-6 show samples eluted following washing of the column 
and lanes 7-15 show eluted fractions that showed a peak in UV absorbance at 
280 nm. An arrow indicates the band corresponding to CASQ1. 
 
For all samples, a large band was identified in one of the eluted fractions 
(elution 6 for CASQ1 WT, elution 6 for p.I138T, elution 4 for p.F186Y and 
elution 7 for p.E364K), corresponding to a molecular weight between 46 kDa 
and 58 kDa.  Whilst the expected molecular weight (Mw) of the CASQ1 
proteins (without the N terminal signal peptide and with the 6His-tag and 3C 
cleavage site) is approximately 43.8 kilodaltons (kDa), reduced migration 
during SDS PAGE has been reported for other acidic proteins (Graceffa et al., 
1992).  Additional eluted fractions contained smaller, yet substantial, bands at 
the same molecular weight.  No significant bands at the same molecular weight 
were identified in the pellet, flow through or wash steps in CASQ1 WT, CASQ1 
p.I138T, CASQ1 p.F186Y or CASQ1 p.E364K; however, all of the fractions 
contained contaminant proteins.  To remove contaminants, the eluted fractions 
containing the supposed CASQ1 protein were pooled and size exclusion 
chromatography (SEC) using a HiLoad Superdex 26/600 200 pg column (GE 
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Healthcare) was performed.  Again, protein elution was monitored by UV 
absorbance at 280 nm (Figure 5.18).  Eluted fractions that showed distinct 
peaks in absorbance at 280 nm were analysed by SDS PAGE.  For all CASQ1 
proteins, fractions eluted at approximately 200 ml contained CASQ1, as did 
fractions eluted at approximately 116 ml.  The other peaks did not contain 
detectable amounts of protein by SDS-PAGE and InstantBlueTM Coomassie 
staining.  Since larger species are eluted first, it is likely that the fractions eluted 
at 116 ml contained CASQ1 proteins that were not present in monomeric form; 
however, at the time of these experiments, the AKTA Pure FPLC system had 
not been calibrated with Mw standards to enable Mw determination of the 
peaks.  Nonetheless, fractions containing CASQ1 following SEC elution were 
pooled and concentrated using PierceTM spin concentrators.  SDS PAGE was 
performed followed by 2D densitometry to determine the purity of the CASQ1 
proteins produced (Figure 5.19).  Across the 2 batches of protein used to 
generate the data presented in this chapter, CASQ1 WT had a mean 
percentage purity of 89.4%.  The mean percentage purities of CASQ1 p.I138T, 
CASQ1 p.F186Y and CASQ1 p.E364K were 91.5%, 93.0% and 94.0%, 
respectively. 
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Figure 5.18 – SEC chromatogram for CASQ1 purification 
Increases in UV absorbance at 280 nm (blue line) are shown as mAUs.  
Conductance, which remains stable since a single buffer is used for SEC, is 
shown by an orange line.  The concentration of elution buffer, which is not 
required for SEC and thus remains at 0, is shown by a green line.  Numbers 
above the peaks show the number of mls at which that peak is present.  Note 
that the chromatogram has been cropped at the left side to enable fitting to the 
page.  The actual total volume of solution applied to the column was 356 ml; 
however, no further increases in absorbance at 280 nm were observed after 
the return to 0 mAUs shown here at 274 ml.  For reference, a representative 
trace is shown here from the SEC purification of CASQ1 F186Y; however, all 
proteins consistently showed a similar elution pattern.  Chromatograms were 
generated in UNICORN software (GE Healthcare).   
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Figure 5.19 – Purified CASQ1 WT, CASQ1 p.I138T, CASQ1 p.F186Y and 
CASQ1 p.E364K proteins 
CASQ1 proteins were purified by nickel affinity chromatography followed by 
SEC.  To calculate percentage purity, 10 μg protein was heated at 95oC for 5 
min with loading buffer and loaded onto a 12% acrylamide SDS-PAGE gel.  
Densitometry was performed using ImageJ. 
 
5.2.8 Confirmation of protein identity 
To confirm the identity of the proteins produced, samples of purified CASQ1 
WT, CASQ1 p.I138T, CASQ1 p.F186Y and CASQ1 p.E364K proteins were 
submitted to the Leeds Mass Spectrometry facility for digestion and peptide 
mass fingerprinting by MS.  The resultant peptides were searched against 
against a Uniprot database for CASQ1 for amino acid sequence assembly. (Figure 
5.20).  The presence of each variant was confirmed within the amino acid 
sequences, although coverage was not obtained across all of the variant 
residues in the CASQ1 WT sample.  The identity of the CASQ1 WT protein 
was confirmed by determination of its Mw by denatured intact liquid 
chromatography MS (LC-MS) (Figure 5.21; Figure 5.22). 
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Figure 5.20 – Protein ID of variant CASQ1 proteins 
Samples of purified CASQ1 variant proteins were submitted for peptide mass 
fingerprinting as a service at the Leeds Mass Spectrometry facility.  An asterisk 
indicates the substituted residue.  Coverage of the region is indicated by blue 
bars beneath the amino acid sequence and oxidation events are shown by O.  
 
The expected molecular weights (Mw) of each CASQ1 protein (taking into 
account the loss of the N terminal signal peptide and introduction of an N 
terminal 6His-tag and 3C cleavage site) were calculated using the ExPASy 
pI/Mw tool (available at web.expasy.org/compute_pi/) (Table 5.3).  For all 
CASQ1 proteins, the major species present within the MS spectrum 
represented the full-length protein minus the 132 Da N terminal methionine 
residue (Table 5.3).  Cleavage of the N terminal methionine residue is a 
common occurrence during recombinant protein expression in E. coli via the 
activity of methionine aminopeptidase (Wingfield, 2017).  In addition to N 
terminal methionine cleavage, the denatured intact analysis revealed a range 
of modifications to the CASQ1 proteins; however these were present in 
considerably smaller amounts than the desired protein (Figure 5.21; Figure 
5.22).  The putative identities of these species are provided in Appendix D. 
Table 5.3 – Predicted and identified Mw by denatured intact MS 
Values are shown in kDa. 
Protein Predicted Mw  Identified Mw  Predicted Mw 
minus N’ Met 
CASQ1 WT 43.829 43.697.36±0.62 43.697 
CASQ1 p.I138T 43.817 43.685.21±0.68 43.685 
CASQ1 p.F186Y 43.845 43.713.49±0.71 43.713 
CASQ1 p.E364K 43.828 43696.57±0.69 43.696 
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Figure 5.21 – Denatured intact LC-MS of CASQ1 WT and CASQ1 p.I138T 
Denatured intact LC-MS and analysis was provided as a service by the Leeds Mass Spectrometry Facility at the Astbury Centre for 
Structural Molecular Biology using the Synapt G1 mass spectrometer (Waters).  Spectra were analysed in MassLynxTM (Waters) and 
the maximum peak normalised to 100% intensity (Y axis).  The Mw in Da is shown on the X axis.  The Mws of the most resolved peaks 
are shown to the left of the spectra.  Note that the labelling does not correspond between CASQ1 proteins i.e. species B in the CASQ1 
WT sample (panel A) does not correspond to species B in the CASQ1 p.I138T sample (panel B).  Where species are labelled to the left 
of the spectrum, but the peak is not labelled on the trace, this is due to the trace not being sufficiently ‘zoomed in’ on the software to 
achieve resolution.  In such cases, the peaks to which the label corresponds can be inferred from the Mw of adjacent peaks. 
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Figure 5.22 – Denatured intact LC-MS of CASQ1 p.F186Y and CASQ1 p.E364K 
Denatured intact LC-MS and analysis was provided as a service by the Leeds Mass Spectrometry Facility at the Astbury Centre for 
Structural Molecular Biology using the Synapt G1 mass spectrometer (Waters).  Spectra were analysed in MassLynxTM (Waters) and 
the maximum peak normalised to 100% intensity (Y axis).  The Mw in Da is shown on the X axis.  The Mws of the most intense peaks 
are shown to the left of each spectrum with colour-coded labels.  Note that the labelling does not correspond between CASQ1 proteins 
i.e. species C in the CASQ1 p.F186Y sample (panel A) does not correspond to species C in the CASQ1 p.E364K sample (panel B).  
Where species are labelled to the left of the spectrum, but the peak is not labelled on the trace, this is due to the trace not being 
sufficiently ‘zoomed in’ on the software to achieve resolution.  In such cases, the peaks to which the label corresponds can be inferred 
from the Mw of adjacent peaks.
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5.2.9 Investigation of Ca2+ binding by MST 
MST was used to investigate the effect of Ca2+ addition on the CASQ1 WT, 
CASQ1 p.I138T, CASQ1 p.F186Y and CASQ1 p.E364K proteins (Figure 5.23).  
MST is based on the thermophoresis (movement along a temperature gradient) 
of fluorescently labelled protein molecules.  Thermophoresis, and subsequently 
the fluorescent signal, is altered by changes in the size, charge, conformation 
and hydration shell of the protein (Jerabek-Willemsen et al., 2011).  CASQ1 
proteins were labelled with FITC and allowed to equilibrate with a Ca2+ titration 
from 100 mM-6 μM (including a no Ca2+ control), prior to loading on the 
Monolith NT.115 system (NanoTemper).  As expected, the CASQ1 WT protein 
(Figure 5.23; Panel B) produced a multiphasic binding curve that appeared to 
contain at least two phases, in agreement with reports in the literature 
(Sanchez et al., 2012; Beard et al., 2004).  The first binding phase was initiated 
at 0.1 mM Ca2+, indicated by a reduction in the fluorescence signal (i.e. 
increased thermophoresis) between 0.1 mM Ca2+  to 0.4 mM Ca2+.  Between 
0.4 mM Ca2+ and 1.5 mM Ca2+, the fluorescence signal stabilised prior to 
another reduction in fluorescence between 1.5 mM Ca2+ and 3 mM Ca2+.  It is 
unclear whether the apparent stabilisation in fluorescence between 3 mM Ca2+ 
and 6 mM Ca2+ represents a plateau of the second binding phase.  As such, 
the reduction in fluorescence observed from 6 mM Ca2+ may represent a third 
binding phase or may be a continuation of the second binding phase.  Between 
0 mM Ca2+ and 100 mM Ca2+, the fluorescence values reduced by 
approximately 40 FUs. 
The binding phases observed for the CASQ1 p.I138T and CASQ1 p.F186Y 
proteins were less distinct than that of CASQ1 WT (Figure 5.23; Panel C) with 
normalised fluorescence values not reducing by more than 20 FUs across the 
Ca2+ serial dilution.  For both proteins, fluorescence measurements between 0 
mM Ca2+ and 0.1 mM Ca2+ were similar to CASQ1 WT.  For CASQ1 p.I138T, a 
minor reduction in fluorescence was observed between 0.4 mM Ca2+ and 3 mM 
Ca2+ and between 12 mM Ca2+ and 50 mM Ca2+ at which the signal plateaus.  
For CASQ1 p.F186Y, a minor reduction in fluorescence is seen between 0.1 
mM Ca2+ and 0.4 mM Ca2+.  At 12 mM Ca2+, another reduction in the 
fluorescence signal is observed.  For CASQ1 p.E364K, the fluorescence values 
were increased compared to CASQ1 WT and the two other variant CASQ1 
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proteins; however, the magnitude of changes in thermophoresis, as indicated 
by reductions in fluorescence, were comparable to CASQ1 WT.  Between 0 
mM Ca2+ and 0.1 mM Ca2+, fluorescence values were generally stable and, 
with the exception of values at 0.2 mM Ca2+ and 0.4 mM Ca2+, a similar pattern 
in fluorescence changes were observed as in CASQ1 WT.  
Since changes in thermophoresis depend on several factors including size, 
charge and conformation, the binding events shown in these data likely 
represent changes in thermophoresis as a result of CASQ1 polymerisation in 
addition to Ca2+ binding.  As such, Ca2+ binding affinities could not be derived.  
Nonetheless, qualitatively, these data suggest alterations in Ca2+ binding and 
polymerisation in at least CASQ1 p.I138T and CASQ1 p.F186Y. 
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Figure 5.23 – Effect of Ca2+ addition on CASQ1 WT and variant proteins 
determined by MST 
FITC-labelled proteins were incubated with a 2-fold CaCl2 serial dilution to final 
concentrations of 6 μM to 100 mM.  MST was performed using the Monolith 
NT.115 (NanoTemper Technologies) and values obtained using MST power 
20% are shown.  Fluorescence units were normalised to baseline 
measurements taken prior to thermophoresis and are shown on the Y axis.  
Ca2+ concentration is on the X axis.  Panel A shows an overlay of the binding 
events for CASQ1 WT (blue squares), CASQ1 p.I138T (green circles), CASQ1 
p.F186Y (red triangles) and CASQ1 p.E364K (orange diamonds) without error 
bars for clarity.  Individual graphs for CASQ1 WT (panel B), CASQ1 p.I138T 
(panel C), CASQ1 p.F186Y (panel D) and CASQ1 p.E364K (panel E) are 
shown, with CASQ1 variant graphs showing an overlay of the CASQ1 WT trace 
in grey.  Fluorescence values from two experiments were averaged and error 
bars show the SD.  Where error bars are not shown, their height was shorter 
than the symbol indicating the fluorescence value with the exception of the 200 
μM and 100 mM points for p.F186Y which are comprised of 1 n since the 
others showed anomalous fluctuations in fluorescence. 
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5.2.10 Native MS in the absence of Ca2+ and presence of 1 mM Ca2+ 
Since a single quantitative effect on Ca2+ binding could not be distinguished by 
MST, a combination of native and denatured MS was performed to determine 
whether Ca2+ binding to the CASQ1 proteins could be detected.  In theory, Ca2+ 
binding to CASQ1 would result in a shift of the expected mass in the native 
samples by a number divisible by 40 Da (the size of a Ca2+ ion), that would not 
be observed in the denatured samples due to Ca2+ release following unfolding.  
X-ray crystallography has previously shown that CASQ1 is purified bound to 3 
high affinity Ca2+ ions that are important for protein folding (Sanchez et al., 
2012).  To determine whether that was the case here, the CASQ1 WT protein 
was initially submitted for native analysis without added Ca2+.  The 
heterogenous nature of the CASQ1 complicated the determination of the 
number of Ca2+ bound to CASQ1.  Two major species were resolved that had 
masses of 43818.05 Da and 44037.91 Da (Figure 5.24).  The major species at 
43818 Da was ~120 Da larger than the predominant peak identified by the 
denatured analysis which was the expected mass of CASQ1 WT minus the N 
terminal methionine residue (43696 Da), suggesting that 3 Ca2+ ions were 
bound to CASQ1 WT following purification which is in agreement with reports in 
the literature (Sanchez et al., 2012).  The second species at 44037 Da was 
~340 kDa larger than CASQ1 WT minus the N-terminal methionine, and 324 
Da larger than the second most intense peak identified in the denatured 
analysis (43713 Da).  This mass could represent CASQ1 WT minus the N 
terminal methionine residue with an oxidation event (+16 Da) bound to 8 Ca2+ 
ions (+320 Da).  These masses were unaltered following dialysis against 1 mM 
EGTA, suggesting that if Ca2+ was bound, it was with high affinity. 
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Figure 5.24 – Native MS of CASQ1 WT with no added Ca2+ using the 
Synapt G1 instrument 
CASQ1 WT samples were buffer exchanged into 200 mM ammonium acetate 
and native mass spectrometry was performed in ESI TOF positive ion mode 
using the Synapt G1 high definition mass spectrometer.  The Y axis shows the 
percentage intensity of each peak identified, where the predominant peak is 
normalised to 100%.  The X axis shows the mass to charge ratio (m/z) and 
peaks are labelled with their m/z ratio and charge state.  The masses of the 
most resolved peaks are shown to the left of the m/z spectrum. 
 
The heterogeneity of CASQ1 WT-Ca2+ stoichiometries (in the absence of 
added Ca2+) was further revealed using the Q ExactiveTM Plus mass 
spectrometer which provided increased resolution of species in the absence of 
Ca2+; however, the parameters of this instrument were still in the process of 
optimisation at the time of these experiments and masses may not be accurate 
to the Dalton (Dr Rachel George, pers comms.) (Figure 5.25).  The 
predominant species (species C) had a mass of 43810 Da.  This was 114 Da 
greater than predominant mass detected in the denatured analysis 
corresponding to CASQ1 WT minus the N terminal methionine residue (43696 
Da; Figure 5.21) and 6 Da less than the predominant species detected in the 
initial native analysis (Figure 5.24).  Interestingly, species A identified in this 
native analysis was ~39 Da larger than CASQ1 WT minus the N terminal 
methionine and species B was, in turn, 40 Da larger than species A.  The 
predominant species C was 35 Da larger than species B.  As such, it is 
possible that species C represents 3 Ca2+ bound to CASQ1 WT minus the N 
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terminal methionine, as identified in previous analyses (Figure 5.24).  The 
pattern of the sequential addition of 35-40 Da continued until species M and 
could reflect different CASQ1-Ca2+ stoichiometries.   
 
Figure 5.25 – Native MS of CASQ1 WT with no added Ca2+ using the Q 
ExactiveTM Plus instrument 
A CASQ1 WT sample was buffer exchanged into 200 mM ammonium acetate 
and native mass spectrometry was performed using the Q ExactiveTM Plus 
mass spectrometer.  The Y axis shows the percentage intensity of each peak 
identified, where the predominant peak is normalised to 100%.  The X axis 
shows the mass in Da and the masses of the resolved peaks are shown 
beneath the mass spectrum. 
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Species with masses corresponding to dimeric CASQ1 were identified (species 
U-H2), supporting previous observations of the elution of non-monomeric 
CASQ1 species during SEC (Figure 5.18).  Sample heterogeneity meant that 
the accurate determination of the number of Ca2+ ions bound to dimer species 
was not possible, since the monomeric form of each dimer species was not 
known; however, the sequential addition of ~80 Da (potentially corresponding 
to 2 Ca2+ ions) was observed between species U and V, V and  W, C2 and D2, 
D2 and E2 and G2 and H2.  A single increase in mass by 40 Da was observed 
between species A2 and B2.  Whilst the ability to determine the number of Ca2+ 
ions bound to each dimer species was limited, these data suggested that 
CASQ1-CASQ1 interactions could be maintained in the gas phase.  As such, 
further experiments were performed to investigate whether a difference in the 
polymerisation capacity of each CASQ1 protein could be detected by MS.  All 
of the CASQ1 proteins with and without 1 mM Ca2+ were submitted for analysis 
by native MS.   Sample heterogeneity meant that the identity of each species 
was ambiguous, hence general trends in the data have been presented here.  
The possible identities of each species are speculated in Appendix D. 
 
As expected, in the absence of added Ca2+, CASQ1 WT existed in a 
predominantly monomeric form (Figure 5.26).  The most abundant mass was 
43728 Da with two additional species corresponding to monomers of 43890 Da 
and 43972 Da identified.  Masses corresponding to dimeric CASQ1 were also 
identified ranging from 87488 Da to 87936 Da.  Consistent with the well-
established function of CASQ1, CASQ1 WT showed Ca2+ dependent 
polymerisation following addition of 1 mM Ca2+, with dimeric (88200 Da) and 
higher order species identified.  A peak corresponding to tetrameric CASQ1 
(~175000 Da) was identified; however, a mass was not assigned due to the 
broadness of the peaks that prevented mass determination by the software 
used for analysis (Dr Rachel George, pers. comms.).  The presence of a 
species at 132 kDa was unexpected, since CASQ1 forms back-to-back dimers 
that interact to form front-to-front tetramers.  The presence of this seemingly 
trimeric species could reflect a limitation in the maintenance of CASQ1 
polymers into the gas phase. 
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In the absence of Ca2+, the CASQ1 p.I138T sample contained masses 
comparable to wild-type (Figure 5.26).  Again, these were predominantly 
monomeric (43990 Da and 44182 Da) with a proportion of dimeric CASQ1s 
(88190 Da).  In contrast to CASQ1 WT, no species larger than dimeric CASQ1 
were identified in the CASQ1 p.I138T following 1 mM Ca2+ addition (44252 Da, 
88148 Da and 88166 Da).  In the absence of added Ca2+, CASQ1 p.F186Y 
existed primarily as a monomer (43830 Da and 43986 Da) (Figure 5.27).  
Whilst a mass was not assigned, it appeared that dimeric species were 
present; however, the broadness of the peaks precluded mass determination 
(Dr Rachel George, pers. comms.).  Similarly to CASQ1 p.I138T, p.F186Y did 
not appear to polymerise in response to 1 mM Ca2+ with only monomeric 
species identified (44172 Da and 44474 Da).  For CASQ1 p.E364K, only 
monomeric species were identified in the absence of Ca2+ (43724 Da, 43906 
Da and 43962 Da); however, Ca2+ dependent polymerisation occurred in a 
manner similar to that observed for CASQ1 WT (Figure 5.27), with species 
corresponding to tetrameric CASQ1 identified (175970 Da).  Sample 
heterogeneity and a plethora of CASQ1-Ca2+ stoichiometries meant the 
determination of the number of Ca2+ ions bound to each species was not 
possible.  Nonetheless, qualitatively, these data suggest that CASQ1 p.I138T 
and CASQ1 p.F186Y have impaired polymerisation capacities at 1 mM Ca2+ 
compared to CASQ1 WT and CASQ1 p.E364K, which is in agreement with 
data obtained from MST measurements.  
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Figure 5.26 – Native MS of CASQ1 WT and CASQ1 p.I138T in the absence 
and presence of 1 mM Ca2+ 
CASQ1 samples were buffer exchanged into 200 mM ammonium acetate (no 
added Ca2+) or 200 mM ammonium acetate with 1 mM calcium acetate and 
native mass spectrometry was performed using the Q ExactiveTM Plus mass 
spectrometer.  The predominant peak is normalised to 100%.  Masses of the 
resolved peaks are shown to the right of the mass spectra in Da. 
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Figure 5.27 – Native MS of CASQ1 p.F186Y and p.E364K in the absence 
and presence of 1 mM Ca2+ 
CASQ1 samples were buffer exchanged into 200 mM ammonium acetate (no 
added Ca2+) or 200 mM ammonium acetate with 1 mM calcium acetate and 
native mass spectrometry was performed using the Q ExactiveTM Plus mass 
spectrometer.  The predominant peak is normalised to 100% intensity.  Masses 
of the resolved peaks are shown to the right of the mass spectra in Da. 
 
5.2.11 Dynamic light scattering in the absence and presence of Ca2+ 
Since native MS takes place in the gas phase and the data obtained suggested 
limitations in the preservation of CASQ1-CASQ1 interactions, DLS was used to 
further explore the effect of Ca2+ on the polymerisation properties of CASQ1 
WT and the variant CASQ1 proteins in solution.  Due to usage limitations of the 
DLS instrument, a single Ca2+ concentration was selected to determine 
whether there were differences in the size of polymers produced by CASQ1 
variants compared to CASQ1 WT.  Ca2+ at 10 mM was selected since CASQ1 
WT polymerisation has previously been shown to plateau at this concentration 
(Lewis et al., 2015).  The CASQ1 p.I138T and CASQ1 p.E364K samples 
appeared to aggregate prior to the experiment with only species with higher 
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hydrodynamic radii (Rh) (>100 nm) present in both the 0 mM Ca2+ and 10 mM 
Ca2+ samples (data not shown).  Light scattering data for CASQ1 WT and 
CASQ1 p.F186Y was analysed by the method of regularisation due to the 
anticipated polydispersity of samples (Hassan et al., 2015). 
 
 
Figure 5.28 – DLS regularisation plots of CASQ1 WT and CASQ1 p.F186Y 
with and without 10 mM Ca2+ 
DLS was performed for CASQ1 WT and CASQ1 p.F186Y in the absence of 
added Ca2+ (panel A and C, respectively) and in the presence of 10 mM Ca2+ 
(panel B and D, respectively).  Data were analysed using ASTRA® 6.0.3 
software.  Regularisation graphs were plotted using Prism 7 (GraphPad), 
where the X axis shows the Rh differential intensity fraction (log nm-1) i.e. the 
relative intensity of each Rh species and the Y axis shows the Rh in nm.  
Values are derived from a single experiment. 
 
For the both CASQ1 WT and CASQ1 p.F186Y, four peaks were apparent in 
the absence of added Ca2+ (Figure 5.28; panel A and panel B); however the 
second and third peaks (from left to right) were merged due to high sample 
dispersity that precluded resolution into distinct peaks.  As such, peaks 2 and 3 
are collectively referred to as peak 2 here onwards.  Rh values are reported as 
the species with the highest relative intensity within the peak.  In the CASQ1 
WT sample, peak 1 had an Rh of 3.76 nm.  The two major species within peak 
1, of near equal relative intensity, had Rh values of 2.92 nm and 3.76 nm.  In 
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the presence of 300 mM KCl, at which these DLS assays were performed, 
CASQ1 monomers should be fully folded, as previously determined by circular 
dichroism (Sanchez et al., 2012).  The estimated Rh for a folded globular 
protein of 43.8 kDa is 2.97 nm (determined using the hydrodynamic radius 
calculator available at fluidics.com/resources/hydrodynamic-radius-converter).  
Indeed, the globular protein ovalbumin (44 kDa) has an Rh of 3.05 nm, 
determined by gel filtration (Erickson, 2009).  The estimated Rh for a folded 
globular protein of 87.6 kDa (i.e. dimeric CASQ1) is 3.81 nm.  As such, the two 
most intense species at 2.92 nm and 3.76 nm appeared to correspond to 
CASQ1 monomers and dimers, respectively. 
The Rh values of the second and third peaks in the CASQ1 WT sample were 
260 nm and 9075 nm, respectively.  Since the estimation of Rh from the Mw 
assumes a globular structure, and CASQ1 polymers form linear structures, the 
Mw of these larger species could not be determined accurately.  For the 
CASQ1 p.F186Y sample, in the absence of added Ca2+, peaks 1, 2 and 3 had 
Rh values of 2.92 nm, 405 nm and 14,988 nm, respectively.  The proportion of 
peak 1 in the CASQ1 p.F186Y sample was decreased compared to CASQ1 
WT, potentially reflecting an increased tendency of CASQ1 p.F186Y to 
aggregate.  Indeed, CASQ1 p.F186Y peaks 2 and 3 were comprised of larger 
Rh species than the corresponding peaks for CASQ1 WT.  
As expected, in the presence of 10 mM Ca2+, the peak corresponding to 
monomeric/dimeric CASQ1 virtually disappeared in both the CASQ1 WT and 
CASQ1 p.F186Y sample (Figure 5.28; panel B and panel D).  CASQ1 WT 
appeared to contain a minor proportion of monomeric species, with a distinct 
peak corresponding to 2.3 nm (peak 1).  Peak 2 in the CASQ1 WT sample 
represented the major peak which had an Rh value of 163 nm and peak 3 had 
an Rh value of 19250 nm.  The peak corresponding to monomeric CASQ1 
identified in the CASQ1 WT sample was entirely absent from the CASQ1 
p.F186Y sample.  The first peak identified in the CASQ1 p.F186Y sample had 
an Rh of 77 nm (cf. 163 for the corresponding peak in CASQ1 WT).  The 
second and third peaks identified in the p.F186Y sample were merged due to 
insufficient resolution of the polydisperse sample.  As such, these peaks are 
collectively referred to as peak 2 here onwards, of which the Rh value was 
18,881 nm.  It appears that peak 3 in the CASQ1 sample corresponds to peak 
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2 in the CASQ1 p.F186Y sample and due to reduced resolution compared to 
CASQ1 p.F186Y, only a single peak was apparent.   
 
It should be noted that the amount of light scattered increases with Mw 
(Hassan et al., 2015).  As such, the relative proportions of higher Rh species in 
all samples are over-estimated.  Nonetheless, the major species in the CASQ1 
p.F186Y sample (peak 1) had a substantially smaller Rh value than the 
corresponding peak in the CASQ1 WT sample (peak 2), suggesting that 
CASQ1 p.F186Y could have a reduced capacity for Ca2+ dependent 
polymerisation, in agreement with data obtained from MST (Figure 5.23) and 
native MS (Figure 5.27).  
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5.3 Discussion 
The data presented in this chapter are in support of an implication of CASQ1 in 
the MH and EHI phenotype.  In agreement with reports in the literature, Casq1 
null C2C12 myoblasts had an increased sensitivity to caffeine and appear to 
have reductions in the pool of releasable SR Ca2+ compared to wild-type 
C2C12 cells (Dainese et al., 2009; Paolini et al., 2011).  Furthermore, CASQ1 
variants identified in MHS/EHI individuals, CASQ1 p.I138T and p.F186Y, 
showed a reduced polymerisation and likely Ca2+ binding capacity compared to 
CASQ1 WT and CASQ1 p.E364K, validating the variants for future 
characterisation following expression in the Casq1 knockout C2C12 cells. 
 
5.3.1 Mechanisms for the increased sensitivity to caffeine in Casq1 
null C2C12 cells 
All three of the CASQ1 knockout cell lines showed an increased sensitivity to 
caffeine, with significantly different EC50 values, compared to wild-type 
polyclonal C2C12 cells, which has been reported for mouse Casq1 null 
myoblasts and myofibres previously (Dainese et al., 2009).  Increased caffeine 
sensitivity may result from an alleviation of the negative regulation of the RYR1 
in the absence of Casq1 (Protasi et al., 2009).  The polymerisation capacity of 
Casq1 could act to relay conformational signals to the RYR1 via its interactions 
with triadin and junctin (Györke et al., 2004).  In the absence of such 
conformational signals communicated by Casq1, the RYR1 could become 
dysregulated, resulting in increased Ca2+ release.  Increased Ca2+ levels may 
enhance ROS/RNS production that contribute to the MH/EHI phenotype 
(Paolini et al., 2015).  It has also been reported previously that Casq1 null 
myotubes have increased resting Ca2+ levels (Dainese et al., 2009).  Increased 
baseline fluorescence was observed in the C2C12 Casq1 knockout cells (data 
not shown); however, since this could be attributed to increased Fluo-8 AM 
loading in these cell lines, no conclusions can be made about the resting Ca2+ 
status of the C2C12 Casq1 null myotubes generated here without the use of a 
ratiometric Ca2+ indicator such as Fura-2 AM (Tong et al., 1999a).  Since the 
SR provides a limited pool of Ca2+, and Ca2+ leak from the SR would be 
rectified by the Na2+/Ca2+ exchanger embedded in the sarcolemma, it has been 
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suggested that increased resting Ca2+ must be maintained by extracellular Ca2+ 
entry (Calderón et al., 2014).  Indeed, CASQ1 knockdown has been shown to 
increase SOCE in mouse myofibres (Zhao et al., 2010), which has been 
postulated as a mechanism by which the rise in Ca2+ in MH is maintained 
(Duke et al., 2010).  
 
The C2C12 Casq1 knockout cell lines 3B9 and 8E10 showed a modest, yet 
significant, reduction in the amplitude of fluorescence signal following caffeine 
stimulation compared to wild-type C2C12 cells, suggesting a reduced pool of 
SR Ca2+ stores.  Indeed, this has been reported in Casq1 null mouse myotubes 
and Casq1 null mouse myofibres previously (Dainese et al., 2009; Paolini et al., 
2007).  Interestingly, a significant reduction in signal amplitude was not 
observed in cell line 7E5.  Furthermore, cell line 7E5 consistently responded 
differently to cell lines 3B9 and 8E10 throughout the caffeine dose response 
experiments.  The normalised increase in fluorescence signal in cell line 7E5 
following caffeine perfusion was similar to wild-type cells until 10 mM caffeine 
perfusion at which cell line 7E5 responded maximally.  One possibility for the 
apparent differential response in cell line 7E5 is the rescue of the Casq1 null 
phenotype by Casq2, the cardiac isoform of Casq which is also expressed in 
slow-twitch skeletal muscle fibres (Paolini et al., 2011).  C2C12 cells have been 
shown to form predominantly fast twitch fibres based on MHC isoform 
expression (Brown et al., 2012); however, increases in slow twitch fibres have 
been observed in C2C12 cells following a range of treatments including Ca2+ 
ionophore treatment (Meissner et al., 2000), betaine supplementation (Du et 
al., 2018) and arginine supplementation (Chen et al., 2018).  Increases in the 
proportion of slow twitch fibre types has been associated a range of pathways 
including upregulation of nuclear factor of activated T cell (NFATc1) that, in 
turn, downregulates MyoD expression (Du et al., 2018; Ehlers et al., 2014).   
Alternatively, arginine supplementation is thought to promote the 
transformation from fast to slow twitch fibres via the Sirt1/AMPK pathway 
(Chen et al., 2018).  Slow to fast fibre type transitions in C2C12 cells have 
been observed in the presence of high glucose (25 mM) – the glucose 
concentration at which C2C12 cells were cultured in this project as 
recommended by the supplier, ATCC (www. https://www.lgcstandards-
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atcc.org/).  Interestingly, western blotting of the MHC in cell line 7E5 revealed 
an additional high Mw band that may correspond to an additional type 1, slow 
twitch, MHC isoform, potentially suggesting a preferential formation of slow 
twitch myotubes in cell line 7E5.  Indeed, SDS-PAGE using 8% acrylamide gels 
has previously resulted in the successful resolution of MHC isoforms (Toniolo 
et al., 2005); however, all MHC species were detected within the 200 kDa 
region and the additional band observed here appeared to migrate 
corresponding to a molecular weight of ~150 kDa.  As such, the identity of this 
additional band is unclear and could also represent degradation products or 
non-specific binding  Nonetheless, if myotubes derived from the 7E5 cell line 
comprised predominantly slow twitch fibres, it is possible that Casq2 acted to 
rescue the function of ablated Casq1, at least at caffeine concentrations <10 
mM.  Indeed, Casq1 ablation in mice has been shown to have a lesser effect in 
slow twitch soleus fibres due to the abundance of Casq2 compared to fast 
twitch extensor digitorum longus fibres (Paolini et al., 2011). Despite the results 
presented here and a wealth of literature detailing the detrimental effect of 
Casq1 ablation in mouse myotubes and myofibres (Dainese et al., 2009; 
Tomasi et al., 2012; Paolini et al., 2015), siRNA-mediated Casq1/Casq2 
knockdown in C2C12 myotubes has previously shown that Casq2 knockdown, 
but not Casq1 knockdown, resulted in reduced SR Ca2+ and reduced Ca2+ 
release following RYR1 agonist stimulation.  The reasons for this finding are 
unclear but could be due to low levels of Casq1 expression in the knockdown 
cells that still contributed functional effects.  Nonetheless, these data 
emphasise the incomplete understanding of the roles of calsequestrin isoforms 
in mouse skeletal muscle.  Investigation of Casq2 protein levels in C2C12 
myotubes generated from protocols used in this project and in the Casq1 
knockout cell lines would provide further insight into the differential response of 
cell line 7E5. 
 
Alternatively, since the western blot to confirm Casq1 knockout showed a 
reduction in the loading control for cell line 7E5 and chromosome 1 (where the 
Casq1 gene lays) has four copies, it could be possible that Casq1 is not 
completely knocked out in this cell line and either 1 or 2 copies of it remain that 
precluded detection by western blot due to deceased loading of the sample.  
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This interpretation is complicated by the fact that no wild-type alleles were 
identified during sequencing of cell line 7E5.  In fact, a seemingly diploid 
Sanger sequencing chromatogram was produced.  In theory, if cell line 7E5 
had at least one copy of wild-type Casq1, this would appear on the Sanger 
sequencing chromatogram as an overlapping trace in addition to the two 
sequences already identified.  One possible explanation for seemingly diploid 
Sanger sequencing chromatogram is that the cell from which cell line 7E5 was 
derived could represent a rare subpopulation within the polyclonal C2C12 cell 
line that has 2 copies of chromosome 1 and was not identified by karyotyping.  
Indeed, karyotyping was performed on 20 individual cells that, whilst may 
represent the majority of the population, could have missed more rare 
subpopulations.  An alternative could be that the two indels identified are 
present on at least one chromosome, since data presented here and in 
previous chapters has shown that the same indels are identified multiple times 
and in different cell lines, likely as a result of MMEJ (Bae et al., 2014).  Whilst 
deep sequencing is becoming the gold-standard method to determine the 
consequences of genome editing, a more cost-effective method to investigate 
chromosome copy number or Casq1 copy number in cell line 7E5 would be 
karyotyping or quantitative PCR (qPCR).  Finally, it is possible that, for reasons 
unknown, PCR of the regions surrounding the Cas9 cut site preferentially 
amplified the two alleles detected, meaning that Sanger sequencing lacked the 
sensitivity to identify the remaining alleles.     
 
5.3.2 Evaluation of the CRISPR-Cas9 gene-editing process for the 
production of Casq1 knockout C2C12 cells 
The gRNAs designed for use in this chapter were of high quality with gRNA 
selected for use having just 6 predicted off-target sites.  Unlike gRNA design 
for HDR, the only locational restriction of the gRNA was targeting of exon 1 of 
the Casq1 gene, with the aim of generating a severely truncated, non-
functional protein that would be degraded by cellular mechanisms (Heck et al., 
2010).  Edited cell lines occurred at a frequency of 25%, with 8 out of the 32 
lines screened showing some form of editing event; however, since some of 
these cell lines did not form myotubes, and differentiation into myotubes is 
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required to confirm a lack of Casq1 protein, the efficiency of producing 
knockout cell lines cannot be reported.  Nonetheless, out of the 3 cell lines that 
formed myotubes comparable to wild-type polyclonal C2C12 cells, all of them 
showed Casq1 ablation by western blotting (although cell line 7E5 had reduced 
sample loading, the implications of which have been discussed in 5.3.1).  The 
observed gene-editing efficiency of 25% was higher than that predicted by the 
T7 assay.  Indeed, the estimation of gene-editing efficiency relies on four 
factors; i) that the range of mutations introduced into each allele are diverse 
enough to avoid re-annealing of identical strands, ii) that the strands of DNA 
are completely denatured prior to random re-annealing, iii) that strands do 
randomly re-anneal and iv) that T7I cleaves all mismatches between strands.  
Deviation from the above presumptions can result in an under-estimated gene-
editing efficiency (Guschin et al., 2010).  Furthermore, 2D densitometry is 
inherently subjective, requiring the manual assignment of peaks and could lead 
to inconsistencies in predicted gene-editing efficiencies.  As mentioned in 
Chapter 4, the near-tetraploid genome of C2C12 cells complicated the 
determination of gene-editing events on each allele.  Indeed, only 3 editing 
events were detected in cell lines 3B9 and 8E10 despite repeated attempts at 
TA cloning.  Ultimately, deep sequencing of the region surrounding the Cas9 
cut site would provide a comprehensive understanding of the gene-editing 
events on each allele.  Overall, the CRISPR-Cas9 gene-editing process for the 
generation of Casq1 knockout C2C12 cells was largely efficient and achieved 
encouraging gene-editing efficiencies, validating the use of the tool for further 
knockout studies of genes potentially implicated in MH.   
 
5.3.3 Impact of CASQ1 variants on Ca2+ binding and 
polymerisation 
The in-vitro data presented in this chapter highlighted the complex Ca2+ binding 
and self-association events exhibited by CASQ1.  MST was initially explored as 
a means to investigate the effect of the CASQ1 variants on the Ca2+ binding 
capacity of CASQ1.  MST relies on the phenomenon by which molecules move 
in a directed manner in temperature gradients and fluorescent labelling of 
proteins enables their detection (Jerabek-Willemsen et al., 2011).  Variations in 
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the hydrodynamic radius, charge or conformation result in altered movement of 
molecules that in turn, alter the fluorescence signal of the molecules.  As such, 
in a simple binding system whereby there is a 1:1 stoichiometry of binding 
partners, a concentration gradient of the ligand incubated with protein of 
interest results in a sigmoidal binding curve from which binding constants can 
be derived.  In contrast, CASQ1 monomers can bind up to 50-80 molecules of 
Ca2+ and these binding events are comprised of low and high affinity 
interactions (MacLennan and Wong 1971; Park et al., 2003; Sanchez et al., 
2012).  Furthermore, CASQ1 polymerises with increasing Ca2+.  As a result, a 
multiphasic binding curve was generated by MST that is likely to reflect not only 
Ca2+ binding but also CASQ1 self-association.  The first binding event in 
CASQ1 WT appeared to occur at 100 μM Ca2+, which is consistent with 
previous reports alterations in the conformation of CASQ1 monomers at this 
concentration (Park et al., 2003), the emergence of small proportions of higher 
order CASQ1 species, determined by cross-linking of CASQ1 polymers 
followed by SDS-PAGE (Wei et al., 2006), and increases in the turbidity of 
CASQ1 solutions (as a measure of aggregation) (Beard and Dulhunty, 2015).  
Further changes in the fluorescence signal were detected at ~1 mM Ca2+, 
which is consistent with reports of a steep increase in Ca2+ binding of CASQ1 
at 1 mM Ca2+, determined by atomic absorption spectroscopy.  Compared to 
CASQ1 WT, CASQ1 p.I138T and p.F186Y appeared to show a considerable 
reduction in the alteration of fluorescence signal, suggesting a Ca2+ binding or 
polymerisation defect induced by these variants.  Whilst the signal from CASQ1 
p.E364K differed from CASQ1 WT between 200 μM and 400 μM Ca2+, this 
variant also showed an unstable baseline that could reflect experimental noise.  
Overall, the CASQ1 p.E364K variant showed a magnitude in the change in 
fluorescence comparable to CASQ1 WT.   
 
A combination of native and denatured MS was used in an attempt to detect 
the number of Ca2+ ions bound to CASQ1.  Data interpretation was complicated 
by sample heterogeneity and ultimately, the identity of each mass identified 
was ambiguous.  Despite this, CASQ1 p.I138T and CASQ1 p.F186Y failed to 
produce tetrameric structures at 1 mM Ca2+ that were observed in CASQ1 WT 
and CASQ1 p.E364K.  The presence of a 132 kDa species (trimeric CASQ1) in 
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the CASQ1 WT and CASQ1 p.E364K samples suggested a potential limitation 
in the maintenance of CASQ1 polymers in the gas phase, perhaps due to the 
absence of an aqueous environment that permits the stabilisation of 
hydrophobic interactions.  Indeed, as CASQ1 polymerises, its structure 
becomes increasingly dependent on hydrophobic contacts (Kumar et al., 2013).  
Since results from MST indicated that CASQ1 WT behaved in a manner 
comparable to reports in the literature, it is unlikely that the 132 kDa species 
reflects aberrant polymerisation in the CASQ1 WT protein produced. 
 
An additional possibility for the presence of trimeric species is that the +258 Da 
and +178 Da N-terminal 6His-tag modifications (Appendix D) affected N-
terminal arm exchange required for the stabilisation of front-to-front dimer 
interactions that were ultimately destabilised and not maintained into the gas 
phase.  Since the denatured intact analysis indicated that these modified 
species were present in considerably smaller proportions than the desired 
CASQ1 protein (and were present in roughly equal amounts across each 
CASQ1 protein), this was not a major concern for other experiments.  The N-
terminal 6His-tag was selected due to its small size and neutral charge at pH 
7.5 (the pH at which CASQ1 assays were performed in the literature and 
consequently in this study).  As such, 6His-tags tend not to affect protein 
structure and function (Kimple et al., 2013).  Furthermore, the decision to locate 
the 6His-tag at the N-terminus was due to the dependence of the C-terminal tail 
for Ca2+ binding and polymerisation (Beard and Dulhunty, 2015).  Indeed, 
CASQ1 WT appeared to polymerise in a manner comparable to previous 
reports (Wei et al., 2006).  Nonetheless, 6His-tag cleavage should be 
considered for future work. 
 
DLS is inherently suited to monodisperse systems (i.e. samples containing 
proteins of a single Mw) since it cannot accurately distinguish between 
molecules <3-5-fold different in size (Kaszuba et al., 2007).  By its very nature, 
CASQ1 is heterogenous and this increased the complexity of DLS data 
interpretation (Hassan et al., 2015).  Whilst aggregates were present in both 
CASQ1 WT and CASQ1 p.F186Y in the absence of Ca2+, the proportion of 
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these aggregates compared to monomeric/dimeric CASQ1 was increased in 
p.F186Y.  Furthermore, despite the increased aggregates in the absence of 
Ca2+, the Rh values of each peak generated following incubation with 10 mM 
Ca2+ were smaller in p.F186Y compared to CASQ1 WT.  This is in support of a 
reduction in the polymerisation capacity of CASQ1 p.F186Y previously 
observed by MST and MS.  For future investigations, an optimised 
experimental design for DLS would include the incubation of CASQ1 proteins 
with a Ca2+ titration and the optimisation of protein concentration, since the 
movement of molecules by Brownian motion in DLS is dependent on 
concentration as well as size (Stetefeld et al., 2016).  In summary, the 
preliminary in-vitro data generated from CASQ1 heterologous expression, 
purification and downstream in-vitro assays suggests impaired polymerisation 
and consequently Ca2+ binding in CASQ1 p.F186Y and CASQ1 p.I138T. 
 
In the absence of Ca2+, the CASQ1 proteins produced here contained a 
proportion of dimeric CASQ1, as determined my native MS and DLS.  Cross-
linking of CASQ1 samples has previously shown small proportions of dimeric 
CASQ1 at low Ca2+ concentrations (100 nM) but samples without added Ca2+ 
were not shown (Wei et al., 2006).  Sanchez et al., (2012) showed by SEC and 
multi-angle light scattering (SEC-MALS) that in the absence of added Ca2+, 
CASQ1 exists as a monomer. The differences observed between our results 
and those obtained elsewhere could be from differences in sample preparation 
that meant CASQ1 was able to remain bound to more Ca2+ throughout the 
purification process performed within this project.  Dialysis of CASQ1 WT 
against 1 mM EGTA did not alter the masses of monomeric species identified 
by native MS that were speculated to result from Ca2+ binding, although the 
effect of 1 mM EGTA on dimeric species was not investigated.  It may be 
worthwhile for future experiments to determine whether EGTA dialysis reduces 
dimeric CASQ1 populations.   
 
5.3.4 A potential role of CASQ1 p.I138T and p.F186Y in MH/EHI 
Alterations in the polymerisation of CASQ1 variants have previously been 
shown to cause disease in human muscle fibres (Barone et al., 2017; Lewis et 
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al., 2015).  Whilst investigation of the effect of the CASQ1 p.I138T and CASQ1 
p.F186Y variants on Ca2+ release within a cellular system is required, it is 
reasonable to speculate that impaired CASQ1 polymerisation could alter RYR1 
regulation, resulting in the dysregulated Ca2+ release that underlies MH and 
potentially EHI.  Whether the CASQ1 p.I138T variant acts to influence the MH 
phenotype by a major gene effect or, whether it potentiates an MH response in 
the presence of additional genes is unclear.  The individual in which the 
CASQ1 p.I138T variant was identified did not harbour any variants in the RYR1 
or CACNA1S genes.  As such, if these variants acted to potentiate an MH 
response, this must occur in combination with variants identified in genes yet 
unassociated with MH. 
 
The underlying pathophysiology of EHI has not been fully elucidated; however, 
Ca2+ dysregulation that leads to mitochondrial dysfunction is thought to be 
implicated (Sagui et al., 2015; Dainese et al., 2009; Lopez et al., 2018; Yang et 
al., 2006).  An analysis of genetic variants associated with EHI conducted by 
our group suggests that variants in multiple genes could cause or contribute to 
the EHI response, accounting for the variability in clinical phenotypes 
(unpublished data).  The role of CASQ1 in RYR1 regulation and SOCE could 
present mechanisms by which the CASQ1 p.F186Y variant may contribute to 
the EHI phenotype.   
 
Neither CASQ1 p.I138T or p.F186Y have been identified as residues 
associated with Ca2+ coordination, nor do they appear to be located within the 
front-to-front or back-to-back dimer interfaces (Sanchez et al., 2012; Park et al., 
2003).  In-silico analysis did reveal that the residues are highly conserved and 
suggested that they could have a structural role.  Ultimately, structural 
interrogation of the CASQ1 p.I138T and p.F186Y proteins would be required to 
determine the mechanism by which the variants appear to affect 
polymerisation.   
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5.3.5 Future directions 
 
5.3.5.1 Lentiviral transduction of CASQ1 knockout cell lines and 
functional analysis 
The characterisation of edited lines was prioritised over screening of the entire 
monoclonal cell bank that had been processed for cryostorage.  As such, there 
remains a pool of 52 monoclonal lines that require screening for editing events.  
Given that 25% of the 32 lines screened appeared to have undergone gene-
editing, it is possible that up to ~20 Casq1 knockout cell lines have been 
generated in this project that provide an ample pool for further investigation of 
the role of CASQ1 in MH.  One of the primary downstream uses of the Casq1 
knockout C2C12 cells generated here is their transduction with lentiviral 
vectors encoding human CASQ1 WT and CASQ1 p.I138T, CASQ1 p.F186Y 
and CASQ1 p.E364K.  Following the generation of stable, polyclonal cells 
(polyclonal cells would be used to eliminate the effects of random lentiviral 
integration), Ca2+ imaging would be performed to investigate the functional 
effect of the variants by determining whether the cell lines have altered 
sensitives to caffeine.  Other areas that would be interesting to explore are 
whether the CASQ1 variants affect SOCE, via manganese quench assays 
(Pan et al., 2018), and the investigation of whether resting Ca2+ levels differ 
between cells expressing CASQ1 WT or the variant CASQ1s, via the use of 
ratiometric Ca2+ indicator, Fura-2 AM. 
 
In addition to the work presented within this thesis, three pLenti-based 
(addgene plasmid #17448; a gift from Eric Campeau and Paul Kaufman) 
vectors have been constructed that encode CASQ1 WT, CASQ1 p.I138T, 
CASQ1 p.F186Y and CASQ1 p.E364K.  Briefly, restriction digest cloning was 
used to replace the GFP sequence within pLenti-CMV-GFP-Hygromycin with 
the CASQ1 coding sequences.  GFP was removed since it would interfere with 
fluorescence Ca2+ imaging using Ca2+ indicators that are excited at and emit at 
~480-490 nm and ~510-520 nm, respectively.  Generation of these data would 
provide corroboration, or would challenge, the in-vitro data presented in this 
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chapter.  Ultimately, this would provide a more comprehensive analysis of the 
effects of the CASQ1 p.I138T, p.F186Y and p.E364K variants and better 
elucidate the potential for a role in MH/EHI.  At the time of these experiments, 
despite the generation of Casq1 null mouse models, an immortalised Casq1 
null mouse cell line was not available for use.  In recent months, the Leeds MH 
unit has made significant progress in the immortalisation of primary mouse 
myoblasts by stable transduction with CDK4 (Xiaochen Liu, pers. comms.).  
The generation of consistent results between the immortalised Casq1 null 
myoblasts and Casq1 knockout C2C12 cells would provide increased 
confidence of the results observed and would validate the use of the fast 
growing and relatively easy to culture C2C12 cell line.  Whilst the underlying 
theme of previous chapters has been a drive to progress from the cloning and 
heterologous expression of RYR1 variant cDNAs in cell lines void of the gene 
of interest, the CASQ1 coding sequence is ~1 kb (cf. ~15 kb for the RYR1 
gene).  As such, CASQ1 is considerably more amenable to cloning and this 
approach exploits the efficiency of knockout generation by CRISPR-Cas9 
genome editing, whilst overcoming the efficiency limitations associated with 
HDR by CRISPR-Cas9 genome editing. 
 
5.3.5.2 Further in-vitro investigations 
Techniques that would enable the determination of Ca2+ binding kinetics were 
limited within the Biomolecular Interactions Facility in the Astbury Centre for 
Structural Molecular Biology, where this work was performed, primarily due to 
the complex binding events observed for CASQ1 in the presence of Ca2+.  A 
commonly used method to investigate binding affinities is isothermal titration 
calorimetry (ITC; Duff et al., 2011).  This technique was not selected for use 
since it requires large sample consumption and most importantly, was unlikely 
to produce a quantitative read out for Ca2+ binding.  ITC measures heat transfer 
that occurs during binding to produce binding curves and dissociation 
constants; however, the binding of CASQ1 monomers to form dimeric species 
and higher order structures would undoubtedly result in heat transfer, 
precluding the direct measurement of Ca2+ binding.  A technique that may 
enable the determination of Ca2+ binding, at least at the monomeric level, 
would be surface plasmon resonance (SPR; Tang et al., 2010).  SPR requires 
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the immobilisation of protein and subsequent incubation with a titration of the 
ligand, measuring alterations in reflected light that occur following binding.  
Immobilisation would likely hinder the ability of CASQ1 monomers to form 
dimeric structures and beyond; as such, this could enable a comparison of the 
Ca2+ binding capacity of CASQ1 monomers.  Nonetheless, it is important to 
consider that some dimeric portions of CASQ1 were identified in samples 
without added Ca2+ which could affect the interpretation of data if certain 
proteins contained greater proportions of higher order structures in the absence 
of Ca2+.  As mentioned previously, it may be useful to investigate whether 
EGTA ‘stripping’ of CASQ1 would reduce dimeric structures that appear to 
have bound Ca2+ during the purification process.   
 
Further methods to investigate CASQ1 polymerisation include SEC-MALS 
(Sanchez et al., 2012) which, in contrast to DLS, enables the clear resolution 
between species by gel filtration prior to light scattering; however, SEC 
columns will limit the size of CASQ1 polymers that can be analysed since 
larger species would clog the column.  A turbidity assay, which measures 
absorbance at 350 nm (as a measure of protein aggregation), would provide 
insight into the polymerisation capacities of the CASQ1 variants compared to 
CASQ1 WT at increasing Ca2+ concentrations; however, no information about 
the mass of the polymers produced is obtained (Lewis et al., 2015).   
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Chapter 6 - General discussion 
This thesis has provided the first report of the introduction of MH-associated 
VUS into a myoblast cell line by CRISPR-Cas9 genome editing, identifying key 
achievements and areas for future development of the process that will 
accelerate variant characterisation.  Furthermore, multiple Casq1 null C2C12 
cell lines were developed in a highly efficient manner that corroborated 
previous observations in Casq1 null mouse myotubes and fibres (Dainese et 
al., 2009).  These Casq1 null cell lines provide immortalised lines into which 
CASQ1 variants can be introduced using lentiviral vectors for Ca2+ imaging in 
response to RYR1 agonists and for the investigations of alternative Ca2+ influx 
pathways such as SOCE.  CASQ1 variants, p.I138T and CASQ1 p.F186Y, 
were shown to have impaired Ca2+ dependent polymerisation that ultimately, 
would affect the amount of Ca2+ bound and stored.  These data provide further 
insight into the pathological mechanisms underlying MH and EHI and have 
validated these variants for further characterisation in the cellular systems 
generated within this project.  Overall, this work provides a substantial 
contribution to the MH field and contributes to our fundamental understanding 
of the complex Ca2+ handling mechanisms in skeletal muscle.   
 
6.1 Is CRISPR-Cas9 for MH-associated RYR1 variant 
characterisation feasible? 
The primary aim of this thesis was to develop a novel CRISPR-Cas9 genome 
editing pipeline for the introduction of MH-associated VUS into a myoblast cell 
line and explore the feasibility of this strategy for MH variant characterisation.  
Indeed, for the first time in the MH field, CRISPR-Cas9 was utilisied to 
introduce two MH-associated VUS into a myoblast cell line, namely the 
p.D3986E and p.S1728F variants into C2C12 cells.  Variant characterisation 
methods without the need for cloning the large 15 kb RYR1 gene have been 
long sought after within the MH field and have so far amounted to isolation of 
patient myoblast or blood samples for Ca2+ imaging in response to RYR1 
agonists.  Variable genetic background between patient samples means that 
large numbers of unrelated samples are required to determine that an 
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observed effect can be attributed to a variant question.  Since the majority of 
MH-associated RYR1 variants are unique to single families, this method of 
characterisation is not possible for a vast proportion of MH cases (Miller et al., 
2018).  Furthermore, inconsistencies between techniques are widely reported 
(Merritt et al., 2017; Ducreux et al., 2006).  The work presented here has 
provided proof of principle for the introduction of MH-associated VUS into a 
myoblast cell line, avoiding the laborious procedure for cloning of the 15 kb 
RYR1 gene.  This work undoubtedly provides the foundation for the future of 
MH variant characterisation.  Whilst the complex mutational patterns in the 
resultant cell lines precluded determination of the functional effect of the 
p.D3986E variant in C2C12 myotubes, they have provided support for the 
proposed role of SDSA in the integration of single stranded HDR templates 
(Paix et al., 2017).  The elucidation of the mechanisms that allow for strand 
incorporation are essential to strategy optimisation such as repair template 
design (Boel et al., 2018).  
 
The selection of RYR1 variants for characterisation in this project assumed a 
major gene mechanism of pathogenicity, whereby a single variant could act to 
determine MH susceptibility.  RYR1 variants were required to be rare and 
identified in multiple families.  This strategy enabled the prioritisation of variants 
for characterisation and validation the CRISPR-Cas9 pipeline; however, a 
growing body of evidence suggests a role for modifier variants in MH.  Indeed, 
the p.D3986E variant, despite high levels of conservation, a high C-score and 
enrichment in MHS individuals, has previously been shown not to result in 
reduced sensitivity to caffeine (Merritt et al., 2017).  Whilst this could reflect 
limitations of the HEK293 functional characterisation system, it could also 
reflect the requirement of additional, potentially more common variants, that 
together potentiate the MH phenotype.  This modifier variant theory could 
explain high levels of discordance observed in MH (Miller et al., 2018).  The 
impact of the development of a CRISPR-Cas9 genome editing characterisation 
pipeline goes beyond the introduction of single variants into C2C12 cells for 
functional characterisation.  To date, the power to investigate the theory of 
modifier variants has been limited.  Indeed, by current methods, this would 
require the site directed mutagenesis and transfection of multiple RYR1 
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vectors.  This is laborious and random integration means that more copies of 
one than the other could be inserted at unknown locations that could 
complicate data interpretation.  Co-transfection of cells with multiple gRNAs 
and HDR templates (or, the sequential transfection) would enable the 
introduction of multiple variant combinations into the same cell line, enabling 
the study of potential modifiers.  Whilst the near-tetraploid genome of C2C12 
cells would complicate the study of modifiers, recent advances in the Leeds 
MH Unit in immortalising primary mouse cells would enable the study of 
modifiers in a diploid background.  This strategy has recently been used to 
investigate the effect of modifier variants in childhood-onset cardiomyopathy 
(Gifford et al., 2019).  Three rare variants in the MKL2, MYH7, and NKX2-5 
genes were identified in an infant with left ventricular noncompaction (LVNC).  
The asymptomatic father harboured the MYH7 variant and the MKL2 variant.  
Mice homozygous for the MYH7 variant died at day 9 or 10, whereas mice 
homozygous for either the MKL2 or NKX2-5 variants (the latter of which was 
inherited from the unaffected mother) demonstrated only minor ventricular 
alterations.  Mice heterozygous for all three variants recapitulated the LVNC 
phenotype, elucidating the role of modifier variants in the disorder.  A study 
with a similar aim characterised a childhood-onset cardiomyopathy associated 
variant in the PBX3 gene in zebrafish, which was found to enhance the 
phenotype caused by the loss of a known causative gene, HAND2 (Farr et al., 
2018).  Another interesting avenue for exploration using CRISPR-Cas9 
genome editing is the correction of MH-associated VUS to a ‘wild-type’ state for 
the study of causality and proof-of-concept for the future of gene therapy.  
Indeed, such advances have been made for the correction of Duchenne 
Muscular Dystrophy (DMD) mutations by adeno-associated virus delivery into 
DMD mouse models that enabled a significant improvement in the phenotype 
(Nelson et al., 2016). 
 
CRISPR-Cas9 genome editing is, despite a wealth of achievements, still in its 
infancy.  Rapid developments in the technology are likely to guide further use 
of the technique for the introduction of MH-associated VUS.  Recent 
developments in cytidine deaminase base editors fused to catalytically inactive 
Cas9 were explored as a method for MH-associated VUS characterisation 
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(Komor et al., 2016; Banno et al., 2018).  In general, MH-associated VUS were 
not amenable to editing in this way in murine cells, with the exception of the the 
p.R3366H variant.  Whilst this presents an avenue for investigation of the 
p.R3366H variant, this method does not provide ample opportunity for 
characterisation of a range MH-associated VUS in murine cells and is unlikely 
to provide a comprehensive means for variant characterisation in human cells.  
The use of alternative Cas proteins, namely Cpf1 (derived from Prevotella and 
Franscisella 1), allows for diversification since it utilises an alternative PAM 
sequence and reductions in off-target activity have been reported (Moon et al., 
2018).  Furthermore, where possible, single-strand inducing Cas9 nickases can 
be utilised for increased on-target specificity (Ran et al., 2013b). 
 
In conclusion, CRISPR-Cas9 remains an attractive and feasible method for the 
characterisation of MH-associated VUS.  The progress presented in this thesis 
provides a foundation for future development and has highlighted key areas for 
optimisation that will enable the determination of the functional significance of 
desired variants, the investigation of modifier variants and proof-of-principle 
editing of variants back to a ‘wild-type’ state.  This work will accelerate the 
development of a DNA-level diagnostic approach to MH.    
 
6.2 Future work for CRISPR-Cas9 mediated introduction of 
RYR1 variants 
The primary area to explore for future use of CRISPR-Cas9 in the 
characterisation of MH-associated VUS is the suppression of NHEJ, potentially 
using Ligase IV inhibitors, to reduce the incorporation of undesired editing 
events in the resultant cell lines (Maruyama et al., 2015).  In addition, it has 
been shown that HDR template incorporation can occur following the 
introduction of single stranded DNA breaks, such as those induced by Cas9 
nickase, and this can reduce NHEJ events, presenting another area for future 
consideration (Liu et al., 2019).  Indeed, undesired editing events presented a 
major limitation in obtaining cell lines that would enable functional 
characterisation of the p.D3986E and p.S1728F variants due to the unknown 
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effect of the undesired indels.  In addition, whilst the mouse RYR1 protein and 
human RYR1 proteins share homology at 96% and mouse models are widely 
used to investigate the underlying pathophysiology of MH-associated RYR1 
variants (Chelu et al., 2006; Yang et al., 2006; Lopez et al., 2018), it is 
important to consider that effects observed in a murine context may not entirely 
reflect that in a human context.  Ultimately, variant characterisation in a human 
cell line provides an optimal strategy.  Further optimisation of the CRISPR-
Cas9 process in human myoblasts is required, potentially by implementing 
strategies that circumvent the use of FACS.  As mentioned, one of the major 
advantages of the CRISPR-Cas9 genome editing technique is its amenability to 
investigating the effect of modifier variants.  Ultimately, this would provide 
unprecedented insight into the mechanisms underlying MH susceptibility.   
 
6.3 Could variants in the CASQ1 gene influence the MH and 
EHI phenotypes? 
The secondary aim of this thesis was to generate a Casq1 knockout C2C12 
cell line that would i) enable the determination of whether the effect of Casq1 
ablation in C2C12 myotubes is consistent with reports in existing Casq1 null 
models and ii) enable the re-introduction of CASQ1 variants using lentiviral 
vectors encoding variant cDNAs.  Furthermore, the third aim of this thesis was 
to perform preliminary investigations into the effects of two CASQ1 variants, 
p.I138T and p.F186Y, on the polymerisation and Ca2+ binding capacities of the 
CASQ1 protein.  Casq1 null C2C12 cells showed increased sensitivity to 
caffeine and reduced SR Ca2+, consistent with previous findings in Casq1 null 
mouse myotubes and fibres (Dainese et al., 2009).  Furthermore, the finding 
that polymerisation was impaired in both the CASQ1 p.I138T and p.F186Y 
variants suggests that these variants could, at least, act to potentiate an 
MH/EHI response.  Indeed, despite these variants showing similarities in the 
effects on Ca2+ dependent polymerisation, the individuals in which the variants 
were detected had different phenotypes determined by IVCT i.e. MHSh for 
p.I138T vs. MHN for p.F186Y.  It is therefore likely that the presence of variants 
in other genes act in parallel to determine the observed phenotype.  Since the 
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dynamic polymerisation of CASQ1 is thought to enable regulation of the RYR1, 
reduced polymerisation of CASQ1 could perturb normal gating of the channel, 
resulting in increased activity and Ca2+ release observed in MH and possibly 
EHI.  Alternatively, a CASQ1 variant that results in diminished Ca2+ dependent 
polymerisation has been shown to increase SOCE in patients with tubular 
aggregate myopathy (Barone et al., 2017).  SOCE has previously been 
hypothesised to allow for the sustained Ca2+ release observed in MH (Duke et 
al., 2010).  Since ~25% of MH cases could be attributed to defects in genes 
other than the RYR1 and CACNA1S, the elucidation of the role of variants in 
other genes further facilitates the development of a DNA-level approach to MH 
diagnosis and contributes to our understanding of the fundamental 
mechanisms underlying these complex disorders.  The hypothesis of multiple 
genes acting to confer susceptibility to MH and EHI provides an explanation for 
the range of clinical severities observed.  
 
Whilst variants in the CASQ1 gene are certainly a promising candidate for a 
role in MH/EHI, the CASQ1 p.I138T and p.F186Y variants selected for use in 
this project have been identified in single individuals within Leeds MH Unit 
referrals (although, the presence of the p.I138T variant in family members of 
the individual in which the variant was identified remains to be determined).  In 
total, 5 CASQ1 variants have been identified in referalls to the Leeds MH Unit 
(one of which is the common p.M87T variant).  Of course, these variants 
require functional characterisation; however, their prevalence suggests that 
they do not represent a major mechanism by which susceptibility MH/EHI is 
determined in the UK population.  Nonetheless, the findings presented in this 
thesis provide further substantiation of the role of multiple gene products in 
conferring susceptibility.   
 
6.4 Future work for the investigation of CASQ1 variants in 
MH 
The Casq1 null C2C12 cells provide an immortalised system for the study of 
the effects of variants identified in the CASQ1 gene.  Based on the finding that 
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CASQ1 p.I138T and p.F186Y proteins appear to have impaired polymerisation, 
a primary area for exploration is whether these variants alter sensitivity to 
caffeine compared to the CASQ1 WT in myotubes.  The determination of the 
effect of these variants in myotubes will provide further information about how 
they may contribute to the MH/EHI phenotypes.  Indeed, in addition to the 
determination of caffeine sensitivity, resting Ca2+ levels can be determined by 
the use of ratiometric Ca2+ indictors such as Fura-2 AM and manganese 
quench assays would provide insight into whether these variants affect SOCE.  
Lentiviral vectors encoding the cDNAs for CASQ1 WT and the three variants 
selected for investigation in this project have been generated to allow for the 
stable transduction of Casq1 null C2C12 cells.  Lentiviral vectors have 
previously been used for the expression of MH-associated Cav1.1 p.R174W 
variant channels into dysgenic myoblasts for functional characterisation (Eltit et 
al., 2012), the delivery and stable expression of the full-length dystrophin gene 
(~15 kb) expression in myoblasts for DMD therapy (Counsell et al., 2017), and 
the delivery of short hairpin RNAs (shRNAs) to investigate the roles of genes 
involved in differentiation (Shu et al., 2009).   
 
Since the outset of this project, the CASQ1 p.Y140F c. 418A>T (MAF 0.006; 
gnomAD) variant has been identified one MHShc individual and one EHI/MHSh 
individual.  Interestingly, both of these individuals also harboured a variant in 
the RYR1 gene of unknown significance in MH.  The first variant, identified in 
the EHI individual was the relatively common RYR1 p.S1342G variant (MAF 
0.02; ExAC).  This variant has previously been associated with MH and 
exertional rhabdomyolysis and has been identified in another EHI individual 
and two MH families referred to the MH unit, each in the presence of an 
additional uncharacterised RYR1 variant (Levano et al.,2009; Sambuughin et 
al., 2009).  The MHShc individual in which the CASQ1 p.F140Y variant was 
identified in also harboured the RYR1 p.P4496L (no MAF available) variant that 
has not been detected in any other individuals referred to the Leeds MH Unit.  
As such, the investigation of the role of the CASQ1 p.Y140F variant would be 
an interesting avenue for future characterisation, potentially using CRISPR-
Cas9 genome editing as a tool for the investigation of a modifier effect resulting 
from the combination of CASQ1 and RYR1 variants identified. 
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The in-vitro studies performed for the investigation of the effect of CASQ1 
p.I138T and p.F186Y were complicated by the inherent size heterogeneity of 
the CASQ1 protein and the complex self-association and Ca2+ binding events it 
undergoes.  Structural analysis of the variant proteins by X-ray crystallography 
would elucidate the mechanism by which polymerisation is impaired.   
 
6.5 Final summary 
To summarise, significant progress has been presented in the development of 
the CRISPR-Cas9 genome editing technique for the characterisation of MH 
associated VUS in C2C12 cells.  This was achieved by both the insertion of 
specific RYR1 variants and the generation of a Casq1 null C2C12 cell line.  
The work presented here has provided insight into the potential role of variants 
in the CASQ1 gene in MH and EHI.  Improvements in variant characterisation 
as a result of the progress made in this project will facilitate the elucidation of 
the complex genetic factors that underly MH and accelerate the establishment 
of a DNA-level diagnostic pipeline for MH.  The transition to a whole-exome 
sequencing approach being explored by the Leeds MH Unit for variant 
detection offers increased scope for the detection of genetic variants in 
MHS/EHI individuals.  Ultimately, a DNA-level pipeline for MH diagnosis would 
alleviate the need for the invasive IVCT procedure and would realise a 
personalised medicines approach to anaesthesia.   
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Appendix A – Ryr1 p.D3986E off-target site Sanger sequencing 
chromatograms 
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Appendix A continued (1) 
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Appendix A continued (2) 
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Appendix B – Ryr1 p.S1728F off-target site Sanger sequencing 
chromatograms 
 
 
 
 
 
 
310 
Appendix B continued (1) 
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Appendix C – Casq1 off-target site Sanger sequencing chromatograms 
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Appendix C continued (1) 
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Appendix D – Putative identities of CASQ1 species identified by denatured and native mass spectrometry 
Table S1 - Summary of the modifications identified on CASQ1 proteins by denatured intact mass spectrometry 
Species have been assigned arbitrary species numbers to allow for ease of comparison.  Italicised values indicate those that do not show an exact 
Mw match to the proposed adduct but when error is taken into account, they could represent exact matches.  Brackets indicate the Mw difference 
between the variant CASQ1 proteins compared to CASQ1 WT in DaMST to investigate Ca2+ binding to CASQ1 
 
 
 
 
 
 
 
 
 
 
Species WT I138T (-12) F186Y (+16) E364K (-1) Modification 
1 43679.6992  43695.1992  Unknown modification/contaminant 
2 43697.36±0.62 43685.21±0.68 43713.49±0.71 43696.57±0.69 CASQ1 -132 Da = loss of N terminal 
methionine 
3 43713.3984 43700.6992 43728.14±0.8 43711.38±0.62 2 + 16 Da = oxidation 
4    43722.66±3.24 Unknown modification/contaminant 
5 43733.53±2.33  43745.1.5±0.9 43728.01±2.18 2 + 32 Da = 2 oxidations 
6    43742.6992 3 + 32 Da = 2 oxidations 
7 43813.1992 43800.500 43828.8984 43811.6016 Unknown modification/contaminant 
8 43875.61±1.17 43863.57±1.08 43891.0000±0.90 43874.90±2.16 2 + 178.8 Da = His-tag modification 
9   43908.5000 43890.1016 8 + 16 Da = oxidation 
10   43922.8984  8 + 32 = 2 oxidations 
11 43955.89±1.38 43943.61±0.61 43971.25±1.32 43954.72±1.21 2 + 258.2 Da = His-tag modification 
12   44005.8984 43985.0000 11 + 31-33 Da = 2 oxidations 
13 44010.8008    Unknown modification/contaminant 
14  44121.0000  44134.3984 Unknown modification 
15    44212.3008 Unknown modification/contaminant 
316 
 
 
 
Appendix D continued (1) 
*Addition of a 258 Da a-6-N-phosphogluconyl group to the His-tag occurs via the activity of 6-phosphoglucono-1,5-lactone which is 
produced from the dehydrogenation of glucose-6-phosphate.  Subsequent dephosphorylation of the a-6-N-phosphogluconyl group 
yields a 178 Da a-6-N-gluconyl adduct (Geoghegan et al., 1999).   
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Appendix D continued (2) 
Possible identities of species identified by native mass spectrometry 
using the Q ExactiveTM Plus mass spectrometer 
For CASQ1 WT, the predominant species (species A) was 43728 Da (Figure 
5.26).  This was ~80 Da smaller than the predominant species identified in the 
previous native analysis (species C, 43810 Da), suggesting a single Ca2+ ion 
could be bound to species A.  Species B (43890) was 80 Da larger than the 
predominant species identified in the previous analysis (species C, 43810 Da) 
and consequently, 160 Da larger than species A identified in this analysis, 
suggesting 5 bound Ca2+ ions.  Species C identified in this analysis (43972 Da) 
was ~80 Da larger than species B, suggesting 7 Ca2+ ions were bound to 
species C.  Three dimeric species were also identified in this second native 
analysis (Figure 5.26) without added Ca2+.  An alternative interpretation of 
these data for the monomeric forms of CASQ1 WT would be that species A 
identified in both native analyses (Figure 5.25 and Figure 5.26), at 39 Da and 
32 Da larger than WT CASQ1 minus the N terminal methionine, respectively, 
represent a species with 2 oxidations.  Furthermore, differences of 80 Da could 
reflect the 80 Da difference between the +178 Da 6His-tag modification and the 
+258 6His-tag modification identified in the denatured analysis.  When 1 mM 
Ca2+ was added, the monomeric species (species A) was 44136 Da, which is 
440 Da larger than CASQ1 WT minus the N terminal methionine, suggesting 
11 Ca2+ ions were bound.  Alternatively, if this species represents CASQ1 
minus the N terminal methionine with 2 oxidation events, this could reflect 10 
bound Ca2+ ions.  Assuming that the dimeric species identified was derived 
from the CASQ1 WT protein minus the N terminal methionine, a mass of 88200 
Da indicates 20 bound Ca2+ ions.  For CASQ1 p.I138T, in the absence of Ca2+, 
the predominant species was 44182 Da (species B; Figure 5.26), which is ~497 
Da larger than CASQ1 p.I138T without the N terminal methionine.  This 497 Da 
difference does not correspond to a number divisible by 40 (the mass of a Ca2+ 
ion).  It may be possible that this species represents the CASQ1 p.I138T 
protein with an oxidation event (+16 Da), leaving a difference compared to 
p.I138T minus the N terminal methionine of ~480 Da, or 12 Ca2+ ions.  
Alternatively, this species could represent CASQ1 p.I138T with the +258 Da 
6His-tag modification, leaving a difference of ~240 Da, or 6 Ca2+ ions.  The 
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identity of species A (43990 Da) is also unclear, which is 192 Da smaller than 
species B.  This could reflect 200 Da (5 Ca2+ ions) or, if species B contains 2 
additional oxidation events (+32), this would indicate 4 bound Ca2+ ions to 
species B.  Alternatively, the difference between species A and the mass of 
p.I138T minus N terminal methionine is 305 Da, which again is not divisible by 
40 Da.  This mass could reflect the CASQ1 p.I138T protein with the +32 Da 
double oxidation event, leaving a difference of 273 Da (280 Da would represent 
7 Ca2+ ions).  In the presence of 1 mM Ca2+, the predominant species was 
44254 Da (species A) which is 569 Da larger than CASQ1 p.I138T minus the N 
terminal methionine.  A total of 560 Da would correspond to 14 Ca2+ ions.  
Subtraction of all of the other masses of the modifications identified in the 
CASQ1 p.I138T denatured sample from 44254 Da did not yield any values that 
were divisible by 40 Da.  The second and third species identified (species B 
and species C, respectively) represented dimeric CASQ1 p.I138T at 88148 Da 
and 88166 Da.  As described previously, the identities of dimeric species can 
be speculated; however, it is not possible to conclusively determine their 
composition.  Species B may correspond to a CASQ1 p.I138T minus the N 
terminal methionine protein bound to the CASQ1 p.I138T minus the N terminal 
methionine with a single oxidation event.  This would correspond to the dimer 
being bound 19 Ca2+ ions.  Species C was 18 Da larger than species B, 
potentially reflecting an additional oxidation event (+16).  For CASQ1 p.F186Y, 
in the absence of added Ca2+, the predominant species (species A) was 43830 
Da which was 117 Da larger than the CASQ1 p.F186Y protein minus the N 
terminal methionine residue (43713 Da) which could reflect 3 bound Ca2+ ions.  
The second species identified (species B) was 43986 Da which was 273 Da 
larger than CASQ1 p.F186Y protein minus the N terminal methionine residue, 
which could reflect 7 bound Ca2+ ions (280 Da).  An alternative to this is that 
the species B 43986 Da mass could reflect a previously undetected species 
containing the +258 Da 6His-tag modification in addition to a single oxidation 
event (+16 Da).  The addition of 1 mM Ca2+ did not appear to induce the 
formation higher order CASQ1 species, with only monomers and dimers 
detected.  The predominant species (species A) was 44172 Da, which is 459 
Da larger than the CASQ1 p.F186Y protein minus the N terminal methionine.  
Whilst this value is not divisible by 40 Da, it could reflect the CASQ1 p.F186Y 
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protein minus the N terminal signal peptide in addition to an oxidation event 
(+16) and 11 Ca2+ ions (+440 Da).  Alternatively, this value could also 
correspond to the CASQ1 p.F186Y protein minus the N terminal methionine 
with the +258 Da 6His-tag modification, in addition to 5 Ca2+ ions (+200 Da) or 
the +178 Da 6His-tag modification in addition to 3 Ca2+ ions.  The second 
species identified in the presence of 1 mM Ca2+ was 44474 Da.  This was 761 
Da larger than the CASQ1 p.F186Y protein minus the N terminal methionine, 
which could correspond to 19 bound Ca2+ ions.  Finally, for CASQ1 p.E364K, in 
the absence of Ca2+, the predominant species was 43724 Da, which was 28 Da 
larger than the CASQ1 p.E364K protein without the N terminal methionine 
residue.  This mass could correspond to the CASQ1 p.E364K protein without 
the N terminal methionine residue in addition to 2 oxidation events (+32 Da).  
The second species identified was 43906 Da, which was 210 Da larger than 
the the CASQ1 p.E364K protein without the N terminal methionine residue.  
This 210 Da difference could reflect the +178 Da 6His-tag modification in 
addition to 2 oxidation events (+32 Da).  CASQ1 p.E364K appeared to 
polymerise in a manner similar to CASQ1 WT, with the presence of CASQ1 
species up to tetrameric level following the addition of 1 mM Ca2+.  The 
predominant species (species A) detected in the presence of 1 mM Ca2+ was 
43930 Da, which was 234 Da larger than the CASQ1 p.E364K protein without 
the N terminal methionine residue.  This 234 Da difference could reflect the 
CASQ1 p.E364K protein without the N terminal methionine residue with 2 
oxidation events (+32 Da) and 5 bound Ca2+ ions (+200 Da).  The second most 
prominent species identified, species B, was 43940 Da which was 244 Da 
larger than CASQ1 p.E364K protein without the N terminal methionine residue.  
The 244 Da difference could reflect 6 bound Ca2+ ions.  The dimeric species 
(species C) identified was 88098 Da which was 706 Da larger than the mass of 
two CASQ1 p.E364K proteins without the N terminal methionine residue.  This 
706 Da difference could reflect 4 oxidation events (+64 Da).  
